

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 2997132 T3**

(12) Oversættelse af
europæisk patentskrift

-
- (51) Int.Cl.: **C 12 N 5/0783 (2010.01)** **C 07 K 14/725 (2006.01)** **C 07 K 14/735 (2006.01)**
C 07 K 16/28 (2006.01)
- (45) Oversættelsen bekendtgjort den: **2020-11-09**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2020-08-12**
- (86) Europæisk ansøgning nr.: **14727626.5**
- (86) Europæisk indleveringsdag: **2014-05-13**
- (87) Den europæiske ansøgnings publiceringsdag: **2016-03-23**
- (86) International ansøgning nr.: **IB2014061409**
- (87) Internationalt publikationsnr.: **WO2014184741**
- (30) Prioritet: **2013-05-13 US 201313892805** **2013-05-13 WO PCT/US2013/040755**
2013-05-13 WO PCT/US2013/040766 **2013-07-15 US 201313942191**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Collectis, 8, rue de la Croix Jarry, 75013 Paris, Frankrig**
- (72) Opfinder: **GALETTO, Roman, 12 Rue Ernest Cresson, 75014 Paris, Frankrig**
GOUBLE, Agnes, 65, Rue de Tocqueville, 75017 Paris, Frankrig
GROSSE, Stephanie, 7 rue de Moras, 77750 Saint Cyr Sur Morin, Frankrig
SCHIFFER-MANNIOUI, Cécile, 8 bis rue Maurice Roy, 94350 Villiers sur Marne, Frankrig
Poirot, Laurent, 4 Rue De Torcy, 75018 Paris, Frankrig
SCHARENBERG, Andrew, 1222 NW Norcross Way, Seattle, Washington 98177, USA
SMITH, Julianne, 13 Rue de la Ferme, 92350 Le Plessis Robinson, Frankrig
- (74) Fuldmægtig i Danmark: **Patrade A/S, Ceresbyen 75, 8000 Århus C, Danmark**
- (54) Benævnelse: **Fremgangsmåder til konstruering af allogenisk og høj-aktiv T-celle til immunoterapi**
- (56) Fremdragne publikationer:
MIZOGUCHI E ET AL: "Pathogenic role of IL-4, but not IFN-gamma in colitis of TCRalpha knockout mice", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 114, 15 April 1998 (1998-04-15), page A1041, XP027469136, ISSN: 0016-5085, DOI: 10.1016/S0016-5085(98)84235-2 [retrieved on 1998-04-15]
H. TORIKAI ET AL: "A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR", BLOOD, vol. 119, no. 24, 14 June 2012 (2012-06-14), pages 5697-5705, XP55071623, ISSN: 0006-4971, DOI: 10.1182/blood-2012-01-405365
ZACHARY A. COOPER ET AL: "Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma", ONCOIMMUNOLOGY, vol. 2, no. 5, 1 May 2013 (2013-05-01), page e24320, XP055133315, ISSN: 2162-4011, DOI: 10.4161/onci.24320
M. M. MAHFOUZ ET AL: "De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with

Fortsættes ...

novel DNA binding specificity creates double-strand breaks", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 6, 8 February 2011 (2011-02-08), pages 2623-2628, XP055007615, ISSN: 0027-8424, DOI: 10.1073/pnas.1019533108

PARTOW KEBRIAEI ET AL: "Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies", HUMAN GENE THERAPY, vol. 23, no. 5, 1 May 2012 (2012-05-01), pages 444-450, XP055130799, ISSN: 1043-0342, DOI: 10.1089/hum.2011.167

UTTENTHAL B J ET AL: "Challenges in T cell receptor gene therapy", JOURNAL OF GENE MEDICINE, JOHN WILEY & SONS, INC, US, vol. 14, no. 6, 1 June 2012 (2012-06-01), pages 386-399, XP002760096, ISSN: 1099-498X, DOI: 10.1002/JGM.2637 [retrieved on 2012-06-27]

Michael S Magee ET AL: "Immunotherapeutic strategies to target prognostic and predictive markers of cancer", Biomarkers in Medicine, vol. 7, no. 1, 1 February 2013 (2013-02-01), pages 23-35, XP55486731, UK ISSN: 1752-0363, DOI: 10.2217/bmm.12.110

DESCRIPTION

Field of the invention

[0001] The present invention relates to methods for developing engineered non-alloreactive T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and at least one immune checkpoint gene to unleash the potential of immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention also relates to further attributes, which can be brought into such engineered T cells, such as preTCR α ("pTalpha") and functional derivatives thereof, Chimeric Antigen Receptor (CAR), multichain CAR and their use thereof to enhance the efficiency of immunotherapy. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

Background of the invention

[0002] Adoptive immunotherapy, which involves the transfer of autologous antigen-specific T cells generated *ex vivo*, is a promising strategy to treat viral infections and cancer. The T cells used for adoptive immunotherapy can be generated either by expansion of antigen-specific T cells or redirection of T cells through genetic engineering (Park, Rosenberg et al. 2011). Transfer of viral antigen specific T cells is a well-established procedure used for the treatment of transplant associated viral infections and rare viral-related malignancies. Similarly, isolation and transfer of tumor specific T cells has been shown to be successful in treating melanoma.

[0003] Novel specificities in T cells have been successfully generated through the genetic transfer of transgenic T cell receptors or chimeric antigen receptors (CARs) (Jena, Dotti et al. 2010). CARs are synthetic receptors consisting of a targeting moiety that is associated with one or more signaling domains in a single fusion molecule. In general, the binding moiety of a CAR consists of an antigen-binding domain of a single-chain antibody (scFv), comprising the light and variable fragments of a monoclonal antibody joined by a flexible linker. Binding moieties based on receptor or ligand domains have also been used successfully. The signaling domains for first generation CARs are derived from the cytoplasmic region of the CD3zeta or the Fc receptor gamma chains. First generation CARs have been shown to successfully redirect T cell cytotoxicity, however, they failed to provide prolonged expansion and anti-tumor activity *in vivo*. Signaling domains from co-stimulatory molecules including CD28, OX-40 (CD134), and 4-1BB (CD137) have been added alone (second generation) or in combination (third generation) to enhance survival and increase proliferation of CAR modified T cells. CARs have successfully allowed T cells to be redirected against antigens expressed at the surface of tumor cells from various malignancies including lymphomas and solid tumors (Jena, Dotti et al. 2010).

[0004] Present CAR architectures are built on a design in which all relevant domains are contained within a single polypeptide. This design necessitates serial appending of signaling domains, thus necessitating moving some domains from their natural juxtamembrane positions. Thus, architectures in which ligands and signaling domains are separate may allow for improved function of costimulatory domains placed on different chains in their normal juxtamembrane positions, rather than appended together with some domains positioned distal from the plasma membrane. A natural receptor, the high affinity receptor for IgE (Fc ϵ RI) would afford such architecture. Fc ϵ RI present on mast cells and basophils binds IgE with high affinity. Fc ϵ RI is a tetrameric receptor complex consisting of ligand binding alpha subunit, a beta subunit and a homodimer of two signal-transducing gamma subunits (Metzger, Alcaraz et al. 1986). Fc ϵ RI alpha domain consists of an extracellular domain containing two Ig-like domains that bind IgE, a transmembrane domain and a short cytoplasmic tail. Beta subunit contains four transmembrane segments separating amino and carboxy terminal cytoplasmic tails. The gamma chain consists essentially of a transmembrane region and cytoplasmic tail containing one immunoreceptor tyrosine-based activation motif (ITAM) (Cambier 1995). The zeta chain of the TCR complex is closely related to the gamma chain and can substitute for the gamma chain of Fc ϵ RI (Howard, Rodewald et al. 1990). H. TORIKAI ET AL, BLOOD, 2012, 119: 5697-5705, discloses elimination of

endogenous TCR in CAR Tcells.

[0005] The current protocol for treatment of patients using adoptive immunotherapy is based on autologous cell transfer. In this approach, T lymphocytes are recovered from patients, genetically modified or selected *ex vivo*, cultivated *in vitro* in order to amplify the number of cells if necessary and finally infused into the patient. In addition to lymphocyte infusion, the host may be manipulated in other ways that support the engraftment of the T cells or their participation in an immune response, for example pre-conditioning (with radiation or chemotherapy) and administration of lymphocyte growth factors (such as IL-2). Each patient receives an individually fabricated treatment, using the patient's own lymphocytes (i.e. an autologous therapy). Autologous therapies face substantial technical and logistic hurdles to practical application, their generation requires expensive dedicated facilities and expert personnel, they must be generated in a short time following a patient's diagnosis, and in many cases, pretreatment of the patient has resulted in degraded immune function, such that the patient's lymphocytes may be poorly functional and present in very low numbers. Because of these hurdles, each patient's autologous cell preparation is effectively a new product, resulting in substantial variations in efficacy and safety. Ideally, one would like to use a standardized therapy in which allogeneic therapeutic cells could be pre-manufactured, characterized in detail, and available for immediate administration to patients. By allogeneic it is meant that the cells are obtained from individuals belonging to the same species but are genetically dissimilar. However, the use of allogeneic cells presently has many drawbacks. In immune-competent hosts allogeneic cells are rapidly rejected, a process termed host versus graft rejection (HvG), and this substantially limits the efficacy of the transferred cells. In immune-incompetent hosts, allogeneic cells are able to engraft, but their endogenous TCR specificities recognize the host tissue as foreign, resulting in graft versus host disease (GvHD), which can lead to serious tissue damage and death. In order to effectively use allogeneic cells, both of these problems must be overcome.

[0006] In immunocompetent hosts, allogeneic cells are rapidly rejected by the host immune system. It has been demonstrated that, allogeneic leukocytes present in non-irradiated blood products will persist for no more than 5 to 6 days. (Boni, Muranski et al. 2008). Thus, to prevent rejection of allogeneic cells, the host's immune system must be effectively suppressed. Glucocorticosteroids are widely used therapeutically for immunosuppression (Coutinho and Chapman 2011). This class of steroid hormones binds to the glucocorticoid receptor (GR) present in the cytosol of T cells resulting in the translocation into the nucleus and the binding of specific DNA motifs that regulate the expression of a number of genes involved in the immunologic process. Treatment of T cells with glucocorticoid steroids results in reduced levels of cytokine production leading to T cell anergy and interfering in T cell activation. Alemtuzumab, also known as CAMPATH1-H, is a humanized monoclonal antibody targeting CD52, a 12 amino acid glycosylphosphatidylinositol- (GPI) linked glycoprotein (Waldmann and Hale 2005). CD52 is expressed at high levels on T and B lymphocytes and lower levels on monocytes while being absent on granulocytes and bone marrow precursors. Treatment with Alemtuzumab, a humanized monoclonal antibody directed against CD52, has been shown to induce a rapid depletion of circulating lymphocytes and monocytes. It is frequently used in the treatment of T cell lymphomas and in certain cases as part of a conditioning regimen for transplantation. However, in the case of adoptive immunotherapy the use of immunosuppressive drugs will also have a detrimental effect on the introduced therapeutic T cells. Therefore, to effectively use an adoptive immunotherapy approach in these conditions, the introduced cells would need to be resistant to the immunosuppressive treatment.

[0007] On the other hand, T cell receptors (TCR) are cell surface receptors that participate in the activation of T cells in response to the presentation of antigen. The TCR is generally made from two chains, alpha and beta, which assemble to form a heterodimer and associates with the CD3-transducing subunits to form the T-cell receptor complex present on the cell surface. Each alpha and beta chain of the TCR consists of an immunoglobulin-like N-terminal variable (V) and constant (C) region, a hydrophobic transmembrane domain, and a short cytoplasmic region. As for immunoglobulin molecules, the variable region of the alpha and beta chains are generated by V(D)J recombination, creating a large diversity of antigen specificities within the population of T cells. However, in contrast to immunoglobulins that recognize intact antigen, T cells are activated by processed peptide fragments in association with an MHC molecule, introducing an extra dimension to antigen recognition by T cells, known as MHC restriction. Recognition of MHC disparities between the donor and recipient through the T cell receptor leads to T cell proliferation and the potential development of GVHD. It has been shown that normal surface expression of the TCR depends on the coordinated synthesis and assembly of all seven components of the complex (Ashwell and Klusner 1990). The inactivation of TCRalpha or TCRbeta can result in the elimination of the TCR from the surface of T cells preventing recognition of alloantigen and thus GVHD. However, TCR disruption results in the elimination of the CD3

signaling component and alters the means of further T cell expansion.

[0008] T-cell mediated immunity includes multiple sequential steps regulated by a balance between co-stimulatory and inhibitory signals that fine-tune the immunity response. The inhibitory signals referred to as immune checkpoints are crucial for the maintenance of self-tolerance and also to limit immune-mediated collateral tissue damage. The expression of immune checkpoints protein can be deregulated by tumours. The ability of tumours to co-opt these inhibitory pathways represents an important mechanism in immune resistance and limits the success of immunotherapy. One of promising approaches to activating therapeutic T-cell immune response is the blockade of these immune checkpoints (Pardoll 2012). Immune checkpoints represent significant barriers to activation of functional cellular immunity in cancer, and antagonistic antibodies specific for inhibitory ligands on T cells including CTLA4 and programmed death-1 (PD-1) are examples of targeted agents being evaluated in the clinics.

[0009] Cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4; also known as CD152) downregulates the amplitude of T cell activation and treatment with antagonist CTLA4 antibodies (ipilimumab) has shown a survival benefit in patients with melanoma (Robert and Mateus 2011). Programmed cell death protein 1 (PD1 or PDCD1 also known as CD279) represent another very promising target for immunotherapy (Pardoll and Drake 2012; Pardoll 2012). In contrast to CTLA-4, PD1 limits T cell effector functions in peripheral tissue at the time of an inflammatory response to infection and to limit autoimmunity. The first clinical trial with PD1 antibody shows some cases of tumour regression (Brahmer, Drake et al. 2010). Multiple additional immune checkpoint protein represent promising targets for therapeutic blockade based on recently studies.

[0010] In normal T-cells, T cell receptors emanate from the pre-T cell receptors (pTCR) which are expressed by immature thymocytes and are crucial for T cell development from the double negative (CD4- CD8-) to the double-positive (CD4+ CD8+) stages. Pre-T cells that succeed in productive rearrangements of the TCRbeta locus express a functional TCRbeta chain which pairs with an invariant preTalpha chain and CD3 signaling components to form the pre-TCR complex. The expression of the preTCR at the cell surface is necessary for triggering beta-selection, a process that induces the expansion of developing T cells, enforces allelic exclusion of the TCRbeta locus and results in the induction of rearrangements at the TCRalpha locus (von Boehmer 2005). After productive TCRalpha rearrangements and substitution of pTalpha by TCRalpha to form a mature TCR, thymocytes undergo a second step of selection, referred to as positive or TCRalpha/beta selection upon binding of self peptide MHC complexes expressed on thymic epithelial cells. Thus, mature T cells recognize and respond to the antigen/MHC complex through their TCR. The most immediate consequence of TCR activation is the initiation of signaling pathways via the associated CD3 subunits that result in multiple events including clonal expansion of T cells, upregulation of activation markers on the cell surface and induction of cytotoxicity or cytokine secretion.

[0011] Because of the nature of selection of TCRbeta chains through pairing with preTalpha during thymic development, in T cells in which TCRalpha has been inactivated, the heterologous introduction of the pTalpha transgene can result in the formation of a preTCR. This pTCR can serve as a means of T cell activation or stimulation in a manner that is non-MHC dependent, thus for example allowing continued expansion of alpha/beta T-cells following TCRalpha inactivation. Importantly, the pTCR complex displays a similar biochemical composition as the TCR in terms of associated CD3 subunits (Carrasco, Ramiro et al. 2001). In addition, in contrast to the TCR, pre-TCR signaling may occur in part by a ligand independent event. The crystal structure of the pTCR extracellular domain has provided a structural basis for the possible ligand-independence of pTCR signaling. The pTCR has been shown to form a head to tail dimer where two pTalpha-TCRbeta heterodimers associate (Pang, Berry et al. 2010).

[0012] In the present invention, the inventors have achieved the production of genetically modified T-cells, which overcome the limitations of present immunotherapy strategies, allowing them to be non-alloreactive and highly active. Although, the blockade of immune checkpoints has been realized using antibodies, another way to accomplish inhibition is by the inactivation of the expression of immune checkpoint genes in T cells that allow the production of engineered allogeneic T cells ideally as an "off the shelf" product. This was made possible by gene inactivation using specific TALE-nucleases directed against TCRalpha or TCRbeta coupled with inactivation of genes encoding immune checkpoint protein such as PD1 and CTLA-4.

[0013] In particular, the inactivation of TCRalpha or TCRbeta coupled with inactivation of immune checkpoint genes in

T lymphocytes derived from an allogeneic donor significantly reduces the risk of GVHD, by eliminating the TCR, responsible for recognition of MHC disparities, while permitting proliferation and activity of the introduced lymphocytes. Thus, these modified allogeneic T cells are expected to be highly active in patient's blood, where they can target tumor cells or infected cells.

[0014] In addition to the above conception of genetically modified T cells, which can be both non alloreactive and highly active, the inventors, by the use and design of specific TALE-nucleases, have concomitantly inactivated these different genes in T-cells, thereby obtaining double mutants. As a matter of fact, double gene targeting by DSB has been so far unachieved in T cells due to the difficulty of yielding and maintaining T-cells in culture over time, to their low transformation rates, and loss during selection procedures. These difficulties result in a low probability of success for obtaining such cells.

[0015] Thus, one significant part of the disclosure is to have designed specific TALE-nucleases, allowing higher rates of DSB events within the T-cells, which are well tolerated by the cells, (especially upon co-transfection), able to target the selection of genes according to the invention. By using rare-cutting endonucleases, such as the TALE-nucleases described therein, the probability of obtaining double inactivation of the genes in the transfected T-cells was significantly increased, so that it now appears possible to produce engineered T cells available from donors on a regular basis, using standard procedures.

[0016] In addition, the present disclosure proposes an embodiment where T-cells are engineered to allow proliferation when TCRalpha is inactivated. A significant problem with T-cells that have undergone TCR subunit inactivation is that the cells can no longer be expanded through the CD3 complex. To overcome this problem, means to expand T-cells in which TCRalpha has been inactivated through the CD3 complex are herein described, by expression of preTalpha in the cells, thus restoring a functional CD3 complex in the absence of a functional alpha/beta TCR.

[0017] According to the invention, T cells are further transformed with CAR to redirect allogeneic cells specificity towards tumor associated antigens independent of MHC. In particular, the invention relates to a multi-chain CAR, in which costimulatory domains are placed in their normal juxtamembrane positions to improve their functions and so enhance survival and increase proliferation of engineered T-cells. As a result, the invention provides methods, polypeptides and polynucleotides that allow the effective transformation of allogeneic T cells for adoptive immunotherapy, and their facile expansion.

Summary of the invention

[0018] In one aspect, the present invention discloses methods to engineer T cells, in particular allogeneic T cells obtainable from donors, to make them suitable for immunotherapy purposes. The methods of the present invention more particularly allow the precise modification of the genome of cells relevant for immunotherapy by inactivating or replacing genes involved in MHC recognition and/or immune checkpoint proteins. The modified cells relevant for immunotherapy further comprise exogenous recombinant polynucleotides encoding CARs for specific cell recognition. Present CARs are single fusion molecules that necessitate serial appending of signaling domains. Moving signaling domains from their natural juxtamembrane position may interfere with their function. Thus, to overcome this drawback, the inventors design a multi-chain CAR derived from FcεRI to allow normal juxtamembrane position of all relevant signaling domains. The high affinity IgE binding domain of FcεRI alpha chain is replaced by an extracellular ligand-binding domain such as scFv to redirect T-cell specificity to cell targets and the N and/or C-termini tails of FcεRI beta chain is used to place costimulatory signals in normal juxtamembrane positions.

[0019] In another aspect of the disclosure, in order to promote activation or stimulation of T cells in which TCRalpha has been inactivated, pTalpha or functional variant thereof are introduced into the engineered T-cells. The pTalpha or functional variant thereof used can be either full-length pTalpha, a splice variant (Saint-Ruf, Lechner et al. 1998), a C-terminal truncated version that has been shown to increase preTCR cell surface expression (Carrasco, Ramiro et al. 2001). Other additional truncations either smaller or larger than that described could be used. Different preTalpha versions may further comprise signaling moieties from other molecules (CD28, CD137, CD8, TCRalpha, etc.) to

promote proliferation and survival or comprise mutations that affect its ability to dimerize, such as the D22A, R24A, R102A or R117A mutations previously described in mice (Yamasaki, Ishikawa et al. 2006) or the W46R mutation described in humans (Pang, Berry et al. 2010) to decrease the proliferation potential. The scFv portion of the CAR may also be fused to the extracellular domain of a pTalpha or a functional variant thereof, thus coupling the specificity towards target antigens directly with the proliferative activity of the preTCR.

[0020] In another aspect, the present disclosure relates to the polypeptides and the polynucleotides, which encode the rare-cutting endonucleases, to precisely target the above genes of interest, in particular TCRalpha, TCRbeta, immune checkpoint genes, thereby enabling the genetic modification of the T-cells for immunotherapy. The present invention provides more particularly specific target sequences within these genes and TALE-nucleases designed to respectively target those genes.

[0021] The present disclosure also relates to the isolated cells or cell lines comprising any of the proteins, polypeptides or vectors described herein. In certain embodiments, the T cells of the present disclosure comprise inactivated TCRalpha, TCRbeta, immune checkpoint genes for their use in immunotherapy. The isolated cells of the present disclosure or cell lines can further comprise exogenous recombinant polynucleotides, in particular polynucleotides encoding pTalpha or functional variant thereof, CARs or multi-chain CARs.

[0022] In a preferred embodiment of the disclosure, the modified T cells are used as a therapeutic product, ideally as an "off the shelf" product.

[0023] In another aspect, the present disclosure concerns the method for treating or preventing cancer or infections in the patient by administering an engineered T-cell obtainable by the above methods.

Brief description of the figures and Tables

[0024] In addition to the preceding features, the disclosure further comprises other features which will emerge from the description which follows, as well as to the appended drawings. A more complete appreciation of the disclosure and many of the attendant advantages thereof will be readily obtained as the same becomes better understood by reference to the following Figures in conjunction with the detailed description.

Figure 1: Schematic representation of the normal relationship between T-cells and antigen presenting cell.

Figure 2: Schematic representation of the genetically modified therapeutic T-cells and the patient's tumor cells.

Figure 3: Schematic representation of multi-chain CAR.

Figure 4: Schematic of different versions of multi-chain CARs. A. Schematic of the FcεRI receptor. B-C Different versions of multi-chain CARs (csm1 to csm10) comprising a scFv and a CD8 stalk region fused to the transmembrane domain of FcεRI alpha chain. At least one 41BB, CD28 and/or CD3 zeta domains can be fused to a FcεRI alpha, beta and/or gamma chain.

Figure 5: Schematic representation of one example of the method of engineering human allogenic cells for immunotherapy

Figure 6: Concentration in cells per milliliter of live CD52-positive or CD52-negative cells after treatment with anti-CD52 antibody (CAMPATH1-H) with complement or controls.

Figure 7: Comparison of the forward side scatter (FSC) distribution, an indicator of cell size, between TCR-positive and TCR-negative cells, or between CD52-positive and CD52-negative cells, and non activated cells as control.

Figure 8: Flow cytometry analysis of CD107a expression (marker of degranulation) on targeted CD52 and TCRalpha inactivated T cells. CD107 expression is analyzed on CD52+TCRαβ+ cells (first column), CD52-TCRαβ- cells (second column), CD52-TCRαβ+ cells (third column) and CD52+TCRαβ- cells (fourth column) before (A) and after incubation with Daudi cells (B); C) represents flow cytometry analysis of T cells further transfected with a CAR and incubated with Daudi cells; D) represents flow cytometry analysis of T cells transfected with a CAR but not incubated with Daudi cells

and E) represents flow cytometry analysis of T cells transfected with a CAR and treated to PMA/ionomycin (positive control).

Figure 9: Deep sequencing analysis of CD52 and TRAC TALE-nucleases potential off-site targets.

Figure 10: Analysis of PDCD1 and CTLA-4 genomic locus by T7-endonuclease assay. Arrows point to digested PCR products.

Figure 11: Schematic representation of some examples of preTalpha constructs.

Figure 12: Flow cytometry analysis of transduction efficiency (% BFP+ cells) and activity of the FL, Δ18, Δ48 pTalpha constructs (% CD3 surface expression) in TCR alpha inactivated Jurkat cells.

Figure 13: Schematic representation of a lentiviral construct coding for pTalpha protein (preTCRα).

Figure 14: **A.** Representation of the experimental protocol. **B.** Flow cytometry analysis of TCR alpha/beta, CD3 expression and BFP expression on TCRalpha inactivated T cells (KO) transduced with either BFP-2A-pTalphaΔ48 (KO/Δ48) or control BFP lentiviral vector (KO/BFP) before and after purification. **C.** Flow cytometry analysis of TCR alpha/beta and CD3 expression on purified TCR alpha inactivated cells transduced (BFPpos) or not (BFPneg) with BFP-2A-pTalphaΔ48 lentiviral vector. NEP represents non electroporated cells with TRAC TALE-nucleases.

Figure 15: **A-B.** Flow cytometry analysis of early activation marker CD69 (A), late activation marker CD25 (B) expression 24 and 48 hours after re-activation with anti-CD3/CD28 beads respectively on non electroporated cells (NEP) and TCRalpha inactivated cells (KO) transduced with BFP-2A-pTα-Δ48 lentiviral vector (pTα-Δ48), BFP-2A-pTα-A48.41BB lentiviral vector (pTα-A48.BB) or control BFP vector (BFP). pTα-Δ48 histograms correspond to the signal detected in TCR inactivated cells expressing pTα-Δ48 (BFP+ cells) while the KO histograms correspond to TCRalpha inactivated cells which do not express pTα-Δ48 (BFP- cells) pTα-A48.BB histograms correspond to the signal detected in TCR inactivated cells expressing pTα-A48.41BB (BFP+ cells) while the KO histograms correspond to TCRalpha inactivated cells which do not express pTα-A48.41BB (BFP- cells). NEP (non electroporated) histograms correspond to signal detected in non engineered cells. **C.** Flow cytometry analysis of the size of cells 72 hours after re-activation with anti-CD3/CD28 beads on non electroporated cells (NEP) and TCRalpha inactivated cells (KO) transduced with BFP-2A-pTα-Δ48 lentiviral vector (pTα-A48), BFP-2A-pTα-A48.41BB lentiviral vector (pTα-A48.BB) or control BFP vector (BFP). The values indicated in the upper part of each graph correspond to the geometrical mean of the fluorescence of each population.

Figure 16: Cell growth analysis of TCR alpha inactivated cells (KO) transduced with pTalpha-Δ48 (pTaΔ48) or control BFP vector (BFP) maintained in IL2 or in IL2 with anti- CD3/CD28 beads at different time points (x-axis). The BFP+ cells number is estimated at different time points for each condition and the fold induction of these cells (y-axis) was estimated with respect to the value obtained at day 2 post re-activation. The results are obtained from two independent donors. For the second donor, cell growth was also determined for cells transduced with pTalpha-Δ48.41BB (pTa-Δ48.BB) and full-length pTalpha- (pTa-FL).

Figure 17: Flow cytometry analysis of GFP positive cells on PBMCs electroporated with the five different Cytopulse programs. The upper line corresponds to transfection of 6×10^6 cells per cuvette, while the lower line corresponds to transfection of 3×10^6 cells per cuvette.

Figure 18: Flow cytometry analysis of purified T cell mortality using viability dye (eFluor-450) and of GFP positive cells among the viable population after electroporation with GFP mRNA, GFP DNA and control pUC DNA. NEP corresponds to cells that were maintained in electroporation buffer but were not electroporated and NT corresponds to non electroporated cells maintained in culture medium.

Figure 19: Flow cytometry analysis of TCR alpha/beta and CD3 expression on human primary T cells following TRAC TALE-nuclease mRNA electroporation (top). Deep sequencing analysis of genomic DNA extracted from human primary T cells following TRAC TALE-nuclease mRNA electroporation (bottom).

Figure 20: **A.** Flow cytometry analysis of CAR expression (anti F(ab')₂) after electroporation of T cells with or without mRNA encoding a single chain CAR. **B.** Flow cytometry analysis of CD107a expression (marker of degranulation) on electroporated T cells cocultured with daudi cells.

Figure 21: **A.** Representation of mRNA encoding a multi-chain CAR. **B.** Flow cytometry analysis of CAR expression (anti F(ab')₂) on viable T cells electroporated with or without a polycistronic mRNA encoding a multi-chain CAR. **C.** Flow cytometry analysis of CD107a expression (marker of degranulation) on electroporated T cells cocultured with daudi cells.

Figure 22: Multi-chain CARs expression in human T cells after electroporation of polycistronic mRNAs.

Figure 23: The expression of the multi-subunit CARs is conditioned by the expression of the three chains: α , β and γ .

Figure 24: The human T cells transiently expressing the multi-chain CARs degranulate following coculture with target cells. **A:** csm1 to csm5 CAR constructs. **B:** csm6 to csm10 CAR constructs.

Figure 25: The human T cells transiently expressing the multi-chain CARs secrete cytokines following coculture with target cells (Tcells vs. Daudi cells or K562). **A:**IL8 release. **B:**IFN γ release. **C:**IL5 release.

Figure 26: The human T cells transiently expressing the multi-chain CARs (scm1 to csm10 constructs) lyse target cells.

Figure 27: CTLA4 inactivation in primary T cells measured by intracellular staining using fluorescent antibody and flow cytometry analysis.

Figure 28: distribution of fluorescent T-cells expressing CTLA4 upon transfection with TALENs T1, T2 and T3. Proportion of cells expressing CTLA4 is dramatically reduced with respect to control cells.

Figure 29: PD1 inactivation in primary T cells measured by intracellular staining using fluorescent antibody and flow cytometry analysis. Proportion of cells expressing PD1 is dramatically reduced with respect to control cells.

Figure 30: Diagram showing deletions frequencies observed in T-cells upon transfection with TALEN T01 and T03 targeting PD1 gene.

Figure 31 : Diagram showing that cytotoxic activity is enhanced in T-cells disrupted for PD1 as per the experiment described in Example 3.

Table 1: List of immune checkpoint genes identified by the inventors as appropriate to make allogeneic T-cells more active for immunotherapy.

Table 2: Description of the GR TALE-nucleases and sequences of the TALE-nucleases target sites in the human GR gene.

Table 3: Cleavage activity of the GR TALE-nucleases in yeast. Values are comprised between 0 and 1. Maximal value is 1.

Table 4: Percentage of targeted mutagenesis at endogenous TALE-nuclease target sites in 293 cells.

Table 5: Percentage of targeted mutagenesis at endogenous TALE-nuclease target sites in primary T lymphocytes.

Table 6: Description of the CD52, TRAC and TRBC TALE-nucleases and sequences of the TALE-nucleases target sites in the human corresponding genes.

Table 7: Additional target sequences for TRAC and CD52 TALE-nucleases.

Table 8: Percentage of indels for TALE-nuclease targeting CD52_T02, TRAC_T01, TRBC_T01 and TRBC_T02 targets.

Table 9: Percentages of CD52- negative, TCR-negative and CD52/TCR-double negative T lymphocytes after transfection of corresponding TALE-nuclease-expressing polynucleotides.

Table 10: Percentages of TCR-negative T lymphocytes after transfection of TRBC TALE-nuclease-expressing polynucleotides.

Table 11: Description of the CTLA4 and PDCD1 TALE-nucleases and sequences of the TALE-nucleases target sites

in the human corresponding genes.

Table 12: Description of a subset of pTalpha constructs.

Table 13: Activity of the different pTalpha constructs in Jurkat TCR alpha inactivated cell. Activity was measured by flow cytometry analysis of CD3 expression on jurkat TCR alpha inactivated cell transfected with the different preTalpha constructs.

Table 14: Different cytopulse programs used to determine the minimal voltage required for electroporation in PBMC derived T-cells.

Table 15: Cytopulse program used to electroporate purified T-cells.

Detailed description of the invention

[0025] Unless specifically defined herein, all technical and scientific terms used have the same meaning as commonly understood by a skilled artisan in the fields of gene therapy, biochemistry, genetics, and molecular biology.

[0026] All methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, with suitable methods and materials being described herein. In case of conflict, the present specification, including definitions, will prevail. Further, the materials, methods, and examples are illustrative only and are not intended to be limiting, unless otherwise specified.

[0027] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Current Protocols in Molecular Biology (Frederick M. AUSUBEL, 2000, Wiley and son Inc, Library of Congress, USA); Molecular Cloning: A Laboratory Manual, Third Edition, (Sambrook et al, 2001, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (B. D. Harries & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the series, Methods In ENZYMOLOGY (J. Abelson and M. Simon, eds.-in-chief, Academic Press, Inc., New York), specifically, Vols.154 and 155 (Wu et al. eds.) and Vol. 185, "Gene Expression Technology" (D. Goeddel, ed.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); and Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

[0028] In a general aspect, the present invention relates to methods for new adoptive immunotherapy strategies in treating cancer and infections.

Non alloreactive and highly active T cells for immunotherapy

[0029] In a particular aspect, the present disclosure relates to a method of engineering T-cells, especially for immunotherapy. In a particular embodiment, the method comprises:

1. (a) providing a T cell,
2. (b) introducing into said T cell a rare-cutting endonuclease able to selectively inactivate by DNA cleavage an immune checkpoint gene; and
3. (c) expanding said cells.

According to the invention, this method comprises:

- 1. (a) modifying T-cells by inactivating at least:
 - a first gene encoding an immune checkpoint protein selected amongst PD1, CTLA-4, LAG3, Tim3, BTLA, BY55, TIGIT, B7H5, LAIR1, SIGLEC10 and 2B4, and
 - a second gene encoding a component of the T-cell receptor (TCR);
- 2. (b) Introducing into said T cell(s) a chimeric antigen receptor (CAR); and
- 3. (c) expanding said cells.

[0030] T cell-mediated immunity includes multiple sequential steps involving the clonal selection of antigen specific cells, their activation and proliferation in secondary lymphoid tissue, their trafficking to sites of antigen and inflammation, the execution of direct effector function and the provision of help (through cytokines and membrane ligands) for a multitude of effector immune cells. Each of these steps is regulated by counterbalancing stimulatory and inhibitory signal that fine-tune the response. It will be understood by those of ordinary skill in the art, that the term "immune checkpoints" means a group of molecules expressed by T cells. These molecules effectively serve as "brakes" to down-modulate or inhibit an immune response. Immune checkpoint molecules include, but are not limited to Programmed Death 1 (PD-1, also known as PDCD1 or CD279, accession number: NM_005018), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4, also known as CD152, GenBank accession number AF414120.1), LAG3 (also known as CD223, accession number: NM_002286.5), Tim3 (also known as HAVCR2, GenBank accession number: JX049979.1), BTLA (also known as CD272, accession number: NM_181780.3), BY55 (also known as CD160, GenBank accession number: CR541888.1), TIGIT (also known as VSTM3, accession number: NM_173799), B7H5 (also known as C10orf54, homolog of mouse vista gene, accession number: NM_022153.1), LAIR1 (also known as CD305, GenBank accession number: CR542051.1), SIGLEC10 (GeneBank accession number: AY358337.1), 2B4 (also known as CD244, accession number: NM_001166664.1), which directly inhibit immune cells. For example, CTLA-4 is a cell-surface protein expressed on certain CD4 and CD8 T cells; when engaged by its ligands (B7-1 and B7-2) on antigen presenting cells, T-cell activation and effector function are inhibited. Thus the present invention relates to a method of engineering T-cells, especially for immunotherapy, comprising genetically modifying T-cells by inactivating at least one protein involved in the immune check-point, in particular PD1 and/or CTLA-4.

[0031] In a particular embodiment, the genetic modification step of the method relies on the inactivation of two genes selected from the group consisting of PD1, CTLA-4, LAG3, Tim3, BTLA, BY55, TIGIT, B7H5, LAIR1, SIGLEC10, 2B4, TCR alpha and TCR beta. In another embodiment, the genetic modification step of the method relies on the inactivation of two genes selected from the group consisting of PD1 and TCR alpha, PD1 and TCR beta, CTLA-4 and TCR alpha, CTLA-4 and TCR beta, LAG3 and TCR alpha, LAG3 and TCR beta, Tim3 and TCR alpha, Tim3 and TCR beta, BTLA and TCR alpha, BTLA and TCR beta, BY55 and TCR alpha, BY55 and TCR beta, TIGIT and TCR alpha, TIGIT and TCR beta, B7H5 and TCR alpha, B7H5 and TCR beta, LAIR1 and TCR alpha, LAIR1 and TCR beta, SIGLEC10 and TCR alpha, SIGLEC10 and TCR beta, 2B4 and TCR alpha, 2B4 and TCR beta. In another embodiment of the disclosure, the genetic modification step of the method relies on the inactivation of more than two genes. The genetic modification is preferably operated ex-vivo.

[0032] Table 1 below, without being exhaustive, shows immune checkpoint genes that can be inactivated according to the teaching of the present text in order to improve the efficiency and fitness of the engineered T-cells. The immune checkpoints gene are preferably selected from such genes having identity to those listed in this table involved into co-inhibitory receptor function, cell death, cytokine signaling, arginine tryptophan starvation, TCR signaling, Induced T-reg repression, transcription factors controlling exhaustion or anergy, and hypoxia mediated tolerance.

Table 1: Immune checkpoint genes appropriate to make allogeneic T-cells more active for immunotherapy

Pathway	Genes that can be inactivated in pathway	NCBI database gene ID (<i>Homo sapiens</i>) on May 13 th , 2014
	LAG3 (CD223)	3902
	HAVCR2 (TIM3)	84868
	BTLA (CD272)	151888
	CD160 (NK1)	11126

<u>Pathway</u>	Genes that can be inactivated in pathway	NCBI database gene ID (<i>Homo sapiens</i>) on May 13th, 2014
Co-inhibitory receptors	TIGIT (VSIG9)	201633
	CD96 (TACTILE)	10225
	CRTAM (CD355)	56253
	LAIR1 (CD305)	3903
	SIGLEC7 (CD328)	27036
	A2A (IGKV2-29)	28882
	SIGLEC9 (CD329)	27180
	CD244 (2B4))	51744
Cell death	TNFRSF10B (CD262)	8795
	TNFRSF10A (CD261)	8797
	CASP3	836
	CASP6	839
	CASP7	840
	CASP8	841
	CASP10	843
	Arhgap5 (GFI2)	394
	Akap8i	10270
	FADD (GIG3)	8772
	FAS(RP11)	355
	Stk17b (DRAK2)	9262
	TGFBRII (AAT3)	7048
	TGFBRI	7046
	SMAD2 (JV18)	4087
	SMAD3	4088
	SMAD4	4089
	SMAD10 (SMAD7)	394331
Cytokine signalling	SKI (SGS)	6497
	SKIL (SNO)	6498
	TGIF1 (HPE4)	7050
	IL10RA (CD210)	3587
	IL10RB	3588
	HMOX2 (HO-2)	3163
	Jun (AP1)	3725
	Ppp3cc	5533
	Ppm1g	5496
	Socs1	8651
	Soc3	9021
	IL6R (CD126)	3570
	IL6ST (CD130)	3572
	Lck	3932
	Fyn	2534
	ADAP (FYB)	2533

<u>Pathway</u>	Genes that can be inactivated in pathway	NCBI database gene ID (<i>Homo sapiens</i>) on May 13th, 2014
	Carmal (CARD11)	84433
	Bcl10	8915
	Malt1 (IMD12)	10892
	TAK1(NR2C2)	7182
arginine/tryptophan starvation	EIF2AK4 (GCN2)	440275
	Nuak2	81788
	CSK	1445
	PAG1 (CBP)	55824
	SIT1	27240
	CRTAM (CD355)	56253
	Egr2 (AT591)	1959
	DGK-a (DAGK)	1606
	DGK-z	8525
TCR signalling	Cblb	868
	Inpp5b	3633
	Ptpn2 (PTN2)	5771
	Vamp7	6845
	Mast2	23139
	tnk1	8711
	stk17b (DRAK2)	9262
	Mdfic (HIC)	29969
	F11r (CD321)	50848
Induced Treg	FOXP3 (JM2)	50943
	Entpd1 (CD39)	953
Transcription factors controlling exhaustion/anergy	PRDM1 (blimp1)	12142
	BATF	10538
	Ypel2	388403
	Ppp2r2d	55844
	Rock1	6093
	Sbf1	6305
	Hipk1 (MYAK)	204851
	Map3k3	4215
	Grk6	2870
	Elf2ak3 (PEK)	9451
	Fyn	2534
	NFAT1(NFATC2)	4773
Hypoxia mediated tolerance	GUCY1A2	2977
	GUCY1A3	2982
	GUCY1B2	2974
	GUCY1B3	2983

[0033] By inactivating a gene it is intended that the gene of interest is not expressed in a functional protein form. In

particular embodiment, the genetic modification of the method relies on the expression, in provided cells to engineer, of one rare-cutting endonuclease such that said rare-cutting endonuclease specifically catalyzes cleavage in one targeted gene thereby inactivating said targeted gene. The nucleic acid strand breaks caused by the rare-cutting endonuclease are commonly repaired through the distinct mechanisms of homologous recombination or non-homologous end joining (NHEJ). However, NHEJ is an imperfect repair process that often results in changes to the DNA sequence at the site of the cleavage. Mechanisms involve rejoining of what remains of the two DNA ends through direct re-ligation (Critchlow and Jackson 1998) or via the so-called microhomology-mediated end joining (Ma, Kim et al. 2003). Repair via non-homologous end joining (NHEJ) often results in small insertions or deletions and can be used for the creation of specific gene knockouts. Said modification may be a substitution, deletion, or addition of at least one nucleotide. Cells in which a cleavage-induced mutagenesis event, i.e a mutagenesis event consecutive to an NHEJ event, has occurred can be identified and/or selected by well-known method in the art.

[0034] In a particular embodiment, said method to engineer cells comprises at least one of the following steps:

1. (a) providing a T-cell, preferably from a cell culture or from a blood sample;
2. (b) introducing into said T-cell a rare-cutting endonuclease able to selectively inactivate by DNA cleavage, preferably by double-strand break respectively:
 - said gene encoding a immune checkpoint protein, and
 - at least one gene encoding a component of the T-cell receptor (TCR).
3. (c) expanding said cells.

In a more preferred embodiment, said method comprises:

1. (a) providing a T-cell, preferably from a cell culture or from a blood sample;
2. (b) transforming said T cell with nucleic acid encoding a rare-cutting endonuclease able to selectively inactivate by DNA cleavage, preferably by double-strand break respectively:
 - said gene encoding a immune checkpoint protein and
 - at least one gene encoding a component of the T-cell receptor (TCR)
3. (c) expressing said rare-cutting endonucleases into said T-cells;
4. (d) sorting the transformed T-cells, which do not express TCR on their cell surface;
5. (e) expanding said cells.

[0035] In particular embodiment, said rare-cutting endonuclease specifically targets one gene selected from the group consisting of: PD1, CTLA-4, LAG3, Tim3, BTLA, BY55, TIGIT, B7H5, LAIR1, SIGLEC10, 2B4, TCR alpha and TCR beta. In another embodiment, the genetic modification of the method relies on the expression, in provided cells to engineer, of two rare-cutting endonucleases such that said each of the two rare-cutting endonucleases specifically and respectively catalyzes cleavage in each of the pairs of genes selected from the group consisting of PD1 and TCR alpha, PD1 and TCR beta, CTLA-4 and TCR alpha, CTLA-4 and TCR beta, LAG3 and TCR alpha, LAG3 and TCR beta, Tim3 and TCR alpha, Tim3 and TCR beta, BTLA and TCR alpha, BTLA and TCR beta, BY55 and TCR alpha, BY55 and TCR beta, TIGIT and TCR alpha, TIGIT and TCR beta, B7H5 and TCR alpha, B7H5 and TCR beta, LAIR1 and TCR alpha, LAIR1 and TCR beta, SIGLEC10 and TCR alpha, SIGLEC10 and TCR beta, 2B4 and TCR alpha, 2B4 and TCR beta, thereby inactivating said targeted genes. In another embodiment of the disclosure, more than two rare-cutting endonucleases can be expressed in cells to engineer in order to target and/or inactivate more than two genes.

[0036] In another embodiment of the disclosure, said rare-cutting endonuclease can be a meganuclease, a Zinc finger nuclease or a TALE-nuclease. In a preferred embodiment, said rare-cutting endonuclease is a TALE-nuclease. By TALE-nuclease is intended a fusion protein consisting of a DNA-binding domain derived from a Transcription Activator Like Effector (TALE) and one nuclease catalytic domain to cleave a nucleic acid target sequence. (Boch, Scholze et al. 2009; Moscou and Bogdanove 2009; Christian, Cermak et al. 2010; Cermak, Doyle et al. 2011; Geissler, Scholze et al. 2011; Huang, Xiao et al. 2011; Li, Huang et al. 2011; Mahfouz, Li et al. 2011; Miller, Tan et al. 2011; Morbitzer, Romer et al. 2011; Mussolino, Morbitzer et al. 2011; Sander, Cade et al. 2011; Tesson, Usal et al. 2011; Weber, Gruetzner et al. 2011; Zhang, Cong et al. 2011; Deng, Yan et al. 2012; Li, Piatek et al. 2012; Mahfouz, Li et al. 2012; Mak, Bradley et al. 2012).

[0037] In the present disclosure new TALE-nucleases have been designed for precisely targeting relevant genes for adoptive immunotherapy strategies. Preferred TALE-nucleases according to the invention are those recognizing and cleaving the target sequence selected from the group consisting of: SEQ ID NO: 77 and SEQ ID NO: 78 (PD1), SEQ ID NO: 74 to SEQ ID NO: 76 (CTLA-4), SEQ ID NO: 37, 57 to 60 (TCRalpha), SEQ ID NO: 38 or 39 (TCRbeta). The present disclosure also relates to TALE-nuclease polypeptides which comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 79 to SEQ ID NO: 88 and SEQ ID NO: 41 to 46.

[0038] The present disclosure also relates to polypeptides comprising an amino acid sequence that has at least 70%, preferably at least 80%, more preferably at least 90 %, 95 % 97 % or 99 % sequence identity with amino acid sequence selected from the group consisting of SEQ ID NO: 79 to SEQ ID NO: 88. Are also described herein, polynucleotides, vectors encoding the above described rare-cutting endonucleases. This method can be associated with any one of the different methods described in the present disclosure.

[0039] In another embodiment of the disclosure, additional catalytic domain can be further introduced into the cell with said rare-cutting endonuclease to increase mutagenesis in order to enhance their capacity to inactivate targeted genes. In particular, said additional catalytic domain is a DNA end processing enzyme. Non limiting examples of DNA end-processing enzymes include 5-3' exonucleases, 3-5' exonucleases, 5-3' alkaline exonucleases, 5' flap endonucleases, helicases, hosphatase, hydrolases and template-independent DNA polymerases. Non limiting examples of such catalytic domain comprise of a protein domain or catalytically active derivate of the protein domain selected from the group consisting of hExoI (EXO1_HUMAN), Yeast ExoI (EXO1_YEAST), E.coli ExoI, Human TREX2, Mouse TREX1, Human TREX1, Bovine TREX1, Rat TREX1, TdT (terminal deoxynucleotidyl transferase) Human DNA2, Yeast DNA2 (DNA2_YEAST). In a preferred embodiment of the disclosure, said additional catalytic domain has a 3'-5'-exonuclease activity, and in a more preferred embodiment, said additional catalytic domain is TREX, more preferably TREX2 catalytic domain (WO2012/058458). In another preferred embodiment of the disclosure, said catalytic domain is encoded by a single chain TREX polypeptide (WO2013/009525). Said additional catalytic domain may be fused to a nuclease fusion protein or chimeric protein optionally by a peptide linker.

[0040] Endonucleolytic breaks are known to stimulate the rate of homologous recombination. Thus, in another embodiment of the disclosure, the genetic modification step of the method further comprises a step of introduction into cells an exogenous nucleic acid comprising at least a sequence homologous to a portion of the target nucleic acid sequence, such that homologous recombination occurs between the target nucleic acid sequence and the exogenous nucleic acid. In particular embodiments, said exogenous nucleic acid comprises first and second portions which are homologous to region 5' and 3' of the target nucleic acid sequence, respectively. Said exogenous nucleic acid in these embodiments also comprises a third portion positioned between the first and the second portion which comprises no homology with the regions 5' and 3' of the target nucleic acid sequence. Following cleavage of the target nucleic acid sequence, a homologous recombination event is stimulated between the target nucleic acid sequence and the exogenous nucleic acid. Preferably, homologous sequences of at least 50 bp, preferably more than 100 bp and more preferably more than 200 bp are used within said donor matrix. Therefore, the exogenous nucleic acid is preferably from 200 bp to 6000 bp, more preferably from 1000 bp to 2000 bp. Indeed, shared nucleic acid homologies are located in regions flanking upstream and downstream the site of the break and the nucleic acid sequence to be introduced should be located between the two arms.

[0041] In particular, said exogenous nucleic acid successively comprises a first region of homology to sequences upstream of said cleavage, a sequence to inactivate one targeted gene selected from the group consisting of immune checkpoint genes, TCR alpha and TCR beta and a second region of homology to sequences downstream of the cleavage. Said polynucleotide introduction step can be simultaneous, before or after the introduction or expression of said rare-cutting endonuclease. Depending on the location of the target nucleic acid sequence wherein break event has occurred, such exogenous nucleic acid can be used to knock-out a gene, e.g. when exogenous nucleic acid is located within the open reading frame of said gene, or to introduce new sequences or genes of interest. Sequence insertions by using such exogenous nucleic acid can be used to modify a targeted existing gene, by correction or replacement of said gene (allele swap as a non-limiting example), or to up- or down-regulate the expression of the targeted gene (promoter swap as non-limiting example), said targeted gene correction or replacement. In preferred embodiment, inactivation of genes from the group consisting of immune checkpoint genes, TCR alpha and TCR beta can be done at a precise genomic location targeted by a specific TALE-nuclease, wherein said specific TALE-

nuclease catalyzes a cleavage and wherein said exogenous nucleic acid successively comprising at least a region of homology and a sequence to inactivate one targeted gene selected from the group consisting of immune checkpoint genes, TCR alpha and TCR beta which is integrated by homologous recombination. In another embodiment of the disclosure, several genes can be, successively or at the same time, inactivated by using several TALE-nucleases respectively and specifically targeting one defined gene and several specific polynucleotides for specific gene inactivation.

[0042] By additional genomic modification step, can be intended also the inactivation of another gene selected from the group consisting of immune checkpoint genes, TCR alpha and TCR beta. As mentioned above, said additional genomic modification step can be an inactivation step comprising:

1. (a) introducing into said cells at least one rare-cutting endonuclease such that said rare-cutting endonuclease specifically catalyzes cleavage in one targeted sequence of the genome of said cell.
2. (b) Optionally introducing into said cells a exogenous nucleic acid successively comprising a first region of homology to sequences upstream of said cleavage, a sequence to be inserted in the genome of said cell and a second region of homology to sequences downstream of said cleavage,

wherein said introduced exogenous nucleic acid inactivates a gene and integrates at least one exogenous polynucleotide sequence encoding at least one recombinant protein of interest. In another embodiment of the disclosure, said exogenous polynucleotide sequence is integrated within a gene selected from the group consisting of immune checkpoint genes, TCR alpha and TCR beta.

[0043] In particular embodiment of the disclosure, said method to engineer cell further comprises an additional genomic modification step. By additional genomic modification step, can be intended the introduction into cells to engineer of one protein of interest. Said protein of interest can be, as non limiting examples, pTalpha or functional variant thereof, a Chimeric Antigen Receptor (CAR), a multi-chain CAR, a bispecific antibody as described in the present disclosure. Said method to engineer cell can also further comprises the introduction of rare-cutting endonuclease able to selectively inactivate by DNA cleavage a gene encoding a target for said immunosuppressive agent as described in the present disclosure.

[0044] The disclosure also relates to TALE-nucleases. Generally, the disclosure relates to TALE-nuclease comprising:

1. (a) A Transcription Activator-Like Effector (TALE) DNA binding domain that has been engineered to bind a target sequence within genes selected from the group consisting of immune checkpoint genes, TCR alpha and TCR beta;
2. (b) A cleavage domain or a cleavage half-domain.

[0045] Preferred TALE-nucleases according to the disclosure are those recognizing and cleaving the target sequence selected from the group consisting of:

- SEQ ID NO: 77 and SEQ ID NO: 78 (PD1)
- SEQ ID NO: 74 to SEQ ID NO: 76 (CTLA-4),
- SEQ ID NO: 37, 57 to 60 (TCRalpha), and
- SEQ ID NO: 38 or 39 (TCRbeta),

[0046] Said TALE-nucleases preferably comprise a polypeptide sequence selected from the group consisting of SEQ ID NO: 79 to SEQ ID NO: 88 in order to cleave the respective target SEQ ID NO: 74 to 78 and SEQ ID NO: 41 to SEQ ID NO: 46, in order to cleave the respective target sequences SEQ ID NO: 37 to 39.

[0047] Because some variability may arise from the genomic data from which these polypeptides derive, and also to take into account the possibility to substitute some of the amino acids present in these polypeptides without significant loss of activity (functional variants), polypeptides variants of the above polypeptides are also described, that share at least 70%, preferably at least 80 %, more preferably at least 90 % and even more preferably at least 95 % identity

with the sequences provided herein.

[0048] The present disclosure is thus drawn to polypeptides comprising a polypeptide sequence that has at least 70%, preferably at least 80%, more preferably at least 90 %, 95 % 97 % or 99 % sequence identity with amino acid sequence selected from the group consisting of SEQ ID NO: 79 to SEQ ID NO: 88 and SEQ ID NO: 41 to SEQ ID NO: 46.

[0049] Are also comprised in the scope of the present disclosure, polynucleotides, vectors encoding the above described rare-cutting endonucleases.

[0050] In the scope of the present disclosure are also encompassed isolated cells or cell lines susceptible to be obtained by said method to engineer cells, in particular T cells, in which at least one gene selected from the group consisting of immune checkpoint genes, preferably genes selected from the group of: PD1, CTLA-4, LAG3, Tim3, BTLA, BY55, TIGIT, B7H5, LAIR1, SIGLEC10, 2B4, TCR alpha and TCR beta has been inactivated. Preferably, two genes selected from the group consisting of: PD1 and TCR alpha, PD1 and TCR beta, CTLA-4 and TCR alpha, CTLA-4 and TCR beta, LAG3 and TCR alpha, LAG3 and TCR beta, Tim3 and TCR alpha, Tim3 and TCR beta, BTLA and TCR alpha, BTLA and TCR beta, BY55 and TCR alpha, BY55 and TCR beta, TIGIT and TCR alpha, TIGIT and TCR beta, B7H5 and TCR alpha, B7H5 and TCR beta, LAIR1 and TCR alpha, LAIR1 and TCR beta, SIGLEC10 and TCR alpha, SIGLEC10 and TCR beta, 2B4 and TCR alpha, 2B4 and TCR beta have been inactivated.

[0051] According to the disclosure, those genes are preferably inactivated by at least one rare-cutting endonuclease. It has been shown by the inventors that the use of TALE-nucleases was particularly advantageous to achieve double inactivation in T-cells. The disclosure encompasses an isolated T-cell comprising at least two polynucleotides, said polynucleotides encoding at least a first and second TALE-nucleases, preferably the first TALE-nuclease being directed against a gene encoding TCR and the second being directed against a gene encoding a immune checkpoint protein, such as PD1, CTLA-4, LAG3, Tim3, BTLA, BY55, TIGIT, B7H5, LAIR1, SIGLEC10, 2B4. In another embodiment of the disclosure, said isolated cell further comprises one additional genomic modification. In another embodiment, of the disclosure said additional genomic modification is the integration of at least one exogenous polynucleotide sequence. In another embodiment, said exogenous sequence is integrated into one gene selected from the group consisting of PD1, CTLA-4, LAG3, Tim3, BTLA, BY55, TIGIT, B7H5, LAIR1, SIGLEC10, 2B4, TCR alpha and TCR beta.

Non alloreactive and immunosuppressive resistant T cells:

[0052] In a particular aspect of the disclosure, the present invention relates to a method of engineering T-cells, especially for immunotherapy. In particular this method comprises:

1. (a) modifying T-cells by inactivating at least:
 - A first gene expressing a target for an immunosuppressive agent, and
 - A second gene encoding a component of the T-cell receptor (TCR) (b) Expanding said cells, optionally in presence of said immunosuppressive agent.

[0053] An immunosuppressive agent is an agent that suppresses immune function by one of several mechanisms of action. In other words, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. As non limiting example, an immunosuppressive agent can be a calcineurin inhibitor, a target of rapamycin, an interleukin-2 α -chain blocker, an inhibitor of inosine monophosphate dehydrogenase, an inhibitor of dihydrofolic acid reductase, a corticosteroid or an immunosuppressive antimetabolite. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. The method according to the disclosure allows conferring immunosuppressive resistance to T cells for immunotherapy by inactivating the target of the immunosuppressive agent in T cells. As non limiting examples, targets for immunosuppressive agent can be a receptor for an immunosuppressive agent such as: CD52, glucocorticoid receptor (GR), a FKBP family gene member

and a cyclophilin family gene member.

[0054] In a particular embodiment of the disclosure, the genetic modification step of the method relies on the inactivation of one gene selected from the group consisting of CD52, GR, TCR alpha and TCR beta. In another embodiment of the disclosure, the genetic modification step of the method relies on the inactivation of two genes selected from the group consisting of CD52 and GR, CD52 and TCR alpha, CDR52 and TCR beta, GR and TCR alpha, GR and TCR beta, TCR alpha and TCR beta. In another embodiment of the disclosure, the genetic modification step of the method relies on the inactivation of more than two genes. The genetic modification is preferably operated ex-vivo.

[0055] By inactivating a gene it is intended that the gene of interest is not expressed in a functional protein form. In particular embodiment of the disclosure, the genetic modification of the method relies on the expression, in provided cells to engineer, of one rare-cutting endonuclease such that said rare-cutting endonuclease specifically catalyzes cleavage in one targeted gene thereby inactivating said targeted gene. In a particular embodiment of the disclosure, said method to engineer cells comprises at least one of the following steps:

1. (a) Providing a T-cell, preferably from a cell culture or from a blood sample;
2. (b) Selecting a gene in said T-cell expressing a target for an immunosuppressive agent;
3. (c) Introducing into said T-cell a rare-cutting endonuclease able to selectively inactivate by DNA cleavage, preferably by double-strand break respectively:
 - said gene encoding a target for said immunosuppressive agent, and
 - at least one gene encoding a component of the T-cell receptor (TCR).
4. (d) Expanding said cells, optionally in presence of said immunosuppressive agent.

[0056] In a more preferred embodiment of the disclosure, said method comprises:

1. (a) Providing a T-cell, preferably from a cell culture or from a blood sample;
2. (b) Selecting a gene in said T-cell expressing a target for an immunosuppressive agent;
3. (c) Transforming said T cell with nucleic acid encoding a rare-cutting endonuclease able to selectively inactivate by DNA cleavage, preferably by double-strand break respectively:
 - said gene encoding a target for said immunosuppressive agent, and
 - at least one gene encoding a component of the T-cell receptor (TCR);
4. (d) Expressing said rare-cutting endonucleases into said T-cells;
5. (e) Sorting the transformed T-cells, which do not express TCR on their cell surface;
6. (f) Expanding said cells, optionally in presence of said immunosuppressive agent.

[0057] In particular embodiment of the disclosure, said rare-cutting endonuclease specifically targets one gene selected from the group consisting of CD52, GR, TCR alpha and TCR beta. In another embodiment of the disclosure, the genetic modification of the method relies on the expression, in provided cells to engineer, of two rare-cutting endonucleases such that said each of the two rare-cutting endonucleases specifically and respectively catalyzes cleavage in each of the pairs of genes selected from the group consisting of CD52 and GR, CD52 and TCR alpha, CDR52 and TCR beta, GR and TCR alpha, GR and TCR beta, TCR alpha and TCR beta, thereby inactivating said targeted genes. In another embodiment of the disclosure, more than two rare-cutting endonucleases can be expressed in cells to engineer in order to target and/or inactivate more than two genes.

[0058] In another embodiment of the disclosure, said gene of step (b), specific for an immunosuppressive treatment, is CD52 and the immunosuppressive treatment of step (d) or (e) comprises a humanized antibody targeting CD52 antigen.

[0059] In another embodiment of the disclosure, said gene of step (b), specific for an immunosuppressive treatment, is a glucocorticoid receptor (GR) and the immunosuppressive treatment of step d) or (e) comprises a corticosteroid such as dexamethasone.

[0060] In another embodiment of the disclosure, said target gene of step (b), specific for an immunosuppressive treatment, is a FKBP family gene member or a variant thereof and the immunosuppressive treatment of step (d) or (e) comprises FK506 also known as Tacrolimus or fujimycin. In another embodiment of the disclosure, said FKBP family gene member is FKBP12 or a variant thereof.

[0061] In another embodiment of the disclosure, said gene of step (b), specific for an immunosuppressive treatment, is a cyclophilin family gene member or a variant thereof and the immunosuppressive treatment of step (d) or (e) comprises cyclosporine.

[0062] In another embodiment of the disclosure, said rare-cutting endonuclease can be a meganuclease, a Zinc finger nuclease or a TALE-nuclease. In a preferred embodiment of the disclosure, said rare-cutting endonuclease is a TALE-nuclease. Preferred TALE-nucleases are those recognizing and cleaving the target sequence selected from the group consisting of:

- SEQ ID NO: 1 to 6 (GR),
- SEQ ID NO: 37, 57 to 60 (TCRalpha),
- SEQ ID NO: 38 or 39 (TCRbeta), and
- SEQ ID NO: 40, 61 to 65 (CD52)

[0063] Said TALE-nucleases preferably comprise a polypeptide sequence selected from SEQ ID NO: 7 to SEQ ID NO: 18 and SEQ ID NO: 41 to SEQ ID NO: 48, in order to cleave the respective target sequences SEQ ID NO: 1 to 6 and SEQ ID NO: 37 to 40.

[0064] In another embodiment of the disclosure, additional catalytic domain can be further introduced into the cell with said rare-cutting endonuclease to increase mutagenesis in order to enhance their capacity to inactivate targeted genes. In particular, said additional catalytic domain is a DNA end processing enzyme. Non limiting examples of DNA end-processing enzymes include 5-3' exonucleases, 3-5' exonucleases, 5-3' alkaline exonucleases, 5' flap endonucleases, helicases, phosphatase, hydrolases and template-independent DNA polymerases. Non limiting examples of such catalytic domain comprise of a protein domain or catalytically active derivate of the protein domain selected from the group consisting of hExo1 (EXO1_HUMAN), Yeast Exo1 (EXO1_YEAST), E.coli Exo1, Human TREX2, Mouse TREX1, Human TREX1, Bovine TREX1, Rat TREX1, TdT (terminal deoxynucleotidyl transferase) Human DNA2, Yeast DNA2 (DNA2_YEAST). In a preferred embodiment of the disclosure, said additional catalytic domain has a 3'-5'-exonuclease activity, and in a more preferred embodiment of the disclosure, said additional catalytic domain is TREX, more preferably TREX2 catalytic domain (WO2012/058458). In another preferred embodiment of the disclosure, said catalytic domain is encoded by a single chain TREX polypeptide. Said additional catalytic domain may be fused to a nuclease fusion protein or chimeric protein according to the invention optionally by a peptide linker.

[0065] Endonucleolytic breaks are known to stimulate the rate of homologous recombination. Thus, in another embodiment of the disclosure, the genetic modification step of the method further comprises a step of introduction into cells an exogenous nucleic acid comprising at least a sequence homologous to a portion of the target nucleic acid sequence, such that homologous recombination occurs between the target nucleic acid sequence and the exogenous nucleic acid. In particular embodiments, said exogenous nucleic acid comprises first and second portions which are homologous to region 5' and 3' of the target nucleic acid sequence, respectively. Said exogenous nucleic acid in these embodiments also comprises a third portion positioned between the first and the second portion which comprises no homology with the regions 5' and 3' of the target nucleic acid sequence. Following cleavage of the target nucleic acid sequence, a homologous recombination event is stimulated between the target nucleic acid sequence and the exogenous nucleic acid. Preferably, homologous sequences of at least 50 bp, preferably more than 100 bp and more preferably more than 200 bp are used within said donor matrix. Therefore, the exogenous nucleic acid is preferably from 200 bp to 6000 bp, more preferably from 1000 bp to 2000 bp. Indeed, shared nucleic acid homologies are located in regions flanking upstream and downstream the site of the break and the nucleic acid sequence to be introduced should be located between the two arms.

[0066] In particular, said exogenous nucleic acid successively comprises a first region of homology to sequences

upstream of said cleavage, a sequence to inactivate one targeted gene selected from the group consisting of CD52, GR, TCR alpha and TCR beta and a second region of homology to sequences downstream of the cleavage. Said polynucleotide introduction step can be simultaneous, before or after the introduction or expression of said rare-cutting endonuclease. Depending on the location of the target nucleic acid sequence wherein break event has occurred, such exogenous nucleic acid can be used to knock-out a gene, e.g. when exogenous nucleic acid is located within the open reading frame of said gene, or to introduce new sequences or genes of interest. Sequence insertions by using such exogenous nucleic acid can be used to modify a targeted existing gene, by correction or replacement of said gene (allele swap as a non-limiting example), or to up- or down-regulate the expression of the targeted gene (promoter swap as non-limiting example), said targeted gene correction or replacement. In preferred embodiment of the disclosure, inactivation of genes from the group consisting of CD52, GR, TCR alpha and TCR beta can be done at a precise genomic location targeted by a specific TALE-nuclease, wherein said specific TALE-nuclease catalyzes a cleavage and wherein said exogenous nucleic acid successively comprising at least a region of homology and a sequence to inactivate one targeted gene selected from the group consisting of CD52, GR, TCR alpha and TCR beta which is integrated by homologous recombination. In another embodiment of the disclosure, several genes can be, successively or at the same time, inactivated by using several TALE-nucleases respectively and specifically targeting one defined gene and several specific polynucleotides for specific gene inactivation.

[0067] By additional genomic modification step, can be intended also the inactivation of another gene selected from the group consisting of CD52, GR, TCR alpha and TCR beta. As mentioned above, said additional genomic modification step can be an inactivation step comprising:

1. (a) introducing into said cells at least one rare-cutting endonuclease such that said rare-cutting endonuclease specifically catalyzes cleavage in one targeted sequence of the genome of said cell.
2. (b) Optionally introducing into said cells a exogenous nucleic acid successively comprising a first region of homology to sequences upstream of said cleavage, a sequence to be inserted in the genome of said cell and a second region of homology to sequences downstream of said cleavage,

wherein said introduced exogenous nucleic acid inactivates a gene and integrates at least one exogenous polynucleotide sequence encoding at least one recombinant protein of interest. In another embodiment, said exogenous polynucleotide sequence is integrated within a gene selected from the group consisting of CD52, GR, TCR alpha and TCR beta.

[0068] In particular embodiment of the disclosure said method to engineer cell further comprises an additional genomic modification step. By additional genomic modification step, can be intended the introduction into cells to engineer of one protein of interest. Said protein of interest can be, as non limiting examples, pTalpha or functional variant thereof, a Chimeric Antigen Receptor (CAR), a multi-chain CAR, a bispecific antibody or rare-cutting endonuclease targeting PDCD1 or CTLA-4 as described in the present disclosure.

[0069] The disclosure also relates to TALE-nucleases. Generally, the disclosure relates to TALE-nuclease comprising:

1. (a) A Transcription Activator-Like Effector (TALE) DNA binding domain that has been engineered to bind a target sequence within genes selected from the group consisting of CD52, GR, TCR alpha and TCR beta;
2. (b) A cleavage domain or a cleavage half-domain.

[0070] Preferred TALE-nucleases according to the disclosure are those recognizing and cleaving the target sequence selected from the group consisting of:

- SEQ ID NO: 1 to 6 (GR),
- SEQ ID NO: 37, 57 to 60 (TCRalpha),
- SEQ ID NO: 38 or 39 (TCRbeta), and
- SEQ ID NO: 40, 61 to 65 (CD52)

[0071] Said TALE-nucleases preferably comprise a polypeptide sequence selected from SEQ ID NO: 7 to SEQ ID NO: 18 and SEQ ID NO: 41 to SEQ ID NO: 48, in order to cleave the respective target sequences SEQ ID NO: 1 to 6 and SEQ ID NO: 37 to 40.

[0072] Because some variability may arise from the genomic data from which these polypeptides derive, and also to take into account the possibility to substitute some of the amino acids present in these polypeptides without significant loss of activity (functional variants), polypeptides variants of the above polypeptides are also mentioned, that share at least 70%, preferably at least 80 %, more preferably at least 90 % and even more preferably at least 95 % identity with the sequences provided herein.

[0073] The present disclosure is thus drawn to polypeptides comprising a polypeptide sequence that has at least 70%, preferably at least 80%, more preferably at least 90 %, 95 % 97 % or 99 % sequence identity with amino acid sequence selected from the group consisting of SEQ ID NO: 7 to SEQ ID NO: 18 and SEQ ID NO: 41 to SEQ ID NO: 48.

[0074] Are also comprised in the scope of the present disclosure, polynucleotides, vectors encoding the above described rare-cutting endonucleases.

[0075] In the scope of the present disclosure are also encompassed isolated cells or cell lines susceptible to be obtained by said method to engineer cells, in particular T cells, in which at least one gene selected from the group consisting of CD52, GR, TCR alpha and TCR beta has been inactivated. Preferably, two genes selected from the group consisting of CD52 and GR, CD52 and TCR alpha, CD52 and TCR beta, GR and TCR alpha, GR and TCR beta, TCR alpha and TCR beta have been inactivated.

[0076] According to the disclosure, those genes are preferably inactivated by at least one rare-cutting endonuclease. It has been shown by the inventors that the use of TALE-nucleases was particularly advantageous to achieve double inactivation in T-cells. The disclosure encompasses an isolated T-cell comprising at least two polynucleotides, said polynucleotides encoding at least a first and second TALE-nucleases, preferably the first TALE-nuclease being directed against a gene encoding TCR and the second being directed against a gene encoding a receptor for an immunosuppressive agent, such as CD52 or GR.

[0077] In another embodiment of the disclosure, said isolated cell further comprises one additional genomic modification. In another embodiment of the disclosure, said additional genomic modification is the integration of at least one exogenous polynucleotide sequence. In another embodiment of the disclosure, said exogenous sequence is integrated into one gene selected from the group consisting of CD52, GR, TCR alpha and TCR beta.

PreTalpha

[0078] In another aspect, the disclosure relates to a method of expanding TCR alpha deficient T-cell comprising introducing into said T-cell pTalpha (also named preTCR α) or a functional variant thereof and expanding said cells, optionally through stimulation of the CD3 complex. In a preferred embodiment of the disclosure, the method comprises:

1. a) Transforming said cells with nucleic acid encoding at least a fragment of pTalpha to support CD3 surface expression
2. b) Expressing said pTalpha into said cells
3. c) Expanding said cells optionally, optionally through stimulation of the CD3 complex.

[0079] The disclosure also relates to a method of preparing T-cells for immunotherapy comprising steps of the method for expansion for T-cell.

[0080] In particular embodiment of the disclosure, the pTalpha polynucleotide sequence can be introduced randomly

or else through homologous recombination, in particular the insertion could be associated with the inactivation of the TCRalpha gene.

[0081] According to the disclosure, different functional variants of pTalpha are used. A "functional variant" of the peptide refers to a molecule substantially similar to either the entire peptide or a fragment thereof. A "fragment" of the pTalpha or functional variant thereof, refers to any subset of the molecule, that is, a shorter peptide. Preferred pTalpha or functional variants can be full length pTalpha or a C-terminal truncated pTalpha version. C-terminal truncated pTalpha lacks in C-terminal end one or more residues. As non limiting examples, C-terminal truncated pTalpha version lacks 18, 48, 62, 78, 92, 110 or 114 residues from the C-terminus of the protein (SEQ ID NO: 107 to SEQ ID NO: 114). Moreover, amino acid sequence variants of the peptide can be prepared by mutations in the DNA which encodes the peptide. Such functional variants include, for example, deletions from, or insertions or substitutions of, residues within the amino acid sequence. Any combination of deletion, insertion, and substitution may also be made to arrive at the final construct, provided that the final construct possesses the desired activity, in particular the restoration of a functional CD3 complex. In preferred embodiment of the disclosure, at least one mutation is introduced in the different pTalpha versions as described above to affect dimerization. As non limiting example, mutated residue can be at least W46R, D22A, K24A, R102A or R117A of the human pTalpha protein or aligned positions using CLUSTALW method on pTalpha family or homologue member. Preferably pTalpha or variant thereof as described above comprise the mutated residue W46R (SEQ ID NO:123) or the mutated residues D22A, K24A, R102A and R117A (SEQ ID NO: 124). In particular embodiment of the disclosure, said pTalpha or variants are also fused to a signal-transducing domain such as CD28, OX40, ICOS, CD27, CD137 (4-1BB) and CD8 as non limiting examples (SEQ ID NO: 115 to SEQ ID NO: 120). The extracellular domain of pTalpha or variants as described above can be fused to a fragment of the TCRalpha protein, particularly the transmembrane and intracellular domain of TCRalpha (SEQ ID NO: 122). pTalpha variants can also be fused to the intracellular domain of TCRalpha (SEQ ID NO:121).

[0082] In another embodiment of the disclosure, said pTalpha versions are fused to an extracellular ligand-binding domain and more preferably pTalpha or functional variant thereof is fused to a single chain antibody fragment (scFV) comprising the light (V_L) and the heavy (V_H) variable fragment of a target antigen specific monoclonal antibody joined by a flexible linker. As a non limiting example, amino acid sequence of pTalpha or functional variant thereof is selected from the group consisting of SEQ ID NO: 107 to SEQ ID NO: 124.

[0083] Because some variability may arise from the genomic data from which these polypeptides derive, and also to take into account the possibility to substitute some of the amino acids present in these polypeptides without significant loss of activity (functional variants), the disclosure encompasses polypeptides variants of the above polypeptides that share at least 70%, preferably at least 80 %, more preferably at least 90 % and even more preferably at least 95 % identity with the sequences provided herein.

[0084] The present disclosure is thus drawn to polypeptides comprising a polypeptide sequence that has at least 70%, preferably at least 80%, more preferably at least 90 %, 95 % 97 % or 99 % sequence identity with amino acid sequence selected from the group consisting of SEQ ID NO:107 to SEQ ID NO: 124.

[0085] By TCR alpha deficient T cell is intended an isolated T cell that lacks expression of a functional TCR alpha chain. This may be accomplished by different means, as non limiting examples, by engineering a T cell such that it does not express any functional TCR alpha on its cell surface or by engineering a T cell such that it produces very little functional TCR alpha chain on its surface or by engineering a T cell to express mutated or truncated form of TCR alpha chain.

[0086] TCR alpha deficient cells can no longer be expanded through CD3 complex. Thus, to overcome this problem and to allow proliferation of TCR alpha deficient cells, pTalpha or functional variant thereof is introduced into said cells, thus restoring a functional CD3 complex. In a preferred embodiment of the disclosure, the method further comprises introducing into said T cells rare-cutting endonucleases able to selectively inactivate by DNA cleavage one gene encoding one component of the T-cell receptor (TCR). In particular embodiment of the disclosure, said rare-cutting endonuclease is a TALE-nucleases. As non limiting examples, TALE-nuclease is directed against one of the gene target sequences of TCRalpha selected from the group consisting of SEQ ID NO: 37 and SEQ ID NO: 57 to 60. Preferably, TALE-nucleases are selected from the group consisting of SEQ ID NO: 41 and SEQ ID NO: 42.

[0087] In particular embodiment of the disclosure, said method for expansion of TCR alpha deficient T-cells comprises an additional genomic modification step. By additional genomic modification step, can be intended the introduction into cells to engineer of one protein of interest. Said protein of interest can be, as non limiting examples, a Chimeric Antigen Receptor (CAR), particularly CAR comprising amino acid sequence SEQ ID NO: 73, a multi-chain CAR, particularly multi-chain CAR comprising amino acid sequence SEQ ID NO: 125 a bispecific antibody, rare-cutting endonucleases targeting PDCD1 or CTLA-4, particularly targeting nucleic acid sequence SEQ ID NO: 74 to SEQ ID NO: 78 or a rare-cutting endonuclease targeting a target for immunosuppressive agent as described in the present disclosure.

[0088] Are also described herein polypeptides encoding pTalpha, particularly functional variants described above. In a preferred embodiment the disclosure relates to a pTalpha or functional variant thereof fused to a signal transducing domain such as CD28, OX40, ICOS, CD137 and CD8. More particularly, the disclosure relates to pTalpha functional variant comprising amino acid sequence selected from the group consisting of SEQ ID NO: 107 to SEQ ID NO: 124. Are also described herein polynucleotides, vectors encoding pTalpha or functional variants thereof described above.

[0089] Isolated cells or cell lines susceptible to be obtained by said method are also described herein. In particular said isolated cells or cell lines are obtained by introducing into said cells a pTalpha or a functional variant thereof to support CD3 surface expression. In a preferred embodiment of the disclosure, said isolated cell or cell line are further genetically modified by inactivating TCRalpha gene. This gene is preferably inactivated by at least one rare-cutting endonuclease. In a preferred embodiment of the disclosure, said rare-cutting endonuclease is TALE-nuclease.

Multi-chain Chimeric Antigen Receptor (CAR)

[0090] In another embodiment, the disclosure relates to a multi-chain chimeric antigen receptor (CAR) particularly adapted to the production and expansion of engineered T-cells of the present disclosure. The multi-chain CAR comprising at least two of the following components:

1. a) one polypeptide comprising the transmembrane domain of FcεRI alpha chain and an extracellular ligand-binding domain,
2. b) one polypeptide comprising a part of N- and C- terminal cytoplasmic tail and the transmembrane domain of FcεRI beta chain and/or
3. c) two polypeptides comprising each a part of intracytoplasmic tail and the transmembrane domain of FcεRI gamma chain, whereby different polypeptides multimerize together spontaneously to form dimeric, trimeric or tetrameric CAR.

[0091] One example of tetrameric CAR is illustrated in Figure 3. Different versions of multichain CARs are represented in Figure 4. One example of multi-chain CAR comprises amino acid sequence SEQ ID NO: 125. The term "a part of" used herein refers to any subset of the molecule, that is a shorter peptide. Alternatively, amino acid sequence functional variants of the polypeptide can be prepared by mutations in the DNA which encodes the polypeptide. Such functional variants include, for example, deletions from, or insertions or substitutions of, residues within the amino acid sequence. Any combination of deletion, insertion, and substitution may also be made to arrive at the final construct, provided that the final construct possesses the desired activity, especially to exhibit a specific anti-target cellular immune activity.

[0092] In a preferred embodiment of the disclosure, said extracellular ligand-binding domain is a scFv. Other binding domain than scFv can also be used for predefined targeting of lymphocytes, such as camelid single-domain antibody fragments or receptor ligands like a vascular endothelial growth factor polypeptide, an integrin-binding peptide, heregulin or an IL-13 mutein, antibody binding domains, antibody hypervariable loops or CDRs as non limiting examples.

[0093] In a preferred embodiment of the disclosure, said polypeptide of a) further comprises a stalk region between

said extracellular ligand-binding domain and said transmembrane domain. The term "stalk region" used herein generally means any oligo- or polypeptide that functions to link the transmembrane domain to the extracellular ligand-binding domain. In particular, stalk region are used to provide more flexibility and accessibility for the extracellular ligand-binding domain. A stalk region may comprise up to 300 amino acids, preferably 10 to 100 amino acids and most preferably 25 to 50 amino acids. Stalk region may be derived from all or part of naturally occurring molecules, such as from all or part of the extracellular region of CD8, CD4 or CD28, or from all or part of an antibody constant region. Alternatively the stalk region may be a synthetic sequence that corresponds to a naturally occurring stalk sequence, or may be an entirely synthetic stalk sequence.

[0094] In a preferred embodiment of the disclosure, said polypeptide of a), b) and/or c) further comprises at least one signal-transducing domain. In a most preferred embodiment, said signal-transducing domain is selected from the group consisting of CD28, OX40, ICOS, CD137 and CD8.

[0095] In a preferred embodiment of the disclosure, said C-terminal cytoplasmic tail of FcεRI alpha, beta and/or gamma chain fragment further comprises TNFR-associated Factor 2 (TRAF2) binding motifs. In a most preferred embodiment of the disclosure, said C-terminal cytoplasmic tail of FcεRI alpha, beta and/or gamma chain is replaced by intracytoplasmic tail of costimulatory TNFR member family. Cytoplasmic tail of costimulatory TNFR family member contains TRAF2 binding motifs consisting of the major conserved motif (P/S/A)X(Q/E)E or the minor motif (PXQXXD), wherein X is any amino acid. TRAF proteins are recruited to the intracellular tails of many TNFRs in response to receptor trimerization.

[0096] In another preferred embodiment of the disclosure, said intracytoplasmic domain of FcεRI alpha, beta and/or gamma chain is replaced by intracytoplasmic domain of TCR zeta chain (also named CD3 zeta). In another preferred embodiment of the disclosure, said intracytoplasmic domain of FcεRI alpha, beta and/or gamma chain comprises at least one additional immunoreceptor tyrosine-based activation motif (ITAM). ITAMs are well defined signaling motifs found in the intracytoplasmic tail of a variety of receptors that serve as binding sites for syk/zap70 class tyrosine kinases. Examples of ITAM used in the invention include those derived from TCRzeta, FcRgamma, FcRbeta, CD3gamma, CD3delta, CD3epsilon, CD5, CD22, CD79a, CD79b, and CD66d.

[0097] As non limiting example, different versions of multi-chain CAR are illustrated in Figure 4.

[0098] In a preferred embodiment of the disclosure, the multi-chain CAR comprise the amino acid sequence SEQ ID NO: 125. The present disclosure relates to polypeptides comprising a polypeptide sequence that has at least 70%, preferably at least 80%, more preferably at least 90 %, 95 % 97 % or 99 % sequence identity with amino acid sequence selected from the group consisting of SEQ ID NO: 125.

[0099] Are also described herein, polynucleotides, vectors encoding the above described multi-chain CAR.

[0100] In encompassed particular embodiment, the disclosure relates to a method of preparing T-cells for immunotherapy comprising introducing into said T-cells the different polypeptides composing said multi-chain CAR and expanding said cells.

[0101] In another embodiment of the disclosure, said method further comprises a step of genetically modifying said cells by inactivating at least one gene expressing one component of the TCR and/or a target for an immunosuppressive agent. In a preferred embodiment, said gene is selected from the group consisting of TCRalpha, TCRbeta, CD52 and GR. In a preferred embodiment of the disclosure, said method further comprises introducing into said T cells a rare-cutting endonuclease able to selectively inactivate by DNA cleavage said genes. In a more preferred embodiment of the disclosure, said rare-cutting endonuclease is TALE-nuclease. Preferred TALE-nucleases are those recognizing and cleaving the target sequence selected from the group consisting of: SEQ ID NO: 1 to 6 (GR), SEQ ID NO: 37, 57 to 60 (TCRalpha), SEQ ID NO: 38 or 39 (TCRbeta), and SEQ ID NO: 40, SEQ ID NO: 61 to SEQ ID NO: 65 (CD52).

[0102] In particular embodiment of the disclosure, said method further comprises an additional genomic modification step. By additional genomic modification step, can be intended the introduction into cells to engineer of one protein of interest. Said protein of interest can be, as non limiting examples a bispecific antibody, rare-cutting endonuclease

targeting PDCD1 or CTLA-4, a pTalpha or a functional variant thereof as described in the present disclosure.

[0103] The present disclosure also relates isolated cells or cell lines susceptible to be obtained by said method to engineer cells. In particular said isolated cell comprises exogenous polynucleotide sequences encoding polypeptides composing said multi-chain CAR.

Bispecific antibodies

[0104] According to a further embodiment of the disclosure, engineered T cells obtained by the different methods as previously described can be further exposed with bispecific antibodies. Said T-cells could be exposed to bispecific antibodies *ex vivo* prior to administration to a patient or *in vivo* following administration to a patient. Said bispecific antibodies comprise two variable regions with distinct antigen properties that allow bringing the engineered cells into proximity to a target antigen. As a non limiting example, said bispecific antibody is directed against a tumor marker and lymphocyte antigen such as CD3 and has the potential to redirect and activate any circulating T cells against tumors.

Delivery methods

[0105] The different methods described above involve introducing pTalpha or functional variants thereof, rare cutting endonuclease, TALE-nuclease, CAR or multi-chain CAR optionally with DNA-end processing enzyme or exogenous nucleic acid into a cell.

[0106] As non-limiting example, said pTalpha or functional variant thereof, rare cutting endonucleases, TALE-nucleases, CAR or multi-chain CAR optionally with DNA-end processing enzyme or exogenous nucleic acid can be introduced as transgenes encoded by one or as different plasmidic vectors. Different transgenes can be included in one vector which comprises a nucleic acid sequence encoding ribosomal skip sequence such as a sequence encoding a 2A peptide. 2A peptides, which were identified in the Aphthovirus subgroup of picornaviruses, causes a ribosomal "skip" from one codon to the next without the formation of a peptide bond between the two amino acids encoded by the codons (see Donnelly et al., J. of General Virology 82: 1013-1025 (2001); Donnelly et al., J. of Gen. Virology 78: 13-21 (1997); Doronina et al., Mol. And. Cell. Biology 28(13): 4227-4239 (2008); Atkins et al., RNA 13: 803-810 (2007)). By "codon" is meant three nucleotides on an mRNA (or on the sense strand of a DNA molecule) that are translated by a ribosome into one amino acid residue. Thus, two polypeptides can be synthesized from a single, contiguous open reading frame within an mRNA when the polypeptides are separated by a 2A oligopeptide sequence that is in frame. Such ribosomal skip mechanisms are well known in the art and are known to be used by several vectors for the expression of several proteins encoded by a single messenger RNA. As non-limiting example, 2A peptides have been used to express into the cell the rare-cutting endonuclease and a DNA end-processing enzyme or the different polypeptides of the multi-chain CAR.

[0107] Said plasmid vector can contain a selection marker which provides for identification and/or selection of cells which received said vector.

[0108] Polypeptides may be synthesized *in situ* in the cell as a result of the introduction of polynucleotides encoding said polypeptides into the cell. Alternatively, said polypeptides could be produced outside the cell and then introduced thereto. Methods for introducing a polynucleotide construct into animal cells are known in the art and including as non limiting examples stable transformation methods wherein the polynucleotide construct is integrated into the genome of the cell, transient transformation methods wherein the polynucleotide construct is not integrated into the genome of the cell and virus mediated methods. Said polynucleotides may be introduced into a cell by for example, recombinant viral vectors (e.g. retroviruses, adenoviruses), liposome and the like. For example, transient transformation methods include for example microinjection, electroporation or particle bombardment. Said polynucleotides may be included in vectors, more particularly plasmids or virus, in view of being expressed in cells.

- Electroporation

[0109] A more preferred embodiment of the disclosure, polynucleotides encoding polypeptides as above-described can be mRNA which is introduced directly into the cells, for example by electroporation. The inventors determined the optimal condition for mRNA electroporation in T-cell.

[0110] The inventor used the cytoPulse technology which allows, by the use of pulsed electric fields, to transiently permeabilize living cells for delivery of material into the cells. The technology, based on the use of PulseAgile (Cellestis property) electroporation waveforms grants the precise control of pulse duration, intensity as well as the interval between pulses (U.S. patent 6,010,613 and International PCT application WO2004083379). All these parameters can be modified in order to reach the best conditions for high transfection efficiency with minimal mortality. Basically, the first high electric field pulses allow pore formation, while subsequent lower electric field pulses allow to move the polynucleotide into the cell. The inventors describe the steps that led to achievement of >95% transfection efficiency of mRNA in T cells, and the use of the electroporation protocol to transiently express different kind of proteins in T cells. A method of transforming T cell is described herein, comprising contacting said T cell with RNA and applying to T cell an agile pulse sequence consisting of:

1. (a) one electrical pulse with a voltage range from 2250 to 3000 V per centimeter, a pulse width of 0.1 ms and a pulse interval of 0.2 to 10 ms between the electrical pulses of step (a) and (b);
2. (b) one electrical pulse with a voltage range from 2250 to 3000 V with a pulse width of 100 ms and a pulse interval of 100 ms between the electrical pulse of step (b) and the first electrical pulse of step (c) ; and
3. (c) 4 electrical pulses with a voltage of 325 V with a pulse width of 0.2 ms and a pulse interval of 2 ms between each of 4 electrical pulses.

[0111] In particular embodiment of the disclosure, the method of transforming T cell comprises contacting said T cell with RNA and applying to T cell an agile pulse sequence consisting of:

1. (a) one electrical pulse with a voltage of 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2400, 2450, 2500, 2600, 2700, 2800, 2900 or 3000V per centimeter, a pulse width of 0.1 ms and a pulse interval of 0.2, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 ms between the electrical pulses of step (a) and (b);
2. (b) one electrical pulse with a voltage range from 2250, of 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2400, 2450, 2500, 2600, 2700, 2800, 2900 or 3000V with a pulse width of 100 ms and a pulse interval of 100 ms between the electrical pulse of step (b) and the first electrical pulse of step (c); and
3. (c) 4 electrical pulses with a voltage of 325 V with a pulse width of 0.2 ms and a pulse interval of 2 ms between each of 4 electrical pulses.

[0112] Any values included in the value range described above are disclosed in the present application. Electroporation medium can be any suitable medium known in the art. Preferably, the electroporation medium has conductivity in a range spanning 0.01 to 1.0 milliSiemens.

[0113] In particular embodiments of the disclosure, as non limiting examples, said RNA encodes a rare-cutting endonuclease, one monomer of the rare-cutting endonuclease such as Half-TALE-nuclease, a Chimeric Antigen Receptor, at least one component of the multi-chain chimeric antigen receptor, a pTalpha or functional variant thereof, an exogenous nucleic acid, one additional catalytic domain.

Activation and expansion of T cells

[0114] Whether prior to or after genetic modification of the T cells, the T cells can be activated and expanded generally using methods as described, for example, in U.S. Patents 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874;

6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005. T cells can be expanded *in vitro* or *in vivo*.

[0115] Generally, the T cells of the disclosure are expanded by contact with a surface having attached thereto an agent that stimulates a CD3 TCR complex associated signal and a ligand that stimulates a co-stimulatory molecule on the surface of the T cells.

[0116] In particular, T cell populations may be stimulated *in vitro* such as by contact with an anti-CD3 antibody, or antigen-binding fragment thereof, or an anti-CD2 antibody immobilized on a surface, or by contact with a protein kinase C activator (e.g., bryostatin) in conjunction with a calcium ionophore. For co-stimulation of an accessory molecule on the surface of the T cells, a ligand that binds the accessory molecule is used. For example, a population of T cells can be contacted with an anti-CD3 antibody and an anti-CD28 antibody, under conditions appropriate for stimulating proliferation of the T cells. To stimulate proliferation of either CD4+ T cells or CD8+ T cells, an anti-CD3 antibody and an anti-CD28 antibody. For example, the agents providing each signal may be in solution or coupled to a surface. As those of ordinary skill in the art can readily appreciate, the ratio of particles to cells may depend on particle size relative to the target cell. In further embodiments of the present invention, the cells, such as T cells, are combined with agent-coated beads, the beads and the cells are subsequently separated, and then the cells are cultured. In an alternative embodiment, prior to culture, the agent-coated beads and cells are not separated but are cultured together. Cell surface proteins may be ligated by allowing paramagnetic beads to which anti-CD3 and anti-CD28 are attached (3x28 beads) to contact the T cells. In one embodiment of the disclosure, the cells (for example, 4 to 10 T cells) and beads (for example, DYNABEADS® M-450 CD3/CD28 T paramagnetic beads at a ratio of 1:1) are combined in a buffer, preferably PBS (without divalent cations such as, calcium and magnesium). Again, those of ordinary skill in the art can readily appreciate any cell concentration may be used. The mixture may be cultured for several hours (about 3 hours) to about 14 days or any hourly integer value in between. In another embodiment of the disclosure, the mixture may be cultured for 21 days. Conditions appropriate for T cell culture include an appropriate media (e.g., Minimal Essential Media or RPMI Media 1640 or, X-vivo 5, (Lonza)) that may contain factors necessary for proliferation and viability, including serum (e.g., fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN- γ , 1L-4, 1L-7, GM-CSF, -10, -2, 1L-15, TGF β , and TNF- or any other additives for the growth of cells known to the skilled artisan. Other additives for the growth of cells include, but are not limited to, surfactant, plasmanate, and reducing agents such as N-acetyl-cysteine and 2-mercaptoethanol. Media can include RPMI 1640, A1M-V, DMEM, MEM, α -MEM, F-12, X-Vivo 1, and X-Vivo 20, Optimizer, with added amino acids, sodium pyruvate, and vitamins, either serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones, and/or an amount of cytokine(s) sufficient for the growth and expansion of T cells. Antibiotics, e.g., penicillin and streptomycin, are included only in experimental cultures, not in cultures of cells that are to be infused into a subject. The target cells are maintained under conditions necessary to support growth, for example, an appropriate temperature (e.g., 37° C) and atmosphere (e.g., air plus 5% CO₂) . T cells that have been exposed to varied stimulation times may exhibit different characteristics

[0117] In another particular embodiment of the disclosure, said cells can be expanded by co-culturing with tissue or cells. Said cells can also be expanded *in vivo*, for example in the subject's blood after administering said cell into the subject.

Modified T-cells

[0118] In the scope of the present disclosure is also encompassed an isolated T cell obtained according to any one of the methods previously described. Said T-cell can be derived from a stem cell. The stem cells can be adult stem cells, embryonic stem cells, more particularly non-human stem cells, cord blood stem cells, progenitor cells, bone marrow stem cells, induced pluripotent stem cells, non-human totipotent stem cells or hematopoietic stem cells. Representative human cells are CD34+ cells. Said isolated cell can also be a dendritic cell, a NK-cell, a B-cell or a T-cell selected from the group consisting of inflammatory T-lymphocytes, cytotoxic T-lymphocytes, regulatory T-lymphocytes or helper T-lymphocytes. In another example, said cell can be derived from the group consisting of CD4+ T-lymphocytes and CD8+ T-lymphocytes. Prior to expansion and genetic modification of the cells, a source of cells can be obtained from a subject through a variety of non-limiting methods. T cells can be obtained from a number

of non-limiting sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In certain embodiments of the present disclosure, any number of T cell lines available and known to those skilled in the art, may be used. In another embodiment of the disclosure, said cell can be derived from a healthy donor, from a patient diagnosed with cancer or from a patient diagnosed with an infection. In another embodiment of the disclosure, said cell is part of a mixed population of cells which present different phenotypic characteristics. Also described herein is a cell line obtained from a transformed T-cell according to the method previously described. Modified cells resistant to an immunosuppressive treatment and susceptible to be obtained by the previous method are also cited herein.

[0119] In another embodiment of the disclosure, said isolated cell comprises one inactivated gene selected from the group consisting of CD52, GR, PD1, CTLA-4, LAG3, Tim3, BTLA, BY55, TIGIT, B7H5, LAIR1, SIGLEC10, 2B4, TCR alpha and TCR beta and/or expresses a CAR, a multi-chain CAR and/or a pTalpha transgene. In another embodiment of the disclosure, said isolated cell according to the present invention comprises two inactivated genes selected from the group consisting of CD52 and GR, CD52 and TCR alpha, CDR52 and TCR beta, GR and TCR alpha, GR and TCR beta, TCR alpha and TCR beta, PD1 and TCR alpha, PD1 and TCR beta, CTLA-4 and TCR alpha, CTLA-4 and TCR beta, LAG3 and TCR alpha, LAG3 and TCR beta, Tim3 and TCR alpha, Tim3 and TCR beta, BTLA and TCR alpha, BTLA and TCR beta, BY55 and TCR alpha, BY55 and TCR beta, TIGIT and TCR alpha, TIGIT and TCR beta, B7H5 and TCR alpha, B7H5 and TCR beta, LAIR1 and TCR alpha, LAIR1 and TCR beta, SIGLEC10 and TCR alpha, SIGLEC10 and TCR beta, 2B4 and TCR alpha, 2B4 and TCR beta and/or expresses a CAR, a multi-chain CAR and/or a pTalpha transgene.

[0120] In another embodiment of the disclosure, TCR is rendered not functional in the cells according to the invention by inactivating TCR alpha gene and/or TCR beta gene(s). The above strategies are used more particularly to avoid GvHD. In a particular aspect of the present disclosure is a method to obtain modified cells derived from an individual, wherein said cells can proliferate independently of the Major Histocompatibility Complex signaling pathway. Said method comprises the following steps:

1. (a) Recovering cells from said individual;
2. (b) Genetically modifying said cells ex-vivo by inactivating TCR alpha or TCR beta genes;
3. (c) Cultivating genetically modified T-cells in vitro in appropriate conditions to amplify said cells.

[0121] Modified cells, which can proliferate independently of the Major Histocompatibility Complex signaling pathway, are susceptible to be obtained by this method. Said modified cells can be used for treating patients in need thereof against Host versus Graft (HvG) rejection and Graft versus Host Disease (GvHD); therefore also described herein is a method of treating patients in need thereof against Host versus Graft (HvG) rejection and Graft versus Host Disease (GvHD), comprising treating said patient by administering to said patient an effective amount of modified cells comprising inactivated TCR alpha and/or TCR beta genes.

Therapeutic applications

[0122] In another embodiment, isolated cell obtained by the different methods or cell line derived from said isolated cell as previously described can be used as a medicament. In another embodiment, said medicament can be used for treating cancer or infections in a patient in need thereof. In another embodiment, said isolated cell according to the invention or cell line derived from said isolated cell can be used in the manufacture of a medicament for treatment of a cancer or a viral infection in a patient in need thereof.

[0123] In another aspect, the present disclosure relies on methods for treating patients in need thereof, said method comprising at least one of the following steps:

1. (a) providing a T-cell obtainable by any one of the methods previously described;
2. (b) Administering said transformed T-cells to said patient,

[0124] On one embodiment, said T cells can undergo robust *in vivo* T cell expansion and can persist for an extended amount of time.

[0125] Said treatment can be ameliorating, curative or prophylactic. It may be either part of an autologous immunotherapy or part of an allogenic immunotherapy treatment. By autologous, it is meant that cells, cell line or population of cells used for treating patients are originating from said patient or from a Human Leucocyte Antigen (HLA) compatible donor. By allogeneic is meant that the cells or population of cells used for treating patients are not originating from said patient but from a donor.

[0126] The invention is particularly suited for allogenic immunotherapy, insofar as it enables the transformation of T-cells, typically obtained from donors, into non-alloreactive cells. This may be done under standard protocols and reproduced as many times as needed. The resulted modified T cells may be pooled and administrated to one or several patients, being made available as an "off the shelf" therapeutic product.

[0127] Cells that can be used with the disclosed methods are described in the previous section. Said treatment can be used to treat patients diagnosed with cancer, viral infection, autoimmune disorders or Graft versus Host Disease (GvHD). Cancers that may be treated include tumors that are not vascularized, or not yet substantially vascularized, as well as vascularized tumors. The cancers may comprise nonsolid tumors (such as hematological tumors, for example, leukemias and lymphomas) or may comprise solid tumors. Types of cancers to be treated with the CAR T cells described herein, but are not limited to, carcinoma, blastoma, and sarcoma, and certain leukemia or lymphoid malignancies, benign and malignant tumors, and malignancies e.g., sarcomas, carcinomas, and melanomas. Adult tumors/cancers and pediatric tumors/cancers are also included.

[0128] It can be a treatment in combination with one or more therapies against cancer selected from the group of antibodies therapy, chemotherapy, cytokines therapy, dendritic cell therapy, gene therapy, hormone therapy, laser light therapy and radiation therapy.

[0129] According to a preferred embodiment of the disclosure, said treatment can be administrated into patients undergoing an immunosuppressive treatment. Indeed, the present disclosure preferably relies on cells or population of cells, which have been made resistant to at least one immunosuppressive agent due to the inactivation of a gene encoding a receptor for such immunosuppressive agent. In this aspect, the immunosuppressive treatment should help the selection and expansion of the T-cells according to the invention within the patient.

[0130] The administration of the cells or population of cells according to the present disclosure may be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation. The compositions described herein may be administered to a patient subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous or intralymphatic injection, or intraperitoneally. In one embodiment, the cell compositions of the present invention are preferably administered by intravenous injection.

[0131] The administration of the cells or population of cells can consist of the administration of 10^4 - 10^9 cells per kg body weight, preferably 10^5 to 10^6 cells/kg body weight including all integer values of cell numbers within those ranges. The cells or population of cells can be administrated in one or more doses. In another embodiment, said effective amount of cells are administrated as a single dose. In another embodiment of the disclosure, said effective amount of cells are administrated as more than one dose over a period time. Timing of administration is within the judgment of managing physician and depends on the clinical condition of the patient. The cells or population of cells may be obtained from any source, such as a blood bank or a donor. While individual needs vary, determination of optimal ranges of effective amounts of a given cell type for a particular disease or conditions within the skill of the art. An effective amount means an amount which provides a therapeutic or prophylactic benefit. The dosage administrated will be dependent upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired.

[0132] In another embodiment of the disclosure, said effective amount of cells or composition comprising those cells

are administrated parenterally. Said administration can be an intravenous administration. Said administration can be directly done by injection within a tumor.

[0133] In certain embodiments of the present disclosure, cells are administered to a patient in conjunction with (e.g., before, simultaneously or following) any number of relevant treatment modalities, including but not limited to treatment with agents such as antiviral therapy, cidofovir and interleukin-2, Cytarabine (also known as ARA-C) or natalizimab treatment for MS patients or efalizimab treatment for psoriasis patients or other treatments for PML patients. In further embodiments, the T cells of the invention may be used in combination with chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAM PATH, anti-CD3 antibodies or other antibody therapies, cytoxin, fludarabine, cyclosporin, FK506, rapamycin, mycoplienolic acid, steroids, FR901228, cytokines, and irradiation. These drugs inhibit either the calcium dependent phosphatase calcineurin (cyclosporine and FK506) or inhibit the p70S6 kinase that is important for growth factor induced signaling (rapamycin) (Liu et al., Cell 66:807-815, 1991; Henderson et al., Immun. 73:316-321, 1991; Bierer et al., Citrr. Opin. mm n. 5:763-773, 93). In a further embodiment, the cell compositions of the present disclosure are administered to a patient in conjunction with (e.g., before, simultaneously or following) bone marrow transplantation, T cell ablative therapy using either chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH. In another embodiment, the cell compositions of the present invention are administered following B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan. For example, subjects may undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. Following the transplant, subjects may receive an infusion of the expanded immune cells of the present disclosure. Expanded cells may also administered before or following surgery. Said modified cells obtained by any one of the methods described here can be used for treating patients in need thereof against Host versus Graft (HvG) rejection and Graft versus Host Disease (GvHD); therefore in the scope of the present disclosure is a method of treating patients in need thereof against Host versus Graft (HvG) rejection and Graft versus Host Disease (GvHD) comprising treating said patient by administering to said patient an effective amount of modified cells comprising inactivated TCR alpha and/or TCR beta genes.

Example of method to engineer human allogeneic cells for immunotherapy

[0134] For a better understanding of the disclosure, one example of method to engineer human allogeneic cells for immunotherapy is illustrated in Figure 5. The method comprising a combination of one or several of the following steps:

1. 1. Providing T-cells from a cell culture or from a blood sample from one individual patient or from blood bank and activating said T cells using anti-CD3/C28 activator beads. The beads provide both the primary and co-stimulatory signals that are required for activation and expansion of T cells.
2. 2.
 1. a) Transducing said cells with pTalpha or functional variant thereof transgene to support CD3 surface expression and allow cell expansion through stimulation of CD3 complex. TCR disruption is expected to the elimination of the TCR complex and removes alloreactivity (GvHD) but may alter allogeneic cells expansion due to the loss of CD3 signaling component. Transduced cells are expected to express pTalpha chain or functional variant thereof. This pTalpha chain pairs with TCRbeta chain and CD3 signaling components to form the preTCR complex and, thus restore a functional CD3 complex and support activation or stimulation of inactivated TCRalpha cells. Transduction of T-cells with pTalpha lentiviral vector can be realized before or after TCRalpha inactivation.
 2. b) Transducing said cells with multi-chain CARs allow redirecting T cells against antigens expressed at the surface of target cells from various malignancies including lymphomas and solid tumors. To improve the function of co-stimulatory domain, the inventors have designed a multi-chain CAR derived from FcεRI as previously described. Transduction can be realized before or after the inactivation of TCRalpha and the other genes, such as CD52 genes.
3. 3. Engineering non alloreactive and immunosuppressive resistant T cells:
 1. a) It is possible to Inactivate TCR alpha in said cells to eliminate the TCR from the surface of the cell and prevent recognition of host tissue as foreign by TCR of allogeneic and thus to avoid GvHD.

2. b) It is also possible to inactive one gene encoding target for immunosuppressive agent to render said cells resistant to immunosuppressive treatment to prevent graft rejection without affecting transplanted T cells. In this example, target of immunosuppressive agents is CD52 and immunosuppressive agent is a humanized monoclonal anti-CD52 antibody.

It has been shown by the inventors that the use of TALE-nuclease by allowing higher rates of DSB events within T-cells was particularly advantageous to achieve the above double inactivation in T-cells. Preferably, TCRalpha and CD52 genes are inactivated by electroporating T cells with mRNA coding for TALE-nuclease targeting said genes. It has been found by the inventors that using mRNA resulted into high transformation rate was less harmful to T-cells and so, was critical in the process of engineering T-cells. Then, inactivated T cells are sorted using magnetic beads. For example, T cells expressing CD52 are removed by fixation on a solid surface, and inactivated cells are not exposed of the stress of being passed through a column. This gentle method increases the concentration of properly engineered T-cells.

4. 4. Expansion *in vitro* of engineered T-cells prior to administration to a patient or *in vivo* following administration to a patient through stimulation of CD3 complex. Before administration step, patients can be subjected to an immunosuppressive treatment such as CAMPATH1-H, a humanized monoclonal antibody anti-CD52.
5. 5. Optionally exposed said cells with bispecific antibodies *ex vivo* prior to administration to a patient or *in vivo* following administration to a patient to bring the engineered cells into proximity to a target antigen.

Other definitions

[0135]

- Amino acid residues in a polypeptide sequence are designated herein according to the one-letter code, in which, for example, Q means Gln or Glutamine residue, R means Arg or Arginine residue and D means Asp or Aspartic acid residue.
- Amino acid substitution means the replacement of one amino acid residue with another, for instance the replacement of an Arginine residue with a Glutamine residue in a peptide sequence is an amino acid substitution.
- Nucleotides are designated as follows: one-letter code is used for designating the base of a nucleoside: a is adenine, t is thymine, c is cytosine, and g is guanine. For the degenerated nucleotides, r represents g or a (purine nucleotides), k represents g or t, s represents g or c, w represents a or t, m represents a or c, y represents t or c (pyrimidine nucleotides), d represents g, a or t, v represents g, a or c, b represents g, t or c, h represents a, t or c, and n represents g, a, t or c.
- "As used herein, "nucleic acid" or "polynucleotides" refers to nucleotides and/or polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action. Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g., enantiomeric forms of naturally-occurring nucleotides), or a combination of both. Modified nucleotides can have alterations in sugar moieties and/or in pyrimidine or purine base moieties. Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters. Moreover, the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs. Examples of modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Nucleic acids can be either single stranded or double stranded.
- by "polynucleotide successively comprising a first region of homology to sequences upstream of said double-stranded break, a sequence to be inserted in the genome of said cell and a second region of homology to sequences downstream of said double-stranded break" it is intended to mean a DNA construct or a matrix comprising a first and second portion that are homologous to regions 5' and 3' of a DNA target *in situ*. The DNA construct also comprises a third portion positioned between the first and second portion which comprise some

homology with the corresponding DNA sequence *in situ* or alternatively comprise no homology with the regions 5' and 3' of the DNA target *in situ*. Following cleavage of the DNA target, a homologous recombination event is stimulated between the genome containing the targeted gene comprised in the locus of interest and this matrix, wherein the genomic sequence containing the DNA target is replaced by the third portion of the matrix and a variable part of the first and second portions of said matrix.

- by "DNA target", "DNA target sequence", "target DNA sequence", "nucleic acid target sequence", "target sequence", or "processing site" is intended a polynucleotide sequence that can be targeted and processed by a rare-cutting endonuclease as described herein. These terms refer to a specific DNA location, preferably a genomic location in a cell, but also a portion of genetic material that can exist independently to the main body of genetic material such as plasmids, episomes, virus, transposons or in organelles such as mitochondria as non-limiting example. As non-limiting examples of TALE-nuclease targets, targeted genomic sequences generally consist of two 17-bp long sequences (called half targets) separated by a 15-bp spacer. Each half-target is recognized by repeats of TALE-nucleases listed in tables 2, 6, 7 and 11 as non-limiting examples, encoded in plasmids, under the control of EF1-alpha promoter or T7 promoter. The nucleic acid target sequence is defined by the 5' to 3' sequence of one strand of said target, as indicated in tables 2, 6, 7 and 11.
- By chimeric antigen receptor (CAR) is intended molecules that combine a binding domain against a component present on the target cell, for example an antibody-based specificity for a desired antigen (e.g., tumor antigen) with a T cell receptor-activating intracellular domain to generate a chimeric protein that exhibits a specific anti-target cellular immune activity. Generally, CAR consists of an extracellular single chain antibody (scFvFc) fused to the intracellular signaling domain of the T cell antigen receptor complex zeta chain (scFvFc:ζ) and have the ability, when expressed in T cells, to redirect antigen recognition based on the monoclonal antibody's specificity. One example of CAR used in the present invention is a CAR directing against CD19 antigen and can comprise as non-limiting example the amino acid sequence : SEQ ID NO: 73
- By "delivery vector" or "delivery vectors" is intended any delivery vector which can be used to put into cell contact (i.e "contacting") or deliver inside cells or subcellular compartments (i.e "introducing") agents/chemicals and molecules (proteins or nucleic acids) needed. It includes, but is not limited to liposomal delivery vectors, viral delivery vectors, drug delivery vectors, chemical carriers, polymeric carriers, lipoplexes, polyplexes, dendrimers, microbubbles (ultrasound contrast agents), nanoparticles, emulsions or other appropriate transfer vectors. These delivery vectors allow delivery of molecules, chemicals, macromolecules (genes, proteins), or other vectors such as plasmids, peptides developed by Diatos. In these cases, delivery vectors are molecule carriers. By "delivery vector" or "delivery vectors" is also intended delivery methods to perform transfection.
- The terms "vector" or "vectors" refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. A "vector" herein includes, but is not limited to, a viral vector, a plasmid, a RNA vector or a linear or circular DNA or RNA molecule which may consists of a chromosomal, non chromosomal, semi-synthetic or synthetic nucleic acids. Preferred vectors are those capable of autonomous replication (episomal vector) and/or expression of nucleic acids to which they are linked (expression vectors). Large numbers of suitable vectors are known to those of skill in the art and commercially available.

[0136] Viral vectors include retrovirus, adenovirus, parvovirus (e. g. adenoassociated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e. g., influenza virus), rhabdovirus (e. g., rabies and vesicular stomatitis virus), paramyxovirus (e. g. measles and Sendai), positive strand RNA viruses such as picornavirus and alphavirus, and double-stranded DNA viruses including adenovirus, herpesvirus (e. g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e. g., vaccinia, fowlpox and canarypox). Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example. Examples of retroviruses include: avian leukosis-sarcoma, mammalian C-type, B-type viruses, D type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields, et al., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).

- By "lentiviral vector" is meant HIV-Based lentiviral vectors that are very promising for gene delivery because of their relatively large packaging capacity, reduced immunogenicity and their ability to stably transduce with high efficiency a large range of different cell types. Lentiviral vectors are usually generated following transient transfection of three (packaging, envelope and transfer) or more plasmids into producer cells. Like HIV, lentiviral vectors enter the target cell through the interaction of viral surface glycoproteins with receptors on the

cell surface. On entry, the viral RNA undergoes reverse transcription, which is mediated by the viral reverse transcriptase complex. The product of reverse transcription is a double-stranded linear viral DNA, which is the substrate for viral integration in the DNA of infected cells. By "integrative lentiviral vectors (or LV)", is meant such vectors as non limiting example, that are able to integrate the genome of a target cell. At the opposite by "non integrative lentiviral vectors (or NILV)" is meant efficient gene delivery vectors that do not integrate the genome of a target cell through the action of the virus integrase.

- Delivery vectors and vectors can be associated or combined with any cellular permeabilization techniques such as sonoporation or electroporation or derivatives of these techniques.
- By cell or cells is intended any eukaryotic living cells, primary cells and cell lines derived from these organisms for *in vitro* cultures.
- By "primary cell" or "primary cells" are intended cells taken directly from living tissue (i.e. biopsy material) and established for growth in vitro, that have undergone very few population doublings and are therefore more representative of the main functional components and characteristics of tissues from which they are derived from, in comparison to continuous tumorigenic or artificially immortalized cell lines.

[0137] As non limiting examples cell lines can be selected from the group consisting of CHO-K1 cells; HEK293 cells; Caco2 cells; U2-OS cells; NIH 3T3 cells; NSO cells; SP2 cells; CHO-S cells; DG44 cells; K-562 cells, U-937 cells; MRC5 cells; IMR90 cells; Jurkat cells; HepG2 cells; HeLa cells; HT-1080 cells; HCT-116 cells; Hu-h7 cells; Huvec cells; Molt 4 cells.

[0138] All these cell lines can be modified by the method herein described to provide cell line models to produce, express, quantify, detect, study a gene or a protein of interest; these models can also be used to screen biologically active molecules of interest in research and production and various fields such as chemical, biofuels, therapeutics and agronomy as non-limiting examples.

- by "mutation" is intended the substitution, deletion, insertion of up to one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, twenty, twenty five, thirty, forty, fifty, or more nucleotides/amino acids in a polynucleotide (cDNA, gene) or a polypeptide sequence. The mutation can affect the coding sequence of a gene or its regulatory sequence. It may also affect the structure of the genomic sequence or the structure/stability of the encoded mRNA.
- by "variant(s)", it is intended a repeat variant, a variant, a DNA binding variant, a TALE-nuclease variant, a polypeptide variant obtained by mutation or replacement of at least one residue in the amino acid sequence of the parent molecule.
- by "functional variant" is intended a catalytically active mutant of a protein or a protein domain; such mutant may have the same activity compared to its parent protein or protein domain or additional properties, or higher or lower activity.
- By "gene" is meant the basic unit of heredity, consisting of a segment of DNA arranged in a linear manner along a chromosome, which codes for a specific protein or segment of protein. A gene typically includes a promoter, a 5' untranslated region, one or more coding sequences (exons), optionally introns, a 3' untranslated region. The gene may further comprise a terminator, enhancers and/or silencers.
- As used herein, the term "locus" is the specific physical location of a DNA sequence (e.g. of a gene) on a chromosome. The term "locus" can refer to the specific physical location of a rare-cutting endonuclease target sequence on a chromosome. Such a locus can comprise a target sequence that is recognized and/or cleaved by a rare-cutting endonuclease as described herein. It is understood that the locus of interest can not only qualify a nucleic acid sequence that exists in the main body of genetic material (i.e. in a chromosome) of a cell but also a portion of genetic material that can exist independently to said main body of genetic material such as plasmids, episomes, virus, transposons or in organelles such as mitochondria as non-limiting examples.
- The term "endonuclease" refers to any wild-type or variant enzyme capable of catalyzing the hydrolysis (cleavage) of bonds between nucleic acids within a DNA or RNA molecule, preferably a DNA molecule. Endonucleases do not cleave the DNA or RNA molecule irrespective of its sequence, but recognize and cleave the DNA or RNA molecule at specific polynucleotide sequences, further referred to as "target sequences" or "target sites". Endonucleases can be classified as rare-cutting endonucleases when having typically a polynucleotide recognition site greater than 12 base pairs (bp) in length, more preferably of 14-55 bp. Rare-

cutting endonucleases significantly increase HR by inducing DNA double-strand breaks (DSBs) at a defined locus (Rouet, Smih et al. 1994; Choulika, Perrin et al. 1995; Pingoud and Silva 2007). Rare-cutting endonucleases can for example be a homing endonuclease (Paques and Duchateau 2007), a chimeric Zinc-Finger nuclease (ZFN) resulting from the fusion of engineered zinc-finger domains with the catalytic domain of a restriction enzyme such as FokI (Porteus and Carroll 2005) or a chemical endonuclease (Eisenschmidt, Lanio et al. 2005; Arimondo, Thomas et al. 2006). In chemical endonucleases, a chemical or peptidic cleaver is conjugated either to a polymer of nucleic acids or to another DNA recognizing a specific target sequence, thereby targeting the cleavage activity to a specific sequence. Chemical endonucleases also encompass synthetic nucleases like conjugates of orthophenanthroline, a DNA cleaving molecule, and triplex-forming oligonucleotides (TFOs), known to bind specific DNA sequences (Kalish and Glazer 2005). Such chemical endonucleases are comprised in the term "endonuclease" used herein.

[0139] Rare-cutting endonucleases can also be for example TALE-nucleases, a new class of chimeric nucleases using a FokI catalytic domain and a DNA binding domain derived from Transcription Activator Like Effector (TALE), a family of proteins used in the infection process by plant pathogens of the *Xanthomonas* genus (Boch, Scholze et al. 2009; Moscou and Bogdanove 2009; Christian, Cermak et al. 2010; Li, Huang et al.). The functional layout of a FokI-based TALE-nuclease (TALE-nuclease) is essentially that of a ZFN, with the Zinc-finger DNA binding domain being replaced by the TALE domain. As such, DNA cleavage by a TALE-nuclease requires two DNA recognition regions flanking an unspecific central region. Rare-cutting endonucleases can also be derived from TALE-nucleases.

[0140] Rare-cutting endonuclease can be a homing endonuclease, also known under the name of meganuclease. Such homing endonucleases are well-known to the art (Stoddard 2005). Homing endonucleases recognize a DNA target sequence and generate a single- or double-strand break. Homing endonucleases are highly specific, recognizing DNA target sites ranging from 12 to 45 base pairs (bp) in length, usually ranging from 14 to 40 bp in length. The homing endonuclease may for example correspond to a LAGLIDADG endonuclease, to a HNH endonuclease, or to a GIY-YIG endonuclease. Preferred homing endonuclease can be an I-CreI variant.

- By a "TALE-nuclease" (TALEN) is intended a fusion protein consisting of a nucleic acid-binding domain typically derived from a Transcription Activator Like Effector (TALE) and one nuclease catalytic domain to cleave a nucleic acid target sequence. The catalytic domain is preferably a nuclease domain and more preferably a domain having endonuclease activity, like for instance I-TevI, CoIE7, NucA and Fok-I. In a particular embodiment, the TALE domain can be fused to a meganuclease like for instance I-CreI and I-OnuI or functional variant thereof. In a more preferred embodiment, said nuclease is a monomeric TALE-Nuclease. A monomeric TALE-Nuclease is a TALE-Nuclease that does not require dimerization for specific recognition and cleavage, such as the fusions of engineered TAL repeats with the catalytic domain of I-TevI described in WO2012138927. Transcription Activator like Effector (TALE) are proteins from the bacterial species *Xanthomonas* comprise a plurality of repeated sequences, each repeat comprising di-residues in position 12 and 13 (RVD) that are specific to each nucleotide base of the nucleic acid targeted sequence. Binding domains with similar modular base-per-base nucleic acid binding properties (MBBBD) can also be derived from new modular proteins recently discovered by the applicant in a different bacterial species. The new modular proteins have the advantage of displaying more sequence variability than TAL repeats. Preferably, RVDs associated with recognition of the different nucleotides are HD for recognizing C, NG for recognizing T, NI for recognizing A, NN for recognizing G or A, NS for recognizing A, C, G or T, HG for recognizing T, IG for recognizing T, NK for recognizing G, HA for recognizing C, ND for recognizing C, HI for recognizing C, HN for recognizing G, NA for recognizing G, SN for recognizing G or A and YG for recognizing T, TL for recognizing A, VT for recognizing A or G and SW for recognizing A. In another embodiment, critical amino acids 12 and 13 can be mutated towards other amino acid residues in order to modulate their specificity towards nucleotides A, T, C and G and in particular to enhance this specificity. TALE-nuclease have been already described and used to stimulate gene targeting and gene modifications (Boch, Scholze et al. 2009; Moscou and Bogdanove 2009; Christian, Cermak et al. 2010; Li, Huang et al.). Engineered TAL-nucleases are commercially available under the trade name TALEN™ (Collectis, 8 rue de la Croix Jarry, 75013 Paris, France).
- The term "cleavage" refers to the breakage of the covalent backbone of a polynucleotide. Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a

phosphodiester bond. Both single-stranded cleavage and double-stranded cleavage are possible, and double-stranded cleavage can occur as a result of two distinct single-stranded cleavage events. Double stranded DNA, RNA, or DNA/RNA hybrid cleavage can result in the production of either blunt ends or staggered ends.

- By "fusion protein" is intended the result of a well-known process in the art consisting in the joining of two or more genes which originally encode for separate proteins or part of them, the translation of said "fusion gene" resulting in a single polypeptide with functional properties derived from each of the original proteins.
- "identity" refers to sequence identity between two nucleic acid molecules or polypeptides. Identity can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base, then the molecules are identical at that position. A degree of similarity or identity between nucleic acid or amino acid sequences is a function of the number of identical or matching nucleotides at positions shared by the nucleic acid sequences. Various alignment algorithms and/or programs may be used to calculate the identity between two sequences, including FASTA, or BLAST which are available as a part of the GCG sequence analysis package (University of Wisconsin, Madison, Wis.), and can be used with, e.g., default setting. For example, polypeptides having at least 70%, 85%, 90%, 95%, 98% or 99% identity to specific polypeptides described herein and preferably exhibiting substantially the same functions, as well as polynucleotide encoding such polypeptides, are contemplated.
- "similarity" describes the relationship between the amino acid sequences of two or more polypeptides. BLASTP may also be used to identify an amino acid sequence having at least 70%, 75%, 80%, 85%, 87.5%, 90%, 92.5%, 95%, 97.5%, 98%, 99% sequence similarity to a reference amino acid sequence using a similarity matrix such as BLOSUM45, BLOSUM62 or BLOSUM80. Unless otherwise indicated a similarity score will be based on use of BLOSUM62. When BLASTP is used, the percent similarity is based on the BLASTP positives score and the percent sequence identity is based on the BLASTP identities score. BLASTP "Identities" shows the number and fraction of total residues in the high scoring sequence pairs which are identical; and BLASTP "Positives" shows the number and fraction of residues for which the alignment scores have positive values and which are similar to each other. Amino acid sequences having these degrees of identity or similarity or any intermediate degree of identity of similarity to the amino acid sequences disclosed herein are contemplated and encompassed by this disclosure. The polynucleotide sequences of similar polypeptides are deduced using the genetic code and may be obtained by conventional means. For example, a functional variant of pTalpha can have 70%, 75%, 80%, 85%, 87.5%, 90%, 92.5%, 95%, 97.5%, 98%, 99% sequence similarity to the amino acid sequence of SEQ ID NO : 107. A polynucleotide encoding such a functional variant would be produced by reverse translating its amino acid sequence using the genetic code.
- "signal-transducing domain" or "co-stimulatory ligand" refers to a molecule on an antigen presenting cell that specifically binds a cognate co-stimulatory molecule on a T-cell, thereby providing a signal which, in addition to the primary signal provided by, for instance, binding of a TCR/CD3 complex with an MHC molecule loaded with peptide, mediates a T cell response, including, but not limited to, proliferation activation, differentiation and the like. A co-stimulatory ligand can include but is not limited to CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, 4-1BBL, OX40L, inducible costimulatory ligand (ICOS-L), intercellular adhesion molecule (ICAM, CD30L, CD40, CD70, CD83, HLA-G, MICA, M1CB, HVEM, lymphotoxin beta receptor, 3/TR6, ILT3, ILT4, an agonist or antibody that binds Toll ligand receptor and a ligand that specifically binds with B7-H3. A co-stimulatory ligand also encompasses, inter alia, an antibody that specifically binds with a co-stimulatory molecule present on a T cell, such as but not limited to, CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LTGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83.

[0141] A "co-stimulatory molecule" refers to the cognate binding partner on a Tcell that specifically binds with a co-stimulatory ligand, thereby mediating a co-stimulatory response by the cell, such as, but not limited to proliferation. Co-stimulatory molecules include, but are not limited to an MHC class I molecule, BTLA and Toll ligand receptor.

[0142] A "co-stimulatory signal" as used herein refers to a signal, which in combination with primary signal, such as TCR/CD3 ligation, leads to T cell proliferation and/or upregulation or downregulation of key molecules.

- "bispecific antibody" refers to an antibody that has binding sites for two different antigens within a single antibody molecule. It will be appreciated by those skilled in the art that other molecules in addition to the

canonical antibody structure may be constructed with two binding specificities. It will further be appreciated that antigen binding by bispecific antibodies may be simultaneous or sequential. Bispecific antibodies can be produced by chemical techniques (see e.g., Kranz et al. (1981) Proc. Natl. Acad. Sci. USA 78, 5807), by "polydoma" techniques (See U.S. Pat. No. 4,474,893) or by recombinant DNA techniques, which all are known per se. As a non limiting example, each binding domain comprises at least one variable region from an antibody heavy chain ("VH or H region"), wherein the VH region of the first binding domain specifically binds to the lymphocyte marker such as CD3, and the VH region of the second binding domain specifically binds to tumor antigen.

- The term "extracellular ligand-binding domain" as used herein is defined as an oligo-or polypeptide that is capable of binding a ligand. Preferably, the domain will be capable of interacting with a cell surface molecule. For example, the extracellular ligand-binding domain may be chosen to recognize a ligand that acts as a cell surface marker on target cells associated with a particular disease state. Thus examples of cell surface markers that may act as ligands include those associated with viral, bacterial and parasitic infections, autoimmune disease and cancer cells.

[0143] The term "subject" or "patient" as used herein includes all members of the animal kingdom including non-human primates and humans.

[0144] The above written description of the disclosure provides a manner and process of making and using it such that any person skilled in this art is enabled to make and use the same, this enablement being provided in particular for the subject matter of the appended claims, which make up a part of the original description.

[0145] Where a numerical limit or range is stated herein, the endpoints are included. Also, all values and subranges within a numerical limit or range are specifically included as if explicitly written out.

[0146] The above description is presented to enable a person skilled in the art to make and use the invention, and is provided in the context of a particular application and its requirements. Various modifications to the preferred embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments and applications. Thus, this invention is not intended to be limited to the embodiments shown.

[0147] Having generally described this invention, a further understanding can be obtained by reference to certain specific examples, which are provided herein for purposes of illustration only, and are not intended to be limiting unless otherwise specified.

Examples

Example 1: TALE-nucleases cleaving the human GR gene

[0148] Six heterodimeric TALE-nucleases targeting exons of the human GR gene were designed and produced. Table 2 below indicates the target sequences cleaved by each TALE-nuclease. GR TALE-nuclease was composed of two independent entities (called half TALE-nucleases) each containing a repeat sequence engineered to bind and cleave GR target sequences consisting of two 17-bp long sequences (called half targets) separated by a 15-bp spacer.

Table 2: Description of the GR TALE-nucleases and sequences of the TALE-nucleases target sites in the human GR gene.

Target name	Target sequence	Repeat sequence	Half TALE-nuclease sequence
GRex2	TATTCAGTGATGGACTC caaagaatcattaac	Repeat GRex2-LPT9-L1 (SEQ ID NO: 7)	GRex2-LTALEN (SEQ ID NO: 19)

Target name	Target sequence	Repeat sequence	Half TALE-nuclease sequence
	TCCTGGTAGAGAAGAAA (SEQ ID NO: 1)	Repeat -GRex2-LPT9-R1 (SEQ ID NO: 8)	GRex2-R TALEN (SEQ ID NO: 20)
GRex3T2	TGCCTGGTGTGCTCTGA tgaagcttcaggatg TCATTATGGAGTCTTAA (SEQ ID NO: 2)	Repeat -GRex3T2-L1 (SEQ ID NO: 9)	GRex3T2-L TALEN (SEQ ID NO: 21)
		Repeat-GRex3T2-R1 (SEQ ID NO: 10)	GRex3T2-R TALEN (SEQ ID NO: 22)
GRex3T4	TGCTCTGATGAAGCTTC aggatgtcattatgg AGTCTTAAGTGTGGAA (SEQ ID NO: 3)	Repeat -GRex3T4-L1 (SEQ ID NO: 11)	GRex3T4-L TALEN (SEQ ID NO: 23)
		Repeat -GRex3T4-R1 (SEQ ID NO: 12)	GRex3T4-R TALEN (SEQ ID NO: 24)
GRex5T1	TGGTGTCAGTGTGGAG gttattgaacctgaa GTGTTATATGCAGGATA (SEQ ID NO: 4)	Repeat -GRex5T1-LPT8-L1 (SEQ ID NO: 13)	GRex5T1-L TALEN (SEQ ID NO: 25)
		Repeat -GRex5T1-LPT8-R1 (SEQ ID NO: 14)	GRex5T1-R TALEN (SEQ ID NO: 26)
GRex5T2	TATGATAGCTCTGTTCC agactcaactggag GATCATGACTACGCTCA (SEQ ID NO: 5)	Repeat -GRex5T2-L1 (SEQ ID NO: 15)	GRex5T2-L TALEN (SEQ ID NO: 27)
		Repeat GRex5T2-R1 (SEQ ID NO: 16)	GRex5T2-R TALEN (SEQ ID NO: 28)
GRex5T3	TTATATGCAGGATATGA tagctctgtccaga CTCAACTGGAGGATCA (SEQ ID NO: 6)	Repeat -GRex5T3-L1 (SEQ ID NO: 17)	GRex5T3-L TALEN (SEQ ID NO: 29)
		Repeat -GRex5T3-R1 (SEQ ID NO: 18)	GRex5T3-R TALEN (SEQ ID NO: 30)

[0149] The amino acid sequences of the N-terminal, C-terminal domains and repeat are based on the AvrBs3 TALE (ref: GenBank: X16130.1). The C-terminal and the N-terminal domains are separated by two BsmBI restriction sites. The repeat arrays (SEQ ID NO: 7 to 18), targeting the desired sequences (SEQ ID NO: 1 to 6) were synthesized using a solid support method composed of consecutive restriction/ligation/washing steps (International PCT application WO2013/017950). In brief, the first block (coding for a di-repeat) was immobilized on a solid support through biotin/streptavidin interaction, the second block (tri-repeat) was then ligated to the first and after SfaNI digestion a third bloc (tri-repeat) was coupled. The process was repeated using tri- or di-repeat blocks upon obtaining the desired repeat array. The product was then cloned in a classical pAPG10 cloning plasmid for amplification in *E. coli* and sequenced. The repeat array sequences thus obtained were subcloned in a yeast expression TALE vector using type IIS restriction enzymes BsmBI for the receiving plasmid and BbvI and SfaNI for the inserted repeat sequence. DNA coding for the half TALE-nuclease, containing a TALE derived DNA binding domain fused to the catalytic domain of the FokI restriction enzyme, was amplified in *E. coli*, recovered by standard miniprep techniques and sequenced to assess the integrity of the insert.

Activity of GR TALE-nucleases in yeast:

[0150] Nuclease activity of the six GR-TALE-nucleases were tested at 37°C and 30°C in our yeast SSA assay previously described (International PCT Applications WO 2004/067736 and in (Epinat, Arnould et al. 2003; Chames, Epinat et al. 2005; Arnould, Chames et al. 2006; Smith, Grizot et al. 2006) on targets containing the two TALE target sequences facing each other on the DNA strand separated by a spacer of 15 bps resulting in SEQ ID NO: 1 to 6. All the yeast target reporter plasmids containing the TALE-nuclease DNA target sequences were constructed as previously described (International PCT Applications WO 2004/067736 and in (Epinat, Arnould et al. 2003; Chames,

Epinat et al. 2005; Arnould, Chames et al. 2006; Smith, Grizot et al. 2006). TALE-nuclease cleavage activity levels, in yeast, of individual clones on the targets are presented in table 3.

Table 3: Cleavage activity of the GR TALE-nucleases in yeast.

Target	Half TALE-nuclease transfected	yeast gal37°C	yeast gal30°C
GRex2	Gre2-L TALEN	1	1
	Gre2-R TALEN		
GRex3T2	GRex3T2-L TALEN	0,92	0,87
	GRex3T2-R TALEN		
GRex3T4	GRex3T4-L TALEN	0,94	0,87
	GRex3T4-R TALEN		
GRex5T1	GRex5T1-L TALEN	0,48	0,36
	GRex5T1-R TALEN		
GRex5T2	GRex5T2-L TALEN	0,97	0,91
	GRex5T2-R TALEN		
GRex5T3	GRex5T3-L TALEN	1	0,98
	GRex5T3-R TALEN		
Values are comprised between 0 and 1. Maximal value is 1.			

Activity of GR TALE-nucleases in HEK293 cells:

[0151] Each TALE-nuclease construct was subcloned using restriction enzyme digestion in a mammalian expression vector under the control of a pEF1alpha long promoter.

[0152] One million HEK293cells were seeded one day prior to transfection. Cells were co-transfected with 2.5 µg of each of two plasmids encoding left and right half of GRex2, GRex3T2, GRex3T4, GRex5T1, GRex5T2 or GRex5T3 TALE-nuclease recognizing the two half targets genomic sequences of interest in the GR gene under the control of EF1alpha promoter using 25µL of lipofectamine (Invitrogen) according to the manufacturer's instructions. As a control, cells were co-transfected with 2.5 µg of each of the two plasmids encoding the left and the right half of TALE-nucleases targeting the T-cell receptor alpha constant chain region (TRAC_T01) target site ((TRAC_T01-L and -R TALE-nuclease (SEQ ID NO: 41 and SEQ ID NO: 42, TRAC_T01 target site (SEQ ID NO: 37)) under the control of EF1alpha promoter. The double strand break generated by TALE-nucleases in GR coding sequence induces non homologous end joining (NHEJ), which is an error-prone mechanism. Activity of TALE-nucleases is measured by the frequency of insertions or deletions at the genomic locus targeted.

[0153] 2 or 7 days post transfection cells were harvested and locus specific PCRs were performed on genomic DNA extracted using the following primers: 5'-CCATCTCATCCCTGCGTGTCTCCGACTCAG-3' (forward adaptor sequence)- 10N (TAG)- locus specific forward sequence for GR exon 2: 5'-GGTTCATTTAACAAGCTGCC-3' (SEQ ID NO: 31), for GR exon 3: 5'-GCATTCTGACTATGAAGTGA-3' (SEQ ID NO: 32) and for GR exon 5: 5'-TCAGCAGGCCACTACAGGAGTCTCACAAG-3' (SEQ ID NO: 33) and the reverse primer 5'-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG-3' (reverse adaptor sequence)- locus specific reverse sequence for GR exon 2 : 5'-AGCCAGTGAGGGTGAAGACG-3' (SEQ ID NO: 34), for GR exon 3 : 5'-GGGCTTTGCATATAATGGAA-3' (SEQ ID NO: 35) and for GR exon 5 : 5'-CTGACTCTCCCCTTCATAGTCCCCAGAAC-3' (SEQ ID NO: 36).

[0154] PCR products were sequenced by a 454 sequencing system (454 Life Sciences). Approximately 10,000 sequences were obtained per PCR product and then analyzed for the presence of site-specific insertion or deletion events. Table 4 indicates the percentage of the sequences showing insertions or deletions at the TALE-nuclease target site among the total number of sequences in the sample. In table 4 are listed for GRex2, GRex3T2 and GRex3T4 the results of a representative experiment.

[0155] In all cases tested, the % of mutagenesis was similar at day 7 compared to the one of the sample at day 2 post transfection. The nature of the mutagenic events was also analyzed, revealing a majority of deletions in all cases compared to insertions.

Table 4: Percentage of targeted mutagenesis at endogenous TALE-nuclease Target sites in HEK293 cells.

Target	% Indels at 2 days with GR TALE-nuclease transfection	% Indels at 7 days with GR TALE-nuclease transfection	% Indels at 2 days with TRAC_T01 TALE-nuclease control transfection
GRex2	20.3	24.9	0.5
GRex3T2	9.3	9.8	0
GRex3T4	19	18.3	0.0
GRex5T1	11.2	NA	0.7
GRex5T2	3.4	NA	0
GRex5T3	8.3	NA	0

Activity of GR TALE-nucleases in primary T lymphocytes:

[0156] Each TALE-nuclease construct was subcloned using restriction enzyme digestion in an expression vector under the control of a T7 promoter.

[0157] mRNA encoding TALE-nucleases cleaving GR genomic sequences were synthesized from each plasmid carrying the coding sequences downstream from the T7 promoter. T lymphocytes isolated from peripheral blood were activated for 5 days using anti-CD3/CD28 activator beads (Life technologies) and 5 million cells were transfected by electroporation with 10 µg of each of 2 mRNAs encoding both half TALE-nucleases using a CytoLVT-P instrument (BTX-Harvard apparatus). T cells transfected with 10µg of each of the 2 mRNAs encoding both half TALE-nucleases targeting the CD52 gene (CD52_T02-L and -R TALEN (SEQ ID NO: 55 and 56), target sequence CD52_T02 SEQ ID NO: 40) are used as a control.

[0158] 3 and 7 days after transfection, genomic DNA was isolated from transfected cells and locus specific PCRs were performed using the primers described previously. PCR products were sequenced by a 454 sequencing system (454 Life Sciences). Approximately 10,000 sequences were obtained per PCR product and then analyzed for the presence of site-specific insertion or deletion events; results are in Table 5.

Table 5: Percentage of targeted mutagenesis at endogenous TALE-nuclease target sites in primary T lymphocytes.

Target	% Indels at day 3 with GR TALE-nuclease transfection	% Indels at day 7 with GR TALE-nuclease transfection	% Indels at day 3 with CD52 TALE-nuclease control transfection
GRex2	26.2	30.7	0.7
GRex3T2	1.09	0.86	0.02
GRex3T4	6.3	6.93	0
GRex5T1	0.04	0.035	0.05
GRex5T2	1.3	1.0	0.22
GRex5T3	17.4	NA	0.41

Example 2: TALE-nucleases cleaving the human CD52 gene, the human T-cell receptor alpha constant chain (TRAC) and the human T-cell receptor beta constant chains 1 and 2 (TRBC)

[0159] As described in example 1, heterodimeric TALE-nucleases targeting respectively CD52, TRAC and TRBC genes were designed and produced. The targeted genomic sequences consist of two 17-bp long sequences (called

half targets) separated by an 11 or 15-bp spacer. Each half-target is recognized by repeats of half TALE-nucleases listed in table 6. The human genome contains two functional T-cell receptor beta chains (TRBC1 and TRBC2). During the development of alpha/beta T lymphocytes, one of these two constant chains is selected in each cell to be spliced to the variable region of TCR-beta and form a functional full length beta chain. The 2 TRBC targets were chosen in sequences conserved between TRBC1 and TRBC2 so that the corresponding TALE-nuclease would cleave both TRBC1 and TRBC2 at the same time.

Table 6: Description of the CD52, TRAC and TRBC TALE-nucleases and sequences of the TALE-nucleases target sites in the human corresponding genes.

Target	Target sequence	Repeat sequence	Half TALE-nuclease
TRAC_T01	TTGTCCACAGATATCC Agaaccctgaccctg CCGTGTACCAGCTGAGA (SEQ ID NO: 37)	Repeat TRAC_T01-L (SEQ ID NO: 41)	TRAC_T01-L TALEN (SEQ ID NO: 49)
		Repeat TRAC_T01-R (SEQ ID NO: 42)	TRAC_T01-R TALEN (SEQ ID NO: 50)
TRBC_T01	TGTGTTTGAGCCATCAG aagcagagatctccc ACACCCAAAAGGCCACA (SEQ ID NO: 38)	Repeat TRBC_T01-L (SEQ ID NO: 43)	TRBC_T01-L TALEN (SEQ ID NO: 51)
		Repeat TRBC_T01-R (SEQ ID NO: 44)	TRBC_T01-R TALEN (SEQ ID NO: 52)
TRBC_T02	TTCCACCCGAGGTCGC tgtgtttgagccatca GAAGCAGAGATCTCCA (SEQ ID NO: 39)	Repeat TRBC_T02-L (SEQ ID NO: 45)	TRBC_T02-L TALEN (SEQ ID NO: 53)
		Repeat TRBC_T02-R (SEQ ID NO: 46)	TRBC_T02-R TALEN (SEQ ID NO: 54)
CD52_T02	TTCCTCTACTACCAT cagcctcctggttat GGTACAGGTAAGAGCAA (SEQ ID NO: 40)	Repeat CD52_T02-L (SEQ ID NO: 47)	CD52_T02-L TALEN (SEQ ID NO: 55)
		Repeat CD52_T02-R (SEQ ID NO: 48)	CD52_T02-R TALEN (SEQ ID NO: 56)

[0160] Other target sequences in TRAC and CD52 genes have been designed, which are displayed in Table 7.

Table 7: Additional target sequences for TRAC and CD52 TALE-nucleases.

Target	Target sequence
TRAC_T02	TTAGAAAGTTCCTGTG atgtcaagctggtcg AGAAAAGCTTTGAAACA (SEQ ID NO: 57)
TRAC_T03	TCCAGTGACAAGTCTGT ctgcctattcaccga TTTTGATTCTCAAACAA (SEQ ID NO: 58)
TRAC_T04	TATATCACAGACAAAAC tgtgctagacatgag GTCTATGGACTTCAAGA (SEQ ID NO: 59)
TRAC_T05	TGAGGTCTATGGACTTC aagagcaacagtgct GTGGCCTGGAGCAACAA (SEQ ID NO: 60)

Target	Target sequence
CD52_T01	TTCCTCTTCCTCCTAC caccatcagcctcct TTACCTGTACCATAAC (SEQ ID NO: 61)
CD52_T04	TTCCTCCTACTCACCA cagcctcctgg TCTTACCTGTACCATA (SEQ ID NO: 62)
CD52_T05	TCCTACTCACCATCAG ctcctggttat TTGCTCTTACCTGTAC (SEQ ID NO: 63)
CD52_T06	TTATCCCACTTCTCCT ctacagatacaaact TTTTGTCCTGAGAGTC (SEQ ID NO: 64)
CD52_T07	TGGACTCTCAGGACAA acgacaccagccaaa TGCTGAGGGGCTGCTG (SEQ ID NO: 65)

Activity of CD52-TALE-nuclease, TRAC-TALE-nuclease and TRBC-TALE-nuclease in HEK293 cells

[0161] Each TALE-nuclease construct was subcloned using restriction enzyme digestion in a mammalian expression vector under the control of pEF1alpha long promoter. One million HEK293 cells were seeded one day prior to transfection. Cells were co-transfected with 2.5 µg of each of the two plasmids encoding the TALE-nucleases recognizing the two half targets in the genomic sequence of interest in the CD52 gene, T-cell receptor alpha constant chain region (TRAC) or T-cell receptor beta constant chain region (TRBC) under the control of the EF1-alpha promoter or 5 µg of a control pUC vector (pCLS0003) using 25 µl of lipofectamine (Invitrogen) according to the manufacturer's instructions. The double stranded cleavage generated by TALE-nucleases in CD52 or TRAC coding sequences is repaired in live cells by non homologous end joining (NHEJ), which is an error-prone mechanism. Activity of TALE-nucleases in live cells is measured by the frequency of insertions or deletions at the genomic locus targeted. 48 hours after transfection, genomic DNA was isolated from transfected cells and locus specific PCRs were performed using the following primers: 5'-CCATCTCATCCCTGCGTGTCTCCGACTCAG (forward adaptor sequence)-10N (TAG)- locus specific forward sequence for CD52: 5'-CAGATCTGCAGAAAGGAAGC-3' (SEQ ID NO: 66), for TRAC: 5'-ATCACTGGCATCTGGACTCCA-3' (SEQ ID NO: 67), for TRBC1: 5'-AGAGCCCCTACCAGAACCAGAC-3' (SEQ ID NO: 68), or for TRBC2: 5'-GGACCTAGTAACATAATTGTGC-3' (SEQ ID NO: 69), and the reverse primer 5'-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG (reverse adaptor sequence)- endogenous locus specific reverse sequence for CD52: 5'-CCTGTTGGAGTCCATCTGCTG-3' (SEQ ID NO: 70), for TRAC: 5'-CCTCATGTCTAGCACAGTTT-3' (SEQ ID NO: 71), for TRBC1 and TRBC2: 5'-ACCAGCTCAGCTCCACGTGGT-3' (SEQ ID NO: 72). PCR products were sequenced by a 454 sequencing system (454 Life Sciences). Approximately 10,000 sequences were obtained per PCR product and then analyzed for the presence of site-specific insertion or deletion events; results are in Table 8.

Table 8: Percentages of indels for TALE-nuclease targeting CD52_T02, TRAC_T01, TRBC_T01 and TRBC_T02 targets.

Target	% Indels with TALE-nuclease transfection	% Indels with pUC control transfection
CD52_T02	28.0	0.9
TRAC_T01	41.9	0.3
TRBC_T01 in constant chain 1	3.81	0
TRBC_T01 in constant chain 2	2.59	0
TRBC_T02 in constant chain 1	14.7	0
TRBC_T02 in constant chain 1	5.99	0

Activity of CD52-TALE-nuclease, TRBC-TALE-nuclease and TRAC-TALE-nuclease in primary T lymphocytes

[0162] Each TALE-nuclease construct was subcloned using restriction enzyme digestion in a mammalian expression vector under the control of the T7 promoter.

[0163] mRNA encoding TALE-nuclease cleaving CD52 TRAC and TRBC genomic sequence were synthesized from plasmid carrying the coding sequences downstream from the T7 promoter. T lymphocytes isolated from peripheral blood were activated for 5 days using anti-CD3/CD28 activator beads (Life technologies) and 5 million cells were then transfected by electroporation with 10 µg of each of 2 mRNAs encoding both half TALE-nuclease (or non coding RNA as controls) using a CytoLVT-P instrument. As a consequence of the insertions and deletions induced by NHEJ, the coding sequence for CD52 and/or TRAC will be out of frame in a fraction of the cells resulting in non-functional genes. 5 days after electroporation, cells were labeled with fluorochrome-conjugated anti-CD52 or anti-TCR antibody by flow cytometry for the presence of CD52 or TCR at their cell surface. Since all T lymphocytes expanded from peripheral blood normally express CD52 and TCR, the proportion of CD52-negative or TCR-negative cells is a direct measure of TALE-nuclease activity. In table 9 are listed the results of a representative experiment. The table 10 shows the results of a representative experiment testing the efficiency of TRBC TALE-nucleases.

Table 9: Percentages of CD52- negative, TCR-negative and CD52/TCR-double negative T lymphocytes after transfection of corresponding TALE-nuclease-expressing polynucleotides.

ARN transfected	% CD52-negative cells	% TCR-negative cells	% CD52/TCR double negative cells
non coding RNA	1,21	1,531	0,111
TALEN CD52_T02	49,2	1,6	0,78
TALEN TRAC_T01	2,16	44,8	0,97
TALEN CD52_T02 + TALEN TRAC_T01	29,3	39,6	15,5

Table 10: Percentages of TCR-negative T lymphocytes after transfection of TRBC TALE-nuclease-expressing polynucleotides.

ARN transfected	% TCR-negative cells
no RNA	1,22
TALEN TRBC_T01	6,52
TALEN TRBC_T02	23,5

Functional analysis of T cells with targeted CD52 gene

[0164] The goal of CD52 gene inactivation is to render T lymphocytes resistant to anti-CD52 antibody mediated immunosuppression. As described in the previous paragraph, T lymphocytes were transfected with mRNA encoding TALE-nuclease cleaving CD52. 7 days after transfection, cells were treated with 50µg/ml anti-CD52 monoclonal

antibody (or rat IgG as control) with or without 30% rabbit complement (Cedarlane). After 2 hours of incubation at 37°C, the cells were labeled with a fluorochrome-conjugated anti-CD52 antibody together with a fluorescent viability dye (eBioscience) and analyzed by flow cytometry to measure the frequency of CD52-positive and CD52-negative cells among live cells. Figure 6 shows the result of a representative experiment, demonstrating that CD52-negative cells are completely resistant to complement-mediated anti-CD52 antibody toxicity.

Functional analysis of T cells with targeted TRAC gene

[0165] The goal of TRAC gene inactivation is to render T lymphocytes unresponsive to T-cell receptor stimulation. As described in the previous paragraph, T lymphocytes were transfected with mRNA encoding TALE-nuclease cleaving TRAC or CD52. 16 days after transfection, cells were treated with up to 5µg/ml of phytohemagglutinin (PHA, Sigma-Aldrich), a T-cell mitogen acting through the T cell receptor. Cells with a functional T-cell receptor should increase in size following PHA treatment. After three days of incubation, cells were labeled with a fluorochrome-conjugated anti-CD52 or anti-TCR antibody and analyzed by flow cytometry to compare the cell size distribution between TCR-positive and TCR-negative cells, or between CD52-positive and CD52-negative cells. Figure 7 shows that TCR-positive cells significantly increase in size after PHA treatment whereas TCR-negative cells have the same size as untreated cells indicating that TRAC inactivation rendered them unresponsive to TCR-signaling. By contrast, CD52-positive and CD52-negative increase in size to same extent.

Functional analysis of T cells with targeted CD52 and TRAC genes

[0166] To verify that genome engineering did not affect the ability of T cells to present anti-tumor activity when provided with a chimeric antigen receptor (CAR), we transfected T cells that had been targeted with CD52-TALE-nuclease and TRAC-TALE-nuclease with 10µg of RNA encoding an anti-CD19 CAR (SEQ ID NO: 73). 24 hours later, T cells were incubated for 4 hours with CD19 expressing Daudi cells. The cell surface upregulation of CD107a, a marker of cytotoxic granule release by T lymphocytes (called degranulation) was measured by flow cytometry analysis (Betts, Brenchley et al. 2003). The results are included in Figure 8 and show that CD52-negative/TCRαβ-negative cells and CD52-positive/TCRαβ-positive have the same ability to degranulate in response to PMA/ionomycin (positive control) or CD19+ Daudi cells. CD107 upregulation is dependent on the presence of a CD19+. These data suggest that genome engineering has no negative impact on the ability of T cells to mount a controlled anti-tumor response.

Genomic safety of CD52-TALE-nuclease and TRAC-TALE-nuclease in primary T lymphocytes

[0167] As our constructs include nuclease subunits, an important question is whether multiple TALE-nuclease transfection can lead to genotoxicity and off-target cleavage at 'close match' target sequences or by mispairing of half-TALE-nucleases. To estimate the impact of TRAC-TALE-nuclease and CD52-TALE-nuclease on the integrity of the cellular genomes, we listed sequences in the human genome that presented the potential for off-site cleavage. To generate this list, we identified all the sequences in the genome with up to 4 substitutions compared to the original half targets and then identified the pairs of potential half targets in a head to head orientation with a spacer of 9 to 30 bp from each other. This analysis included sites potentially targeted by homodimers of one half-TALE-nuclease molecule or heterodimers formed by one CD52 half TALE-nuclease and one TRAC half-TALE-nuclease. We scored the potential off-site targets based on the specificity data taking into account the cost of individual substitutions and the position of the substitutions (where mismatches are better tolerated for bases at the 3' end of the half target). We obtained 173 unique sequences with a score reflecting an estimation of the likelihood of cleavage. We selected the 15 top scores and analyzed by deep sequencing the frequency of mutations found at these loci in T cells simultaneously transfected with CD52 and TRAC TALE-nuclease and purified by magnetic separation as CD52-negative, TCRαβ-negative. Results are in Figure 9. The highest frequency of insertion/deletion is 7×10^{-4} . These results make the putative offsite target at least 600 times less likely to be mutated than the intended targets. The TALE-nuclease reagents used in this study therefore appear extremely specific.

Example 3: TALE-nucleases cleaving the human CTLA4 gene and the human PDCD1 gene.

[0168] As described in example 1, heterodimeric TALE-nucleases targeting respectively PDCD1 and CTLA4 genes were designed and produced. The targeted genomic sequences consist of two 17-bp long sequences (called half targets) separated by an 11 or 15-bp spacer. Each half-target is recognized by repeats of half TALE-nucleases listed in table 11.

Table 11: Description of the CTLA4 and PDCD1 TALE-nucleases and sequences of the TALE-nucleases target sites in the human corresponding genes.

Target	Target sequence	Repeat sequence	Half TALE-nuclease
CTLA4_T01	TGGCCCTGCACTCTCCT gttttttcttctctt CATCCCTGTCTTCTGCA (SEQ ID NO: 74)	Repeat CTLA4_T01-L (SEQ ID NO: 79)	CTLA4_T01-L TALEN (SEQ ID NO: 89)
		Repeat CTLA4_T01-R (SEQ ID NO: 80)	CTLA4_T01-R TALEN (SEQ ID NO: 90)
CTLA4_T03	TTTTCCATGCTAGCAAT gcacgtggcccagcc TGCTGTGGTACTGGCCA (SEQ ID NO : 75)	Repeat CTLA4_T03-L (SEQ ID NO: 81)	CTLA4_T03-L TALEN (SEQ ID NO: 91)
		Repeat CTLA4_T03-R (SEQ ID NO: 82)	CTLA4_T03-R TALEN (SEQ ID NO: 92)
CTLA4_T04	TCCATGCTAGCAATGCA cgtggcccagcctgc TGTGGTACTGGCCAGCA (SEQ ID NO: 76)	Repeat CTLA4_T04-L (SEQ ID NO: 84)	CTLA4_T04-L TALEN (SEQ ID NO: 93)
		Repeat CTLA4_T04-R (SEQ ID NO: 85)	CTLA4_T04-R TALEN (SEQ ID NO: 94)
PDCD1_T01	TTCTCCCCAGCCCTGCT cgtggtgaccgaagg GGACAACGCCACCTTCA (SEQ ID NO : 77)	Repeat PDCD1_T01-L (SEQ ID NO: 86)	PDCD1_T01-L TALEN (SEQ ID NO: 95)
		Repeat PDCD1_T01-R (SEQ ID NO: 87)	PDCD1_T01-R TALEN (SEQ ID NO: 96)
PDCD1_T03	TACCTCTGTGGGGCCAT ctccctggcccccaa GGCGCAGATCAAAGAGA (SEQ ID NO : 78)	Repeat PDCD1_T03-L (SEQ ID NO: 88)	PDCD1_T03-L TALEN (SEQ ID NO: 97)
		Repeat PDCD1_T03-R (SEQ ID NO: 89)	PDCD1_T03-R TALEN (SEQ ID NO: 98)

Activity of CTLA4-TALE-nuclease and PDCD1-TALE-nuclease in HEK293 cells

[0169] Each TALE-nuclease construct was subcloned using restriction enzyme digestion in a mammalian expression vector under the control of the pEF1alpha long promoter. One million HEK293 cells were seeded one day prior to transfection. Cells were co-transfected with 2.5 µg of each of two plasmids encoding the TALE-nucleases recognizing the two half targets in the genomic sequence of interest in the PDCD1 and CTLA-4 gene under the control of the EF1-alpha promoter or 5 µg of a control pUC vector (pCLS0003) using 25 µl of lipofectamine (Invitrogen) according to the manufacturer's instructions.

[0170] The double stranded cleavage generated by TALE-nucleases in PDCD1 or CTLA-4 coding sequences is repaired in live cells by non homologous end joining (NHEJ), which is an error-prone mechanism. Activity of TALE-nucleases in live cells is measured by the frequency of insertions or deletions at the genomic locus targeted. 48 hours after transfection, genomic DNA was isolated from transfected cells and locus specific PCRs were performed using the following primers: 5'-CCATCTCATCCCTGCGTGTCTCCGACTCAG (forward adaptor sequence)- 10N (TAG)- locus specific forward sequence for CTLA4_T01: 5'-CTCTACTTCCTGAAGACCTG-3' (SEQ ID NO: 99), for

CTLA4_T03/T04: 5'-ACAGTTGAGAGATGGAGGGG-3' (SEQ ID NO: 100), for PDCD1_T01: 5'-CCACAGAGGTAGGTGCCGC-3' (SEQ ID NO: 101) or for PDCD1_T03: 5'-GACAGAGATGCCGGTCACCA-3' (SEQ ID NO: 102) and the reverse primer 5'-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG (reverse adaptor sequence)-endogenous locus specific reverse sequence for CTLA4_T01: 5'-TGGAATACAGAGCCAGCCAA-3' (SEQ ID NO: 103), for CTLA4_T03/T04: 5'-GGTGCCCGTGCGAGATGGAAT-3' (SEQ ID NO: 104), for PDCD1_T01: 5'-GGCTCTGCAGTGGAGGCCAG-3' (SEQ ID NO: 105) or for PDCD1_T03: 5'-GGACAACGCCACCTTCACCT-3' (SEQ ID NO: 106).

[0171] PCR products were analyzed by T7-endonuclease assay: briefly, after denaturation and reannealing of the PCR product, T7 endonuclease will specifically digest mismatched DNA composed of wild type and mutated strands. The digestion product is then resolved by polyacrylamide gel electrophoresis. The presence of a digested product is indicative of mutated sequences induced by TALE-nuclease activity. Results are displayed in Figure 10 where arrows point to the digested PCR products. They demonstrate that PDCD1_T1, PDCD1_T3, CTLA4_T1, CTLA4_T3 and CTLA4_T4 TALE-nucleases all exhibit mutagenic nuclease activity at their target sites.

CTLA4 inactivation in primary T cells:

[0172] Human primary T cells were activated with CD3/28 beads. Five days later, 5×10^6 cells were electroporated with 20 µg of RNA encoding one of three TALEN™ (T1, T2 and T3) designed with respect to CTLA4 gene or without RNA as control. Three days post electroporation, CTLA4 expression was measured by intracellular staining using fluorescent antibody and flow cytometry analysis (Figures 27 and 28).

[0173] All three TALEN™ induced downregulation of CTLA4 expression in a manner correlated with their efficiency in HEK293 cell lines (T1 was more efficient than T3 and T4).

[0174] Deep sequencing analysis of genomic DNA isolated from transfected cells using 454 technology (Roche) revealed that 96 % of CTLA4 alleles were mutated in TALEN T1-treated cells compared to 0.1% in the control sample without TALEN.

PD1 inactivation in primary T cells:

[0175] Human primary T cells were activated with CD3/28 beads. Five days later 5×10^6 cells were electroporated with 20 µg of RNA encoding one of two TALENs specific for human PD1 gene or without RNA as control. Ten days later, cells were re-activated and 3 days post re-activation, PD1 expression was measured by surface staining using fluorescent antibody and flow cytometry analysis (see Figure 29).

[0176] Both TALENs induced significant downregulation of PD1 expression. Deep sequencing analysis of genomic DNA isolated from cells transfected with TALEN T1 and TALEN T03 respectively using 454 technology (Roche) revealed that 34 % and 39% of PD1 alleles were mutated respectively (results shown in Figure 30).

Enhanced anti-tumor activity PD1-TALEN treated cells:

[0177] Human primary T cells were activated with CD3/28 beads. Five days later 5×10^6 cells were electroporated with 20 µg of RNA encoding a TALEN specific for human PD1 gene or without RNA as control. A week later, cells were electroporated with mRNA encoding a chimeric antigen receptor specific for human CD19 or no RNA as negative control. The next day, their antitumor activity was measured in cellular cytotoxicity assay using CD19+ Daudi cells (vs. K562 as control) or HCT116 cells, which express PD1ligand 1 (PDL1) transduced with CD19 expression vector (vs. parental HCT116 cells as control). Cytotoxic activity was determined by comparing viability of target cells and control cells. Results are shown in the diagrams of Figure 31. PD1 TALEN transfection restored cytotoxic activity against PDL1-expressing HCT116 cells and improved cytotoxic activity against Daudi cells.

Example 4: pTalpha permits CD3 surface expression in inactivated TCR alpha T lymphocytes:

Description of the different preTalpha versions:

[0178] The human pTalpha gene encodes a transmembrane glycoprotein comprising an extracellular Ig-like domain, a hydrophobic transmembrane domain and a large C-terminal intracytoplasmic tail. Different versions derived from human pTalpha glycoprotein have been designed and are described in Table 12 and represented in figure 11.

Table 12: Description of a subset of pTalpha constructs

PTalpha versions	Description	SEQ ID
pTalpha-FL	Full-length of human pTalpha glycoprotein	107
pTalpha-Δ18	Truncated Human pTalpha glycoprotein lacking 18 residues from the C-terminus.	108
pTalpha-Δ48	Truncated Human pTalpha glycoprotein lacking 48 residues from the C-terminus.	109
pTalpha-Δ62	Truncated Human pTalpha glycoprotein lacking 62 residues from the C-terminus.	110
pTalpha-Δ78	Truncated Human pTalpha glycoprotein lacking 78 residues from the C-terminus.	111
pTalpha-Δ92	Truncated Human pTalpha glycoprotein lacking 92 residues from the C-terminus.	112
pTalpha-Δ110	Truncated Human pTalpha glycoprotein lacking 110 residues from the C-terminus.	113
pTalpha-Δ114	Truncated Human pTalpha glycoprotein lacking 114 residues from the C-terminus.	114
pTalpha-FL-CD28	Full-length of human pTalpha glycoprotein fused in C-terminus with CD28 activation domain.	115
pTalpha-FL-CD8	Full-length of human pTalpha glycoprotein fused in C-terminus with CD8 activation domain.	116
pTalpha-FL-4-1BB	Full-length of human pTalpha glycoprotein fused in C-terminus with 4-1BB activation domain.	117
pTalpha-Δ48-CD28	pTalpha-Δ48 glycoprotein fused in C-terminus with CD28 activation domain.	118
pTalpha -Δ48-CD8	pTalpha-Δ48 glycoprotein fused in C-terminus with CD8 activation domain.	119
pTalpha-Δ48-41BB	pTalpha-Δ48 glycoprotein fused in C-terminus with 4-1BB activation domain.	120
pTalpha-Δ114/TCRα.IC	pTalpha-Δ114 glycoprotein fused in C-terminus with the intracellular domain of TCRα	121
pTalpha-EC/TCRα.TM.IC	pTalpha extracellular domain fused in C-terminus with the transmembrane and intracellular domain of TCRα.	122
pTalpha-Δ48-1xMUT	pTalpha-Δ48 glycoprotein with mutated residue W46R.	123
preTalpha-Δ48-4xMUT	pTalpha-Δ48 glycoprotein with mutated residues D22A, K24A, R102A, R117A	124

[0179] The different preTalpha constructs tested include:

- 1) **pTalpha deletion mutants:** Different deletions were generated in the intracellular cytoplasmic tail of the

human pTalpha protein (which comprises 114 amino acids) (SEQ ID NO: 107). The constructs tested include the full length version of the protein (FL) and mutants in which 18, 48, 62, 78, 92, 110 and 114 amino acids were deleted from the C-terminus of the protein (SEQ ID NO: 108 to SEQ ID NO: 114).

2. 2) **pTalpha mutants containing intracellular activation domains:** The FL and $\Delta 48$ variants were fused to the CD8, CD28 or 41BB intracellular activation domains at their C-terminus (SEQ ID NO: 115 to SEQ ID NO: 120).
3. 3) **pTalpha/TCR α chimeric mutants:** In one of the constructs, the TCR α intracellular domain (IC) was fused to a tail-less version ($\Delta 114$) of pTalpha (SEQ ID NO: 121). A second construct was also generated in which the pTalpha extracellular domain was fused to the transmembrane (TM) and the IC domains from TCR α (SEQ ID NO: 122).
4. 4) **pTalpha dimerization mutants:** Some mutations have been described in the literature as being capable to alter the oligomerisation/dimerisation ability of the preTCR complex. These mutants are proposed to allow preTCR expression at the cell surface, without inducing the constitutive signaling (supposed to be induced upon preTCR oligomerization). The mutations have been introduced in the pTalpha $\Delta 48$ variant and are:
 - 1xMUT: W46R (SEQ ID NO: 123)
 - 4x MUT: D22A, K24A, R102A, R117A (SEQ ID NO: 124)

Activity of different preTalpha constructs in TRAC inactivated Jurkat cells:

[0180] In order to screen different pTalpha variants for their ability to restore CD3 surface expression in TCRalpha inactivated cells, a cell line was generated in which the TCRalpha gene was disrupted using TALEN targeting TRAC. Jurkat cells (a T-cell leukemia cell line) were transfected with plasmids coding for the TALEN cleaving TRAC using CytoPulse electroporation, and the KO cells (TCR α/β ^{NEG}; CD3^{NEG}) were then purified by negative selection using CD3 magnetic beads. The KO population (JKT_KOx3 cells) was amplified and used for screening of the different pTalpha variants. Screening was performed by transfection of one million of JKT_KOx3 cells with 15 μ g of plasmid coding the different pTalpha variants under control of the EF1 α promoter, followed by analysis by flow cytometry of CD3 cell surface expression 48h after transfection. Figure 12 is a representative example of the transfection efficiencies (% of BFP+ cells) and activity of the FL, $\Delta 18$ and $\Delta 48$ pTalpha constructs in JKT_KOx3 cells, based on the % of CD3+ cells, determined by flow cytometry. The results from the different constructs are grouped in Table 13.

Mutant	ID	% CD3 _{LOW}	SD
0	NEG	4,69	1,53
1	preTCR α -FL	31,18	4,15
2	preTCR α - $\Delta 18$	20,13	4,56
3	preTCR α - $\Delta 48$	44,86	3,90
4	preTCR α - $\Delta 62$	32,42	2,95
5	preTCR α - $\Delta 78$	24,75	3,87
6	preTCR α - $\Delta 92$	20,63	3,70
7	preTCR α - $\Delta 110$	18,18	3,49
8	preTCR α - $\Delta 114$	4,29	2,74
9	preTCR α -FL-CD8	18,16	5,30
10	preTCR α -FL-CD28	5,67	2,77
11	preTCR α -FL-41BB	27,27	3,66
12	preTCR α - $\Delta 48$ -CD8	11,56	6,01
13	preTCR α - $\Delta 48$ -CD28	12,22	4,72
14	preTCR α - $\Delta 48$ -41BB	35,93	4,55
15	preTCR α - $\Delta 114$ /TCR α .IC	3,94	1,95
16	preTCR α -EC/TCR α .TM.IC	17,80	4,47
17	preTCR α - $\Delta 48$ -1xMUT	26,88	4,37
18	preTCR α - $\Delta 48$ -4xMUT	7,59	1,06

Table 13: Activity of the different pTalpha constructs in Jurkat TCR alpha inactivated cells. Activity was measured by flow cytometry analysis of CD3 expression in jurkat TCR alpha inactivated cells transfected with the different preTalpha constructs.

Activity of pTalpha-FL and pTalpha- $\Delta 48$ in TCR alpha inactivated primary T lymphocytes:

[0181] In order to test the ability of pTalpha-FL and pTalpha-Δ48 versions to induce CD3 surface expression in TCR alpha inactivated T lymphocytes, pTalpha-FL and pTalpha-Δ48 coding sequences were cloned into a self-inactivating pLV-SFFV-BFP-2A-PCTRA lentiviral vector that codes for Blue Fluorescent protein (BFP) under the SFFV promoter followed by the self-cleaving T2A peptide (figure 13).

[0182] T lymphocytes isolated from peripheral blood were activated for 72 hours using anti-CD3/CD28 activator beads (Life technologies) and 4.5 million cells were transfected by electroporation with 10 µg mRNA encoding the TALE-nuclease targeting TCR alpha constant chain region (TRAC) using a CytoLVT-S instrument (BTX-Harvard Harbour). Two days after electroporation, T cells were transduced with either the LV-SFFV-BFP-2A- pTalpha-Δ48 or LV-SFFV-BFP-2A-control lentiviral vectors. CD3 negative and CD3^{low} T cells were then purified using anti-CD3 magnetic beads (Miltenyi Biotech). This experimental protocol is represented in Figure 14A.

[0183] Figure 14B represents flow cytometry analysis of TCRalpha/beta, CD3 cell surface expression, and BFP expression on TCRalpha inactivated T cells (KO) transduced with either BFP-2A-pTalphaΔ48 (KO/Δ48) or control BFP lentiviral vector (KO/BFP) before and after purification with CD3 beads. TCRalpha inactivated cells transduced with the BFP-T2A-pTalpha-Δ48 vector (BFP+ cells) show higher levels of CD3 compared to non transduced cells (BFP- cells). No differences are observed among cells transduced with the control BFP vector. These results indicate that pTalpha mediates restoration of CD3 expression at the cell surface of TCRalpha inactivated cells. In contrast, TCRalpha/beta staining remains, as expected, unchanged in cells transduced or not with the pTalpha-Δ48 expressing vector.

pTalpha-mediated CD3 expression supports activation of TCR-deficient T-cells:

[0184] To determine the capacity of pTalpha to transduce cell activation signals, expression of early and later activation markers was analyzed on TCR alpha inactivated T cells transduced with pTalpha-Δ48 and pTalpha-Δ48.41BB. TCR alpha inactivated T cells transduced with pTalpha-Δ48 and pTalpha-Δ48.41BB were generated from primary human T-cells as described in previous section and in Figure 14A.

[0185] To detect signaling via CD3, cells were re-activated using anti-CD3/CD28-coated beads 3 days after purification of TCR alpha inactivated T cells with CD3 beads (figure 14A). Cells were stained with fluorochrome-conjugated anti-CD69 (early activation marker) and anti-CD25 (late activation marker), 24 and 48 hours after re-activation respectively and analyzed by flow cytometry (Figure 15A-B). As represented in figure 15A-B, TCR alpha inactivated cells expressing pTalpha-Δ48 (KO/pTα-Δ48) or pTalpha-Δ48.41BB (KO/pTα-Δ48.BB) show upregulation of the activation markers, to levels similar to those observed in TCRalpha/beta expressing cells (NEP: non electroporated cells).

Another indicator of T cell activation is an increase in cell size which is sometimes referred to as "blasting". The capacity of the preTCR complexes to induce "blasting" was measured by flow cytometry analysis of the cell size 72 hours after re-activation using anti-CD3/CD28-beads (Figure 15C). Stimulation with anti-CD3/CD28 beads induced comparable increases in cell size in cells expressing TCRalpha/beta complexes vs. cells expressing pTalpha-Δ48 or pTalpha-Δ48.41BB. Taken together, these results suggest that preTCR complexes are competent to transduce signals that efficiently couple to the mechanisms mediating activation marker upregulation.

pTalpha mediated CD3 expression supports expansion of TCR-deficient primary T-cells using stimulatory anti-CD3/CD28 antibodies

[0186] To evaluate the capacity of preTCR complexes to support long term cell proliferation, proliferation of cells generated as previously described was measured. Ten days after the initial activation, cells were maintained in IL2 (non-Re-act) or in IL2 with anti-CD3/CD28 beads (Re-act). For each condition, cells were counted and analyzed by flow cytometry at the different time points to estimate the number of BFP+ cells. The growth of TCRalpha inactivated

cells (KO) transduced with BFP or BFP-T2A-preTCR α - Δ 48 vectors was compared, and the fold induction of these cells was estimated with respect to the value obtained at day 2 post re-activation. Figure 16 shows the results obtained with two independent donors. In both cases, TCRalpha inactivated cells expressing pTalpha- Δ 48 displayed greater expansion than TCR alpha inactivated cells expressing only the BFP control vector. For the second donor, TCRalpha inactivated cells expressing pTalpha- Δ 48.41BB or full-length pTalpha were also included, displaying also greater expansion than TCRalpha inactivated cells expressing only the BFP control vector.

Example 5: optimization of mRNA transfection in T cells using Cytopulse Technology.

Determination of the optimized cytopulse program

[0187] A first set of experiments were performed on non activated PBMCs in order to determine a voltage range in which cells could be transfected. Five different programs were tested as described in Table 14.

Table 14 : Different cytopulse programs used to determine the minimal voltage required for electroporation in PBMC derived T-cells.

	Group 1				Group 2				Group 3			
<u>Cyto-pulse program</u>	Pulses	V	duration (ms)	Interval (ms)	Pulses	V	duration (ms)	Interval (ms)	Pulses	V	duration (ms)	Interval (ms)
1	1	600	0.1	0.2	1	600	0.1	100	4	130	0.2	2
2	1	900	0.1	0.2	1	900	0.1	100	4	130	0.2	2
3	1	1200	0.1	0.2	1	1200	0.1	100	4	130	0.2	2
4	1	1200	0.1	10	1	900	0.1	100	4	130	0.2	2
5	1	900	0.1	20	1	600	0.1	100	4	130	0.2	2

[0188] 3 or 6 million of cells were electroporated in 0.4 cm gap cuvette (30 or 15x10⁶ cells/ml) with 20 μ g of plasmids encoding GFP and control plasmids pUC using the different Cytopulse programs. 24 hours post electroporation, GFP expression was analyzed in electroporated cells by flow cytometry to determine the efficiency of transfection. The data shown in Figure 17 indicates the minimal voltage required for plasmid electroporation in PBMC derived T cells. These results demonstrate that the cytopulse program 3 and 4 allow an efficient transformation of T cells (EP#3 and #4).

Electroporation of mRNA of purified Tcells activated

[0189] After determining the best cytopulse program that allows an efficient DNA electroporation of T cells, we tested whether this method was applicable to the mRNA electroporation.

[0190] 5x10⁶ purified T cells preactivated 6 days with PHA/IL2 were resuspended in cytoporation buffer T (BTX-Harvard apparatus) and electroporated in 0.4 cm cuvettes with 10 μ g of mRNA encoding GFP or 20 μ g of plasmids encoding GFP or pUC using the preferred cytopulse program as determined in the previous section (table 15).

Table 15: Cytopulse program used to electroporate purified T-cells.

	Group 1				Group 2				Group 3			
<u>Cyto-pulse program</u>	Pulse	V	duration (ms)	Interval (ms)	Pulse	V	duration (ms)	Interval (ms)	Pulse	V	duration (ms)	Interval (ms)
3	1	1200	0.1	0.2	1	1200	0.1	100	4	130	0.2	2

[0191] 48h after transfection cells were stained with viability dye (eFluor-450) and the cellular viability and % of viable GFP+ cells was determined by flow cytometry analysis (Figure 18).

[0192] The data shown in Figure 18 indicates that the electroporation of RNA with the optimal condition determined here is no toxic and allows transfection of more than 95% of the viable cells.

[0193] In synthesis, the whole dataset shows that T-cells can be efficiently transfected either with DNA or RNA. In particular, RNA transfection has no impact on cellular viability and allows uniform expression levels of the transfected gene of interest in the cellular population.

[0194] Efficient transfection can be achieved early after cellular activation, independently of the activation method used (PHA/IL-2 or CD3/CD28-coated-beads). The inventors have succeeded in transfecting cells from 72h after activation with efficiencies of >95%. In addition, efficient transfection of T cells after thawing and activation can also be obtained using the same electroporation protocol.

mRNA electroporation in primary human T cells for TALE-nuclease functional expression

[0195] After demonstrating that mRNA electroporation allow efficient expression of GFP in primary human T cells, we tested whether this method was applicable to the expression of other proteins of interest. Transcription activator-like effector nucleases (TALE-nuclease) are site-specific nucleases generated by the fusion of a TAL DNA binding domain to a DNA cleavage domain. They are powerful genome editing tools as they induce double-strand breaks at practically any desired DNA sequence. These double-strand breaks activate Non-homologous end-joining (NHEJ), an error-prone DNA repair mechanism, potentially leading to inactivation of any desired gene of interest. Alternatively, if an adequate repair template is introduced into the cells at the same time, TALE-nuclease-induced DNA breaks can be repaired by homologous recombination, therefore offering the possibility of modifying at will the gene sequence.

[0196] We have used mRNA electroporation to express a TALE-nuclease designed to specifically cleave a sequence in the human gene coding for the alpha chain of the T cell antigen receptor (TRAC). Mutations induced in this sequence are expected to result in gene inactivation and loss of TCR $\alpha\beta$ complex from the cell surface. TRAC TALE-nuclease RNA or non coding RNA as control are transfected into activated primary human T lymphocytes using Cytopulse technology. The electroporation sequence consisted in 2 pulses of 1200 V followed by four pulses of 130 V as described in Table 15.

[0197] By flow cytometry analysis of TCR surface expression 7 days post electroporation (Figure 19, top panel), we observed that 44% of T cells lost the expression of TCR $\alpha\beta$. We analyzed the genomic DNA of the transfected cells by PCR amplification of the TRAC locus followed by 454 high throughput sequencing. 33% of alleles sequenced (727 out of 2153) contained insertion or deletion at the site of TALE-nuclease cleavage. Figure 19 (bottom panel) shows examples of the mutated alleles.

[0198] These data indicate that electroporation of mRNA using cytopulse technology results in functional expression of TRAC TALE-nuclease.

Electroporation of T cells with a monocistronic mRNA encoding for an anti-CD19 single chain chimeric antigen receptor (CAR):

[0199] 5×10^6 T cells preactivated several days (3-5) with anti-CD3/CD28 coated beads and IL2 were resuspended in cytoporation buffer T, and electroporated in 0.4cm cuvettes without mRNA or with 10 μ g of mRNA encoding a single chain CAR (SEQ ID NO: 73) using the program described in Table 15.

[0200] 24 hours post electroporation, cells were stained with a fixable viability dye eFluor-780 and a PE-conjugated goat anti mouse IgG F(ab')₂ fragment specific to assess the cell surface expression of the CAR on the live cells. The

data is shown in the figure 20. A indicates that the vast majority of the live T cells electroporated with the monocistronic mRNA described previously express the CAR at their surface. 24 hours post electroporation, T cells were cocultured with Daudi (CD19⁺) cells for 6 hours and analyzed by flow cytometry to detect the expression of the degranulation marker CD107a at their surface (Betts, Brenchley et al. 2003).

[0201] The data shown in figure 20 indicates that the majority of the cells electroporated with the monocistronic mRNA described previously degranulate in the presence of target cells expressing CD19. These results clearly demonstrate that the CAR expressed at the surface of electroporated T cells is active.

Electroporation of T cells with a polycistronic mRNA encoding for an anti-CD19 multisubunit chimeric antigen receptor (CAR):

[0202] 5X10⁶ T cells preactivated several days (3-5) with anti CD3/CD28 coated beads and IL2 were electroporated in cytoporation buffer T, and electroporated in 0.4cm cuvettes without mRNA or with 45µg of mRNA encoding a multi-chain CAR (SEQ ID NO: 125, encoded by SEQ ID NO: 126, Figure 21A and figure 4B (csm4)) using the program as described in Table 15.

[0203] 24 hours post electroporation, cells were stained with a fixable viability dye eFluor-780 and a PE-conjugated goat anti mouse IgG F(ab')₂ fragment specific to assess the cell surface expression of the CAR on the live cells. The data shown in Figure 21 indicates that the vast majority of the live T cells electroporated with the polycistronic mRNA described previously express the CAR at their surface.

[0204] 24 hours post electroporation, T cells were cocultured with Daudi (CD19⁺) for 6 hours and analyzed by flow cytometry to detect the expression of the degranulation marker CD107a at their surface. The data shown in Figure 21 indicates that the majority of the cells electroporated with the polycistronic mRNA described previously degranulate in the presence of target cells expressing CD19. These results clearly demonstrate that the CAR expressed at the surface of electroporated T cells is active.

List of references cited in the description

[0205]

Arimondo, P. B., C. J. Thomas, et al. (2006). "Exploring the cellular activity of camptothecin-triple-helix-forming oligonucleotide conjugates." *Mol Cell Biol* 26(1): 324-33.

Arnould, S., P. Chames, et al. (2006). "Engineering of large numbers of highly specific homing endonucleases that induce recombination on novel DNA targets." *J Mol Biol* 355(3): 443-58.

Ashwell, J. D. and R. D. Klusner (1990). "Genetic and mutational analysis of the T-cell antigen receptor." *Annu Rev Immunol* 8: 139-67.

Betts, M. R., J. M. Brenchley, et al. (2003). "Sensitive and viable identification of antigen-specific CD8⁺ T cells by a flow cytometric assay for degranulation." *J Immunol Methods* 281(1-2): 65-78.

Boch, J., H. Scholze, et al. (2009). "Breaking the code of DNA binding specificity of TAL-type III effectors." *Science* 326(5959): 1509-12.

Boni, A., P. Muranski, et al. (2008). "Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers." *Blood* 112(12): 4746-54.

Brahmer, J. R., C. G. Drake, et al. (2010). "Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates." *J Clin Oncol* 28(19): 3167-75.

- Cambier, J. C. (1995). "Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM)." *J Immunol* 155(7): 3281-5.
- Carrasso, Y. R., A. R. Ramiro, et al. (2001). "An endoplasmic reticulum retention function for the cytoplasmic tail of the human pre-T cell receptor (TCR) alpha chain: potential role in the regulation of cell surface pre-TCR expression levels." *J Exp Med* 193(9): 1045-58.
- Cermak, T., E. L. Doyle, et al. (2011). "Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting." *Nucleic Acids Res* 39(12): e82.
- Chames, P., J. C. Epinat, et al. (2005). "In vivo selection of engineered homing endonucleases using double-strand break induced homologous recombination." *Nucleic Acids Res* 33(20): e178.
- Choulika, A., A. Perrin, et al. (1995). "Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of *Saccharomyces cerevisiae*." *Mol Cell Biol* 15(4): 1968-73.
- Christian, M., T. Cermak, et al. (2010). "Targeting DNA double-strand breaks with TAL effector nucleases." *Genetics* 186(2): 757-61.
- Coutinho, A. E. and K. E. Chapman (2011). "The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights." *Mol Cell Endocrinol* 335(1): 2-13.
- Critchlow, S. E. and S. P. Jackson (1998). "DNA end-joining: from yeast to man." *Trends Biochem Sci* 23(10): 394-8.
- Deng, D., C. Yan, et al. (2012). "Structural basis for sequence-specific recognition of DNA by TAL effectors." *Science* 335(6069): 720-3.
- Eisenschmidt, K., T. Lanio, et al. (2005). "Developing a programmed restriction endonuclease for highly specific DNA cleavage." *Nucleic Acids Res* 33(22): 7039-47.
- Epinat, J. C., S. Arnould, et al. (2003). "A novel engineered meganuclease induces homologous recombination in yeast and mammalian cells." *Nucleic Acids Res* 31(11): 2952-62.
- Geissler, R., H. Scholze, et al. (2011). "Transcriptional activators of human genes with programmable DNA-specificity." *PLoS One* 6(5): e19509.
- Howard, F. D., H. R. Rodewald, et al. (1990). "CD3 zeta subunit can substitute for the gamma subunit of Fc epsilon receptor type I in assembly and functional expression of the high-affinity IgE receptor: evidence for interreceptor complementation." *Proc Natl Acad Sci U S A* 87(18): 7015-9.
- Huang, P., A. Xiao, et al. (2011). "Heritable gene targeting in zebrafish using customized TALENs." *Nat Biotechnol* 29(8): 699-700.
- Jena, B., G. Dotti, et al. (2010). "Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor." *Blood* 116(7): 1035-44.
- Kalish, J. M. and P. M. Glazer (2005). "Targeted genome modification via triple helix formation." *Ann N Y Acad Sci* 1058: 151-61.
- Li, L., M. J. Piatek, et al. (2012). "Rapid and highly efficient construction of TALE-based transcriptional regulators and nucleases for genome modification." *Plant Mol Biol* 78(4-5): 407-16.
- Li, T., S. Huang, et al. (2011). "TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain." *Nucleic Acids Res* 39(1): 359-72.
- Li, T., S. Huang, et al. (2011). "Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes." *Nucleic Acids Res* 39(14): 6315-25.
- Ma, J. L., E. M. Kim, et al. (2003). "Yeast Mre11 and Rad1 proteins define a Ku-independent mechanism to repair double-strand breaks lacking overlapping end sequences." *Mol Cell Biol* 23(23): 8820-8.

- Mahfouz, M. M., L. Li, et al. (2012). "Targeted transcriptional repression using a chimeric TALE-SRDX repressor protein." *Plant Mol Biol* 78(3): 311-21.
- Mahfouz, M. M., L. Li, et al. (2011). "De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks." *Proc Natl Acad Sci U S A* 108(6): 2623-8.
- Mak, A. N., P. Bradley, et al. (2012). "The crystal structure of TAL effector PthXo1 bound to its DNA target." *Science* 335(6069): 716-9.
- Metzger, H., G. Alcaraz, et al. (1986). "The receptor with high affinity for immunoglobulin E." *Annu Rev Immunol* 4: 419-70.
- Miller, J. C., S. Tan, et al. (2011). "A TALE nuclease architecture for efficient genome editing." *Nat Biotechnol* 29(2): 143-8.
- Morbitzer, R., P. Romer, et al. (2011). "Regulation of selected genome loci using de novo-engineered transcription activator-like effector (TALE)-type transcription factors." *Proc Natl Acad Sci U S A* 107(50): 21617-22.
- Moscou, M. J. and A. J. Bogdanove (2009). "A simple cipher governs DNA recognition by TAL effectors." *Science* 326(5959): 1501.
- Mussolino, C., R. Morbitzer, et al. (2011). "A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity." *Nucleic Acids Res* 39(21): 9283-93.
- Pang, S. S., R. Berry, et al. (2010). "The structural basis for autonomous dimerization of the pre-T-cell antigen receptor." *Nature* 467(7317): 844-8.
- Paques, F. and P. Duchateau (2007). "Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy." *Curr Gene Ther* 7(1): 49-66.
- Pardoll, D. and C. Drake (2012). "Immunotherapy earns its spot in the ranks of cancer therapy." *J Exp Med* 209(2): 201-9.
- Pardoll, D. M. (2012). "The blockade of immune checkpoints in cancer immunotherapy." *Nat Rev Cancer* 12(4): 252-64.
- Park, T. S., S. A. Rosenberg, et al. (2011). "Treating cancer with genetically engineered T cells." *Trends Biotechnol* 29(11): 550-7.
- Pingoud, A. and G. H. Silva (2007). "Precision genome surgery." *Nat Biotechnol* 25(7): 743-4.
- Porteus, M. H. and D. Carroll (2005). "Gene targeting using zinc finger nucleases." *Nat Biotechnol* 23(8): 967-73.
- Robert, C. and C. Mateus (2011). "[Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma]." *Med Sci (Paris)* 27(10): 850-8.
- Rouet, P., F. Smih, et al. (1994). "Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease." *Mol Cell Biol* 14(12): 8096-106.
- Saint-Ruf, C., O. Lechner, et al. (1998). "Genomic structure of the human pre-T cell receptor alpha chain and expression of two mRNA isoforms." *Eur J Immunol* 28(11): 3824-31.
- Sander, J. D., L. Cade, et al. (2011). "Targeted gene disruption in somatic zebrafish cells using engineered TALENs." *Nat Biotechnol* 29(8): 697-8.
- Smith, J., S. Grizot, et al. (2006). "A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences." *Nucleic Acids Res* 34(22): e149.
- Stoddard, B. L. (2005). "Homing endonuclease structure and function." *Q Rev Biophys* 38(1): 49-95.
- Tesson, L., C. Usal, et al. (2011). "Knockout rats generated by embryo microinjection of TALENs." *Nat Biotechnol* 29(8): 695-6.

von Boehmer, H. (2005). "Unique features of the pre-T-cell receptor alpha-chain: not just a surrogate." Nat Rev Immunol 5(7): 571-7.

Waldmann, H. and G. Hale (2005). "CAMPATH: from concept to clinic." Philos Trans R Soc Lond B Biol Sci 360(1461): 1707-11.

Weber, E., R. Gruetzner, et al. (2011). "Assembly of designer TAL effectors by Golden Gate cloning." PLoS One 6(5): e19722.

Yamasaki, S., E. Ishikawa, et al. (2006). "Mechanistic basis of pre-T cell receptor-mediated autonomous signaling critical for thymocyte development." Nat Immunol 7(1): 67-75.

Zhang, F., L. Cong, et al. (2011). "Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription." Nat Biotechnol 29(2): 149-53.

SEQUENCE LISTING

<110> GALETTO ROMAN
GROSSE STEPHANIE
GOUBLE AGNES
MANNIOUI CECILE
POIROT LAURENT
SMITH JULIANNE
SCHARENBERG ANDREW
CELLECTIS

<120> METHODS FOR ENGINEERING ALLOGENEIC AND HIGHLY ACTIVE
T CELL FOR IMMUNOTHERAPY

<130> 435147WO (DI2013-18PCT)

<160> 126

<170> PatentIn version 3.5

<210> 1
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> GRex2

<400> 1
tattcactga tggactccaa agaatcatta actcctggta gagaagaaa 49

<210> 2
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> GRex3T2

<400> 2
tgcttggtgt gctctgatga agcttcagga tgcattatg gagtcttaa 49

<210> 3
<211> 49
<212> DNA

<213> Artificial Sequence

<220>

<223> GRex3T4

<400> 3

tgctctgatg aagcttcagg atgtcattat ggagctcttaa cttgtggaa 49

<210> 4

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> GRex5T1

<400> 4

tggtgtcact gttggagggtt attgaacctg aagtgttata tgcaggata 49

<210> 5

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> GRex5T2

<400> 5

tatgatagct ctgttcaga ctcaacttg aggatcatga ctacgctca 49

<210> 6

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> GReX5T3

<400> 6

ttatatgcag gatatgatag ctctgttcca gactcaactt ggaggatca 49

<210> 7

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat-GRex2-LPT9-L1

<400> 7

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys
1 5 10 15

Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala
20 25 30

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly
35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
50 55 60

1. *Chlorophyll a* (Chl *a*)
 2. *Chlorophyll b* (Chl *b*)
 3. *Chlorophyll c* (Chl *c*)
 4. *Chlorophyll d* (Chl *d*)
 5. *Chlorophyll e* (Chl *e*)
 6. *Chlorophyll f* (Chl *f*)
 7. *Chlorophyll g* (Chl *g*)
 8. *Chlorophyll h* (Chl *h*)
 9. *Chlorophyll i* (Chl *i*)
 10. *Chlorophyll j* (Chl *j*)
 11. *Chlorophyll k* (Chl *k*)
 12. *Chlorophyll l* (Chl *l*)
 13. *Chlorophyll m* (Chl *m*)
 14. *Chlorophyll n* (Chl *n*)
 15. *Chlorophyll o* (Chl *o*)
 16. *Chlorophyll p* (Chl *p*)
 17. *Chlorophyll q* (Chl *q*)
 18. *Chlorophyll r* (Chl *r*)
 19. *Chlorophyll s* (Chl *s*)
 20. *Chlorophyll t* (Chl *t*)
 21. *Chlorophyll u* (Chl *u*)
 22. *Chlorophyll v* (Chl *v*)
 23. *Chlorophyll w* (Chl *w*)
 24. *Chlorophyll x* (Chl *x*)
 25. *Chlorophyll y* (Chl *y*)
 26. *Chlorophyll z* (Chl *z*)
 27. *Chlorophyll aa* (Chl *aa*)
 28. *Chlorophyll ab* (Chl *ab*)
 29. *Chlorophyll ac* (Chl *ac*)
 30. *Chlorophyll ad* (Chl *ad*)
 31. *Chlorophyll ae* (Chl *ae*)
 32. *Chlorophyll af* (Chl *af*)
 33. *Chlorophyll ag* (Chl *ag*)
 34. *Chlorophyll ah* (Chl *ah*)
 35. *Chlorophyll ai* (Chl *ai*)
 36. *Chlorophyll aj* (Chl *aj*)
 37. *Chlorophyll ak* (Chl *ak*)
 38. *Chlorophyll al* (Chl *al*)
 39. *Chlorophyll am* (Chl *am*)
 40. *Chlorophyll an* (Chl *an*)
 41. *Chlorophyll ao* (Chl *ao*)
 42. *Chlorophyll ap* (Chl *ap*)
 43. *Chlorophyll aq* (Chl *aq*)
 44. *Chlorophyll ar* (Chl *ar*)
 45. *Chlorophyll as* (Chl *as*)
 46. *Chlorophyll at* (Chl *at*)
 47. *Chlorophyll au* (Chl *au*)
 48. *Chlorophyll av* (Chl *av*)
 49. *Chlorophyll aw* (Chl *aw*)
 50. *Chlorophyll ax* (Chl *ax*)
 51. *Chlorophyll ay* (Chl *ay*)
 52. *Chlorophyll az* (Chl *az*)
 53. *Chlorophyll aza* (Chl *aza*)
 54. *Chlorophyll abz* (Chl *abz*)
 55. *Chlorophyll acz* (Chl *acz*)
 56. *Chlorophyll adz* (Chl *adz*)
 57. *Chlorophyll aez* (Chl *aez*)
 58. *Chlorophyll afz* (Chl *afz*)
 59. *Chlorophyll agz* (Chl *agz*)
 60. *Chlorophyll ahz* (Chl *ahz*)
 61. *Chlorophyll aiz* (Chl *aiz*)
 62. *Chlorophyll ajz* (Chl *ajz*)
 63. *Chlorophyll akz* (Chl *akz*)
 64. *Chlorophyll alz* (Chl *alz*)
 65. *Chlorophyll amz* (Chl *amz*)
 66. *Chlorophyll anz* (Chl *anz*)
 67. *Chlorophyll aoz* (Chl *aoz*)
 68. *Chlorophyll apz* (Chl *apz*)
 69. *Chlorophyll aqz* (Chl *aqz*)
 70. *Chlorophyll arz* (Chl *arz*)
 71. *Chlorophyll asz* (Chl *asz*)
 72. *Chlorophyll atz* (Chl *atz*)
 73. *Chlorophyll auz* (Chl *auz*)
 74. *Chlorophyll avz* (Chl *avz*)
 75. *Chlorophyll awz* (Chl *awz*)
 76. *Chlorophyll axz* (Chl *axz*)
 77. *Chlorophyll ayz* (Chl *ayz*)
 78. *Chlorophyll ayz* (Chl *ayz*)
 79. *Chlorophyll azz* (Chl *azz*)
 80. *Chlorophyll azaa* (Chl *aza*)
 81. *Chlorophyll abz* (Chl *abz*)
 82. *Chlorophyll acz* (Chl *acz*)
 83. *Chlorophyll adz* (Chl *adz*)
 84. *Chlorophyll aez* (Chl *aez*)
 85. *Chlorophyll afz* (Chl *afz*)
 86. *Chlorophyll agz* (Chl *agz*)
 87. *Chlorophyll ahz* (Chl *ahz*)
 88. *Chlorophyll aiz* (Chl *aiz*)
 89. *Chlorophyll ajz* (Chl *ajz*)
 90. *Chlorophyll akz* (Chl *akz*)
 91. *Chlorophyll alz* (Chl *alz*)
 92. *Chlorophyll amz* (Chl *amz*)
 93. *Chlorophyll anz* (Chl *anz*)
 94. *Chlorophyll aoz* (Chl *aoz*)
 95. *Chlorophyll apz* (Chl *apz*)
 96. *Chlorophyll aqz* (Chl *aqz*)
 97. *Chlorophyll arz* (Chl *arz*)
 98. *Chlorophyll asz* (Chl *asz*)
 99. *Chlorophyll atz* (Chl *atz*)
 100. *Chlorophyll auz* (Chl *auz*)
 101. *Chlorophyll avz* (Chl *avz*)
 102. *Chlorophyll awz* (Chl *awz*)
 103. *Chlorophyll axz* (Chl *axz*)
 104. *Chlorophyll ayz* (Chl *ayz*)
 105. *Chlorophyll ayz* (Chl *ayz*)
 106. *Chlorophyll azz* (Chl *azz*)
 107. *Chlorophyll azaa* (Chl *aza*)
 108. *Chlorophyll abz* (Chl *abz*)
 109. *Chlorophyll acz* (Chl *acz*)
 110. *Chlorophyll adz* (Chl *adz*)
 111. *Chlorophyll aez* (Chl *aez*)
 112. *Chlorophyll afz* (Chl *afz*)
 113. *Chlorophyll agz* (Chl *agz*)
 114. *Chlorophyll ahz* (Chl *ahz*)
 115. *Chlorophyll aiz* (Chl *aiz*)
 116. *Chlorophyll ajz* (Chl *ajz*)
 117. *Chlorophyll akz* (Chl *akz*)
 118. *Chlorophyll alz* (Chl *alz*)
 119. *Chlorophyll amz* (Chl *amz*)
 120. *Chlorophyll anz* (Chl *anz*)
 121. *Chlorophyll aoz* (Chl *aoz*)
 122. *Chlorophyll apz* (Chl *apz*)
 123. *Chlorophyll aqz* (Chl *aqz*)
 124. *Chlorophyll arz* (Chl *arz*)
 125. *Chlorophyll asz* (Chl *asz*)
 126. *Chlorophyll atz* (Chl *atz*)
 127. *Chlorophyll auz* (Chl *auz*)
 128. *Chlorophyll avz* (Chl *avz*)
 129. *Chlorophyll awz* (Chl *awz*)
 130. *Chlorophyll axz* (Chl *axz*)
 131. *Chlorophyll ayz* (Chl *ayz*)
 132. *Chlorophyll ayz* (Chl *ayz*)
 133.

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
 65 70 75 80
 Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 85 90 95
 Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 100 105 110
 Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 115 120 125
 Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 130 135 140
 Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala
 145 150 155 160
 Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
 165 170 175
 Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190
 Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
 195 200 205
 Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu
 210 215 220
 Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240
 Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala
 245 250 255
 Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
 260 265 270
 Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys
 275 280 285
 Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala
 290 295 300
 His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly
 305 310 315 320
 Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 325 330 335
 Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
 340 345 350
 Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 355 360 365
 Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
 370 375 380
 Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 385 390 395 400
 Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 405 410 415
 Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala
 420 425 430
 Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
 435 440 445

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
450 455 460

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
465 470 475 480

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu
485 490 495

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
500 505 510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
515 520 525

Leu Glu
530

<210> 8

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat-GRex2-LPT9-R1

<400> 8

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
20 25 30

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly
35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
50 55 60

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
65 70 75 80

Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
100 105 110

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
115 120 125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
130 135 140

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
145 150 155 160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
165 170 175

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
180 185 190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
195 200 205

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu
 210 215 220
 Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240
 Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala
 245 250 255
 Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
 260 265 270
 Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
 275 280 285
 Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 290 295 300
 His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly
 305 310 315 320
 Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys
 325 330 335
 Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
 340 345 350
 Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 355 360 365
 Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 370 375 380
 Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 385 390 395 400
 Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 405 410 415
 Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala
 420 425 430
 Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 435 440 445
 Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val
 450 455 460
 Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
 465 470 475 480
 Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu
 485 490 495
 Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 500 505 510
 Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
 515 520 525
 Leu Glu
 530
 <210> 9
 <211> 530
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Repeat-GRex3T2-L1

<400> 9

```

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
1          5          10          15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
20          25          30

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
35          40          45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
50          55          60

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
65          70          75          80

Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
85          90          95

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
100         105         110

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
115         120         125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
130         135         140

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
145         150         155         160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
165         170         175

Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val
180         185         190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
195         200         205

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu
210         215         220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
225         230         235         240

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala
245         250         255

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
260         265         270

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
275         280         285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
290         295         300

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly
305         310         315         320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
325         330         335

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
340         345         350

```

Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 355 360 365

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
 370 375 380

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 385 390 395 400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 405 410 415

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 420 425 430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 435 440 445

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val
 450 455 460

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
 465 470 475 480

Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu
 485 490 495

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 500 505 510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
 515 520 525

Leu Glu
 530

<210> 10

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat-GRex3T2-R1

<400> 10

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
 1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 20 25 30

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly
 35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys
 50 55 60

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn
 65 70 75 80

Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val
 85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
 100 105 110

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 115 120 125
 Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 130 135 140
 Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala
 145 150 155 160
 Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
 165 170 175
 Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190
 Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
 195 200 205
 Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu
 210 215 220
 Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240
 Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala
 245 250 255
 Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
 260 265 270
 Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys
 275 280 285
 Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 290 295 300
 His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly
 305 310 315 320
 Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys
 325 330 335
 Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
 340 345 350
 Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 355 360 365
 Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 370 375 380
 Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu
 385 390 395 400
 Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 405 410 415
 Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala
 420 425 430
 Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 435 440 445
 Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val
 450 455 460
 Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
 465 470 475 480

Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu
 485 490 495

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 500 505 510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
 515 520 525

Leu Glu
 530

<210> 11

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat-GRex3T4-L1

<400> 11

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
 1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 20 25 30

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
 35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 50 55 60

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
 65 70 75 80

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 100 105 110

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 115 120 125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
 130 135 140

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 145 150 155 160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 165 170 175

Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
 195 200 205

Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu
 210 215 220

Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala

245										250					255				
Leu	Glu	Thr	Val	Gln	Arg	Leu	Leu	Pro	Val	Leu	Cys	Gln	Ala	His	Gly				
			260					265					270						
Leu	Thr	Pro	Gln	Gln	Val	Val	Ala	Ile	Ala	Ser	Asn	Asn	Gly	Gly	Lys				
		275					280					285							
Gln	Ala	Leu	Glu	Thr	Val	Gln	Arg	Leu	Leu	Pro	Val	Leu	Cys	Gln	Ala				
	290						295				300								
His	Gly	Leu	Thr	Pro	Glu	Gln	Val	Val	Ala	Ile	Ala	Ser	Asn	Ile	Gly				
305					310					315					320				
Gly	Lys	Gln	Ala	Leu	Glu	Thr	Val	Gln	Ala	Leu	Leu	Pro	Val	Leu	Cys				
				325					330						335				
Gln	Ala	His	Gly	Leu	Thr	Pro	Glu	Gln	Val	Val	Ala	Ile	Ala	Ser	Asn				
			340						345					350					
Ile	Gly	Gly	Lys	Gln	Ala	Leu	Glu	Thr	Val	Gln	Ala	Leu	Leu	Pro	Val				
		355						360						365					
Leu	Cys	Gln	Ala	His	Gly	Leu	Thr	Pro	Gln	Gln	Val	Val	Ala	Ile	Ala				
	370						375				380								
Ser	Asn	Asn	Gly	Gly	Lys	Gln	Ala	Leu	Glu	Thr	Val	Gln	Arg	Leu	Leu				
385					390					395					400				
Pro	Val	Leu	Cys	Gln	Ala	His	Gly	Leu	Thr	Pro	Glu	Gln	Val	Val	Ala				
				405					410						415				
Ile	Ala	Ser	His	Asp	Gly	Gly	Lys	Gln	Ala	Leu	Glu	Thr	Val	Gln	Arg				
			420					425						430					
Leu	Leu	Pro	Val	Leu	Cys	Gln	Ala	His	Gly	Leu	Thr	Pro	Gln	Gln	Val				
		435					440					445							
Val	Ala	Ile	Ala	Ser	Asn	Gly	Gly	Gly	Lys	Gln	Ala	Leu	Glu	Thr	Val				
		450					455					460							
Gln	Arg	Leu	Leu	Pro	Val	Leu	Cys	Gln	Ala	His	Gly	Leu	Thr	Pro	Gln				
465					470					475					480				
Gln	Val	Val	Ala	Ile	Ala	Ser	Asn	Gly	Gly	Gly	Lys	Gln	Ala	Leu	Glu				
			485						490					495					
Thr	Val	Gln	Arg	Leu	Leu	Pro	Val	Leu	Cys	Gln	Ala	His	Gly	Leu	Thr				
			500						505					510					
Pro	Gln	Gln	Val	Val	Ala	Ile	Ala	Ser	Asn	Gly	Gly	Gly	Arg	Pro	Ala				
		515					520						525						
Leu	Glu																		
	530																		
<210> 12																			
<211> 530																			
<212> PRT																			
<213> Artificial Sequence																			
<220>																			
<223> Repeat-GRex3T4-R1																			
<400> 12																			
Leu	Thr	Pro	Gln	Gln	Val	Val	Ala	Ile	Ala	Ser	Asn	Gly	Gly	Gly	Lys				
1				5					10						15				

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 20 25 30
 His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
 35 40 45
 Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 50 55 60
 Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
 65 70 75 80
 Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 85 90 95
 Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 100 105 110
 Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu
 115 120 125
 Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 130 135 140
 Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 145 150 155 160
 Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
 165 170 175
 Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190
 Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
 195 200 205
 Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu
 210 215 220
 Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240
 Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala
 245 250 255
 Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
 260 265 270
 Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
 275 280 285
 Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 290 295 300
 His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly
 305 310 315 320
 Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 325 330 335
 Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn
 340 345 350
 Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val
 355 360 365
 Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 370 375 380

Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu
385 390 395 400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
405 410 415

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
420 425 430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
435 440 445

Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val
450 455 460

Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
465 470 475 480

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu
485 490 495

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
500 505 510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
515 520 525

Leu Glu
530

<210> 13

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat-GRex5T1-LPT8-L1

<400> 13

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
20 25 30

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly
35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
50 55 60

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
65 70 75 80

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val

85

90

95

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
100 105 110

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
115 120 125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
130 135 140

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
145 150 155 160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
165 170 175

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
180 185 190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
195 200 205

Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu
210 215 220

Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
225 230 235 240

Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala
245 250 255

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
260 265 270

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
275 280 285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
290 295 300

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly
305 310 315 320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
325 330 335

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
340 345 350

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
355 360 365

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
370 375 380

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
385 390 395 400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
405 410 415

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
420 425 430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
435 440 445

Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val
450 455 460

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
465 470 475 480

Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu
485 490 495

Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
500 505 510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
 515 520 525

Leu Glu
 530

<210> 14

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat-GRex5T1-LPT8-R1

<400> 14

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys
 1 5 10 15

Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala
 20 25 30

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly
 35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 50 55 60

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
 65 70 75 80

Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 100 105 110

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 115 120 125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
 130 135 140

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 145 150 155 160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 165 170 175

Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
 195 200 205

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu
 210 215 220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240

Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala
 245 250 255

Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly
 260 265 270

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
 275 280 285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 290 295 300
 His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly
 305 310 315 320
 Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys
 325 330 335
 Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
 340 345 350
 Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 355 360 365
 Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 370 375 380
 Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu
 385 390 395 400
 Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 405 410 415
 Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala
 420 425 430
 Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
 435 440 445
 Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
 450 455 460
 Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
 465 470 475 480
 Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu
 485 490 495
 Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 500 505 510
 Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
 515 520 525
 Leu Glu
 530
 <210> 15
 <211> 530
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Repeat-GRex5T2-L1
 <400> 15
 Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys
 1 5 10 15
 Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala
 20 25 30
 His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly
 35 40 45
 Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 50 55 60

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
 65 70 75 80

Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 100 105 110

Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu
 115 120 125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
 130 135 140

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 145 150 155 160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
 165 170 175

Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190

Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
 195 200 205

Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu
 210 215 220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240

Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala
 245 250 255

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
 260 265 270

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
 275 280 285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 290 295 300

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
 305 310 315 320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 325 330 335

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
 340 345 350

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 355 360 365

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
 370 375 380

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 385 390 395 400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
 405 410 415

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 420 425 430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 435 440 445

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val
450 455 460

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
465 470 475 480

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu
485 490 495

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
500 505 510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
515 520 525

Leu Glu
530

<210> 16

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat-GRex5T2-R1

<400> 16

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
20 25 30

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly
35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys
50 55 60

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
65 70 75 80

Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
100 105 110

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
115 120 125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
130 135 140

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
145 150 155 160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
165 170 175

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val
180 185 190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
195 200 205

Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu
210 215 220

```

Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
225                230                235                240

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala
                245                250                255

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
                260                265                270

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
                275                280                285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
                290                295                300

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
305                310                315                320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
                325                330                335

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn
                340                345                350

Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val
                355                360                365

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
                370                375                380

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
385                390                395                400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
                405                410                415

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
                420                425                430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
                435                440                445

Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val
                450                455                460

Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
465                470                475                480

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu
                485                490                495

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
                500                505                510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
                515                520                525

Leu Glu
530

```

<210> 17

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat-GRex5T3-L1

<400> 17

```

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
1           5           10           15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
20           25           30

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly
35           40           45

Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys
50           55           60

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
65           70           75           80

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
85           90           95

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
100          105          110

Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu
115          120          125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
130          135          140

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
145          150          155          160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
165          170          175

Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val
180          185          190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
195          200          205

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu
210          215          220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
225          230          235          240

Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala
245          250          255

Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly
260          265          270

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
275          280          285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
290          295          300

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly
305          310          315          320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
325          330          335

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn
340          345          350

Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val
355          360          365

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala

```

Leu Cys Ser Asn His His Gly Leu His His His Val Val His His His
370 375 380

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
385 390 395 400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
405 410 415

Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala
420 425 430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
435 440 445

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val
450 455 460

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
465 470 475 480

Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu
485 490 495

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
500 505 510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
515 520 525

Leu Glu
530

<210> 18

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat-GRex5T3-R1

<400> 18

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
20 25 30

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly
35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys
50 55 60

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
65 70 75 80

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
100 105 110

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
115 120 125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
130 135 140

Ile Ala Ser His Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg

```

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
145              150              155              160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
              165              170              175

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val
              180              185              190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
              195              200              205

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu
              210              215              220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
225              230              235              240

Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala
              245              250              255

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
              260              265              270

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys
              275              280              285

Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala
              290              295              300

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly
305              310              315              320

Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys
              325              330              335

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
              340              345              350

Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
              355              360              365

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
              370              375              380

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
385              390              395              400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
              405              410              415

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
              420              425              430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
              435              440              445

Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val
              450              455              460

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
465              470              475              480

Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu
              485              490              495

Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
              500              505              510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
              515              520              525

```

Leu Glu
530

<210> 19

<211> 2814

<212> DNA

<213> Artificial Sequence

<220>

<223> GRex2-L TALEN

<400> 19

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgattacc	catacgaatgt	tccagattac	60
gctatcgata	tgcgcgatct	acgcacgctc	ggctacagcc	agcagcaaca	ggagaagatc	120
aaaccgaagg	ttcggttcgac	agtggcgag	caccacgagg	cactggtcgg	ccacgggttt	180
acacacgcgc	acatcggttc	gttaagccaa	cacccggcag	cgttagggaac	cgtcgcgtgc	240
aagtatcagg	acatgatgcg	agcgtttgcca	gaggcgacac	acgaaggcat	cgttggcgtc	300
ggcaaacagt	ggtcgggcgc	acgcgctctg	gaggccttgc	tcacggtggc	gggagatttg	360
agaggtccac	cgttacagtt	ggacacaggc	caacttctca	agattgcaaa	acgtggcggc	420
gtgaccgcag	tggaggcagt	gcatgcatgg	cgcaatgcac	tgacgggtgc	cccgcctaac	480
ttgaccccg	agcaggtggt	ggccatcgcc	agcaaatattg	gtggcaagca	ggcgcctgga	540
acggtgcagg	cgctggttgc	ggtgctgtgc	caggccccacg	gcttgacccc	ccaggcaggtg	600
ctggccatcg	ccagcaatgg	cggtggcaag	caggcgctgg	agacggtcca	gcggctgttg	660
cgggtgctgt	gccaggccca	cggcttgacc	ccccagcagg	tggtggccat	cggcagcaat	720
ggcggtgcca	agcaggcgct	ggagacggtc	cagcggctgt	tgccggtgct	gtgccaggcc	780
cacggcttga	ccccggagca	ggtggtggcc	atcgccagcc	acgatggcgg	caagcaggcg	840
ctggagacgg	tccagcggct	gttgccgggtg	ctgtgccagg	cccacggctt	gaccccgga	900
caggtggtgg	ccatcgccag	caaatattggt	ggcaagcagg	cgctggagac	ggtgcaggcg	960
ctgttgccgg	tgctgtgcca	ggccccagcc	ttgaccccg	agcaggtggt	ggccatcgcc	1020
agccacgatg	gcgccaagca	ggcgctggag	acgtgccagc	ggctgttgcc	ggtgctgtgc	1080
cagggccacg	gcttgacccc	ccagcaggtg	gtggccatcg	ccagcaatgg	cgggtggcaag	1140
caggcgctgg	agacgggtcca	gcggctgttg	ccggtgctgt	gccaggccca	cggcttgacc	1200
ccccagcagg	tggtggccat	cgccagcaat	aatggtggca	agcaggcgct	ggagacggtc	1260
cagcggctgt	tgcgggtgct	gtgccaggcc	cacggcttga	ccccggaagca	ggtggtggcc	1320
atcgccagca	atattggtgg	caagcaggcg	ctggagacgg	tgcaggcgct	gttgccggtg	1380
ctgtgccagg	cccacggctt	gacccccag	caggtggtgg	ccatcgccag	caatggcggt	1440
ggcaagcagg	cgctggagac	ggtccagcgg	ctgtgcccgg	tgctgtgcca	ggccccagcg	1500
ttgaccccc	agcaggtggt	ggccatcgcc	agcaataatg	gtggcaagca	ggcgcctgga	1560

acgggtccagc	ggctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ccagcaggtg	1620
gtggccatcg	ccagcaataa	tggtggcaag	caggcgctgg	agacggtcca	gcggtctgtg	1680
ccgggtgctgt	gccaggccca	cggcttgacc	ccggagcagg	tggtggccat	cgccagcaat	1740
attggtggca	agcaggcgct	ggagacgggtg	caggcgctgt	tgccggtgct	gtgccaggcc	1800
cacggcttga	ccccggagca	ggtggtggcc	atcgccagcc	acgatggcgg	caagcaggcg	1860
ctggagacgg	tcacgaggct	gttgccggtg	ctgtgccagg	ccacgagctt	gaccccccaag	1920
cagggtggtg	ccatcgccag	caatggcggt	ggcaagcagg	cgctggagac	ggtccagcgg	1980
ctgttgccgg	tgtgtgccca	ggccccaggg	ttgacccctc	agcaggtggt	ggccatcgcc	2040
agcaatggcg	gcggcaggcc	ggcgctggag	agcattgttg	cccagttatc	tcgcacctgat	2100
ccggcgcttg	ccgcgttgac	caacgaccac	ctcgctgcct	tggctbgcct	cggcggcgct	2160
cctgcgcctg	atgcagtga	aaagggattg	ggggatccta	tcagccgttc	ccagctggtg	2220
aagttccagc	tggaggagaa	gaaatccgag	ttgaggcaca	agctgaagta	cgtgccccac	2280
gagtacatcg	agctgatcga	gatcgccccg	aacagcaccc	aggacggtat	cctggagatg	2340
aaggtgatgg	agttcttcat	gaaggtgtac	ggctacaggg	gcaagcacct	gggcggctcc	2400
aggaagcccc	acggcgccat	ctacaccgtg	ggctccccc	tcgactacgg	cgtgatcgtg	2460
gacaccaagg	cctactccgg	cggctacaac	ctgcccacg	gccaggccga	cgaaatgcag	2520
aggtacgtgg	aggagaacca	gaccaggaac	aagcacatca	acccccacga	gtggtggaag	2580
gtgtaccctt	ccagcgtgac	cgagttcaag	ttcctgttcg	tgtccggcca	cttcaagggc	2640
atactacaagg	ccagctgtgac	caggctgaac	catatcacca	actgcaacgg	cgccgtgctg	2700
tccgtgagag	agctcctgat	cggcggcgag	atgatcaagg	ccggcacctt	gacctggag	2760
gaggtgagga	ggaagttcaa	caacggcgag	atcaacttcg	cggccgactg	ataa	2814

<210> 20

<211> 2832

<212> DNA

<213> Artificial Sequence

<220>

<223> GReX2-R TALEN

<400> 20

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgataagg	agaccgcgc	tgccaagttc	60
gagagacagc	acatggacag	catcgatatc	gccgatctac	gcacgctcgg	ctacagccag	120
cagcaacagg	agaagatcaa	accgaaggtt	cgttcgacag	tggcgacagca	ccacgaggca	180
ctggctcgcc	acgggtttac	acacgcgcac	atcgttgcgt	taagccaaca	cccggcagcg	240
ttagggaccg	tcgtctgtcaa	gtatcaggac	atgatcgcag	cgttgccaga	ggcgacacac	300
gaagcgatcg	ttggcgtcgg	caaacagtgg	tccggcgcac	gcgctctgga	ggccttgctc	360
acgggtggcg	gagagttgag	aggtccaccg	ttacagttgg	acacaggcca	acttctcaag	420
attgcaaaac	gtggcggcgt	gaccgcagtg	gaggcagtg	atgcatggcg	caatgcactg	480
acgggtgcc	cgctcaact	gacccccag	caggttggtg	ccatgcgcag	caatggcgg	540
ccgggtgcgc	ccatgcgcag	ccatgcgcag	ccatgcgcag	ccatgcgcag	ccatgcgcag	600

```

ggcaagcagg cgctggagac ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc 600
ttgaccccc agcaggtggg ggccatcgcc agcaatggcg gtggcaagca ggcgctggag 660
acggtccagc ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc ggagcaggtg 720
gtggccatcg ccagccacga tggcggaag caggcgctgg agacgggtcca gggctgttg 780
cgggtgctgt gccaggccca cggcttgacc cccagcagg tggtgccat cggcagcaat 840
ggcgggtggc agcaggcgct ggagacggtc cagcggctgt tgccgggtgt gtgccaggcc 900
cacggcttga cccccagca ggtgggtggc atcgccagca atggcggtgg caagcaggcg 960
ctggagacgg tccagcggct gttgccgggt ctgtgccagg cccacggctt gaccccgag 1020
caggtgggtg ccacggcgag ccacgatggc ggcaagcagg cgctggagac ggtccagcgg 1080
ctgttgccgg tgctgtgcca ggcccacggc ttgaccccc agcaggtggg ggccatcgcc 1140
agcaatggcg gtggcaagca ggcgctggag acggtccagc ggctgttgcc ggtgctgtgc 1200
caggcccacg gcttgacccc ggagcaggtg gtggccatcg ccagccacga tggcggaag 1260
caggcgctgg agacgggtcca gcgctgttg cgggtgctgt gccaggccca cggcttgacc 1320
ccccagcagg tggtgcccat cggcagcaat ggcggtggca agcaggcgct ggagacggtc 1380
cagcggctgt tgccgggtgt gtgccaggcc cagggcttga ccccgagca ggtgggtggc 1440
atcgccagca atattgggtg caagcaggcg ctggagacgg tgcaaggcgt gttgccgggt 1500
ctgtgccagg cccacggctt gaccccgag caggtgggtg ccacggcgag ccacgatggc 1560
ggcaagcagg cgctggagac ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc 1620
ttgacccccg agcaggtggg ggccatcgcc agccacgatg gcggcaagca ggcgctggag 1680
acggtccagc ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc ggagcaggtg 1740
gtggccatcg ccagcaatat tggtggaag caggcgctgg agacgggtga ggcgctgttg 1800

```

```

ccgggtgctgt gccaggccca cggcttgacc cccagcagg tggtgccat cggcagcaat 1860
aatgggtggc agcaggcgct ggagacggtc cagcggctgt tgccgggtgt gtgccaggcc 1920
cacggcttga cccccagca ggtgggtggc atcgccagca ataatgggtg caagcaggcg 1980
ctggagacgg tccagcggct gttgccgggt ctgtgccagg cccacggctt gacccctcag 2040
caggtgggtg ccacggcgag caatggcgcc ggcaaggcgg cgctggagag cattgttgcc 2100
cagttatctc gccctgatcc ggcttgacc gcgttgacca acgaccacct cgtcgcttg 2160
gcctgcctcg gcgggcgtcc tgctgtggat gcagtgaata agggattggg ggatcctatc 2220
agcggcttcc agctgggtga gtccgagctg gaggagaaga aatccgagtt gaggcacaag 2280
ctgaagtacg tgcccacga gtacatcgag ctgatcgaga tcgcccggaa cagcaccag 2340
gacgtatcc tggagatgaa ggtgatggag ttcttcata aggtgtacgg ctacaggggc 2400
aagcacctgg gcggctccag gaagcccgac ggcgccatct acaccgtggg ctccccatc 2460
gactacggcg tgatcgtgga caccaaggcc tactccggcg gctacaacct gcccatcgcc 2520
caggccgacg aaatgcagag gtacgtggag gagaaccaga ccaggaacaa gcacatcaac 2580
cccaacgagt ggtggaaggt gtacccctcc agcgtgaccg agttcaagtt cctgttcgtg 2640
tccggccact tcaagggcaa ctacaaggcc cagctgacca ggctgaacca catcaccac 2700
tgcaacggcg ccgtgctgtc cgtggaggag ctctgatcg gcggcgagat gatcaaggcc 2760
ggcacctga cctggagga ggtgaggagg aagtcaaca acggcgagat caacttcgag 2820
gccgactgat aa 2832

```

<210> 21

<211> 2814

<212> DNA

<213> Artificial Sequence

<220>

<223> GRex3T2-L TALEN

<400> 21

```

atgggcatc ctaaaaagaa acgtaaggtc atcgattacc catacgaatg tccagattac 60
gctatcgata tcgcogactc agcgaagctc ggctacagcc agcagcaaca ggagaagatc 120
aaaccgaagg ttctgttcgac agtggcgcag caccacgagg cactggtcgg ccacgggttt 180
acacacgcgc acatcgttgc gttaagccaa caccggcgag cgttagggac cgtcgctgtc 240
aagtatcagg acatgatcgc agcgttgcca gaggcgacac acgaagcgat cgttggcgctc 300
ggcaaacagt ggtccggcgc acgcgctctg gaggccttgc tcacgggtggc gggagagttg 360
agaggtccac cgttacagtt ggacacaggc caacttctca agattgcaaa acgtggcggc 420
gtgaccgcag tggaggcagt gcatgcattg cgcaatgcac tgacgggtgc cccgctcaac 480
ttgaccccc agcaggtggg ggccatcgcc agcaataatg gtggcaagca ggcgctggag 540
acggtccagc ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc ggagcaggtg 600
gtggccatcg ccagccacga tggcggaag caggcgctgg agacgggtcca gggctgttg 660
cgggtgctgt gccaggccca cggcttgacc cggagcagg tggtgccat cggcagccac 720
gatggcgcca agcaggcgct ggagacggtc cagcggctgt tgccgggtgt gtgccaggcc 780
cacggcttga cccccagca ggtgggtggc atcgccagca atggcggtgg caagcaggcg 840
ctggagacgg tccagcggct gttgccgggt ctgtgccagg cccacggctt gacccccag 900
caggtgggtg ccacggcgag caataatggg ggcaagcagg cgctggagac ggtccagcgg 960
ctgttgccgg tgctgtgcca ggcccacggc ttgaccccc agcaggtggg ggccatcgcc 1020
agcaataatg gtggcaagca ggcgctggag acggtccagc ggctgttgcc ggtgctgtgc 1080
caggcccacg gcttgacccc ccagcaggtg gtggccatcg ccagcaatgg cggtggaag 1140
caggcgctgg agacgggtcca gcgctgttg cgggtgctgt gccaggccca cggcttgacc 1200
ccccagcagg tggtgcccat cggcagcaat aatggtgga agcaggcgct ggagacggtc 1260
cagcggctgt tgccgggtgt gtgccaggcc cagggcttga cccccagca ggtgggtggc 1320
atcgccagca atggcggtg caagcaggcg ctggagacgg tccagcggct gttgccgggt 1380
ctgtgccagg cccacggctt gacccccag caggtgggtg ccacggcgag caataatgg 1440
ggcaagcagg cgctggagac ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc 1500
ttgacccccg agcaggtggg ggccatcgcc agccacgatg gcggcaagca ggcgctggag 1560
acggtccagc ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc ccagcaggtg 1620
gtggccatcg ccagcaatgg cggtggaag caggcgctgg agacgggtcca gggctgttg 1680
ccgggtgctgt gccaggccca cggcttgacc cggagcagg ccggagcagg tggtgccat 1740
gatggcgcca agcaggcgct ggagacggtc cagcgctgt tgccgggtgt gtgccaggcc 1800
cacggcttga cccccagca ggtgggtggc atcgccagca atggcggtgg caagcaggcg 1860
ctggagacgg tccagcggct gttgccgggt ctgtgccagg cccacggctt gacccccag 1920
caggtgggtg ccacggcgag caataatggg ggcaagcagg cgctggagac ggtccagcgg 1980

```

```

ctgttgccgg tgctgtgcca ggcccacggc ttgacccctc agcaggtggg ggccatcgcc 2040

```

```

agcaatggcg gcggcaggcc ggcgctggag agcattgttg cccagttatc tcgccctgat 2100
ccggcggttg ccgcggttgac caacgaccac ctcgtcgcct tggcctgcct cggcgggcgt 2160
cctgcgctgg atgcagtga aaagggattg ggggatccta tcagccgttc ccagctggtg 2220
aagtccgagc tggaggagaa gaaatccgag ttgaggcaca agctgaagta cgtgcccac 2280
gagtacatcg agctgatcga gatcgcccg aacagcacc aggaccgtat cctggagatg 2340
aaggtgatgg agttcttcat gaaggtgtac ggctacagg gcaagcacct gggcggtcc 2400
aggaagcccg acggcgccat ctacacogtg ggctcccca tcgactacgg cgtgatcgtg 2460
gacaccaagg cctactccgg cggctacaac ctgcccacg gccaggccga cgaaatgcag 2520
aggtacgtgg aggagaacca gaccaggaac aagcacatca accccaacga gtggtggaag 2580
gtgtacccct ccagcgtgac cgagttcaag ttctgttctg tgtccggcca cttcaagggc 2640
aactacaagg cccagctgac caggtgaac cacatcacca actgcaacgg cgccgtgctg 2700
tccgtggagg agctcctgat cggcggcgag atgatcaagg ccggcacct gaccctggag 2760
gaggtgagga ggaagttcaa caacggcgag atcaacttcg cggccgactg ataa 2814

```

<210> 22

<211> 2832

<212> DNA

<213> Artificial Sequence

<220>

<223> GRex3T2-R TALEN

<400> 22

```

atgggcgatc ctaaaaagaa acgtaaggtc atcgataagg agaccgccgc tgccaagttc 60
gagagacagc acatggacag catcgatata gccgatctac gcacgcctcg ctacagccag 120
cagcaacagg agaagatcaa accgaagggt cgttcgacag tggcgagca ccacgaggca 180
ctggtcggcc acgggtttac acacgcgcac atcgttgctg taagccaaca cccggcagcg 240
ttagggaccg tcgctgtcaa gtatcaggac atgatcgca cgttgccaga ggcgacacac 300
gaagcgatcg ttggcgctcg caaacagtg tccggcgca gcgctctgga ggccttgctc 360
acgggtggcg gagagttgag aggtccaccg ttacagttgg acacaggcca acttctcaag 420
attgcaaaac gtggcggcgt gaccgcagtg gaggcagtg atgcatggcg caatgcactg 480
acgggtgccc cgctcaactt gacccccag caggtggtgg ccatcgccag caatggcggt 540
ggcaagcagg cgctggagac ggtccagcgg ctgttgccgg tgcgtgcca ggcccacggc 600
ttgaccccg agcaggtggt ggccatcgcc agcaatattg gtggcaagca ggcgctggag 660
acgggtgcagg cgctgttgcc ggtgctgtgc cagggccacg gcttgacccc ggagcaggtg 720
gtggccatcg ccagcaatat tggtaggaag caggcgctgg agacggtgca ggcgctgttg 780
ccggtgctgt gccaggccca cggcttgacc cccagcagg tggtagccat cgcagcaat 840
aatggtggca agcaggcgct ggagacggtc cagcgctgtg tgccggtgct gtgccaggcc 900
cacggcttga ccccgagca ggtggtggcc atcgccagca atattggtgg caagcaggcg 960
ctggagacgg tgcaggcgct gttgccggtg ctgtgccagg cccacggctt gaccccgag 1020
caggtggtgg ccatcgccag ccacgatggc ggcaagcagg cgctggagac ggtccagcgg 1080
ctgttgccgg tgcgtgtgcca ggcccacggc ttgaccccc agcaggtggt ggccatcgcc 1140
agcaatggcg gtggcaagca ggcgctggag acggtccagc ggctgttgcc ggtgctgtgc 1200
caggcccacg gcttgacccc ggagcaggtg gtggccatcg ccagccacga tggcggaag 1260
caggcgctgg agacgggtcca cgggtgctgt cgggtgctgt gccaggccca cggcttgacc 1320
ccggagcagg tggtagccat cgcagccac gatggcgga agcaggcgct ggagacggtc 1380
cagcggtgtg tgcgggtgct gtgccaggcc cagggcttga ccccgagca ggtggtggcc 1440
atcgccagca atattggtgg caagcaggcg ctggagacgg tgcaggcgct gttgccggtg 1500
ctgtgccagg cccacggctt gacccccag caggtggtgg ccatcgccag caatggcggt 1560
ggcaagcagg cgctggagac ggtccagcgg ctgttgccgg tgcgtgcca ggcccacggc 1620
ttgaccccg agcaggtggt ggccatcgcc agcaatattg gtggcaagca ggcgctggag 1680
acgggtgcagg cgctgttgcc caggcccacg gcttgacccc ggagcaggtg 1740
gtggccatcg ccagcaatat tggtaggaag caggcgctgg agacggtgca ggcgctgttg 1800
ccggtgctgt gccaggccca cggcttgacc cccagcagg tggtagccat cgcagcaat 1860
ggcggtggca agcaggcgct ggagacggtc cagcgctgtg tgccggtgct gtgccaggcc 1920
cacggcttga cccccagca ggtggtggcc atcgccagca ataaggtgg caagcaggcg 1980
ctggagacgg tccagcggct gttgcgggtg ctgtgccagg cccacggctt gaccctcag 2040
caggtggtgg ccatcgccag caatggcggc ggcaggccgg cgctggagag cattgttgcc 2100
cagttatctc gccctgatcc ggcgttgccc gcgttgacca acgaccacct cgtcgcttg 2160
gcctgcctcg gcggcgctcc tgcgctggat gcagtgaaaa agggattggg ggatcctatc 2220

```

```

agccgttccc agctggtgaa gtccgagctg gaggagaaga aatccgagtt gaggcacaag 2280
ctgaagtacg tgcccacga gtacatcgag ctgatcgaga tcgcccggaa cagcaccacg 2340
gaccgtatcc tggagatgaa ggtgatggag ttcttcatga aggtgtacgg ctacaggggc 2400
aagcacctgg gcggctccag gaagcccga cggcgccatc acaccgtgg ctccccatc 2460
gactacggcg tgatcgtgga caccaaggcc tactccggcg gctacaacct gcccatcggc 2520
caggccgacg aaatgcagag gtacgtggag gagaaccaga ccaggaaaca gcacatcaac 2580
cccaacgagt ggtggaaggt gtacccctcc agcgtgaccg agttcaagtt cctgttctg 2640
tccggccact tcaagggcaa ctacaaggcc cagctgacca ggctgaacca catcaccaac 2700
tgcaacggcg ccgtgctgtc cgtggaggag ctctgatcgg gcggcgagat gatcaaggcc 2760
ggcaccctga ccctggagga ggtgaggagg aagttcaaca acggcgagat caacttcgcg 2820
gccgactgat aa 2832

```

<210> 23

<211> 2814

<212> DNA

<213> Artificial Sequence

<220>

<223> GRex3T4-L TALEN

<400> 23

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgattacc	catacgatgt	tccagattac	60
gctatcgata	tgcgcgatct	acgcacgctc	ggctacagcc	agcagcaaca	ggagaagatc	120
aaaccgaagg	ttcgttcgac	agtggcgag	caccacgagg	cactggtcgg	ccacgggttt	180
acacacgcgc	acatcgttgc	gttaagccaa	caccggcag	cgtagggac	cgtcgctgtc	240
aagtatcagg	acatgatcgc	agcgttgcca	gaggcgacac	acgaagcgat	cgttggcgtc	300
ggcaaacagt	ggteccggcg	acgcgctctg	gaggccttgc	tcacgggtgg	gggagagttg	360
agaggtccac	cgttacagtt	ggacacaggc	caacttctca	agattgcaaa	acgtggcggc	420
gtgaccgcag	tggaggcagt	gcatgcatgg	cgcaatgcac	tgacgggtgc	cccgtcaac	480
ttgaccccc	agcaggtggg	ggccatcgcc	agcaataatg	gtggcaagca	ggcgtggag	540
acggtccagc	ggctgttgcc	gtgctgtg	caggccdacg	gcttgacccc	ggagcaggtg	600
gtggccatcg	ccagccacga	tggcggcaag	caggcgctgg	agacgggtcca	gcggctgttg	660
cgggtgctgt	gccaggccca	cggcttgacc	ccccagcagg	tgggtggccat	cggcagcaat	720
ggcgggtggca	agcaggcgct	ggagacggtc	cagcggctgt	tgccgggtgct	gtgccaggcc	780
cacggcttga	ccccggagca	gttgggtggc	atcgccagcc	acgatggcgg	caagcaggcg	840
ctggagacgg	tccagcggct	gttgccgggtg	ctgtgccagg	cccacggctt	gacccccag	900
caggtgggtg	ccatcgccag	caatggcggt	ggcaagcagg	cgctggagac	ggtccagcgg	960
ctgttgccgg	tgctgtgcca	ggccacggc	ttgaccccc	agcaggtggt	ggccatcgcc	1020
agcaataatg	gtggcaagca	ggcgtggag	acggtccagc	ggctgttgcc	ggtgctgtgc	1080
caggccccacg	gcttgacccc	ggagcaggtg	gtggccatcg	ccagcaatat	tgggtggcaag	1140
caggcgctgg	agacgggtgca	ggcgtgttg	cgggtgctgt	gccaggccca	cggcttgacc	1200
ccccagcagg	tgggtggccat	cggcagcaat	ggcgggtggca	agcaggcgct	ggagacggtc	1260
cagcggctgt	tgcgggtgct	gtgccaggcc	cacggcttga	ccccccagca	ggtggtggcc	1320
atcgccagca	ataatgggtg	caagcaggcg	ctggagacgg	tccagcggct	gttgccgggtg	1380
ctgtgccagg	cccacggctt	gacccccggag	cagggtgggtg	ccatcgccag	caatatgtgt	1440
ggcaagcagg	cgctggagac	ggtgcaggcg	ctgttgccgg	tgctgtgcca	ggcccacggc	1500
ttgacccccg	agcaggtggg	ggccatcgcc	agcaatatgt	gtggcaagca	ggcgtggag	1560
acggtgcagg	cgctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ccagcaggtg	1620
gtggccatcg	ccagcaataa	tgggtggcaag	caggcgctgg	agacgggtcca	gcggctgttg	1680
cgggtgctgt	gccaggccca	cggcttgacc	ccggagcagg	tgggtggccat	cggcagccac	1740
gatggcggca	agcaggcgct	ggagacggtc	cagcggctgt	tgcgggtgct	gtgccaggcc	1800
cacggcttga	ccccccagca	ggtgggtggc	atcgccagca	atggcgggtg	caagcaggcg	1860
ctggagacgg	tccagcggct	gttgccgggtg	ctgtgccagg	cccacggctt	gacccccag	1920
caggtgggtg	ccatcgccag	caatggcggt	ggcaagcagg	cgctggagac	ggtccagcgg	1980
ctgttgccgg	tgctgtgcca	ggccacggc	ttgacccctc	agcaggtggt	ggccatcgcc	2040
agcaatggcg	gcggcaggcc	ggcgtggag	agcattgttg	cccagttatc	tgcacctgat	2100
cggcgcttg	ccgcgttgac	caacgaccac	ctcgtcgcc	tggcctgcct	cggcgggcgt	2160
cctgcgctgg	atgcagtga	aaagggattg	ggggatccta	tacgcccgtc	ccagctggtg	2220
aagtcggagc	tggaggagaa	gaaatccgag	ttgaggcaca	agctgaagta	cgtgccccac	2280
gagttacatg	agctgacga	gatcgcccg	aacagcacc	aggaccgtat	cctggagatg	2340
aaggtgatgg	agttcttcat	gaaggtgtac	ggctacaggg	gcaagcacct	gggcggctcc	2400

aggaagcccg	acggcgccat	ctacaccggtg	ggctccccca	tgcactacgg	cgtgatcggtg	2460
gacaccaagg	cctactccgg	cggctacaac	ctgcccacg	gccaggccga	cgaaatgcag	2520
aggtacgtgg	aggagaacca	gaccaggaac	aagcacatca	acccaacga	gtggtggaag	2580
gtgtacccct	ccagcgtgac	cgagttcaag	ttcctgttcg	tgtccggcca	cttcaagggc	2640
aactacaagg	cccagctgac	caggctgaac	catatcacca	actgcaacgg	cgcctgtctg	2700
tccgtggagg	agctcctgat	cggcggcgag	atgatcaagg	ccggcaccc	gacctggag	2760
gaggtgagga	ggaagttcaa	caacggcgag	atcaacttcg	cggccgactg	ataa	2814

<210> 24

<211> 2832

<212> DNA

<213> Artificial Sequence

<220>

<223> GRex3T4-R TALEN

<400> 24

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgataagg	agaccgccc	tgccaagttc	60
gagagacagc	acatggacag	catcgatata	gccgatctac	gcacgctcgg	ctacagccag	120
cagcaacagg	agaagatcaa	accgaagggt	cgctcgacag	tggcgagca	ccacgaggca	180
ctggtcgccc	acgggtttac	acacgcgcac	atcgttgccg	taagccaaca	cccggcagcg	240
ttagggaccg	tgcgtgtcaa	gtatcaggac	atgatcgag	cgttgccaga	ggcgacacac	300
gaagcgatcg	ttggcgctcg	caaacagtgg	tccggcgac	gcgctctgga	ggccttgctc	360
acggtggcgg	gagagttgag	aggtccaccg	ttacagttgg	acacaggcca	acttctcaag	420
attgcaaaac	gtggcggcgt	gaccgcagtg	gaggcagtg	atgcatggcg	caatgcaactg	480
acgggtgccc	cgctcaactt	gacccccccag	cagggtgggtg	ccatcgccag	caatggcggt	540
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggccacggc	600
ttgacccccg	agcaggtggg	ggccatcgcc	agccacgatg	gcggcaagca	ggcgtggag	660
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggccacg	gcttgacccc	ggagcaggtg	720
gtggccatcg	ccagccacga	tggcggcaag	caggcgctgg	agacgggtcca	gcggctgttg	780
cgggtgctgt	gccaggccca	cggcttgacc	ccggagcagg	tgggtggccat	cggcagcaat	840
attgggtggca	agcaggcgct	ggagacgggtg	caggcgctgt	tgcgggtgct	gtgccaggcc	900
cacggcttga	ccccggagca	ggtgggtggc	atcgccagcc	acgatggcgg	caagcaggcg	960
ctggagacgg	tccagcggct	gttgccgggtg	ctgtgccagg	cccacggctt	gacccccggag	1020
caggtgggtg	ccatcgccag	caatatgtgt	ggcaagcagg	cgctggagac	ggtgcaggcg	1080
ctgttgccgg	tgctgtgcca	ggccacggc	ttgacccccg	agcaggtggt	ggccatcgcc	1140
agcaatatgt	gtggcaagca	ggcgtggag	acggtgcagg	cgctgttgcc	ggtgctgtgc	1200
caggcccacg	gcttgacccc	ccagcaggtg	gtggccatcg	ccagcaataa	tgggtggcaag	1260
caggcgctgg	agacgggtcca	gcggctgttg	ccggtgctgt	gccaggccca	cggcttgacc	1320
ccccagcagg	tgggtggccat	cggcagcaat	ggcgggtggca	agcaggcgct	ggagacggtc	1380
cagcggctgt	tgcgggtgct	gtgccaggcc	cacggcttga	ccccccagca	ggtggtggcc	1440
atcgccagca	atggcgggtg	caagcaggcg	ctggagacgg	tccagcggct	gttgccgggtg	1500
ctgtgccaaq	ccccacggctt	qacccccqaaq	caqgtqgtqg	ccatcgccag	caatatqgt	1560

ggcaagcagg	cgctggagac	ggtgcaggcg	ctgttgccgg	tgctgtgcca	ggcccacggc	1620
ttgaccccg	agcaggtgg	ggccatcgcc	agcaatattg	gtggcaagca	ggcgctggag	1680
acggtgcagg	cgctggtgcc	ggtgctgtgc	caggccacag	gcttgacccc	ccagcaggtg	1740
gtggccatcg	ccagcaataa	tggtaggaag	caggcgctgg	agacgggtcca	gcggctgttg	1800
ccggtgctgt	gccaggccca	cggcttgacc	ccggagcagg	tggtagccat	cgccagcaat	1860
attggtggca	agcaggcgct	ggagacgggtg	caggcgctgt	tgccggtgct	gtgccaggcc	1920
caaggcttga	ccccggagca	ggtggtggcc	atcgccagcc	acgatggcgg	caagcaggcg	1980
ctggagacgg	tccagcggct	gttgccgggtg	ctgtgccagg	cccacggctt	gacccctcag	2040
caggtgggtg	ccatcgccag	caatggcggc	ggcaggcccg	cgctggagag	cattgttgcc	2100
cagttatctc	gccctgatcc	ggcgttggcc	gcgttgacca	acgaccacct	cgtcgccttg	2160
gcctgcctcg	gcgggctgcc	tgcgctggat	gcagtgaata	agggattggg	ggatcctatc	2220
agccgttccc	agctggtgaa	gtccgagctg	gaggagaaga	aatccgagtt	gaggcacaag	2280
ctgaagtacg	tgccccacga	gtacatcgag	ctgatcgaga	tcgcccggaa	cagcaccag	2340
gaccgtatcc	tggagatgaa	ggtgatggag	ttcttcatga	aggtgtacgg	ctacaggggc	2400
aagcacctgg	gcggctccag	gaagcccgac	ggcgccatct	acaccgtggg	ctccccatc	2460
gactacggcg	tgatcggtga	caccaaggcc	tactccggcg	gctacaacct	gcccacggc	2520
caggccgacg	aaatgcagag	gtacgtggag	gagaaccaga	ccaggaacaa	gcacatcaac	2580
cccaacgagt	ggtggaaggt	gtacccctcc	agcgtgaccg	agttcaagtt	cctgttcgtg	2640

tccggccact	tcaagggcaa	ctacaaggcc	cagctgacca	ggctgaacca	catcaccaac	2700
tgcaacggcg	ccgtgctgtc	cgtggaggag	ctcctgatcg	gcggcgagat	gatcaaggcc	2760
ggcaccctga	ccctggagga	ggtgaggagg	aagtccaaca	acggcgagat	caacttcgcg	2820
gccgactgat	aa					2832

<210> 25

<211> 2814

<212> DNA

<213> Artificial Sequence

<220>

<223> GRex5T1-L TALEN

<400> 25

atgggagatc	ctaaaaagaa	acgtaaggtc	atcgattacc	catacgatgt	tccagattac	60
gctatcgata	tgcgcgatct	acgcacgctc	ggctacagcc	agcagcaaca	ggagaagatc	120
aaaccgaagg	ttcggttcgac	agtggcgcac	caccacgagg	cactggtcgg	ccacgggttt	180
acacacgogc	acatcggttg	gttaagccaa	caccgcgag	cgtagggac	cgctcgctgtc	240
aagtatcagg	acatgatcgc	agcgttgcca	gaggcgacac	acgaagcgat	cgttggcgctc	300
ggcaaacagt	ggtccggcgc	acgcgctctg	gaggccttgc	tcacgggtggc	gggagagtgtg	360
agaggtccac	cgttacagtt	ggacacaggc	caacttctca	agattgcaaa	acgtggcggc	420
gtgaccgcag	tggaggcgagt	gcacacaggt	cgcaatgcac	tgacgggtgc	cccgcctcaac	480
ttgacccccc	agcaggtggg	ggccatcgcc	agcaataatg	gtggcaagca	ggcgctggag	540
acgggtccagc	ggctgttgcc	agggccacag	gcttgacccc	ccagcaggtg	ccagcaggtg	600
gtggccatcg	ccagcaataa	tggtaggaag	caggcgctgg	agacgggtcca	gcggctgttg	660
ccggtgctgt	gccaggccca	cggcttgacc	ccccagcagg	tggtagccat	cgccagcaat	720
ggcggtggca	agcaggcgct	ggagacgggtc	cagcggtgtg	tgccggtgct	gtgccaggcc	780
caaggcttga	ccccccagca	ggtggtggcc	atcgccagca	ataatggtgg	caagcaggcg	840
ctggagacgg	tccagcggct	gttgccgggtg	ctgtgccagg	cccacggctt	gacccccag	900
caggtgggtg	ccatcgccag	caatggcggt	ggcaagcagg	cgctggagac	ggtccagcgg	960
ctgttgccgg	tgctgttgcca	ggccacggc	ttgaccccg	agcaggtggg	ggccatcgcc	1020
agccacgatg	gcggcaagca	ggcgctggag	acggtccagc	ggctgttgcc	ggtgctgtgc	1080
caggccacag	gcttgacccc	ggagcaggtg	gtggccatcg	ccagcaatat	tggtaggaag	1140
caggcgctgg	agacgggtgca	ggcgctgttg	ccggtgctgt	gccaggccca	cggttgacc	1200
ccggagcagg	tggtagccat	cgccagccac	gatggcgcca	agcaggcgct	ggagacgggtc	1260
cagcggtgtg	tgccggtgct	gtgccaggcc	cacggcttga	ccccccagca	ggtggtggcc	1320
atcgccagca	atggcggtgg	caagcaggcg	ctggagacgg	tccagcggtc	gttgccgggtg	1380
ctgtgccagg	cccacggctt	gacccccag	caggtgggtg	ccatcgccag	caataatggt	1440
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggcccacggc	1500
ttgacccccc	agcaggtggg	ggccatcgcc	agcaatggcg	gtggcaagca	ggcgctggag	1560
acggtccagc	ggctgttgcc	ggtgctgtgc	caggccacag	gcttgacccc	ccagcaggtg	1620
gtggccatcg	ccagcaatgg	cggtaggaag	caggcgctgg	agacgggtcca	gcggctgttg	1680
ccggtgctgt	gccaggccca	cggcttgacc	ccccagcagg	tggtagccat	cgccagcaat	1740
aatggtggca	agcaggcgct	ggagacgggtc	cagcggtgtg	tgccggtgct	gtgccaggcc	1800
caaggcttga	ccccccagca	ggtggtggcc	atcgccagca	ataatggtgg	caagcaggcg	1860
ctggagacgg	tccagcggct	gttgccgggtg	ctgtgccagg	cccacggctt	gacccccgag	1920
caggtgggtg	ccatcgccag	caatattggt	ggcaagcagg	cgctggagac	ggtgcaggcg	1980
ctgttgccgg	tgctgttgcca	ggccacggc	ttgacccctc	agcaggtggt	ggccatcgcc	2040
agcaatggcg	gcggcaggcc	ggcgctggag	agcattgttg	cccagttatc	tcgccctgat	2100
ccggcggttg	ccgcgttgac	caacgaccac	ctcgtgcctc	tggcctgcct	cggcgggctg	2160
cctgcgctgg	atgcagtgaa	aaagggattg	ggggtacctc	tcagccgttc	ccagctggtg	2220
aagtccgagc	tggaggagaa	gaaatccgag	ttgaggcaca	agctgaagta	cgtgccccac	2280
gagtacatcg	agctgatcga	gatcgcccg	aacagcacc	aggaccgtat	cctggagatg	2340
aaggtgatgg	agttcttcat	gaaggtgtac	ggctacagg	gcaagcacct	gggcggctcc	2400
aggaagcccg	acggcgccat	ctacaccgtg	ggctccccca	tcgactacgg	cgtgatcgtg	2460
gacaccaagg	cctactccgg	cggctacaac	ctgcccacag	gccaggccga	cgaaatgcag	2520
aggtacgtgg	aggagaacca	gaccaggaac	aagcacatca	accccaacga	gtggtggaag	2580
gtgtacccct	ccagcgtgac	cgagttcaag	ttcctgttgc	tgtagggcca	cttcaagggc	2640
aactacaagg	cccagctgac	caggctgaac	cacatcacca	actgcaacgg	cgccgtgctg	2700
tccgtggagg	agctcctgat	cggcggcgag	atgatcaagg	ccggcacccct	gaccctggag	2760
gaggtgagga	ggaagttcaa	caacggcgag	atcaacttcg	cggccgactg	ataa	2814

<210> 26

<211> 2832

<212> DNA

<213> Artificial Sequence

<220>

<223> GRex5T1-R TALEN

<400> 26

atggg	cgatc	ctaaaa	agaa	acgta	aggtc	atcgata	agg	agacc	gcgc	tgcca	agttc	60
gagag	acagc	acatg	gacag	catcg	atata	gccga	tctac	gcacg	ctcgg	ctacag	ccag	120
cagca	acagg	agaag	atcaa	accga	aggtt	cgttc	gacag	tggcg	cagca	ccacg	aggca	180
ctggt	cgcc	acggg	tttac	acacg	cgcac	atcgt	tgcgt	taagc	caaca	cccgg	cagcg	240
ttagg	gaccg	tcgct	gtcaa	gtatc	caggac	atgat	cgcag	cgttg	ccaga	ggcga	cacac	300
gaagc	gatcg	ttggc	gtcgg	caaac	cagtgg	tccgg	cgcac	gcgct	ctgga	ggcct	tgtct	360
acggt	ggcgg	gagag	ttgag	aggtc	ccaccg	ttacag	ttgg	acacag	ggcca	acttc	ctcaag	420
attgc	aaaaac	gtggc	ggcgt	gaccg	cagtg	gaggc	cagtgc	atgca	tggcg	caatg	cactg	480
acggg	gtccc	cgctc	aaactt	gaccc	cgag	caggt	ggtag	ccatc	gccag	caata	ttgggt	540
ggcaag	cagg	cgctg	ggagac	ggtgc	caggcg	ctgtt	gccgg	tgctg	tgcca	ggccc	acggc	600
ttgac	cccc	agcag	gtgggt	ggccat	cgc	agcaat	ggcg	gtggc	aaagca	ggcgt	ggag	660
acggt	ccagc	ggctg	ttgcc	ggtgt	gtgtc	caggg	cccacg	gcttg	acccc	ggagc	aggtg	720
gtggc	catcg	ccagc	ccag	tggcg	gcaag	caggc	gctgg	agacg	gtcca	gcggt	gttg	780
ccggt	gtctgt	gccag	ggccca	cggct	tgacc	ccggag	cagg	tggtg	ggccat	cggcag	ccac	840
gatgg	cgcca	agcag	ggcgct	ggaga	cgggtc	cagcg	gctgt	tgccg	gtgct	gtgcc	aggcc	900
cacgg	cttga	cccc	ccagca	ggtgt	gtggc	atcgc	ccagca	atggc	ggtgg	caagc	aggcg	960
ctggag	acgg	tccag	cggtc	gttgc	cggtg	ctgtg	ccagg	cccac	ggctt	gacccc	ccag	1020
caggt	gggtgg	ccatc	gccag	caata	aatgggt	ggcaa	gcagg	cgctg	ggagac	ggtcc	agcgg	1080
ctggt	tgccgg	tgctg	tgcca	ggccc	acggc	ttgac	ccccg	agcag	gtgggt	ggccat	cgc	1140
agccac	gatg	gcgga	agca	ggcgt	ggag	acggt	ccagc	ggctg	ttgcc	ggtgt	gtgtc	1200
caggccc	acg	gcttg	acccc	ggagc	aggtg	gtggc	catcg	ccagc	aatat	tggtg	ggcaa	1260
caggc	gctgg	agacg	gtgca	ggcgt	gtttg	ccggt	gtgtg	gccag	ggcca	cggct	tgacc	1320
ccccag	cagg	tggtg	ggccat	cgccag	caat	ggcgt	ggca	agcag	ggcgt	ggagac	gggtc	1380
cagcg	gctgt	tgccg	gtgtc	gtgcc	aggcc	cacgg	cttga	ccccg	gagca	ggtgt	ggccc	1440
atcgcc	agca	atatt	gggtgg	caagc	aggcg	ctggag	acgg	tgca	ggcgt	gttgcc	gggtg	1500
ctgtg	ccagg	cccac	ggctt	gacccc	ccag	caggt	ggtag	ccatc	gccag	caatg	ggcgt	1560
ggcaag	cagg	cgctg	ggagac	ggtcc	agcgg	ctgtt	gccgg	tgctg	tgcca	ggccc	acggc	1620
ttgac	ccccg	agcag	gtgggt	ggccat	cgc	agcaat	atttg	gtggc	aaagca	ggcgt	ggag	1680
acggt	gcagg	cgctg	ttgcc	ggctgt	gtgc	caggg	cccacg	gcttg	acccc	ggagc	aggtg	1740
gtggc	catcg	ccagc	aatat	tggtg	ggcaa	caggc	gctgg	agacg	gtgca	ggcgt	gttg	1800
ccggt	gtctgt	gccag	ggccca	cggct	tgacc	ccggag	cagg	tggtg	ggccat	cggcag	ccac	1860
gatgg	cgcca	agcag	ggcgct	ggagac	gggtc	cagcg	gctgt	tgccg	gtgct	gtgcc	aggcc	1920
cacgg	cttga	cccc	ggagca	ggtgt	gtggc	atcgcc	agca	atatt	ggtag	caagc	aggcg	1980
ctggag	acgg	tgcag	ggcgct	gttgc	cggtg	ctgtg	ccagg	cccac	ggctt	gacccc	ctcag	2040
caggt	gggtgg	ccatc	gccag	caatg	ggcggc	ggcag	ggccgg	cgctg	ggagag	cattg	ttgcc	2100
cagtt	atctc	gccc	ctgatcc	ggcgt	ttggcc	gcgtt	gacca	acgac	cacct	cgtcg	cccttg	2160
gcctg	cctcg	gcggg	cgctc	tgcg	ctggat	gcagt	gaaaa	aggg	attggg	ggatc	ctatc	2220
agccg	ttccc	agctg	gttgaa	gtccg	agctg	gaggag	aaaga	aatcc	agatt	gaggc	acaa	2280
ctgaag	tacg	tgccc	ccacga	gtacat	cagag	ctgat	cagaga	tcgcc	ccgaa	cagca	cccag	2340
gaccg	tatcc	tggag	atgaa	ggtgat	ggag	ttctt	catga	aggtg	tacgg	ctacag	gggg	2400
aagcac	cctgg	gcggt	ctccag	gaagc	ccgac	ggcgc	catct	acacc	gtggg	ctcccc	ctc	2460
gactac	ggcg	tgatc	gtgga	cacca	aggcc	tactc	cgggc	gctac	aaacct	gccc	atcggc	2520
caggcc	gacg	aaatg	ccagag	gtacgt	ggag	gaga	accaga	ccagg	aaaca	gcac	atcaac	2580
cccaac	cgagt	ggtg	gaagggt	gtaccc	cctcc	agcgt	gaccg	agttc	aaagtt	cctgt	tcgtg	2640
tccgg	ccact	tcaa	gggcaa	ctaca	aggcc	cagct	gacca	ggctg	aaacca	catca	ccaac	2700
tgcaac	ggcg	ccgtg	ctgtc	cgtg	gaggag	ctcct	gatcg	gcggc	gagat	gatca	aggcc	2760
ggcac	cctga	ccctg	gaggga	ggtg	aggagg	aagtt	caaca	acggc	gagat	caact	tcgcg	2820
gccg	actgat	aa										2832

<210> 27

<211> 2814

<212> DNA

<213> Artificial Sequence

<220>

<223> GRex5T2-L TALEN

<400> 27

atggg	cgatc	ctaaaa	agaa	acgta	aggtc	atcgatt	acc	catac	gatgt	tccag	attac	60
gctat	cgata	tgcgc	gatct	acgc	acgctc	ggctac	agcc	agcag	caaca	ggaga	agatc	120
aaacc	gaagg	ttcgt	ttcgac	agtgg	cgcag	caccac	gagg	cactg	gtcgg	ccacg	ggttt	180
acacac	gcgc	acatc	gttgc	gtta	agccaa	cacc	cgccag	cgtag	gggac	cgtcg	ctgtc	240
aagtat	cagg	acatg	atcgc	agcgt	ttgcca	gaggc	gacac	acga	agcgat	cgttg	gcgtc	300
ggcaaa	acagt	ggtc	cggcgc	acgc	gctctg	gaggc	cttgc	tcac	gggtggc	gggag	agttg	360
agaggt	ccac	cgtt	acagtt	ggac	acaggc	caact	ttctca	agatt	gcaaa	acgtg	ggcggc	420
gtgac	cgag	tggag	ggcag	gcat	gcag	cgcaat	gcac	tgac	gggtgc	cccgt	caac	480
ttgac	ccccg	agcag	gtgggt	ggcc	atcgc	agcaat	atttg	gtgg	caagca	ggcgt	ggag	540
acggt	gcagg	cgct	gtttgcc	ggtgt	gtgtc	caggg	cccacg	gcttg	acccc	ccagc	aggtg	600
gtggc	catcg	ccagc	aatgg	cggtg	ggcaag	caggc	gctgg	agac	gggtcca	gcggc	gtttg	660
ccggt	gtctgt	gccag	ggccca	cggct	tgacc	cccc	agcagg	tggtg	ggccat	cggcag	caat	720
aatggt	ggca	agcag	ggcgct	ggag	acgggtc	cagcg	gctgt	tgcc	gggtgct	gtgcc	aggcc	780
cacgg	cttga	cccc	ggagca	ggtgt	gtggc	atcgcc	agca	atatt	ggtag	caagc	aggcg	840
ctggag	acgg	tgcag	ggcgct	gttgc	cggtg	ctgtg	ccagg	cccac	ggctt	gacccc	ccag	900
caggt	gggtgg	ccatc	gccag	caatg	ggcgg	ggcaa	gcagg	cgctg	ggagac	ggtcc	agcgg	960
ctggt	tgccgg	tgctg	tgcca	ggccc	acggc	ttgac	ccccg	agcag	gtgggt	ggccat	cgc	1020
aa	caatattg	ata	caaa	aa	ca	aa	ca	aa	ca	aa	ca	1080

```

caggccacg gcttgacccc ccagcaggtg gtggccatcg ccagcaataa tgggtggcaag 1140
caggcgctgg agacgggtcca gcggtgcttg ccggtgctgt gccaggccca cggcttgacc 1200
cgggagcagg tgggtggccat cggcagccac gatggcggca agcaggcgct ggagacggtc 1260
cagcggctgt tgccgggtgct gtccagggcc cagcgttga cccccagca ggtggtggcc 1320
atcgccagca atggcgggtg caagcaggcg ctggagacgg tccagcggct gttgccggtg 1380
ctgtgccagg cccacggctt gaccccgag caggtggtgg ccacgccag ccacgatggc 1440
ggcaagcagg cgctggagac ggtccagcgg ctgttgccgg tgctgtgcca ggccacaggc 1500
ttgaccccc agcaggtggt ggccatcgcc agcaatggcg gtggcaagca ggcgctggag 1560
acggtccagc ggctgttgcc ggtgctgtgc caggccacag gcttgacccc ccagcaggtg 1620
gtggccatcg ccagcaataa tgggtggcaag caggcgctgg agacgggtcca gcggtgttg 1680
ccggtgctgt gccaggccca cggcttgacc cccagcagg tgggtggccat cgccagcaat 1740
ggcgggtggc agcaggcgct ggagacgggt cagcggctgt tgccgggtgt gtgccaggcc 1800
cacggcttga cccccagca ggtggtggcc atcgccagca atggcgggtg caagcaggcg 1860
ctggagacgg tccagcggct gttgccggtg ctgtgccagg cccacggctt gaccccgag 1920
caggtggtgg ccacgccag ccacgatggc ggcaagcagg cgctggagac ggtccagcgg 1980
ctgttgccgg tgctgtgcca ggccacggc ttgacccctc agcaggtggt ggccatcgcc 2040
agcaatggcg gcggcaggcc gcgctggag agcattgttg ccagttatc tcgccctgat 2100
ccggcgcttg ccgcttgac caacgaccac ctgctgcct tggcctgcct cggcgggctg 2160
cctgcgctgg atgcagtga aaagggttg ggggatccta tcagccgttc ccagctggtg 2220
aagtcggagc tggaggagaa gaaatccgag ttgaggcaca agctgaagta cgtgccccac 2280
gagtacatcg agctgatcga gatcgcccg aacagcacc aggaccgtat cctggagatg 2340
aaggtgatgg agttcttcat gaaggtgtac ggctacagg gcaagcacc gggcggctcc 2400
aggaagcccg acggcgccat ctacaccggt ggctcccca tcgactacgg cgtgatcgtg 2460
gacaccaagg cctactccgg cggctacaac ctgcccacg gccaggccga cgaaatgcag 2520
aggtacgtgg aggagaacca gaccaggaa aagcacatca accccaacga gtggtggaag 2580
gtgtacccct ccagcgtgac cgagttcaag ttcctgttcg tgtccggcca cttcaagggc 2640
aactacaagg ccagctgac caggtgaac cacatcacca actgcaacgg cgccgtgctg 2700
tccgtggagg agctcctgat cggcggcgag atgatcaagg ccggcaccct gaccctggag 2760
gaggtgagga ggaagttcaa caacggcgag atcaacttcg cggccgactg ataa 2814

```

<210> 28

<211> 2832

<212> DNA

<213> Artificial Sequence

<220>

<223> GReX5T2-R TALEN

<400> 28

```

atgggcgatc ctaaaaagaa acgtaaggtc atcgataagg agaccgcgcg tgccaagttc 60
gagagacagc acatggacag catcgatata gccgatctac gcacgctcgg ctacagccag 120
cagcaacagg agaagatcaa accgaagggt cgttcgacag tggcgagca ccacgaggca 180
ctggtcggcc acgggtttac acacgcgcac atcgttgctg taagccaaca cccggcagcg 240
ttagggaccg tcgctgtcaa gtatcaggac atgatcgagc cgttgccaga ggcgacacac 300
gaagcgatcg ttggcgtcgg caaacagtggt tccggcgcac gcgctctgga ggccttgctc 360
acggtggcgg gagagttgag aggtccaccg ttacagttgg acacaggcca acttctcaag 420
attgcaaaac gtggcggtcg gaccgcagtg gaggcagtg atgcatggcg caatgcactg 480
acgggtgccc cgctcaactt gacccccag caggtggtgg ccacgccag caataatggt 540
ggcaagcagg cgctggagac ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc 600
ttgaccccg agcaggtggt ggccatcgcc agcaatattg gtggcaagca ggcgctggag 660
acggtgcagg cgctgttgcc ggtgctgtgc caggccacag gcttgacccc ccagcaggtg 720
gtggccatcg ccagcaataa tgggtggcaag caggcgctgg agacgggtcca ggcgctgttg 780
ccgggtgctg gccaggccca cggcttgacc cggagcagg tggtggccat cgcagccac 840
gatggcggca agcaggcgct ggagacggtc cagcggctgt tgccgggtgt gtgccaggcc 900
cacggcttga cccccagca ggtggtggcc atcgccagca ataatggtgg caagcaggcg 960
ctggagacgg tccagcggct gttgccggtg ctgtgccagg cccacggctt gacccccag 1020
caggtggtgg ccacgccag caatggcggg ggcaagcagg cgctggagac ggtccagcgg 1080
ctgttgccgg tgctgtgcca gggccacggc ttgaccccg agcaggtggt ggccatcgcc 1140
agcaatattg gtggcaagca ggcgctggag acggtgcagg cgctgttgcc ggtgctgtgc 1200
caggccacag gcttgacccc ccagcaggtg tgggtggcaag tgggtggcaag 1260
caggcgctgg agacgggtcca gcggtgctgt gccaggccca cggcttgacc 1320
ccccagcagg tgggtggccat cggcagcaat ggcggtggca agcaggcgct ggagacggtc 1380
cagcggctgt tgccgggtgt gtgccaggcc cagcgttga ccccgagca ggtggtggcc 1440
atcgccagcc acgatggcgg caagcaggcg ctggagacgg tccagcggct gttgccggtg 1500
ctgtgccagg cccacggctt gaccccgag caggtggtgg ccacgccag caatattggt 1560
ggcaagcagg cgctggagac ggtgcaggcg ctgttgccgg tgctgtgcca ggcccacggc 1620
ttgaccccc agcaggtggt ggccatcgcc agcaatggcg gtggcaagca ggcgctggag 1680
acggtccagc ggctgttgcc ggtgctgtgc caggccacag gcttgacccc ccagcaggtg 1740
gtggccatcg ccagcaataa tgggtggcaag caggcgctgg agacgggtcca gcggtgttg 1800
ccggtgctgt gccaggccca cggcttgacc cggagcagg tgggtggccat cgccagcaat 1860
attggtggca agcaggcgct ggagacgggt caggcgctgt tgccgggtgt gtgccaggcc 1920
cacggcttga cccccagca ggtggtggcc atcgccagca atggcgggtg caagcaggcg 1980
ctggagacgg tccagcggct gttgccggtg ctgtgccagg cccacggctt gacccctcag 2040
caggtggtgg ccacgccag caatggcggc ggcaagcagg cgctggagag cattgttgcc 2100
cagttatctc gccctgatcc ggcgttgccc gcgttgacca acgaccacct cgtgccttg 2160
gcctgcctcg gcgggcgtcc tcgctggat gcagtgaata agggattggg ggatcctatc 2220
agcgttccc agctggtgaa gtccgagctg gaggagaaga aatccgagtt gaggcacaag 2280
ctgaagtacg tgccccacga gtacatcgag ctgacgaga tcgcccggaa cagcaccag 2340
gaccgtatcc tggagatgaa ggtgatggag ttcttcatag aggtgtacgg ctacaggggc 2400
aagcacctgg gcggtccag gaagcccag ggcgccatct acacgtggg ctccccatc 2460
gactacggcg tgatcgtgga caccaaggcc tactccggcg gctacaacct gcccatcgcc 2520
caggccgacg aaatgcagag gtacgtggag gagaaccaga ccaggaacaa gcacatcaac 2580
cccaacgagt ggtggaaggt gtacccctcc agcgtgacc agttcaagtt cctgttcgtg 2640
tccggccact tcaagggcaa ctacaaggcc cagctgacca ggctgaacca catcaccaac 2700
tgcaacggcg ccgtgctgtc cgtggaggag ctctgatcg gcggcgagat gatcaaggcc 2760
ggcaccctga ccctggagga ggtgaggagg aagttcaaca acggcgagat caacttcgcg 2820

```

gcccactgat aa 2832

<210> 29

<211> 2814

<212> DNA

<213> Artificial Sequence

<220>

<223> GRex5T3-L TALEN

<400> 29

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgattacc	catacgaatg	tccagattac	60
gctatcgata	tgcgcgatct	acgcacgctc	ggctacagcc	agcagcaaca	ggagaagatc	120
aaaccgaagg	ttcgttcgac	agtggcgag	caccacgagg	cactggtcgg	ccacgggttt	180
acacacgcgc	acatcggttc	gttaagccaa	caccggcgag	cgtagggac	cgtcgctgtc	240
aagtatcagg	acatgatcgc	agcgttgcca	gaggcgacac	acgaagcgat	cgtagggcgtc	300
ggcaaacagt	ggtccggcgc	acgcgctctg	gaggccttgc	tcacgggtgc	gggagagttg	360
agaggtccac	cgttacagtt	ggacacaggg	caacttctca	agattgcaaa	acgtggcggc	420
gtgaccgcag	tggaggcagt	gcatgcatgg	cgcaatgcac	tgacgggtgc	cccgtcaac	480
ttgaccccc	agcagggtgt	ggccatcgcc	agcaatggcg	gtggcaagca	ggcgctggag	540
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggccacag	gcttgacccc	ggagcagggtg	600
gtggccatcg	ccagcaatat	tggtaggcaag	caggcgctgg	agacgggtgca	ggcgctgttg	660
ccggtgctgt	gccaggccca	cggcttgacc	ccccagcagg	tggtaggcat	cgccagcaat	720
ggcggtaggca	agcaggcgct	ggagacggtc	cagcggtgtg	tgccgggtgt	gtgccaggcc	780
cacggcttga	ccccggagca	ggtggtggcc	atcgccagca	atattggtgg	caagcaggcg	840
ctggagacgg	tgcaggcgct	gttgccgggtg	ctgtgccagg	cccacggctt	gacccccag	900
cagggtggtg	ccatcgccag	caatggcggt	ggcaagcagg	cgctggagac	ggtccagcgg	960
ctgttgccgg	tgctgtgcca	ggccacggc	ttgaccccc	agcagggtgt	ggccatcgcc	1020
agcaataatg	gtggcaagca	ggcgctggag	acggtccagc	ggctgttgcc	ggtgctgtgc	1080
caggcccacg	gcttgacccc	ggagcagggtg	gtggccatcg	ccagccacga	tggcggcaag	1140
caggcgctgg	agacgggtcca	gcggtgtgtg	ccggtgctgt	gccaggccca	cggcttgacc	1200
ccggagcagg	tggtaggcat	cgccagcaat	attgtaggca	agcaggcgct	ggagacgggtg	1260
caggcgctgt	tgccgggtgt	gtgccaggcc	caggccttga	ccccccagca	ggtggtggcc	1320
atcgccagca	ataatggtgg	caagcaggcg	ctggagacgg	tccagcggt	gttgccgggtg	1380
ctgtgcccag	cccacggctt	gacccccag	cagggtgtgg	ccatcgccag	caataatggt	1440
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggcccacggc	1500
ttgacccccg	agcagggtgt	ggccatcgcc	agcaatattg	gtggcaagca	ggcgctggag	1560
acgggtgcagg	cgctgttgcc	ggtgctgtgc	caggcccaag	gcttgacccc	ccagcagggtg	1620
gtggccatcg	ccagcaatgg	cggtggcaag	caggcgctgg	agacgggtcca	gcggctgttg	1680
ccggtgctgt	gccaggccca	cggcttgacc	ccggagcagg	tggtaggcat	cgccagcaat	1740
attggtggca	agcaggcgct	ggagacgggtg	caggcgctgt	tgccgggtgt	gtgccaggcc	1800
cacggcttga	ccccccagca	ggtggtggcc	atcgccagca	atggcggtgg	caagcaggcg	1860
ctggagacgg	tccagcggt	gttgccgggtg	ctgtgccagg	cccacggctt	gacccccag	1920
cagggtggtg	ccatcgccag	caataatggt	ggcaagcagg	cgctggagac	ggtccagcgg	1980
ctgttgccgg	tgctgtgcca	ggccacggc	ttgacccctc	agcagggtgt	ggccatcgcc	2040
agcaatggcg	gcggcgagcc	ggcgctggag	agcattgttg	cccagttatc	tcgccctgat	2100
ccggcggttg	ccgcgttgac	caacgaccac	ctcgtgcgt	tggcctgcct	cggcgggcgt	2160
cctgcgctgg	atgcagtga	aaagggttg	gggatccta	tcagccgttc	ccagctggtg	2220
aagtcggagc	tggaggagaa	gaaatccgag	ttgaggcaca	agctgaagta	cgtagccccc	2280
gagtacatcg	agctgatcga	gatcgcccg	aacagcacc	aggaccgtat	cctggagatg	2340
aaggtgatgg	agttcttcat	gaaggtgtac	ggctacagg	gcaagcacct	ggcggtctcc	2400
aggaagcccg	acggcgccat	ctacacogtg	ggctccccca	tcgactacgg	cgtagatcgtg	2460
gacaccaagg	cctactccgg	cggctacaac	ctgccatcg	gccaggccga	cgaaatgcag	2520
aggtacgtgg	aggagaacca	gaccaggaac	aagcacatca	accccaacga	gtggtggaag	2580
gtgtaccct	ccagcgtgac	cgagttcaag	ttcctgttcg	tgtccggcca	cttcaagggc	2640
aactacaagg	cccagctgac	caggctgaac	cacatcacca	actgcaacgg	cgccgtgctg	2700
tccgtggagg	agctcctgat	cggcggcgag	atgatcaagg	ccggcaccct	gaccctggag	2760
gaggtgagga	ggaagttcaa	caacggcgag	atcaacttcg	cggccgactg	ataa	2814

<210> 30

<211> 2832

<212> DNA

<213> Artificial Sequence

<220>

<223> GRex5T3-R TALEN

<400> 30

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgataagg	agaccgccc	tgccaagttc	60
gagagacagc	acatggacag	catcgatatc	gccgatctac	gcacgctcgg	ctacagccag	120
cagcaacagg	agaagatcaa	accgaagggt	cgttcgacag	tggcgagca	ccacgaggca	180
ctggtcgcc	acgggtttac	acacgcgcac	atcgttgctg	taagccaaca	ccggcgagcg	240
ttagggaccg	tcgctgtcaa	gtatcaggac	atgatcgag	cgtagccaga	ggcgacacac	300
gaagcgatcg	ttggcgctcg	caaacagtg	tcggcgccac	gcgctctgga	ggccttctc	360
acggtagggc	gagagttgag	aggtccaccg	ttacagttgg	acacaggcca	acttctcaag	420
attgcaaaac	gtggcgcgct	gaccgcagtg	gaggcagtg	atgcatggcg	caatgcactg	480
acgggtgccc	cgctcaactt	gacccccag	cagggtgtgg	ccatcgccag	caataatggt	540
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggcccacggc	600
ttgacccccg	agcagggtgt	ggccatcgcc	agcaatattg	gtggcaagca	ggcgctggag	660
ccggtgaggg	ccgtcttctg	ccgtctctctg	ccggtgaggg	ccgtctctctg	ccggtgaggg	720

```

acggctgcagg cgtctgttgcg ggtgctgtgc cagggccacg gcttgacccc ccagcaggtg 720
gtggccatcg ccagcaatgg cggtaggcaag caggcgctgg agacggtcca gcggctgttg 780
ccgggtgctgt gccaggccca cggcttgacc ccggagcagg tggtagccat cgcagccac 840
gatggcggca agcaggcgct ggagacggtc cagcggctgt tgccggtgct gtgccaggcc 900
cacggcttga ccccgagca ggtggtggcc atcgccagcc acgatggcgg caagcaggcg 960
ctggagacgg tccagcggct gttgccggtg ctgtgccagg cccacggctt gacccccag 1020
caggtggtgg ccatcgccag caatggcggg ggcaagcagg cgctggagac ggtccagcgg 1080
ctgttgccgg tgctgtgcca gggccacggc ttgaccccgg agcaggtggt ggccatcgcc 1140
agccacgatg gcggcaagca ggcgctggag acggtccagc ggctgttgcc ggtgctgtgc 1200
cagggccacg gcttgacccc ggagcaggtg gtggccatcg ccagccacga tggcggcaag 1260
caggcgctgg agaagggtcca gcggctgttg ccggtgctgt gccaggccca cggcttgacc 1320
ccggagcagg tggtagccat cgcagcaat attggtggca agcaggcgct ggagacggtg 1380
caggcgctgt tgccggtgct gtgccaggcc cagcgcttga ccccgagca ggtggtggcc 1440
atcgccagca atattggtgg caagcaggcg ctggagacgg tgcaggcgct gttgccggtg 1500
ctgtgcccag cccacggctt gacccccag cagtggtgg ccacggccag caataatggt 1560
ggcaagcagg cgctggagac ggtccagcgg ctgtgcccgg tgctgtgcca gggccacggc 1620
ttgacccccc agcaggtggt ggccatcgcc agcaatggcg gtggcaagca ggcgctggag 1680
acggctccagc ggctgttgcc ggtgctgtgc cagggccacg gcttgacccc ccagcaggtg 1740
gtggccatcg ccagcaatgg cggtaggcaag caggcgctgg agacggtcca gcggctgttg 1800
ccgggtgctgt gccaggccca cggcttgacc cccagcagg tggtagccat cgcagcaat 1860
aatggtggca agcaggcgct ggagacggtc cagcgctgt tgccggtgct gtgccaggcc 1920
cacggcttga ccccgagca ggtggtggcc atcgccagca atattggtgg caagcaggcg 1980
ctggagacgg tgcaggcgct gttgccggtg ctgtgccagg cccacggctt gacccctcag 2040
caggtggtgg ccatcgccag caatggcggg ggcaaggccg cgctggagag cattgttgcc 2100
cagttatctc gccctgatcc ggcgttgccc gcgttgacca acgaccacct cgtcgccctg 2160
gcctgcctcg gcgggcgtcc tgcgctggat gcagtgaata agggattggg ggatcctatc 2220
agccgttccc agctggtgaa gtccgagctg gaggagaaga aatccgagtt gaggcacaag 2280
ctgaagtagc tgccccacga gtacatcgag ctgatcgaga tcgcccggaa cagcaccag 2340
gaccgtatcc tggagatgaa ggtgatggag ttcttcatga aggtgtacgg ctacaggggc 2400
aagcacctgg gcggctccag gaagcccgac ggcgccatct acaccgtggg ctccccatc 2460
gactacggcg tgatcgtgga caccaggcc tactccggcg gctacaacct gcccatcgcc 2520
caggccgacg aaatgcagag gtacgtggag gagaaccaga ccaggaacaa gcacatcaac 2580
cccaacgagt ggtggaagggt gtacccctcc agcgtgaccg agttcaagtt cctgttcgtg 2640
tccggccact tcaagggcaa ctacaaggcc cagctgacca ggctgaacca catcaccac 2700
tgcaacggcg ccgtgctgtc cgtggaggag ctctgatcgc gcggcgagat gatcaaggcc 2760
ggcaccctga ccctggagga ggtgaggagg aagttcaaca acggcgagat caacttcgcg 2820
gccgactgat aa 2832

```

<210> 31

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Forward primer GR exon 2

<220>

<221> misc-feature

<222> (31)..(40)

<223> n is a or c or t or g

<400> 31

ccatctcatc cctgcgtgtc tccgactcag nnnnnnnnnn gggtcattta acaagctgcc 60

<210> 32

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Forward primer GR exon 3

<220>

<221> misc_feature

<222> (31)..(40)

<223> n is a or c or t or g

<400> 32

ccatctcatc cctgcgtgtc tccgactcag nnnnnnnnnn gcattctgac tatgaagtga 60

<210> 33

<211> 69

<212> DNA

<213> Artificial Sequence

<220>

<223> Forward primer GR exon 5

<220>

<221> misc_feature

<222> (31)..(40)

<223> n is a or c or t or g

<400> 33

ccatctcatc cctgogtgtc tccgactcag nnnnnnnnnn tcagcaggcc actacaggag	60
tctcacaag	69

<210> 34

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Reverse primer GR exon 2

<400> 34

cctatcccct gtgtgccttg gcagtctcag agccagtgag ggtgaagacg	50
--	----

<210> 35

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Reverse primer GR exon 3

<400> 35

cctatcccct gtgtgccttg gcagtctcag gggctttgca tataatggaa	50
--	----

<210> 36

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Reverse primer GR exon 5

<400> 36

cctatcccct gtgtgccttg gcagtctcag ctgactctcc ccttcatagt ccccagaac	59
--	----

<210> 37

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> TRAC_T01

<400> 37

ttgtcccaca gatatccaga accctgaccc tgccgtgtac cagctgaga	49
---	----

<210> 38

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> TRBC_T01

<400> 38

tgtgtttgag ccatcagaag cagagatctc ccacacccaa aaggccaca 49

<210> 39

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> TRBC_T02

<400> 39

ttcccaccg aggtcgctgt gttgagcca tcagaagcag agatctccca 50

<210> 40

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> CD52_T02

<400> 40

ttctctctac tcaccatcag cctcctgggt atggtacagg taagagcaa 49

<210> 41

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat TRAC_T01-L

<400> 41

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
20 25 30

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly
35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
50 55 60

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
65 70 75 80

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
100 105 110

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
115 120 125

Val Val Val Val Val Val Val Val Val Val Val Val Val Val Val Val
130 135 140 145 150 155 160 165 170 175 180 185 190 195 200

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 130 135 140
 Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 145 150 155 160
 Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
 165 170 175
 Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190
 Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
 195 200 205
 Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu
 210 215 220
 Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240
 Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala
 245 250 255
 Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
 260 265 270
 Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys
 275 280 285
 Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala
 290 295 300
 His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly
 305 310 315 320
 Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 325 330 335
 Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn
 340 345 350
 Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val
 355 360 365
 Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
 370 375 380
 Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 385 390 395 400
 Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 405 410 415
 Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala
 420 425 430
 Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 435 440 445
 Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val
 450 455 460
 Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
 465 470 475 480
 Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu
 485 490 495

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
500 505 510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
515 520 525

Leu Glu
530

<210> 42

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat TRAC_T01-R

<400> 42

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys
1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
20 25 30

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly
35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
50 55 60

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
65 70 75 80

Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
100 105 110

Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu
115 120 125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
130 135 140

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
145 150 155 160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
165 170 175

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
180 185 190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
195 200 205

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu
210 215 220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
225 230 235 240

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala
245 250 255

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
260 265 270

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
275 280 285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
290 295 300

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly
305 310 315 320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
325 330 335

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn
340 345 350

Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val
355 360 365

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
370 375 380

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
385 390 395 400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
405 410 415

Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala
420 425 430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
435 440 445

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
450 455 460

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
465 470 475 480

Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu
485 490 495

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
500 505 510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
515 520 525

Leu Glu
530

<210> 43
<211> 530
<212> PRT
<213> Artificial Sequence

<220>
<223> Repeat TRBC_T01-L

<400> 43
Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
20 25 30

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly

```

35      40      45
Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
50      55      60
Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
65      70      75      80
Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
85      90      95
Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
100     105     110
Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
115     120     125
Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
130     135     140
Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
145     150     155     160
Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
165     170     175
Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val
180     185     190
Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
195     200     205
Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu
210     215     220
Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
225     230     235     240
Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala
245     250     255
Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly
260     265     270
Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
275     280     285
Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
290     295     300
His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
305     310     315     320
Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
325     330     335
Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
340     345     350
Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
355     360     365
Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
370     375     380
Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu
385     390     395     400

```

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
405 410 415

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
420 425 430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
435 440 445

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
450 455 460

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
465 470 475 480

Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu
485 490 495

Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
500 505 510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
515 520 525

Leu Glu
530

<210> 44

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat TRBC_T01-R

<400> 44

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
20 25 30

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly
35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
50 55 60

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
65 70 75 80

Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
100 105 110

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
115 120 125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
130 135 140

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
145 150 155 160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
165 170 175

```

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
180                      185                      190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
195                      200                      205

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu
210                      215                      220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
225                      230                      235                      240

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala
245                      250                      255

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
260                      265                      270

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
275                      280                      285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
290                      295                      300

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly
305                      310                      315                      320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
325                      330                      335

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
340                      345                      350

Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
355                      360                      365

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
370                      375                      380

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
385                      390                      395                      400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
405                      410                      415

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
420                      425                      430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
435                      440                      445

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val
450                      455                      460

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
465                      470                      475                      480

Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu
485                      490                      495

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
500                      505                      510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
515                      520                      525

Leu Glu

```

```

-----
      530

<210> 45
<211> 530
<212> PRT
<213> Artificial Sequence

<220>
<223> Repeat TRBC_T02-L

<400> 45
Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys
1          5          10          15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
20          25          30

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
35          40          45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
50          55          60

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
65          70          75          80

Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
85          90          95

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
100         105         110

Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu
115         120         125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
130         135         140

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
145         150         155         160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
165         170         175

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
180         185         190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
195         200         205

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu
210         215         220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
225         230         235         240

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala
245         250         255

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
260         265         270

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys
275         280         285

Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala
290         295         300

```

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly
305 310 315 320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
325 330 335

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
340 345 350

Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
355 360 365

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
370 375 380

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
385 390 395 400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
405 410 415

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
420 425 430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
435 440 445

Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val
450 455 460

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
465 470 475 480

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu
485 490 495

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
500 505 510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
515 520 525

Leu Glu
530

<210> 46

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat TRBC_T02-R

<400> 46

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
20 25 30

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly

35

40

45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
50 55 60

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
65 70 75 80

Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
100 105 110

Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu
115 120 125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
130 135 140

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
145 150 155 160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
165 170 175

Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val
180 185 190

Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
195 200 205

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu
210 215 220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
225 230 235 240

Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala
245 250 255

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
260 265 270

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
275 280 285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
290 295 300

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
305 310 315 320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
325 330 335

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
340 345 350

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
355 360 365

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
370 375 380

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
385 390 395 400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
405 410 415

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
420 425 430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
435 440 445

```

433          440          443
Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val
450          455          460

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
465          470          475          480

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu
485          490          495

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
500          505          510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
515          520          525

Leu Glu
530

<210> 47
<211> 530
<212> PRT
<213> Artificial Sequence

<220>
<223> Repeat CD52_T02-L

<400> 47
Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
1          5          10          15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
20          25          30

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
35          40          45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
50          55          60

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
65          70          75          80

Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
85          90          95

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
100         105         110

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
115         120         125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
130         135         140

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
145         150         155         160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
165         170         175

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
180         185         190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
195         200         205

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu

```

210	215	220
Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr		
225	230	235 240
Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala		
	245	250 255
Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly		
	260	265 270
Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys		
	275	280 285
Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala		
	290	295 300
His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly		
	305	310 315 320
Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys		
	325	330 335
Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His		
	340	345 350
Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val		
	355	360 365
Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala		
	370	375 380
Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu		
	385	390 395 400
Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala		
	405	410 415
Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg		
	420	425 430
Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val		
	435	440 445
Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val		
	450	455 460
Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu		
	465	470 475 480
Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu		
	485	490 495
Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr		
	500	505 510
Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala		
	515	520 525

Leu Glu
530

<210> 48

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat CD52_T02-R

<400> 48

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
 1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 20 25 30

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly
 35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 50 55 60

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
 65 70 75 80

Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
 100 105 110

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 115 120 125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 130 135 140

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 145 150 155 160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 165 170 175

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
 195 200 205

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu
 210 215 220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240

Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala
 245 250 255

Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly
 260 265 270

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys
 275 280 285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 290 295 300

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
 305 310 315 320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 325 330 335

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
 340 345 350

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 355 360 365

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
370 375 380

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
385 390 395 400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
405 410 415

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
420 425 430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
435 440 445

Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val
450 455 460

Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
465 470 475 480

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu
485 490 495

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
500 505 510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
515 520 525

Leu Glu
530

<210> 49

<211> 2814

<212> DNA

<213> Artificial Sequence

<220>

<223> TRAC_T01-L TALEN

<400> 49

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgattacc	catacgaatg	tccagattac	60
gctatcgata	tgcgccgatct	acgcacgctc	ggctacagcc	agcagcaaca	ggagaagatc	120
aaaccgaagg	ttcggttcgac	agtggcgag	caccacgagg	cactggctcg	ccacgggttt	180
acacacgcgc	acatcggttg	gttaagccaa	caccggcgag	cgtagggac	cgtagctgtc	240
aagtatcagg	acatgatcgc	agcgttgcca	gaggcgacac	acgaagcgat	cgtaggcgtc	300
ggcaaacagt	ggtagggcgc	acgcgctctg	gaggccttgc	tcacgggtgc	gggagagttg	360
agaggtccac	cgtagcagtt	ggacacaggg	caacttctca	agattgcaaa	acgtggcggc	420
gtgaccgcag	tggaggcag	gcagcatgg	cgcaatgcac	tgacgggtgc	cccgtcaac	480
ttgaccccc	agcaggtgg	ggccatcgcc	agcaatggcg	gtggcaagca	ggcgtggag	540
acggtccagc	ggctggttgc	ggtgctgtgc	caggccacg	gcttgacccc	ccagcaggtg	600
gtggccatcg	ccagcaataa	tggtggcaag	caggcgctgg	agacggtcca	gcggctgttg	660

ccggtgctgt	gccaggccca	cggttgacc	ccccagcagg	tggtggccat	cgccagcaat	720
ggcgggtggc	agcaggcgct	ggagacggtc	cagcggtgtg	tgccggtgct	gtgccaggcc	780
cacggcttga	ccccggagca	ggtggtggcc	atcgccagcc	acgatggcgg	caagcaggcg	840
ctggagacgg	tccagcggt	gttgccggtg	ctgtgccagg	cccacggctt	gaccccgag	900
caggtggtgg	ccatcgccag	ccacgatggc	ggcaagcagg	cgctggagac	ggtccagcgg	960
ctgttgccgg	tgctgtgcca	ggcccacggc	ttgaccccg	agcaggtggt	ggccatcgcc	1020
agccacgatg	gcggcaagca	ggcgctggag	acggtccagc	ggctgttgcc	ggtgctgtgc	1080
caggcccacg	gcttgacccc	ggagcaggtg	gtggccatcg	ccagcaatat	tggtggcaag	1140
caggcgctgg	agacggtgca	ggcgctgttg	ccggtgctgt	gccaggccca	cggttgacc	1200
ccggagcagg	tggtggccat	cgccagccac	gatggcgcca	agcaggcgct	ggagacggtc	1260
cagcggtgtg	tgccggtgct	gtgccaggcc	cacggcttga	ccccggagca	ggtggtggcc	1320
atcgccagca	atattggtgg	caagcaggcg	ctggagacgg	tgacggcgct	gttgccggtg	1380
ctgtgccagg	cccacggctt	gacccccag	caggtggtgg	ccatcgccag	caataatggt	1440
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggcccacggc	1500
ttgaccccg	agcaggtggt	ggccatcgcc	agcaatatg	gtggcaagca	ggcgtggag	1560
acggtgcagg	cgctgttgcc	ggtgctgtgc	caggccacg	gcttgacccc	ccagcaggtg	1620
gtggccatcg	ccagcaatgg	cggtggcaag	caggcgctgg	agacggtcca	gcggctgttg	1680
ccggtgctgt	gccaggccca	cggttgacc	ccggagcagg	tggtggccat	cgccagcaat	1740
attggtggca	agcaggcgct	ggagacggtg	caggcgctgt	tgccggtgct	gtgccaggcc	1800
cacggcttga	ccccccagca	ggtggtggcc	atcgccagca	atggcggtgg	caagcaggcg	1860
ctggagacgg	tccagcggt	gttgccggtg	ctgtgccagg	cccacggctt	gaccccgag	1920
caggtgctga	ccatcgccag	ccagcatggc	ggcaagcagg	cactgagac	ggtccagcgg	1980

```

ccggcggtgg  ccccgccag  ccccgccag  ggcccgccg  agcaggtgg  ggcccgccg  2040
ctgttgccgg  tgctgtgcca  ggcccgccg  ttgacccctc  agcaggtgg  ggcccgccg  2100
agcaatggcg  gcggcaggcc  ggcgctggag  agcattgttg  cccagttatc  tcgccctgat  2160
ccggcggttg  ccggcggttg  caacgaccac  ctcgctgcct  tggcctgcct  cggcgggcgt  2220
cctgcgctgg  atgcagtgaa  aaagggattg  ggggatccta  tcagccgttc  ccagctggtg  2280
aagtccgagc  tggaggagaa  gaaatccgag  ttgaggcaca  agctgaagta  cgtgccccac  2340
gagtacatcg  agctgatcga  gatcgcccg  aacagcacc  aggaccgtat  cctggagatg  2400
aaggtgatgg  agttcttcat  gaaggtgtac  ggctacaggg  gcaagcacct  gggcggtcc  2460
aggaagcccg  acggcgccat  ctacaccg  ggctcccc  tcgactacgg  cgtgatcgtg  2520
gacaccaagg  cctactccgg  cggctacaac  ctgcccac  gccaggccga  cgaaatgcag  2580
aggtacgtgg  aggagaacca  gaccaggaac  aagcacatca  accccaacga  gtggtggaag  2640
gtgtacccct  ccagcgtgac  cgagttcaag  ttctgttctg  tgtccggcca  cttcaagggc  2700
aactacaagg  cccagctgac  caggctgaac  cacatcacca  actgcaacgg  cggcgtgctg  2760
tccgtggagg  agctcctgat  cggcgccgag  atgatcaagg  cggcgaccct  gaccctggag  2814
gaggtgagga  ggaagttcaa  caacggcgag  atcaacttcg  cggcgactg  ataa

```

<210> 50

<211> 2832

<212> DNA

<213> Artificial Sequence

<220>

<223> TRAC_T01-R TALEN

<400> 50

```

atggcgcatc  ctaaaaagaa  acgtaaggtc  atcgataagg  agaccggcgc  tgccaagttc  60
gagagacagc  acatggacag  catcgatatc  gccgatctac  gcacgctcgg  ctacagccag  120
cagcaacagg  agaagatcaa  accgaagggt  cgttcgacag  tggcgagca  ccacgaggca  180
ctggtcggcc  acgggtttac  acgcgcgcac  atcgttgctg  taagccaaca  cccggcagcg  240
ttagggaccg  tcgctgtcaa  gtatcaggac  atgatcgag  cgttgccaga  ggcgacacac  300
gaagcgatcg  ttggcgctcg  caaacagtg  tccggcgcac  gcgctctgga  ggccttgctc  360
acgggtggcg  gagagttgag  aggtccacc  ttacagttgg  acacaggcca  acttctcaag  420
attgcaaaac  gtggcggtcg  gaccgcagtg  gaggcagtg  atgcatggcg  caatgcactg  480
acgggtgccc  cgctcaactt  gaccccgag  cagggtggtg  ccacgcccag  ccacgatggc  540
ggcaagcagg  cgctggagac  ggtccagcg  ctgttgccgg  tgctgtgcca  ggcccgccg  600
ttgaccccc  agcaggtggt  ggccatcgcc  agcaatggcg  gtggcaagca  ggcgctggag  660
acgggtccag  ggctgttgcc  ggtgctgtgc  caggcccac  gcttgacccc  ggagcaggtg  720
gtggccatcg  ccagccacga  tggcggaag  caggcgctgg  agacggtcca  ggcgctgttg  780
ccggtgctgt  gccaggccca  cggcttgacc  ccggagcagg  tgggtggccat  cgcagcaat  840
attggtggca  agcaggcgct  ggagacggtg  caggcgctgt  tgccggtgct  gtgcccaggc  900

```

```

cacggcttga  cccccagca  ggtggtggcc  atcgccagca  ataatggtgg  caagcaggcg  960
ctggagacgg  tccagcggt  gttgcccgtg  ctgtgccagg  cccacggctt  gaccccgag  1020
cagggtggtg  ccacgcccag  ccacgatggc  ggcaagcagg  cgctggagac  ggtccagcg  1080
ctgttgccgg  tgctgtgcca  ggcccgccg  ttgaccccc  agcaggtgg  ggccatcgcc  1140
agcaatggcg  gtggcaagca  ggctggtg  agcaggtgg  ggctggtg  ggtgctgtgc  1200
caggcccg  gcttgacccc  ccagcaggtg  gtggccatcg  ccagcaataa  tgggtggcaag  1260
caggcgctgg  agacggtcca  gcgctgttg  ccggtgctgt  gccaggccca  cggcttgacc  1320
ccccagcagg  tgggtggccat  cgccagcaat  aatggtggca  agcaggcgct  ggagacggtc  1380
cagcggtgtg  tgccggtgct  gtgcccagg  cagggcttga  cccccagca  ggtggtggcc  1440
atcgccagca  atggcggtgg  caagcaggcg  ctggagacgg  tccagcggt  gttgcccgtg  1500
ctgtgcccag  cccacggctt  gaccccgag  cagggtggtg  ccacgcccag  caatattggt  1560
ggcaagcagg  cgctggagac  ggtgcccgg  ctgttgccgg  tgctgtgcca  ggcccgccg  1620
ttgaccccc  agcaggtgg  ggccatcgcc  agccacgatg  gcggcaagca  ggcgctggag  1680
acgggtccag  ggctgttgcc  ggtgctgtgc  caggcccac  gcttgacccc  ggagcaggtg  1740
gtggccatcg  ccagcaatat  tgggtggca  caggcgctgg  agacggtgca  ggcgctgttg  1800
ccggtgctgt  gccaggccca  cggcttgacc  ccggagcagg  tgggtggccat  cgcagccac  1860
gatggcgcca  agcaggcgct  ggagacggtc  cagcggtgt  tgccggtgct  gtgcccaggc  1920
cacggcttga  cccccagca  ggtggtggcc  atcgccagca  ataatggtgg  caagcaggcg  1980
ctggagacgg  tccagcggt  gttgcccgtg  ctgtgccagg  cccacggctt  gacccctcag  2040
cagggtggtg  ccacgcccag  caatggcgcc  ggcaggccgg  cgctggagag  cattgttgcc  2100
cagttatctc  gccctgatcc  ggcgttgcc  gcgttgacca  acgaccacct  cgtgccttg  2160
gcctgcctcg  gcgggcgtcc  tgccgtggat  gcagtgaata  agggattggg  ggatcctatc  2220
agccgttccc  agctggtgaa  gtccgagctg  gaggagaaga  aatccgagtt  gaggcacaag  2280
ctgaagtacg  tgccccacga  gtacatcgag  ctgatcgaga  tcgcccggaa  cagcaccag  2340
gaccgtatcc  tggagatgaa  ggtgatggag  ttcttcatga  aggtgtacgg  ctacaggggc  2400
aagcacctgg  gcggctccag  gaagcccgac  ggcccatct  acaccgtgg  ctccccatc  2460
gactacggcg  tgatcgtgga  caccaaggcc  tactccggcg  gctacaacct  gcccatcgcc  2520
caggccgacg  aaatgcagag  gtacgtggag  gagaaccaga  ccaggaacaa  gcacatcaac  2580
cccaacgagt  ggtggaaggt  gtacccctcc  agcgtgaccg  agttcaagtt  cctgttcgtg  2640
tccggccact  tcaagggcaa  ctacaaggcc  cagctgacca  ggctgaacca  catcaccaac  2700
tgcaacggcg  ccgtgctgtc  cgtggaggag  ctctgatcg  gcggcgagat  gatcaaggcc  2760
ggcacccctga  ccctggagga  ggtgaggagg  aagttcaaca  acggcgagat  caacttcgcg  2820
gccgactgat  aa

```

<210> 51

<211> 2814

<212> DNA

<213> Artificial Sequence

<220>

<223> TRBC_T01-L TALEN

<400> 51

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgattacc	catacgaatg	tccagattac	60
gctatcgata	tgcgcgatct	acgcacgctc	ggctacagcc	agcagcaaca	ggagaagatc	120
aaaccgaagg	ttcgttcgac	agtggcgag	caccacgagg	cactggtcgg	ccacgggttt	180
acacacgcgc	acatcggttc	gttaagccaa	caccgcgag	cgtagggac	cgtcgctgtc	240
aagtatcagg	acatgatcgc	agcgttgcca	gaggcgacac	acgaagcgat	cgttggcgtc	300
ggcaaacagt	ggtccggcgc	acgcgctctg	gaggccttgc	tcacggctgg	gggagagttg	360
agagggtccac	cgttacagtt	ggacacaggc	caacttctca	agattgcaaa	acgtggcggc	420
gtgaccgcag	tggaggcgag	gcatgcatgg	cgcaatgcac	tgacgggtgc	cccgtctaac	480
ttgaccccc	agcagggtgt	ggccatcgcc	agcaataatg	gtggcaagca	ggcgctggag	540
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggccacag	gcttgacccc	ccagcagggtg	600
gtggccatcg	ccagcaatgg	cgggtggcaag	caggcgctgg	agacgggtcca	gcggctgttg	660
cgggtgctgt	gccaggccca	cggcttgacc	ccccagcagg	tgggtggccat	cgccagcaat	720
aatgggtggca	agcaggcgct	ggagacggtc	cagcggctgt	tgccgggtgct	gtgccaggcc	780
cacggcttga	ccccccagca	ggtggtggcc	atcgccagca	atggcgggtg	caagcaggcg	840
ctggagacgg	tccagcggct	gttgccgggtg	ctgtgccagg	cccacggctt	gacccccag	900
cagggtggtg	ccatcgccag	caatggcggt	ggcaagcagg	cgctggagac	ggtccagcgg	960
ctggtgccgg	tgctgtgcca	ggcccacggc	ttgaccccc	agcagggtgt	ggccatcgcc	1020
agcaatggcg	gtggcaagca	ggcgctggag	acgggtccagc	ggctgttgcc	ggtgctgtgc	1080

caggccacag	gcttgacccc	ccagcagggtg	gtggccatcg	ccagcaataa	tgggtggcaag	1140
caggcgctgg	agacgggtcca	gcggctgttg	ccgtgctgtg	gccaggccca	cggcttgacc	1200
cggagcagg	tgggtggccat	cgccagcaat	attggtggca	agcaggcgct	ggagacgggtg	1260
caggcgctgt	tgccgggtgct	gtgccaggcc	cacggcttga	ccccccagca	ggtggtggcc	1320
atcgccagca	ataatggtgg	caagcaggcg	ctggagacgg	tcagcggct	gttgccgggtg	1380
ctgtgccagg	cccacggctt	gacccggag	caggtggtgg	ccatcgccag	ccacgatggc	1440
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggcccacggc	1500
ttgacccccg	agcagggtgt	ggccatcgcc	agccacgatg	gcggcaagca	ggcgctggag	1560
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggccacag	gcttgacccc	ggagcagggtg	1620
gtggccatcg	ccagcaatat	tgggtggcaag	caggcgctgg	agacgggtcca	ggcgctgttg	1680
cgggtgctgt	gccaggccca	cggcttgacc	ccccagcagg	tgggtggccat	cgccagcaat	1740
ggcgggtggca	agcaggcgct	ggagacggtc	cagcggctgt	tgccgggtgct	gtgccaggcc	1800
cacggcttga	cccgggagca	ggtggtggcc	atcgccagcc	acgatggcgg	caagcaggcg	1860
ctggagacgg	tcagcggct	gttgccgggtg	ctgtgccagg	cccacggctt	gaccccgag	1920
cagggtggtg	ccatcgccag	caatattggt	ggcaagcagg	cgctggagac	ggtgcaggcg	1980
ctggtgccgg	tgctgtgcca	ggcccacggc	ttgacccctc	agcagggtgt	ggccatcgcc	2040
agcaatggcg	gcggcaggcc	ggcgctggag	agcattgttg	cccagttatc	tcgccctgat	2100
cggcgcttgg	ccgcgttgac	caacgaccac	ctcgtcgct	tggcctgcct	cggcgggcgt	2160
cctgcgctgg	atgcagtga	aaagggttg	gggatcccta	tcagccgttc	ccagctggtg	2220
aagtcgagc	tggaggagaa	gaaatccgag	ttgaggcaca	agctgaagta	cgtgccccac	2280
gagtacatcg	agctgatcga	gatcgccgg	aacagcacc	aggaccgtat	cctggagatg	2340
aagggtgatg	agttcttcat	gaagggtgtac	ggctacagg	gcaagcacct	gggcggctcc	2400
aggaagcccc	acggcgccat	ctacaccgtg	ggctccccc	tcgactacgg	cgtgatcgtg	2460
gacaccaagg	cctactccgg	cggctacaac	ctgcccacg	gccaggccga	cgaaatgcag	2520
aggtacgtg	aggagaacca	gaccaggga	agcacatca	accccaacga	gtggtggaag	2580
gtgtacccct	ccagcgtgac	cgatttcaag	ttcctgttcg	tgtccggcca	cttcaagggc	2640
aactacaagg	cccagctgac	caggctgaac	cacatcacca	actgcaacgg	cgcctgtgctg	2700
tccgtggagg	agctcctgat	cggcgcgag	atgatcaagg	ccggcacccct	gaccctggag	2760
gagggtgagga	ggaagttcaa	caacggcgag	atcaacttcg	cggccgactg	ataa	2814

<210> 52

<211> 2832

<212> DNA

<213> Artificial Sequence

<220>

<223> TRBC_T01-R TALEN

<400> 52

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgataagg	agaccgcgc	tgccaagttc	60
gagagacagc	acatggacag	catcgatatac	gccgatctac	gcacgctcgg	ctacagccag	120
cagcaacagg	agaagatcaa	accgaagggtt	cgttcgacag	tggcgagca	ccacgaggca	180
ctggtcggcc	acgggtttac	acacgcgcac	atcgttgcg	taagccaaca	cccggcagcg	240
ttagggaccg	tcgctgtcaa	gtatcaggac	atgatcgag	cgttgccaga	ggcgacacac	300
gaagcgatcg	ttggcgtcgg	caaacagtg	tcggcgcac	gcgctctga	ggccttctc	360
acgggtggcg	gagagttgag	aggtccacc	ttacagttg	acacaggcca	acttctcaag	420
attgcaaaac	gtggcgcggt	gaccgcagtg	gaggcagtg	atgcatggcg	caatgactg	480
acgggtgccc	cgtccaactt	gacccccag	cagggtggtg	ccatcgccag	caataatggt	540
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggcccacggc	600
ttgaccccc	agcagggtgt	ggccatcgcc	agcaatggcg	gtggcaagca	ggcgctggag	660
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggccacag	gcttgacccc	ccagcagggtg	720
gtggccatcg	ccagcaataa	tgggtggcaag	caggcgctgg	agacgggtcca	gcggctgttg	780
cgggtgctgt	gccaggccca	cggcttgacc	ccccagcagg	tgggtggccat	cgccagcaat	840
aatgggtggca	agcaggcgct	ggagacggtc	cagcggctgt	tgccgggtgct	gtgccaggcc	900
cacggcttga	ccccggagca	ggtggtggcc	atcgccagcc	acgatggcgg	caagcaggcg	960
ctggagacgg	tcagcggct	gttgccgggtg	ctgtgccagg	cccacggctt	gaccccgag	1020
cagggtggtg	ccatcgccag	ccacgatggc	ggcaagcagg	cgctggagac	ggtccagcgg	1080
ctggtgccgg	tgctgtgcca	ggcccacggc	ttgaccccc	agcagggtgt	ggccatcgcc	1140
agcaatggcg	gtggcaagca	ggcgctggag	acgggtccagc	ggctgttgcc	ggtgctgtgc	1200
caggccacag	gcttgacccc	ccagcagggtg	gtggccatcg	ccagcaatgg	cgggtggcaag	1260
caggcgctgg	agacgggtcca	gcggctgttg	ccgtgctgtg	gccaggccca	cggcttgacc	1320

```

ccccagcagg  tgggtggccat  cgccagcaat  ggcggtggca  agcaggcgct  ggagacggtc  1380
cagcggctgt  tgccgggtgt  gtccagggcc  cagcgcttga  ccccccagca  ggtggtggcc  1440
atcgccagca  atggcgggtg  caagcaggcg  ctggagacgg  tccagcggct  gttgccgggtg  1500
ctgtgccagg  cccacggctt  gacccccag  caggtggtgg  ccatcgccag  caataatggt  1560
ggcaagcagg  cgctggagac  ggtccagcgg  ctgttgccgg  tgctgtgcca  ggccccacggc  1620
ttgaccccc  agcagggtgt  ggccatcgcc  agcaataatg  gtggcaagca  ggcgctggag  1680
acggtccagc  ggctgttgcc  ggtgctgtgc  caggcccacg  gcttgacccc  ccagcagggtg  1740
gtggccatcg  ccagcaataa  tgggtggcaag  caggcgctgg  agacgggtcca  gcggctgttg  1800
ccggtgctgt  gccaggccca  cggcttgacc  ccccagcagg  tgggtggccat  cgccagcaat  1860
ggcgggtggca  agcaggcgct  ggagacggtc  cagcggctgt  tgccgggtgt  gtgccaggcc  1920
cacggcttga  ccccccagca  ggtggtggcc  atcgccagca  ataatggtgg  caagcaggcg  1980
ctggagacgg  tccagcggct  gttgccgggtg  ctgtgccagg  cccacggctt  gacccctcag  2040
caggtggtgg  ccatcgccag  caatggcggc  ggcaggccgg  cgctggagag  cattgttgcc  2100
cagttatctc  gccctgatcc  ggcgttgacc  gcgttgacca  acgaccacct  cgtcgccctg  2160
gcctgcctcg  gcgggcgtcc  tgcgctggat  gcagtgaata  agggattggg  ggatcctatc  2220
agccgttccc  agctggtgaa  gtccgagctg  gaggagaaga  aatccgagtt  gaggcacaag  2280
ctgaagtacg  tgcccccagc  gtacatcgag  ctgatcgaga  tcgcccggaa  cagcaccacg  2340
gaccgtatcc  tggagatgaa  ggtgatggag  ttcttcatga  aggtgtacgg  ctacaggggc  2400
aagcacctgg  gcggctccag  gaagcccagc  ggcgccatct  acaccgtggg  ctcccccatc  2460
gactacggcg  tgcctgtgga  caccaaggcc  tactccggcg  gctacaacct  gcccatcgcc  2520
caggccgacg  aaatgcagag  gtacgtggag  gagaaccaga  ccaggaacaa  gcacatcaac  2580
cccaacgagt  ggtggaaggt  gtacccctcc  agcgtgaccg  agttcaagtt  cctgttcgtg  2640
tccggccact  tcaagggcaa  ctacaaggcc  cagctgacca  ggctgaacca  catcaccaac  2700
tgcaacggcg  ccgtgctgtc  cgtggaggag  ctctgatcg  gcggcgagat  gatcaaggcc  2760
ggcacctga  ccctggagga  ggtgaggagg  aagtcaaca  acggcgagat  caacttcgcg  2820
gccgactgat  aa  2832

```

<210> 53

<211> 2814

<212> DNA

<213> Artificial Sequence

<220>

<223> TRBC_T02-L TALEN

<400> 53

```

atgggcgatc  ctaaaaagaa  acgtaaggtc  atcgattacc  catacgatgt  tccagattac  60
gctatcgata  tcgccgatct  acgcacgctc  ggctacagcc  agcagcaaca  ggagaagatc  120
aaaccgaagg  ttcgttcgac  agtggcgag  caccacgagg  cactggtcgg  ccacgggttt  180
acacacgcgc  acatcggttg  gttaaagcaa  caccggcag  cgttaggag  cgtcgctgtc  240
aagtatcagg  acatgatcgc  agcgttgcca  gaggcgacac  acgaagcgat  cgttggcgtc  300
ggcaaacagt  ggtccggcgc  acgcgctctg  gaggccttgc  tcacggtggc  gggagagttg  360
agaggtccac  cgttacagtt  ggacacaggg  caacttctca  agattgcaaa  acgtggcggc  420
gtgaccgcag  tggaggcagt  gcatgcatgg  cgcaatgcac  tgacgggtgc  cccgctcaac  480
ttgacccccg  agcagggtgt  ggccatcgcc  agccacgatg  gcggcaagca  ggcgctggag  540
acggtccagc  ggctgttgcc  ggtgctgtgc  caggcccacg  gcttgacccc  ggagcagggtg  600
gtggccatcg  ccagccacga  tggcggcaag  caggcgctgg  agacgggtcca  gcggctgttg  660
ccggtgctgt  gccaggccca  cggcttgacc  ccggagcagg  tgggtggccat  cgccagccac  720
gatggcgcca  agcaggcgct  ggagacggtc  cagcggctgt  tgccgggtgt  gtgccaggcc  780
cacggcttga  ccccgagca  ggtggtggcc  atcgccagca  atattggtgg  caagcaggcg  840
ctggagacgg  tgcaggcgct  gttgccgggtg  ctgtgccagg  cccacggctt  gaccccgag  900
caggtggtgg  ccatcgccag  ccacgatggc  ggcaagcagg  cgctggagac  ggtccagcgg  960
ctgttgccgg  tgcgtgtgca  ggccacaggg  ttgaccccg  agcagggtgt  ggccatcgcc  1020
agccacgatg  gcggcaagca  ggcgctggag  acggtccagc  ggctgttgcc  ggtgctgtgc  1080
caggccacag  gcttgacccc  ggagcagggt  gtggccatcg  ccagccacga  tggcggcaag  1140
caggcgctgg  agacgggtcca  gcggctgttg  ccggtgctgt  gccaggccca  cggcttgacc  1200
ccccagcagg  tgggtggccat  cgccagcaat  aatggtggca  agcaggcgct  ggagacggtc  1260
cagcggctgt  tgccgggtgt  gtgccaggcc  cagcgcttga  ccccgagca  ggtggtggcc  1320
atcgccagca  atattggtgg  caagcaggcg  ctggagacgg  tgcaggcgct  gttgccgggtg  1380
ctgtgccagg  cccacggctt  gacccccag  caggtggtgg  ccatcgccag  caataatggt  1440
ggcaagcagg  cgctggagac  ggtccagcgg  ctgttgccgg  tgctgtgcca  ggccccacggc  1500

```

```

ttgaccccc  agcagggtgt  ggccatcgcc  agcaataatg  gtggcaagca  ggcgctggag  1560
acggtccagc  ggctgttgcc  ggtgctgtgc  caggcccacg  gcttgacccc  ccagcagggtg  1620
gtggccatcg  ccagcaatgg  cggtggcaag  caggcgctgg  agacgggtcca  gcggctgttg  1680
ccggtgctgt  gccaggccca  cggcttgacc  ccggagcagg  tgggtggccat  cgccagccac  1740
gatggcgcca  agcaggcgct  ggagacggtc  cagcggctgt  tgccgggtgt  gtgccaggcc  1800
cacggcttga  ccccccagca  ggtggtggcc  atcgccagca  ataatggtgg  caagcaggcg  1860
ctggagacgg  tccagcggct  gttgccgggtg  ctgtgccagg  cccacggctt  gaccccgag  1920
caggtggtgg  ccatcgccag  ccacgatggc  ggcaagcagg  cgctggagac  ggtccagcgg  1980
ctgttgccgg  tgcgtgtgca  ggccacaggg  ttgacccctc  agcagggtgt  ggccatcgcc  2040
agcaatggcg  gcggcaggcc  ggcgctggag  agcattgttg  ccagttatc  tcgccctgat  2100
ccggcgcttg  ccgcgttgac  caacgaccac  ctcgctgcct  tggcctgcct  cggcgggcgt  2160
cctgcgctgg  atgcagtga  aaagggtttg  ggggatccta  tcagccgttc  ccagctggtg  2220
aagtccgagc  tggaggagaa  gaaatccgag  ttgaggcaca  agctgaagta  cgtgccccac  2280
gagtacatcg  agctgatcga  gatcgcccg  aacagcacc  aggaccgat  cctggagatg  2340
aaggtgatgg  agttcttcat  gaaggtgtac  ggctacaggg  gcaagcacct  gggcggtcc  2400
aggaagcccg  acggcgccat  ctacaccgtg  ggctccccc  tcgactacgg  cgtgatcgtg  2460
gacaccaagg  cctactccg  ctgcccacg  gcccagccga  cgaatgcaag  gtggtggaag  2520
aggtacgtgg  aggagaacca  gaccaggaac  aagcacatca  accccaacga  gtggtggaag  2580
gtgtacccct  ccagcgtgac  cgagttcaag  ttctgttctg  tgtccggcca  cttcaagggc  2640
aactacaagg  cccagctgac  caggctgaac  cacatcacca  actgcaacgg  cgccgtgctg  2700
tccgtggagg  agctcctgat  cggcgggcag  atgatcaagg  ccggcacct  gaccctggag  2760
gaggtgagga  ggaagttcaa  caacggcgag  atcaacttcg  cggccgactg  ataa  2814

```

<210> 54

<211> 2832

<212> DNA

<213> Artificial Sequence

<220>

<223> TRBC_T02-R TALEN

<400> 54

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgataagg	agaccgccgc	tgccaagttc	60
gagagacagc	acatggacag	catcgatatc	gccgatctac	gcacgctcgg	ctacagccag	120
cagcaacagg	agaagatcaa	accgaagggt	cgttcgacag	tgggcgagca	ccacgaggca	180
ctgggtcgcc	acggggtttac	acacgcgcac	atcgttgcgt	taagccaaca	cccggcagcg	240
ttagggaccg	tcgctgtcaa	gtatcaggac	atgatcgcac	cgttgccaga	ggcgacacac	300
gaagcgatcg	ttggcgtcgg	caaacagtgg	tccggcgcac	gcgctctgga	ggccttgctc	360
acgggtggcgg	gagagttgag	aggtccaccg	ttacagttgg	acacaggcca	acttctcaag	420
attgcaaaac	gtggcggcgt	gaccgcagtg	gaggcagtg	atgcatggcg	caatgcaactg	480
acgggtgccc	cgctcaactt	gacccccccag	caggtgggtgg	ccatcgccag	caataatggt	540
ggcaagcagg	cgctggagac	ggtccagcgg	ctggtgccgg	tgctgtgcca	ggcccacggc	600
ttgaccccc	agcaggtgg	ggccatcgcc	agcaataatg	gtggcaagca	ggcgctggag	660
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggccccacg	gcttgacccc	ccagcaggtg	720
gtggccatcg	ccagcaataa	tggtggcaag	caggcgctgg	agacgggtcca	gcggctgttg	780
ccggtgctgt	gccaggccca	cggcttgacc	ccggagcagg	tggtggccat	cgccagcaat	840
attggtggca	agcaggcgct	ggagacgggtg	caggcgctgt	tgccggtgct	gtgccaggcc	900
cacggcttga	ccccccagca	ggtggtggcc	atcgccagca	ataatggtgg	caagcaggcg	960
ctggagacgg	tccagcgggt	gttgccgggtg	ctgtgccagg	cccacggctt	gaccccgag	1020
caggtgggtgg	ccatcgccag	caatattggt	ggcaagcagg	cgctggagac	ggtgcaggcg	1080
ctggtgcccgg	tgctgtgcca	ggcccacggc	ttgaccccc	agcaggtggt	ggccatcgcc	1140
agcaatggcg	gtggcaagca	ggcgctggag	acgggtccagc	ggctgttgcc	ggtgctgtgc	1200
caggcccacg	gcttgacccc	ggagcaggtg	gtggccatcg	ccagccacga	tggcggcaag	1260
caggcgctgg	agacgggtcca	gcggctgttg	ccggtgctgt	gccaggccca	cggttgacc	1320
ccccagcagg	tggtggccat	cgccagcaat	ggcggtggca	agcaggcgct	ggagacggtc	1380
cagcggtgct	tgccgggtgct	gtgccaggcc	cagggcttga	ccccggagca	ggtggtggcc	1440
atcgccagcc	acgatggcgg	caagcaggcg	ctggagacgg	tccagcggt	ggtgcccgtg	1500
ctgtgccagg	cccacggctt	gacccccccag	caggtgggtgg	ccatcgccag	caatggcggt	1560
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggcccacggc	1620
ttgaccccc	agcaggtggt	ggccatcgcc	agcaataatg	gtggcaagca	ggcgctggag	1680
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggccccacg	gcttgacccc	ggagcaggtg	1740

gtggccatcg	ccagccacga	tgccggcaag	caggcgctgg	agacgggtcca	gcggctgttg	1800
ccggtgctgt	gccaggccca	cggcttgacc	ccccagcagg	tggtggccat	cgccagcaat	1860
ggcgggtggca	agcaggcgct	ggagacggtc	cagcggtgtg	tgccggtgct	gtgccaggcc	1920
cacggcttga	ccccccagca	ggtggtggcc	atcgccagca	atggcggtgg	caagcaggcg	1980
ctggagacgg	tccagcggct	gttgccgggtg	ctgtgccagg	cccacggctt	gacccctcag	2040
caggtgggtgg	ccatcgccag	caatggcggc	ggcaggccgg	cgctggagag	cattgttgcc	2100
cagttatctc	gccctgatcc	ggcgttgccc	gcgttgacca	acgaccacct	cgtcgccttg	2160
gcctgcctcg	gcgggcgtcc	tgcgctggat	gcagtgaaaa	agggattggg	ggatcctatc	2220
agccgttccc	agctggtgaa	gtccgagctg	gaggagaaga	aatccgagtt	gaggcacaa	2280
ctgaagtacg	tgccccacga	gtacatcgag	ctgatcgaga	tcgcccggaa	cagcaccacg	2340
gaccgtatcc	tgagatgaa	ggtgatggag	ttcttcatga	aggtgtacgg	ctacaggggc	2400
aagcacctgg	gcggctccag	gaagcccgac	ggcgccatct	acaccgtggg	ctccccatc	2460
gactacggcg	tgatcgtgga	caccaaggcc	tactccggcg	gctacaacct	gcccacggc	2520
caggccgacg	aaatgcagag	gtacgtggag	gagaaccaga	ccaggaacaa	gcacatcaac	2580
cccaacgagt	ggtggaaggt	gtacccctcc	agcgtgaccg	agttcaagtt	cctgttcgtg	2640
tccggccact	tcaagggcaa	ctacaaggcc	cagctgacca	ggctgaacca	catcaccaac	2700
tgcaacggcg	ccgtgctgtc	cgtggaggag	ctcctgatcg	gcggcgagat	gatcaaggcc	2760
ggcacccctga	ccctggagga	ggtgaggagg	aagttcaaca	acggcgagat	caacttcgcg	2820
gccgactgat	aa					2832

<210> 55

<211> 2814

<212> DNA

<213> Artificial Sequence

<220>

<223> CD52_T02-L TALEN

<400> 55

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgattacc	catacgatgt	tccagattac	60
gctatcgata	tcgccgatct	acgcacgctc	ggctacagcc	agcagcaaca	ggagaagatc	120
aaaccgaagg	ttcgttcgac	agtggcgag	caccacgagg	cactggtcgg	ccacgggttt	180
acacacgcgc	acatcgttgc	gttaagccaa	caccggcgag	cgttagggac	cgtcgctgtc	240
aagtatcagg	acatgatcgc	agcgttgcca	gaggcgacac	acgaagcgat	cgttggcgctc	300
ggcaaacagt	ggtccggcgc	acgcgctctg	gaggccttgc	tcacggtggc	gggagagttg	360
agaggtccac	cgttacagtt	ggacacaggc	caacttctca	agattgcaaa	acgtggcggc	420
gtgaccgcag	tggaggcagt	gcatgcatgg	cgcaatgcac	tgacgggtgc	cccgtcaac	480
ttgaccccc	agcaggtgg	ggccatcgcc	agcaatggcg	gtggcaagca	ggcgctggag	540
acgggtccagc	ggctgttgcc	caggccccacg	gcttgacccc	ggagcaggtg		600
gtggccatcg	ccagccacga	tgccggcaag	caggcgctgg	agacgggtcca	gcggctgttg	660
ccggtgctgt	gccaggccca	cggcttgacc	ccggagcagg	tggtggccat	cgccagccac	720

gatggcggca	agcaggcgct	ggagacggtc	cagcggtgt	tgccggtgct	gtgccaggcc	780
cacggcttga	ccccccagca	ggtggtggcc	atcgccagca	atggcgggtg	caagcaggcg	840
ctggagacgg	tccagcggct	gttgccgggt	ctgtgccagg	cccacggctt	gaccccggag	900
caggtggtgg	ccatcgccag	ccacgatggc	ggcaagcagg	cgctggagac	ggtccagcgg	960
ctgttgccgg	tgctgtgcca	ggcccacggc	ttgaccccgg	agcagggtgt	ggccatcgcc	1020
agccacgatg	gcggcaagca	ggcgctggag	acggtccagc	ggctgttgcc	ggtgctgtgc	1080
caggcccacg	gcttgacccc	ccagcagggt	gtggccatcg	ccagcaatgg	cggtggcaag	1140
caggcgctgg	agacgggtcca	gcggctgttg	ccggtgctgt	gccaggccca	cggttgacc	1200
coggagcagg	tgggtggccat	cgccagcaat	attggtggca	agcaggcgct	ggagacgggt	1260
caggcgctgt	tgccgggtgct	gtgccaggcc	cacggcttga	ccccggagca	ggtggtggcc	1320
atcgccagcc	acgatggcgg	caagcaggcg	ctggagacgg	tccagcggct	ggtgccgggt	1380
ctgtgccagg	cccacggctt	gacccccag	caggtggtgg	ccatcgccag	caatggcgggt	1440
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggcccacggc	1500
ttgaccccgg	agcagggtgt	ggccatcgcc	agccacgatg	gcggcaagca	ggcgctggag	1560
acggtccagc	ggctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ggagcagggt	1620
gtggccatcg	ccagcaatat	tgggtggcaag	caggcgctgg	agacgggtgca	ggcgctgttg	1680
cgggtgctgt	gccaggccca	cggcttgacc	ccgagcagg	tgggtggccat	cgccagccac	1740
gatggcggca	agcaggcgct	ggagacggtc	cagcggtgt	tgccggtgct	gtgccaggcc	1800
cacggcttga	ccccggagca	ggtggtggcc	atcgccagcc	acgatggcgg	caagcaggcg	1860
ctggagacgg	tccagcggct	gttgccgggt	ctgtgccagg	cccacggctt	gaccccggag	1920

caggtggtgg	ccatcgccag	caatatgtgt	ggcaagcagg	cgctggagac	ggtgcaggcg	1980
ctgttgccgg	tgctgtgcca	ggcccacggc	ttgacccctc	agcagggtgt	ggccatcgcc	2040
agcaatggcg	gcggcaggcc	ggcgctggag	agcattgttg	cccagttatc	tcgccctgat	2100
ccggcgcttg	ccgcgttgac	caacgaccac	ctcgtcgctt	tgccctgcct	cgccggcgct	2160
cctgcgctgg	atgcagtga	aaagggtatt	gggatcccta	tcagccgttc	ccagctggtg	2220
aagtcagagc	tggaggagaa	gaaatccgag	ttgaggcaca	agctgaagta	cgtgccccac	2280
gagtacatcg	agctgatcga	gatcgccggg	aacagcacc	aggaccgtat	cctggagatg	2340
aaggtgatgg	agttcttcat	gaaggtgtac	ggctacaggg	gcaagcacct	ggcggtctcc	2400
aggaagcccg	acggcgccat	ctacaccgtg	ggctccccc	tcgactacgg	cgtgatcgtg	2460
gacaccaagg	cctactccgg	cggctacaac	ctgcccacat	gccaggccga	cgaaatgcag	2520
aggtacgtgg	aggagaacca	gaccaggaac	aagcacatca	accccaacga	gtggtggaag	2580
gtgtacccct	ccagcgtgac	cgagttcaag	ttcctgttcc	tgtccggcca	cttcaagggc	2640
aactacaagg	cccagctgac	caggtgaa	acatcacca	actgcaacgg	cgccgtgctg	2700
tccgtggagg	agctcctgat	cggcgccgag	atgatcaagg	ccggcacccct	gaccctggag	2760
gaggtgagga	ggaagttcaa	caacggcgag	atcaacttcc	cgcccgactg	ataa	2814

<210> 56

<211> 2832

<212> DNA

<213> Artificial Sequence

<220>

<223> CD52_T02-R TALEN

<400> 56

atgggcgatc	ctaaaaagaa	acgtaaggct	atcgataagg	agaccgccc	tgccaagtcc	60
gagagacagc	acatggacag	catcgatata	gccgatctac	gcacgctcgg	ctacagccag	120
cagcaacagg	agaagatcaa	accgaagggt	cgctcgacag	tgccgagca	ccacgaggca	180
ctggtcggcc	acgggtttac	acacgcgcac	atcgttgctg	taagccaaca	cccgccagcg	240
ttagggaccg	tcgctgtcaa	gtatcaggac	atgatcgag	cgcttgccaga	ggcgacacac	300
gaagcgatcg	ttggcgctcg	caaacagtg	tcggcgccac	gcgctctgga	ggccttgctc	360
acggtggcgg	gagagttgag	aggtccaccg	ttacagttgg	acacaggcca	acttctcaag	420
attgcaaaac	gtggcgccgt	gaccgcagtg	gaggcagtg	atgcatggcg	caatgcactg	480
acgggtgccc	cgctcaactt	gacccccag	caggtggtgg	ccatcgccag	caatggcggt	540
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggcccacggc	600
ttgaccccc	agcagggtgt	ggccatcgcc	agcaataatg	gtggcaagca	ggcgctggag	660
acggtccagc	ggctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ggagcagggt	720
gtggccatcg	ccagccacga	tgccggcaag	caggcgctgg	agacgggtcca	gcggctgttg	780
ccggtgctgt	gccaggccca	cggttgacc	ccccagcagg	tgggtggccat	cgccagcaat	840
ggcggtggca	agcaggcgct	ggagacggtc	cagcggtgt	tgccggtgct	gtgccaggcc	900
cacggcttga	ccccggagca	ggtggtggcc	atcgccagcc	acgatggcgg	caagcaggcg	960
ctggagacgg	tccagcggct	gttgccgggt	ctgtgccagg	cccacggctt	gacccccag	1020
caggtggtgg	ccatcgccag	caatggcggt	ggcaagcagg	cgctggagac	ggtccagcgg	1080
ctgttgccgg	tgctgtgcca	ggcccacggc	ttgaccccc	agcagggtgt	ggccatcgcc	1140
agcaatggcg	gtggcaagca	ggcgctggag	acggtccagc	ggctgttgcc	ggtgctgtgc	1200
caggcccacg	gcttgacccc	ggagcagggt	gtggccatcg	ccagcaatat	tgggtggcaag	1260
caggcgctgg	agaagggtgca	ggcgctgttg	cgggtgctgt	gccaggccca	cggttgacc	1320
ccggagcagg	tgggtggccat	cgccagccac	gatggcgcca	agcaggcgct	ggagacggtc	1380
cagcggtgt	tgccgggtgct	gtgccaggcc	cacggcttga	ccccggagca	ggtggtggcc	1440
atcgccagcc	acgatggcgg	caagcaggcg	ctggagacgg	tccagcggct	ggtgccgggt	1500
ctgtgccagg	cccacggctt	gacccccag	caggtggtgg	ccatcgccag	caatggcgggt	1560
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggcccacggc	1620
ttgaccccc	agcagggtgt	ggccatcgcc	gtggcaaatg	gtggcaagca	ggcgctggag	1680
acggtccagc	ggctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ccagcagggt	1740
gtggccatcg	ccagcaatgg	cggtggcaag	caggcgctgg	agacgggtcca	gcggctgttg	1800
ccggtgctgt	gccaggccca	cggttgacc	ccggagcagg	tgggtggccat	cgccagcaat	1860
attggtggca	agcaggcgct	ggagacgggt	caggcgctgt	tgccggtgct	gtgccaggcc	1920
cacggcttga	ccccggagca	ggtggtggcc	atcgccagcc	acgatggcgg	caagcaggcg	1980
ctggagacgg	tccagcggct	gttgccgggt	ctgtgccagg	cccacggctt	gacccctcag	2040
caggtggtgg	ccatcgccag	caatggcgcc	ggcaggccgg	cgctggagag	cattgttgcc	2100
cagttatctc	gcctgatcc	ggcggtggcc	gcgttgacca	acgaccacct	cgtcgccttg	2160

gcctgcctcg	gcgggcgtcc	tgcgctggat	gcagtgaaaa	agggattggg	ggatcctatc	2220
agccgttccc	agctggtgaa	gtccgagctg	gaggagaaga	aatccgagtt	gaggcacaag	2280

ctgaagtacg	tgccccacga	gtacatcgag	ctgatcgaga	tcgcccggaa	cagcaccag	2340
gaccgtatcc	tggagatgaa	ggtgatggag	ttcttcatga	aggtgtacgg	ctacaggggc	2400
aagcacctgg	gcggctccag	gaagcccgac	ggcgccatct	acaccgtggg	ctcccccatc	2460
gactacggcg	tgatcgtgga	caccaaggcc	tactccggcg	gctacaacct	gccccatcggc	2520
caggccgacg	aaatgcagag	gtacgtggag	gagaaccaga	ccaggaacaa	gcacatcaac	2580
cccaacgagt	ggtggaaggt	gtacccctcc	agcgtgaccg	agttcaagtt	cctgttcgtg	2640
tccggccact	tcaagggcaa	ctacaaggcc	cagctgacca	ggctgaacca	catcaccaac	2700
tgcaacggcg	ccgtgctgtc	cgtggaggag	ctcctgatcg	gcggcgagat	gatcaaggcc	2760
ggcaccctga	ccctggagga	ggtgaggagg	aagttcaaca	acggcgagat	caacttcgcg	2820
gccgactgat	aa					2832

<210> 57
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> TRAC_T02

<400> 57
tttagaaagt tcctgtgatg tcaagctggt cgagaaaagc ttgaaaca 49

<210> 58
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> TRAC_T03

<400> 58
tccagtgaca agtctgtctg cctattcacc gattttgatt ctcaaaca 49

<210> 59
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> TRAC_T04

<400> 59
tatatcacag acaaaactgt gctagacatg aggtctatgg acttcaaga 49

<210> 60
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> TRAC_T05

<400> 60
tgaggcttat ggacttcaag agcaacagtg ctgtggcctg gagcaaca 49

<210> 61
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> CD52_T01

<400> 61
 ttctcttcc tctaccacc atcagcctcc ttacctgta ccataac 47

<210> 62
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> CD52_T04

<400> 62
 ttctcctac tcaccacagc ctctgggtct tacctgtacc ata 43

<210> 63
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> CD52_T05

<400> 63
 tcctactcac catcagctcc tgggtatttg ctcttacctg tac 43

<210> 64
 <211> 47
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> CD52_T06

<400> 64
 ttatcccaact tctcctctac agatacaaac ttttgcct gagagtc 47

<210> 65
 <211> 47
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> CD52_T07

<400> 65
 tggactctca ggacaaacga caccagccaa atgctgaggg gctgctg 47

<210> 66
 <211> 60
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Forward primer CD52

<220>
 <221> misc_feature
 <222> (31)..(40)
 <223> n is a or c or t or g

<400> 66
ccatctcatc cctgcgtgtc tccgactcag nnnnnnnnnn cagatctgca gaaaggaagc 60

<210> 67
<211> 61
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward primer TRAC

<220>
<221> misc_feature
<222> (31)..(40)
<223> n is a or c or t or g

<400> 67
ccatctcatc cctgcgtgtc tccgactcag nnnnnnnnnn atcactggca tctggactcc 60
a 61

<210> 68
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward primer TRBC1

<220>
<221> misc_feature
<222> (31)..(40)
<223> n is a or c or t or g

<400> 68
ccatctcatc cctgcgtgtc tccgactcag nnnnnnnnnn agagccccta ccagaaccag 60
ac 62

<210> 69
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward primer TRBC2

<220>
<221> misc_feature
<222> (31)..(40)
<223> n is a or c or t or g

<400> 69
ccatctcatc cctgcgtgtc tccgactcag nnnnnnnnnn ggacctagta acataattgt 60
gc 62

<210> 70
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse primer GR CD52

<400> 70
cctatcccct gtgtgccttg gcagtctcag cctgttgag tccatctgct g 51

<210> 71
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse primer GR TRAC

<400> 71
cctatcccct gtgtgccttg gcagtctcag cctcatgtct agcacagttt 50

<210> 72
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse primer GR TRBC1-2

<400> 72
cctatcccct gtgtgccttg gcagtctcag accagctcag ctccacgtgg t 51

<210> 73
<211> 495
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD19 CAR

<400> 73
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Ile
20 25 30

Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr
35 40 45

Phe Thr Ser Tyr Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly
50 55 60

Leu Glu Trp Ile Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr
65 70 75 80

Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser
85 90 95

Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala
100 105 110

Val Tyr Tyr Cys Ala Arg Gly Thr Tyr Tyr Tyr Gly Ser Arg Val Phe
115 120 125

Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly
130 135 140

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met
145 150 155 160

Thr Gln Ala Ala Pro Ser Ile Pro Val Thr Pro Gly Glu Ser Val Ser
165 170 175

Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Asn Ser Asn Gly Asn Thr
180 185 190

Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser Pro Gln Leu Leu
195 200 205

Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser
210 215 220

Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile Ser Arg Val Glu
225 230 235 240

Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His Leu Glu Tyr Pro
245 250 255

Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ser Asp Pro
260 265 270

Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala
275 280 285

Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly
290 295 300

Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile
305 310 315 320

Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val
325 330 335

Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe
340 345 350

Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly
355 360 365

Cys Ser Cys Arg Phe Pro Glu Glu Glu Gly Gly Cys Glu Leu Arg
370 375 380

Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
385 390 395 400

Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
405 410 415

Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
420 425 430

Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
435 440 445

Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
450 455 460

Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
465 470 475 480

Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490 495

<210> 74

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> CTLA4_T01

<400> 74
tggccctgca ctctcctgtt ttttcttctc ttcacccctg tcttctgca 49

<210> 75
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> CTLA4_T03

<400> 75
ttttccatgc tagcaatgca cgtggcccag cctgctgtgg tactggcca 49

<210> 76
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> CTLA4_T04

<400> 76
tccatgctag caatgcacgt ggcccagcct gctgtggtac tggccagca 49

<210> 77
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> PDCD1_T01

<400> 77
ttctccccag ccctgctcgt ggtgaccgaa ggggacaacg ccaccttca 49

<210> 78
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> PDCD1_T03

<400> 78
tacctctgtg gggccatctc cctggccccc aaggcgcaga tcaaagaga 49

<210> 79
<211> 530
<212> PRT
<213> Artificial Sequence

<220>
<223> Repeat CTLA4_T01-L

<400> 79
Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 20 25 30

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly
 35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 50 55 60

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
 65 70 75 80

Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 100 105 110

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 115 120 125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 130 135 140

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 145 150 155 160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 165 170 175

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
 195 200 205

Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu
 210 215 220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240

Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala
 245 250 255

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
 260 265 270

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys
 275 280 285

Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala
 290 295 300

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
 305 310 315 320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 325 330 335

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
 340 345 350

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 355 360 365

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 370 375 380

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 --- --- ---

385 390 395 400
 Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
 405 410 415
 Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 420 425 430
 Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
 435 440 445
 Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
 450 455 460
 Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
 465 470 475 480
 Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu
 485 490 495
 Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 500 505 510
 Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
 515 520 525
 Leu Glu
 530
 <210> 80
 <211> 530
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Repeat CTLA4_T01-R
 <400> 80
 Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
 1 5 10 15
 Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 20 25 30
 His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
 35 40 45
 Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 50 55 60
 Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn
 65 70 75 80
 Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val
 85 90 95
 Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
 100 105 110
 Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 115 120 125
 Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 130 135 140
 Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala
 145 150 155 160
 Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
 165 170 175

165 170 175

Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val
180 185 190

Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
195 200 205

Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu
210 215 220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
225 230 235 240

Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala
245 250 255

Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly
260 265 270

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys
275 280 285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
290 295 300

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly
305 310 315 320

Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys
325 330 335

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
340 345 350

Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
355 360 365

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
370 375 380

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
385 390 395 400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
405 410 415

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
420 425 430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
435 440 445

Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val
450 455 460

Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
465 470 475 480

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu
485 490 495

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
500 505 510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
515 520 525

Leu Glu
530

<210> 81

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> RepeatCTLA4-T03-L

<400> 81

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
 1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 20 25 30

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly
 35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 50 55 60

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
 65 70 75 80

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 100 105 110

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 115 120 125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 130 135 140

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 145 150 155 160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
 165 170 175

Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190

Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
 195 200 205

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu
 210 215 220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala
 245 250 255

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
 260 265 270

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys
 275 280 285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 290 295 300

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly
 305 310 315 320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 325 330 335

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn
 340 345 350

Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val
 355 360 365

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
 370 375 380

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 385 390 395 400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 405 410 415

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 420 425 430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
 435 440 445

Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val
 450 455 460

Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
 465 470 475 480

Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu
 485 490 495

Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 500 505 510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
 515 520 525

Leu Glu

530

<210> 82

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat CTLA4_T03-R

<400> 82

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
 1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 20 25 30

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly
 35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 50 55 60

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
 65 70 75 80

Asn Gln Gln Thr Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val

Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 100 105 110

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 115 120 125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 130 135 140

Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala
 145 150 155 160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 165 170 175

Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
 195 200 205

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu
 210 215 220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240

Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala
 245 250 255

Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly
 260 265 270

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys
 275 280 285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 290 295 300

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
 305 310 315 320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 325 330 335

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn
 340 345 350

Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val
 355 360 365

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 370 375 380

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 385 390 395 400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 405 410 415

Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala
 420 425 430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 435 440 445

Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val

450 455 460
 Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
 465 470 475 480
 Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu
 485 490 495
 Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 500 505 510
 Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
 515 520 525
 Leu Glu
 530
 <210> 83
 <211> 530
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Repeat CTLA4_T04-L
 <400> 83
 Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys
 1 5 10 15
 Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 20 25 30
 His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
 35 40 45
 Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 50 55 60
 Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn
 65 70 75 80
 Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val
 85 90 95
 Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
 100 105 110
 Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 115 120 125
 Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
 130 135 140
 Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 145 150 155 160
 Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
 165 170 175
 Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190
 Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
 195 200 205
 Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu
 210 215 220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240
 Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala
 245 250 255
 Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly
 260 265 270
 Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
 275 280 285
 Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 290 295 300
 His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
 305 310 315 320
 Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 325 330 335
 Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn
 340 345 350
 Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val
 355 360 365
 Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 370 375 380
 Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu
 385 390 395 400
 Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
 405 410 415
 Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 420 425 430
 Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 435 440 445
 Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val
 450 455 460
 Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
 465 470 475 480
 Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu
 485 490 495
 Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 500 505 510
 Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
 515 520 525
 Leu Glu
 530

<210> 84

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat CTLA4_T04-R

<400> 84

```

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
1          5          10          15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
20          25          30

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
35          40          45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
50          55          60

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
65          70          75          80

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
85          90          95

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
100         105         110

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
115         120         125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
130         135         140

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
145         150         155         160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
165         170         175

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
180         185         190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
195         200         205

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu
210         215         220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
225         230         235         240

Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala
245         250         255

Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly
260         265         270

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
275         280         285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
290         295         300

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly
305         310         315         320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
325         330         335

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn
340         345         350

```

Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val
 355 360 365

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 370 375 380

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 385 390 395 400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 405 410 415

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 420 425 430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
 435 440 445

Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val
 450 455 460

Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
 465 470 475 480

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu
 485 490 495

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 500 505 510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
 515 520 525

Leu Glu
 530

<210> 85

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat PDCD1_T01-L

<400> 85

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
 1 5 10 15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 20 25 30

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
 35 40 45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 50 55 60

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
 65 70 75 80

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 85 90 95

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 100 105 110

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 115 120 125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 130 135 140

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 145 150 155 160

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
 165 170 175

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
 195 200 205

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu
 210 215 220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240

Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala
 245 250 255

Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly
 260 265 270

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
 275 280 285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 290 295 300

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
 305 310 315 320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 325 330 335

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
 340 345 350

Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 355 360 365

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala
 370 375 380

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 385 390 395 400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
 405 410 415

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 420 425 430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 435 440 445

Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val
 450 455 460

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
 465 470 475 480

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu

485 490 495
 Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 500 505 510

 Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
 515 520 525

 Leu Glu
 530

 <210> 86
 <211> 529
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Repeat PDCD1_T01-R

 <400> 86
 Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
 1 5 10 15

 Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 20 25 30

 His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly
 35 40 45

 Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys
 50 55 60

 Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn
 65 70 75 80

 Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val
 85 90 95

 Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
 100 105 110

 Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 115 120 125

 Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala

 130 135 140

 Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 145 150 155 160

 Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 165 170 175

 Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190

 Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
 195 200 205

 Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu
 210 215 220

 Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240

 Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala
 245 250 255

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
260 265 270

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Gly Gly Lys Gln
275 280 285

Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His
290 295 300

Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly
305 310 315 320

Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln
325 330 335

Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly
340 345 350

Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu
355 360 365

Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser
370 375 380

Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro
385 390 395 400

Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile
405 410 415

Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu
420 425 430

Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val
435 440 445

Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln
450 455 460

Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln
465 470 475 480

Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr
485 490 495

Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro
500 505 510

Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala Leu
515 520 525

Glu

<210> 87

<211> 530

<212> PRT

<213> Artificial Sequence

<220>

<223> Repeat PDCD1_T03-L

<400> 87

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys
1 5 10 15

Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala
20 25 30

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
 35 40 45
 Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 50 55 60
 Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
 65 70 75 80
 Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 85 90 95
 Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
 100 105 110
 Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 115 120 125
 Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 130 135 140
 Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
 145 150 155 160
 Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 165 170 175
 Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190
 Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
 195 200 205
 Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu
 210 215 220
 Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240
 Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala
 245 250 255
 Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly
 260 265 270
 Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys
 275 280 285
 Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 290 295 300
 His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly
 305 310 315 320
 Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 325 330 335
 Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
 340 345 350
 Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 355 360 365
 Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
 370 375 380
 Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 385 390 395 400

```

385              390              395              400
Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
      405              410              415

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
      420              425              430

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val
      435              440              445

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val
      450              455              460

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu
465              470              475              480

Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu
      485              490              495

Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
      500              505              510

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala
      515              520              525

Leu Glu
      530

<210> 88
<211> 529
<212> PRT
<213> Artificial Sequence

<220>
<223> Repeat PDCD1_T03-R

<400> 88
Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys
1              5              10              15

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
      20              25              30

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly
      35              40              45

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
      50              55              60

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His
65              70              75              80

Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
      85              90              95

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
      100             105             110

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
      115             120             125

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala
      130             135             140

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg
145             150             155             160

```

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val
 165 170 175

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val
 180 185 190

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln
 195 200 205

Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu
 210 215 220

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr
 225 230 235 240

Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala
 245 250 255

Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly
 260 265 270

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys
 275 280 285

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala
 290 295 300

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly
 305 310 315 320

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys
 325 330 335

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn
 340 345 350

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val
 355 360 365

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala
 370 375 380

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu
 385 390 395 400

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala
 405 410 415

Ile Ala Ser Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu
 420 425 430

Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val
 435 440 445

Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln
 450 455 460

Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln
 465 470 475 480

Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr
 485 490 495

Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro
 500 505 510

Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala Leu
 515 520 525

Glu

<210> 89

<211> 2814

<212> DNA

<213> Artificial Sequence

<220>

<223> CTLA4_T01-L TALEN

<400> 89

atggg	cgatc	ctaaaa	agaa	acgta	aggtc	atcgatt	acc	catac	gatgt	tccag	attac	60
gctat	cgata	tgcgcg	atct	acgcac	gctc	ggctac	agcc	agcag	caaca	ggaga	agatc	120
aaacc	gaagg	ttcg	ttcgac	agtgg	cgag	caccac	gagg	cactg	gtcg	ccacg	ggttt	180
acacac	gcgc	acatc	gttg	gttaag	ccaa	cacc	cgag	cg	ttagg	gac	cg	240
aagtat	cagg	acatg	atcgc	agcgt	tgcc	gaggc	gacac	acga	agcg	at	cg	300
ggcaa	acagt	ggtc	cggcgc	acgcg	ctctg	gaggc	cttgc	tcac	ggtg	gc	gggag	360
agagg	tccac	cg	ttacagt	ggac	acaggc	caact	tctca	agatt	gcaaa	acgt	ggcgg	420
gtgac	cgag	tggag	ggcagt	gcat	gc	atgg	cgca	atgc	ac	tgac	gggtg	480
ttgac	cccc	agc	aggtg	ggc	atcgc	agca	ataatg	gtgg	caagca	ggc	gctgg	540
acggt	ccagc	ggct	gttg	ggt	gctgtg	cagg	cccc	gctt	gacccc	ccag	caggtg	600
gtggc	catcg	ccag	caataa	tgg	tggcaag	cagg	cgctgg	agac	ggtcca	gcgg	ctgtt	660
ccggt	gctgt	gcc	aggcca	cg	cttgacc	ccg	gagcag	tgg	tggccat	cgcc	agccac	720
gatgg	cgga	agc	aggcgct	ggag	acggtc	cag	cggtct	tgc	cggtgct	gtg	ccaggcc	780
cacgg	cttga	cccc	ggagca	ggt	ggtggcc	atc	gccagcc	ac	gatggc	gg	caagcag	840
ctggag	acgg	tcc	agcggt	gtt	gcgggtg	ctgt	gccag	ccc	acggctt	gac	ccccggag	900
caggt	ggtgg	ccat	cgccag	ccac	gatggc	ggca	agcag	cg	ctggagac	ggt	ccagcg	960
ctgtt	gccgg	tgt	gttgcca	ggcc	cacggc	ttg	accccc	agc	aggtggt	ggcc	atcgcc	1020
agcaat	ggcg	gtgg	caagca	ggc	gctggag	acg	gtcca	gg	ctgttgcc	ggt	gctgtg	1080
caggc	ccacg	gctt	gacccc	ccag	caggtg	gtgg	ccatcg	ccag	caataa	tgg	tggcaag	1140
caggc	gctgg	agac	gggtcca	gcg	gctgtt	ccg	gtgctgt	gcc	aggccca	cg	gcttgacc	1200
ccggag	cagg	tgg	tggccat	cgcc	agccac	gat	ggcggca	agc	agcgct	ggag	acggtc	1260
cagcg	gctgt	tgcc	gggtgct	gtgc	caggcc	cac	gcttga	cccc	ggagca	ggt	ggtggcc	1320
atcgcc	agca	atatt	ggtgg	caag	caggcg	ctgg	agacgg	tgc	agcgct	gtt	gccgggtg	1380
ctgtg	ccagg	ccc	acggctt	gac	ccccggag	cag	gtggtg	ccat	cgccag	ccac	gatggc	1440
ggcaag	cagg	cgct	ggagac	ggt	ccagcg	ctgt	tgccgg	tgt	gttgcca	ggcc	acggc	1500
ttgac	cccc	agc	aggtggt	ggcc	atcgcc	agca	atggcg	gtgg	caagca	ggc	gctggag	1560
acggt	ccagc	ggct	gtttgcc	ggt	gctgtg	cagg	cccc	gctt	gacccc	ggag	caggtg	1620
gtggc	catcg	ccag	ccacga	tgg	cggaag	cagg	cgctgg	agac	gggtcca	gcgg	ctgtt	1680
ccggt	gctgt	gcc	aggccca	cg	gcttgacc	cccc	agcagg	tgg	tggccat	cgcc	agcaat	1740
ggcgg	tggca	agc	aggcgct	ggag	acggtc	cag	cggtct	tgc	cggtgct	gtg	ccaggcc	1800
cacgg	cttga	cccc	ggagca	ggt	ggtggcc	atc	gccagcc	ac	gatggc	gg	caagcag	1860
ctggag	acgg	tcc	agcggt	gtt	gcgggtg	ctgt	gccagg	ccc	acggctt	gac	ccccggag	1920
caggt	ggtgg	ccat	cgccag	ccac	gatggc	ggca	agcagg	cg	ctggagac	ggt	ccagcg	1980
ctg	ttgccgg	tgt	gttgcca	ggcc	acggc	ttg	acccctc	agc	aggtggt	ggcc	atcgcc	2040
agcaat	ggcg	gcgg	caggcc	ggc	gctggag	agc	attgttg	cc	cagttatc	tgc	ccctgat	2100

ccggc	gcttgg	ccg	cgttgac	caac	gaccac	ctc	gtcgct	tgg	cctgcct	cg	gcgggcgt	2160
cctgc	gctgg	atg	caagtga	aaag	ggattg	ggg	gatccta	tcag	ccgttc	ccag	ctggtg	2220
aagt	ccgagc	tgg	aggagaa	gaa	atccgag	ttg	aggcaca	agct	gaagta	cgt	gccccac	2280
gagt	acatcg	agct	gatcga	gat	cgcccg	aac	agcacc	agg	accgtat	cct	ggagatg	2340
aagg	tgatgg	ag	ttcttcat	ga	aggtgtac	gg	ctacaggg	gca	agcacct	ggg	cggtcc	2400
agga	agcccc	acg	gcgccat	ctac	accgtg	gg	ctccccca	tcg	actacgg	cgt	gatcgtg	2460
gacac	caagg	cct	actccgg	cgg	ctacaac	ctg	cccatcg	gcc	aggccga	cg	aaatgcag	2520
aggt	acgtgg	agg	agaacca	gac	caggaac	aag	cacatca	ac	cccaacga	gtg	gtggaag	2580
gtgt	acccct	ccag	cggtgac	cg	agttcaag	ttc	ctgttcg	tgt	ccggcca	ctt	caagggc	2640
aact	acaagg	ccc	agctgac	cag	gctgaac	cac	atcacca	act	gcaacgg	cg	ccgtgctg	2700
tccg	tggagg	ag	ctcctgat	cgg	cggcgag	atg	atcaagg	ccg	gcaccct	gac	cctggag	2760
gaggt	gagga	gga	agttcaa	caac	ggcgag	atc	aacttcg	cg	gccgactg	ataa		2814

<210> 90

<211> 2832

<212> DNA

<213> Artificial Sequence

<220>

<223> CTLA4_T01-R TALEN

<400> 90

atggg	cgatc	ctaaaa	agaa	acgta	aggtc	atcgata	aagg	agacc	gccgc	tgcca	agttc	60
gagag	acagc	acatg	gacag	catc	gatatc	gcc	gatctac	gcac	gctcg	ctac	agccag	120
cagca	acagg	aga	agatcaa	acc	gaaggtt	cg	ttcgacag	tgg	cgagca	ccac	gaggca	180
ctggt	tcggc	acgg	gttttac	acac	gcgcac	atc	gttgcgt	taag	ccaaca	ccc	ggcagcg	240
ttagg	gaccg	tgc	gtgtcaa	gtat	caggac	atg	atcgag	cg	ttgccaga	ggc	gacacac	300
gaagc	gatcg	ttg	gcgtcg	caa	acagtg	tcc	ggcgac	gcg	ctctgga	ggc	cttgctc	360
acggt	ggcgg	gag	agtttgag	aggt	ccaccg	ttac	agttgg	acac	aggcca	act	tctcaag	420
attg	caaaac	gtg	gcggcg	gac	gcagtg	gagg	cagtg	atg	catggcg	caat	gcactg	480
acggg	tgcc	cgct	caactt	gac	ccccccag	cag	gtggtg	ccat	cgccag	caata	atggt	540
ggca	agcagg	cgct	ggagac	ggt	ccagcg	ctgt	tgccgg	tgt	gttgcca	ggcc	acggc	600
ttgac	ccccgg	agc	aggtggt	ggcc	atcgcc	agcc	acgatg	gcgg	caagca	ggc	gctggag	660
acggt	ccagc	ggct	gtttgcc	ggt	gctgtg	cagg	cccc	gctt	gacccc	ggag	caggtg	720
gtggc	catcg	ccag	caatat	tgg	tggcaag	cagg	cgctgg	agac	ggtgca	ggc	gctgtt	780
ccggt	gctgt	cccc	acccca	ccg	cttgcac	ccg	cttgcac	ccg	cttgcac	ccg	cttgcac	840

```

~ ~ ~ ~ ~
aatggtggca agcaggcgct ggagacggtc cagcggctgt tgccgggtgct gtgccaggcc 900
cacggcttga ccccgagca ggtggtggcc atcgccagca atattggtgg caagcaggcg 960
ctggagacgg tgcaggcgct gttgccggtg ctgtgccagg cccacggctt gaccccgag 1020
caggtggtgg ccatcgccag caatattggt ggcaagcagg cgctggagac ggtgcaggcg 1080
ctgttgccgg tgetgtgcca ggcccacggc ttgaccccc agcagggtgtt ggccatcgcc 1140
agcaataatg gtggcaagca ggcgctggag acggtccagc ggctgttgcc ggtgctgtgc 1200
caggcccacg gcttgacccc ggagcaggtg gtggccatcg ccagcaatat tggtagcaag 1260
caggcgctgg agacggtgca ggcgctgttg ccggtgctgt gccaggccca cggcttgacc 1320
cgggagcagg tggtagccat cgccagccac gatggcggca agcaggcgct ggagacggtc 1380
cagcggctgt tgccgggtgct gtgccaggcc cagcgcttga ccccgagca ggtggtggcc 1440
atcgccagca atattggtgg caagcaggcg ctggagacgg tgacggcgct gttgccggtg 1500
ctgtgccagg cccacggctt gacccccag caggtggtgg ccatcgccag caataatggt 1560
ggcaagcagg cgctggagac ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc 1620
ttgaccccc agcagggtgt ggccatcgcc agcaataatg gtggcaagca ggcgctggag 1680
acggtccagc ggctgttgcc ggtgctgtgc cagggccacg gcttgacccc ccagcaggtg 1740
gtggccatcg ccagcaataa tggtagcaag caggcgctgg agacggtcca gcggctgttg 1800
ccggtgctgt gccaggccca cggcttgacc ccgagcagg tggtggccat cgccagcaat 1860
attggtggca agcaggcgct ggagacggtg caggcgctgt tgccgggtgct gtgccaggcc 1920
cacggcttga ccccccagca ggtggtggcc atcgccagca atggcggtgg caagcaggcg 1980
ctggagacgg tccagcggtt gttgccggtg ctgtgccagg cccacggctt gacccctcag 2040
caggtggtgg ccatcgccag caatggcggc ggcaaggcgg cgctggagag cattgttgcc 2100
cagttatctc gccctgatcc ggcgttggcc gcgttgacca acgaccacct cgtcgcttg 2160
gcctgcctcg gcggcgctcc tgcgctggat gcagtgaata agggattggg ggatcctatc 2220
agcggttccc agctggtgaa gtccgagctg gaggagaaga aatccgagtt gaggcacaag 2280
ctgaagtacg tgccccacga gtacatcgag ctgatcgaga tcgcccggaa cagcaccag 2340

```

```

gaccgtatcc tggagatgaa ggtgatggag ttcttcatga aggtgtacgg ctacaggggc 2400
aagcacctgg gcggctccag gaagcccgac ggccgcatct acaccgtggg ctcccccatc 2460
gactacggcg tgatcggtga caccaaggcc tactccggcg gctacaacct gcccatcgcc 2520
caggccgacg aaatgcagag gtacgtggag gagaaccaga ccaggaacaa gcacatcaac 2580
cccaacgagt ggtggaaggt gtacccctcc agcgtgaccg agttcaagtt cctgttcgtg 2640
tccggccact tcaagggcaa ctacaaggcc cagctgacca ggctgaacca catcaccaac 2700
tgcaacggcg ccgtgctgtc cgtggaggag ctctgatcg gcggcgagat gatcaaggcc 2760
ggcaccctga ccctggagga ggtgaggagg aagtcaaca acggcgagat caacttcgcg 2820
gccgactgat aa 2832

```

<210> 91

<211> 2814

<212> DNA

<213> Artificial Sequence

<220>

<223> CTLA4_T03-L TALEN

<400> 91

```

atgggcgatc ctaaaaagaa acgtaaggtc atcgattacc catacgtatgt tccagattac 60
gctatcgata tcgcgatctt acgcacgctc ggctacagcc agcagcaaca ggagaagatc 120
aaaccgaagg ttcgttcgac agtggcgag caccacgagg cactggctcg ccacgggttt 180
acacacgcgc acatcggttg gtaagccaa caccggcgag cgttaggagc cgtcgctgtc 240
aagtatcagg acatgatcgc agcgttgcca gaggcgacac acgaagcgat cgttggcgct 300
ggcaaacagt ggtccggcgc acgcgctctg gaggccttgc tcacgggtgc gggagagttg 360
agaggtccac cgttacagtt ggacacaggg caacttctca agattgcaaa acgtggcggc 420
gtgaccgcag tggaggcagt gcatgcatgg cgcaatgcac tgacgggtgc cccgctcaac 480
ttgaccccc agcagggtgt ggccatcgcc agcaatggcg gtggcaagca ggcgctggag 540
acggtccagc ggctgttgcc ggtgctgtgc cagggccacg gcttgacccc ccagcaggtg 600
gtggccatcg ccagcaatgg cggtaggcaa caggcgctgg agacggtcca gcggctgttg 660
ccgtgctgtt gccaggccca cggcttgacc cccagcagg tggtggccat cgcagcaat 720
ggcgggtggc agcaggcgct ggagacggtc cagcggctgt tgccgggtgct gtgccaggcc 780
cacggcttga ccccgagca ggtggtggcc atcgccagcc acgatggcgg caagcaggcg 840
ctggagacgg tccagcggtt gttgccggtg ctgtgccagg cccacggctt gaccccgag 900
caggtggtgg ccatcgccag ccacgatggc ggcaagcagg cgctggagac ggtccagcgg 960
ctgttgccgg tgetgtgcca ggcccacggc ttgaccccc agcagggtgtt ggccatcgcc 1020
agcaatattg gtggcaagca ggcgctggag acggtgcagg cgctgttgcc ggtgctgtgc 1080
caggcccacg gcttgacccc ccagcaggtg gtggccatcg ccagcaatgg cggtagcaag 1140
caggcgctgg agacgggtcca gcggctgttg ccggtgctgt gccaggccca cggcttgacc 1200
cccagcagg tggtagccat cgccagcaat aatggtggca agcaggcgct ggagacggtc 1260
cagcggctgt tgccgggtgct gtgccaggcc cagcgcttga ccccgagca ggtggtggcc 1320
atcgccagcc acgatggcgg caagcaggcg ctggagacgg tccagcggtt gttgccggtg 1380
ctgtgcccag cccacggctt gacccccag caggtggtgg ccatcgccag caatggcggt 1440
ggcaagcagg cgctggagac ggtccagcgg ggtccagcgg agcaatattg gtggcaagca ggcgctggag 1500
ttgaccccc agcagggtgt ggccatcgcc agcaatattg gtggcaagca ggcgctggag 1560
acggtgcagg cgctgttgcc ggtgctgtgc cagggccacg gcttgacccc ccagcaggtg 1620
gtggccatcg ccagcaataa tggtagcaag caggcgctgg agacggtcca gcggctgttg 1680
ccggtgctgt gccaggccca cggcttgacc ccggagcagg tggtggccat cgcagccac 1740
gatggcgga agcaggcgct ggagacggtc cagcgctgtt tgccgggtgct gtgccaggcc 1800
cacggcttga ccccgagca ggtggtggcc atcgccagca atattggtgg caagcaggcg 1860
ctggagacgg tgcaggcgct gttgccggtg ctgtgccagg cccacggctt gaccccgag 1920
caggtggtgg ccatcgccag caatattggt ggcaagcagg cgctggagac ggtgcaggcg 1980
ctgttgccgg tgctgtgcca ggcccacggc ttgacccctc agcagggtgtt ggccatcgcc 2040
agcaatggcg gcggcaggcc ggcgctggag agcattgttg ccagttatc tcgccctgat 2100
ccggcgcttg ccgcgttgac caacgacccac ctgctgcctt tggcctgcct cggcgggcgt 2160
cctgcgctgg atgcagtga aaagggattg gggatccta tcagccgttc ccagctggtg 2220
aagtcgagc tggaggagaa gaaatccgag ttgaggacaa agctgaagta cgtgccccac 2280
gagtacatcg agctgatcga gatcgcccg gacagcacc aggaccgtat cctggagatg 2340
aaggtgatgg agttcttcat gaaggtgtac ggctacagg gcaagcacct gggcggtcc 2400
~ ~ ~

```

aggaagcccg	acggcgccat	ctacaccgtg	ggctcccca	tcgactacgg	cgtgatcgtg	2460
gacaccaagg	cctactccgg	cggctacaac	ctgcccacg	gccaggccga	cgaaatgcag	2520

aggtagctgg	aggagaacca	gaccaggaac	aagcacatca	accccaacga	gtggtggaag	2580
gtgtacccct	ccagcgtgac	cgagttcaag	ttcctgttcg	tgtccggcca	cttcaagggc	2640
aactacaagg	cccagctgac	caggctgaac	cacatcacca	actgcaacgg	cgccgtgctg	2700
tccgtggagg	agctcctgat	cggcggcgag	atgatcaagg	ccggcacccct	gaccctggag	2760
gaggtgagga	ggaagttcaa	caacggcgag	atcaacttcg	cgcccgactg	ataa	2814

<210> 92

<211> 2832

<212> DNA

<213> Artificial Sequence

<220>

<223> CTLA4_T03-RTALEN

<400> 92

atgggcatc	ctaaaaagaa	acgtaaggtc	atcgataagg	agaccgccc	tgccaagttc	60
gagagacag	acatggacag	catcgatatc	gccgatctac	gcacgctcgg	ctacagccag	120
cagcaacagg	agaagatcaa	accgaaggtt	cgttcgacag	tggcgagca	ccacgaggca	180
ctggtcggcc	acgggtttac	acacgcgcac	atcgttgccg	taagccaaca	cccggcagcg	240
ttagggaccg	tcgctgtcaa	gtatcaggac	atgatcgacg	cgttgccaga	ggcgacacac	300
gaagcgatcg	ttggcgctcg	caaacagtgg	tccggcgcac	gcgctctgga	ggccttgctc	360
acggtggcgg	gagagttgag	aggtccaccg	ttacagttag	acacaggcca	acttctcaag	420
attgcaaaac	gtggcggtcg	gaccgcagtg	gaggcagtg	atgcatggcg	caatgcactg	480
acgggtgccc	cgctcaactt	gacccccacg	caggtgggtg	ccatcgccag	caataatggt	540
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggccacggc	600
ttgaccccc	agcagggtgg	ggccatcgcc	agcaataatg	gtggcaagca	ggcgctggag	660
acggtccagc	ggctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ggagcaggtg	720
gtggccatcg	ccagccacga	tggcggcaag	caggcgctgg	agacggtcca	gcggctgttg	780
ccggtgctgt	gccaggccca	cggttgacc	ccgagcagg	tggtagccat	cgccagccac	840
gatggcggca	agcaggcgct	ggagacggtc	cagcggctgt	tgccggtgct	gtgccaggcc	900
cacggcttga	ccccggagca	ggtggtggcc	atcgccagca	atattggtgg	caagcaggcg	960
ctggagacgg	tgcaaggcgt	gttgccgggtg	ctgtgccagg	cccacggctt	gacccccacg	1020
cagggtggtg	ccatcgccag	caataatggt	ggcaagcagg	cgctggagac	ggtccagcgg	1080
ctgttgccgg	tgctgtgcca	ggccacggc	ttgaccccc	agcagggtgg	ggccatcgcc	1140
agcaatggcg	gtggcaagca	ggcgctggag	acggtccagc	ggctgttgcc	ggtgctgtgc	1200
caggcccacg	gcttgacccc	ggagcaggtg	gtggccatcg	ccagcaatat	tggtaggaag	1260
caggcgctgg	agacgggtgca	ggcgctgttg	ccggtgctgt	gccaggccca	cggttgacc	1320
ccggagcagg	tggtagccat	cgccagccac	gatggcggca	agcaggcgct	ggagacggtc	1380
cagcggtgtg	tgccgggtgct	gtgccaggcc	cacggcttga	ccccggagca	ggtggtggcc	1440
atcgccagcc	acgatggcgg	caagcaggcg	ctggagacgg	tccagcggtg	gttgccgggtg	1500
ctgtgccagg	cccacggctt	gaccccgag	caggtggtgg	ccatcgccag	caatattggt	1560
ggcaagcagg	cgctggagac	ggtgcaggcg	ctgttgccgg	tgctgtgcca	ggccacggc	1620
ttgacccccg	agcagggtgg	ggccatcgcc	agccacgatg	gcggcaagca	ggcgctggag	1680
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ggagcaggtg	1740
gtggccatcg	ccagcaatat	tggtaggaag	caggcgctgg	agacggtgca	ggcgctgttg	1800
ccggtgctgt	gccaggccca	cggttgacc	ccccagcagg	tggtagccat	cgccagcaat	1860
aatggtggca	agcaggcgct	ggagacggtc	cagcggctgt	tgccggtgct	gtgccaggcc	1920
cacggcttga	ccccggagca	ggtggtggcc	atcgccagcc	acgatggcgg	caagcaggcg	1980
ctggagacgg	tccagcggtg	gttgccgggtg	ctgtgccagg	cccacggctt	gacccctcag	2040
cagggtggtg	ccatcgccag	caatggcggc	ggcaggccgg	cgctggagag	cattgttgcc	2100
cagttatctc	gacctgatcc	ggcgttgccc	gcgttgacca	acgaccacct	cgtcgccttg	2160
gcctgcctcg	gcgggctgct	tgcgctggat	gcagtgaata	agggattggg	ggatcctatc	2220
agccgttccc	agctggtgaa	gtccgagctg	gaggagaaga	aatccgagtt	gaggcacaag	2280
ctgaagtacg	tgccccacga	gtacatcgag	ctgatcgaga	tcgcccggaa	cagcacccag	2340
gaccgtatcc	tggagatgaa	ggtgatggag	ttcttcatga	aggtgtacgg	ctacaggggc	2400
aagcacctgg	gcggctccag	gaagcccagc	ggcgccatct	acaccgtggg	ctcccccatc	2460
gactacggcg	tgatcgtgga	caccaaggcc	tactccggcg	gctacaacct	gcccacggc	2520
caggccgacg	aaatgcagag	gtacgtggag	gagaaccaga	ccaggaacaa	gcacatcaac	2580
cccaacgagt	ggtggaaggt	gtacccctcc	agcgtgaccg	agttcaagtt	cctgttcgtg	2640
tccggccact	tcaagggcaa	ctacaaggcc	cagctgacca	ggctgaacca	catcaccaac	2700
tgcaacggcg	ccgtgctgtc	cgtggaggag	ctcctgatcg	gcggcgagat	gatcaaggcc	2760

ggcacccctga	ccctggagga	ggtgaggagg	aagttcaaca	acggcgagat	caacttcgcg	2820
gccgactgat	aa					2832

<210> 93

<211> 2814

<212> DNA

<213> Artificial Sequence

<220>

<223> CTLA4_T04-L TALEN

<400> 93

atgggcatc	ctaaaaagaa	acgtaaggtc	atcgattacc	catacgtatg	tccagattac	60
gctatcgata	tgcggcatct	acgcacgctc	ggctacagcc	agcagcaaca	ggagaagatc	120
aaaccgaagg	ttcgttcgac	agtggcgag	caccacgagg	cactggctcg	ccacgggttt	180

acacacgcgc	acatcggttc	gttaagccaa	caccgcgcag	cgtagggac	cgtagctgtc	240
aagtatcagg	acatgatcgc	agcggttgcca	gagcgacac	acgaagcgat	cgtaggcgtc	300
ggcaaacagt	ggtccggcgc	acgcgctctg	gagggccttg	tcacgggtgg	gggagagttg	360
agaggtccac	cgttacagtt	ggacacaggc	caacttctca	agattgcaaa	acgtggcggc	420
gtgaccgcag	tggaggcagt	gcattgcattg	cgcaatgcac	tgacgggtgc	cccgctcaac	480
ttgacccccg	agcaggtggt	ggccatcgcc	agccacgatg	gcggcaagca	ggcgctggag	540
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ggagcaggtg	600
gtggccatcg	ccagccacga	tggcggcaag	caggcgctgg	agacgggtcca	gcggctgttg	660
ccggtgctgt	gccaggccca	cggcttgacc	ccggagcagg	tggtagccat	cgccagcaat	720
attggtggca	agcaggcgct	ggagacgggtg	caggcgctgt	tgccggtgct	gtgccaggcc	780
caaggccttga	ccccccagca	ggtggtggcc	atcgccagca	atggcggtgg	caagcaggcg	840
ctggagacgg	tccagcggt	gttgccggtg	ctgtgccagg	cccacggctt	gacccccag	900
caggtggtgg	ccatcgccag	caataatggt	ggcaagcagg	cgctggagac	ggtccagcgg	960
ctgttgccgg	tgctgtgcca	ggccacggc	ttgaccccg	agcaggtggt	ggccatcgcc	1020
agccacgatg	gcggcaagca	ggcgctggag	acggtccagc	ggctgttgcc	ggtgctgtgc	1080
caggcccacg	gcttgacccc	ccagcaggtg	gtggccatcg	ccagcaatgg	cggtggcaag	1140
caggcgctgg	agacgggtcca	gcggctgttg	ccggtgctgt	gccaggccca	cggttgacc	1200
ccggagcagg	tggtagccat	cgccagcaat	attggtggca	agcaggcgct	ggagacgggtg	1260
caggcgctgt	tgccggtgct	gtgccaggcc	caggcttga	ccccccagca	ggtggtggcc	1320
atcgccagca	ataatggtgg	caagcaggcg	ctggagacgg	tccagcggt	gttgccggtg	1380
ctgtgccagg	cccacggctt	gaccccgag	caggtggtgg	ccatcgccag	ccacgatggc	1440
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggcccacggc	1500
ttgacccccg	agcaggtggt	ggccatcgcc	agcaatattg	gtggcaagca	ggcgctggag	1560
acggtgcagg	cgctgttgcc	ggtgctgtgc	caggccacg	gcttgacccc	ggagcaggtg	1620
gtggccatcg	ccagcaatat	tggtagcaag	caggcgctgg	agacgggtgca	ggcgctgttg	1680
ccggtgctgt	gccaggccca	cggcttgacc	ccccagcagg	tggtagccat	cgccagcaat	1740
ggcggtggca	agcaggcgct	ggagacgggtc	cagcgctgt	tgccggtgct	gtgccaggcc	1800
cacggccttga	ccccccagca	ggtggtggcc	atcgccagca	ataatggtgg	caagcaggcg	1860
ctggagacgg	tccagcggt	gttgccggtg	ctgtgccagg	cccacggctt	gaccccgag	1920
caggtggtgg	ccatcgccag	ccacgatggc	ggcaagcagg	cgctggagac	ggtccagcgg	1980
ctgttgccgg	tgctgtgcca	ggccacggc	ttgacccctc	agcaggtggt	ggccatcgcc	2040
agcaatggcg	gcggcaggcc	ggcgctggag	agcattgttg	cccagttatc	tcgccctgat	2100
ccggcgcttg	ccgcgttgac	caacgaccac	ctcgctgcct	tgccctgcct	cgccggcgct	2160
cctgcgctgg	atgcagtga	aaagggttg	gggatccta	tcagccgttc	ccagctggtg	2220
aagtccgagc	tggaggagaa	gaaatccgag	ttgaggcaca	agctgaagta	cgtgccccac	2280
gagtacatcg	agctgatcga	gatcgcccg	aacagcacc	aggaccgtat	cctggagatg	2340
aaggtgatgg	agttcttcat	gaaggtgtac	ggctacagg	gcaagcacct	ggcggtctcc	2400
aggaagcccg	acggcgccat	ctacaccggt	ggctccccc	tcgactacgg	cgtgatcgtg	2460
gacaccaagg	cctaactccg	cggctacaac	ctgcccacg	gccaggccga	cgaaatgcag	2520
aggtacgtgg	aggagaacca	gaccaggaac	aagcacatca	acccaacga	gtggtggaag	2580
gtgtacccct	ccagcgtgac	cgagttcaag	ttcctgttcg	tgtccggcca	cttcaagggc	2640
aactacaagg	cccagctgac	caggctgaac	cacatcacca	actgcaacgg	cgccgtgctg	2700
tccgtggagg	agctcctgat	cggcggcgag	atgatcaagg	ccggcacccct	gaccctggag	2760
gaggtgagga	ggaagttcaa	caacggcgag	atcaacttcg	cggccgactg	ataa	2814

<210> 94

<211> 2832

<212> DNA

<213> Artificial Sequence

<220>

<223> CTLA4_T04-R TALEN

<400> 94

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgataagg	agaccgcgc	tgccaagttc	60
gagagacagc	acatggacag	catcgatatc	gccgatctac	gcacgctcgg	ctacagccag	120
cagcaacagg	agaagatcaa	accgaaggtt	cgttcgacag	tggcgacga	ccacgaggca	180
ctggtcggcc	acgggtttac	acacgcgcac	atcgttgcgt	taagccaaca	cccggcagcg	240
ttagggaccg	tcgctgtcaa	gtatcaggac	atgatcgag	cgtagccaga	ggcgacacac	300
gaagcgatcg	ttggcgtcgg	caaacagtg	tcggcgcac	gcgctctgga	ggccttgctc	360
acggtggcgg	gagagttgag	aggtccaccg	ttacagttgg	acacaggcca	acttctcaag	420
attgcaaaac	gtggcggcgt	gaccgcagtg	gaggcagtg	atgcatggcg	caatgactg	480
acgggtgccc	cgtccaactt	gacccccag	caggtggtgg	ccatcgccag	caataatggt	540
ggcaagcagg	cgctggagac	ggtccagcgg	ctgtgcccgg	tgctgtgcca	ggccacggc	600
ttgacccccg	agcaggtggt	ggccatcgcc	agccacgatg	gcggcaagca	ggcgctggag	660
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ccagcaggtg	720
gtggccatcg	ccagcaatgg	cggtaggaag	caggcgctgg	agacgggtcca	gcggctgttg	780
ccggtgctgt	gccaggccca	cggcttgacc	ccccagcagg	tggtagccat	cgccagcaat	840
aatggtggca	agcaggcgct	ggagacgggtc	cagcgctgt	tgccggtgct	gtgccaggcc	900
cacggccttga	ccccccagca	ggtggtggcc	atcgccagca	ataatggtgg	caagcaggcg	960
ctggagacgg	tccagcggt	gttgccggtg	ctgtgccagg	cccacggctt	gaccccgag	1020
caggtggtgg	ccatcgccag	ccacgatggc	ggcaagcagg	cgctggagac	ggtccagcgg	1080
ctgttgccgg	tgctgtgcca	ggccacggc	ttgaccccg	agcaggtggt	ggccatcgcc	1140
agccacgatg	gcggcaagca	ggcgctggag	acggtccagc	ggctgttgcc	ggtgctgtgc	1200
caggcccacg	gcttgacccc	ggagcaggtg	gtggccatcg	ccagcaatat	tggtaggaag	1260
caggcgctgg	agacgggtgca	ggcgctgttg	ccggtgctgt	gccaggccca	cggttgacc	1320
cccagcagg	tggtagccat	ggccagcaat	aatggtggca	agcaggcgct	ggagacgggtc	1380
cagcgctgt	tgccggtgct	gtgccaggcc	cacggcttga	ccccccagca	ggtggtggcc	1440
atcgccagca	atggcggtgg	caagcaggcg	ctggagacgg	tccagcggt	gttgccggtg	1500
ctgtgccagg	cccacggctt	gaccccgag	caggtggtgg	ccatcgccag	caatattggt	1560
ggcaagcagg	cgctggagac	ggtgcaggcg	ctgtgcccgg	tgctgtgcca	ggcccacggc	1620
ttgacccccg	agcaggtggt	ggccatcgcc	agccacgatg	gcggcaagca	ggcgctggag	1680
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ggagcaggtg	1740
gtggccatcg	ccagccacga	tggcggcaag	caggcgctgg	agacgggtcca	gcggctgttg	1800
ccggtgctgt	gccaggccca	cggcttgacc	ccggagcagg	tggtagccat	cgccagcaat	1860
attggtggca	agcaggcgct	ggagacgggtg	caggcgctgt	tgccggtgct	gtgccaggcc	1920

```

cacggcttga ccccgagca ggtggtggcc atcgccagcc acgatggcgg caagcaggcg 1980
ctggagacgg tccaggggct gttgccgggt ctgtgccagg cccacggctt gacccctcag 2040
caggtggtgg ccatcgccag caatggcggc ggtagggcgg cgctggagag cattgttgcc 2100
cagttatctc gccctgatcc ggcggtggcc gcgttgacca acgaccacct cgtcgccctt 2160
gcctgcctcg gcgggcgtcc tgcgctggat gcagtgaata agggattggg ggatcctatc 2220
agccgttccc agctggtgaa gtccgagctg gaggagaaga aatccgagtt gaggcacaag 2280
ctgaagtacg tggccacga gtacatcgag ctgatcgaga tcgcccggaa cagcaccacg 2340
gaccgtatcc tggagatgaa ggtgatggag ttcttcatga aggtgtacgg ctacaggggc 2400
aagcacctgg gcggctccag gaagcccgac ggccgcatct acaccgtggg ctcccccatc 2460
gactacggcg tgatcgtgga caccaaggcc tactccggcg gctacaacct gccatcggc 2520
caggccgacg aaatgcagag gtacgtggag gagaaccaga ccaggaacaa gcacatcaac 2580
cccaacgagt ggtggaaggt gtacccctcc agcgtgaccg agttcaagtt cctgttcgtg 2640
tccggccact tcaagggcaa ctacaaggcc cagctgacca ggctgaacca catcaccaac 2700
tgcaacggcg ccgtgctgtc cgtggaggag ctctgatcgc gcggcgagat gatcaaggcc 2760
ggcacctga ccctggagga ggtgaggagg aagtcaaca acggcgagat caacttcgcg 2820
gccgactgat aa 2832

```

<210> 95

<211> 2814

<212> DNA

<213> Artificial Sequence

<220>

<223> PDCD1_T01-L TALEN

<400> 95

```

atgggcgatc ctaaaaagaa acgtaaggtc atcgattacc catacgaatg tccagattac 60
gctatcgata tcgccgatct acgcacgctc ggctacagcc agcagcaaca ggagaagatc 120
aaaccgaagg ttcgttcgac agtggcgagc caccacgagg cactggtcgg ccacgggttt 180
acacacgcgc acatcggttc gttaaagcaa caccggcag cgttaggagc cgtcgctgtc 240
aagtatcagg acatgatcgc agcggttgcc gaggcgacac acgaagcgat cgttggcgtc 300
ggcaaacagt ggtccggcgc acgcgctctg gaggccttgc tcacggtggc gggagagttg 360
agaggtccac cgttacagtt ggacacaggg caacttctca agattgcaaa acgtggcggc 420
gtgaccgcag tggaggcagt gcatgcatgg cgcaatgcac tgacgggtgc cccgctcaac 480
ttgaccccc agcaggtggt ggccatcgcc agcaatggcg gtggcaagca ggcgctggag 540
acggtccagc ggctgttgcc ggtgctgtgc cagggccacg gcttgacccc ggagcaggtg 600
gtggccatcg ccagccacga tggcggcaag acgcgctgg agacggtcca gcggctgtt 660
ccgtgctgt gccaggcca cggcttgacc ccccgagagg tgggtggccat cggcagcaat 720
ggcgggtggc agcaggcgct ggagacggtc cagcggtgtg tgccggtgct gtgccaggcc 780
cacggcttga ccccgagca ggtggtggcc atcgccagcc acgatggcgg caagcaggcg 840
ctggagacgg tccagcggt gtgcccgggt ctgtgccagg cccacggctt gaccccgag 900
caggtggtgg ccatcgccag ccacgatggc ggcaagcagg cgctggagac ggtccagcgg 960
ctgttgccgg tgctgtgcca gggccacggc ttgaccccg agcaggtggt gggccatcgcc 1020
agccacgatg gcggcaagca gcgctggag acggtccagc ggctgttgcc ggtgctgtgc 1080
caggcccacg gcttgacccc ggagcaggtg gtggccatcg ccagccacga tggcggcaag 1140
caggcgctgg agacggtcca gcgctgttg ccggtgctgt gccaggccca cggcttgacc 1200
ccggagcagg tgggtggccat cgcagcaat attggtggca agcaggcgct ggagacggtg 1260
caggcgctgt tgccggtgct gtgccaggcc cagcgcttga cccccagca ggtggtggcc 1320
atcgccagca ataaggtgg caagcaggcg ctggagacgg tccagcggt gttgccggtg 1380
ctgtgcccag cccacggctt gaccccgagc aggtggtgg ccacgcccag ccacgatggc 1440
ggcaagcagg cgctggagac ggtccagcgg tgcgtgcca gggccacggc 1500
ttgaccccg agcaggtggt ggccatcgcc agccacgatg gcggcaagca ggcgctggag 1560
acggtccagc ggctgttgcc ggtgctgtgc cagggccacg gcttgacccc ggagcaggtg 1620
gtggccatcg ccagccacga tggcggcaag cagcgctgg agacggtcca gcggctgtt 1680
ccggtgctgt gccaggccca cggcttgacc ccccgagagg tgggtggccat cggcagcaat 1740
ggcgggtggc agcaggcgct ggagacggtc cagcggtgtg tgccggtgct gtgccaggcc 1800
cacggcttga ccccccagca ggtggtggcc atcgccagca ataaggtgg caagcaggcg 1860
ctggagacgg tccagcggt ccacgatggc ggcaagcagg cgctggagac ggtccagcgg 1920
caggtggtgg ccatcgccag ccacgatggc ttgacccctc agcaggtggt ggccatcgcc 2040
ctgttgccgg gcggcaggcc gcgctggag agcattgttg cccagttatc tcgccctgat 2100
agcaatggcg ccgctgtgac caacgaccac ctgctgcct tggcctgcct cggcgggcgt 2160
cctgctgtgg atgcagtga aaagggattg ggggatccta tcagccgttc ccagctggtg 2220
aagtccgagc tggaggagaa gaaatccgag ttgaggcaca agctgaagta cgtgccccac 2280
gagtacatcg agctgatcga gatcgcccg aacagcacc aggaccgtat cctggagatg 2340
aaggtgatgg agttcttcat gaaggtgtac ggctacaggg gcaagcacct gggcggctcc 2400
aggaagcccg acggcgccat ctacaccgtg ggctcccca tcgactacgg cgtgatcgtg 2460
gacaccaagg cctactccgg cggtacaac ctgcccacg gccaggccga cgaaatgcag 2520
aggtacgtgg aggagaacca gaccaggaac aagcacatca accccaacga gtggtggaag 2580
gtgtacccct ccagcgtgac cgagttcaag ttctgttgcg tgtccggcca cttcaagggc 2640
aactacaagg cccagctgac cagctgaac cacatacca actgcaacgg ccgctgctg 2700
tccgtggagg agtcctgat cggcggcgag atgatcaagg ccggcaccct gaccctggag 2760
gaggtgagga ggaagttcaa caacggcgag atcaacttcg cggccgactg ataa 2814

```

<210> 96

<211> 2829

<212> DNA

<213> Artificial Sequence

<220>

<223> PDCD1_T01-R TALEN

<400> 96

atgggagatc	ctaaaaagaa	acgtaaggtc	atcgataagg	agaccgccc	tgccaagttc	60
gagagacagc	acatggacag	catcgatatc	gccgatctac	gcacgctcgg	ctacagccag	120
cagcaacagg	agaagatcaa	accgaaggtt	cggttcgacag	tgggcgagca	ccacgaggca	180
ctgggtcggc	acgggttttac	acacgcgcac	atcggttgcgt	taagccaaca	cccggcagcg	240
ttagggaccg	tcgctgtcaa	gtatcaggac	atgatcgag	cggtgccaga	ggcgacacac	300
gaagcgatcg	ttggcgtcgg	caaacagtg	tccggcgcac	gcgctctgga	ggccttgctc	360
acgggtggcg	gagagttgag	aggtccaccg	ttacagttgg	acacaggcca	acttctcaag	420
attgcaaaac	gtggcgggcg	gaccgcagtg	gaggcgagtg	atgcatggcg	caatgcactg	480
acgggtgccc	cgctcaactt	gacccccag	caagtcgtcg	caatcgccag	caataacgga	540
gggaagcaag	ccctcgaaac	cgtgcagcgg	ttgcttcctg	tgctctgcca	ggcccacggc	600
cttaccctcg	agcaggtggg	ggccatcgca	agtaacattg	gaggaaagca	agccttggag	660
acagtgcagg	ccctggttgc	cgtgctgtgc	caggcacacg	gcctcacacc	agagcaggtc	720
gtggccattg	cctccaacat	cggggggaaa	caggctctgg	agaccgtcca	ggcctgctg	780
cccgctcctc	gtcaagctca	cggcctgact	ccccacaag	tggtcgccat	cgcctctaag	840
aacggcgggg	agcaggcact	ggaacagtg	cagagactgc	tccctgtgct	ttgccaagct	900
catgggttga	ccccccaaca	ggtcgtcgct	attgcctcaa	acaacggggg	caagcaggcc	960
cttgagactg	tgagagggct	gttgccagtg	ctgtgtcagg	ctcacgggct	cactccacaa	1020
caggtggctg	caattgccag	caacggcggc	ggaaagcaag	ctcttgaaac	cgtgcaacgc	1080
ctcctgcccg	tgctctgtca	ggctcatggc	ctgacaccac	aacaagtcgt	ggccatcgcc	1140
agtaataatg	gogggaaaca	ggctcttgag	accgtccaga	ggctgctccc	agtgtctctg	1200
caggcacacg	ggctgacccc	ccagcaggtg	gtggctatcg	ccagcaataa	tgggggcaag	1260
caggccctgg	aaacagtcca	gcgcctgctg	ccagtgcctt	gccaggctca	cgggctcact	1320
cccgaacagg	tcgtggcaat	cgctccaac	ggagggaagc	aggctctgga	gaccgtgcag	1380
agactgctgc	ccgtcttgtg	ccaggccccac	ggactcacac	ctcagcaggt	cgtcgccatt	1440
gcctctaaca	acgggggcaa	acaagccctg	gagacagtg	agcggctgtt	gcctgtgttg	1500
tgccaagccc	acggcttgac	tcctcaacaa	gtggtcgcca	tcgcctcaa	tgggcgcgga	1560
aaacaagctc	tgagagagtg	gcagaggttg	ctgcccgctc	tctgccaaag	ccacggcctg	1620
actccccaac	aggtcgtcgc	cattgccagc	aacggcgag	gaaagcaggc	tctcgaaact	1680
gtgcagcggc	tgcttcctgt	gctgtgtcag	gctcatgggc	tgacccccca	gcaagtgggtg	1740
gctattgcct	ctaacaatgg	aggcaagcaa	gcccttgaga	cagtccagag	gctgttgcca	1800
gtgctgtgcc	aggccccacg	gctcacaccc	cagcaggtgg	tcgccatcgc	cagtaacggc	1860
ggggggcaac	aggcatttga	aaccgtccag	cgctgcttc	cagtgtctctg	ccaggcacac	1920
ggactgacac	ccgaacagg	ggtggccatt	gcatcccatg	atgggggcaa	gcaggccctg	1980
gagaccgtgc	agagactcct	gccagtgttg	tgccaagctc	acggcctcac	ccctcagcaa	2040
gtcgtggcca	tcgcctcaa	cggggggggc	cggcctgcac	tgagagcat	tgttgcccag	2100
ttatctcgcc	ctgatccggc	gttgcccgcg	ttgaccaacg	accacctcgt	cgccttggcc	2160
tgccctcgcg	ggcgtcctgc	gctggatgca	gtgaaaaagg	gattggggga	tcctatcagc	2220
cgttcccagc	tggtgaagtc	cgagctggag	gagaagaaat	ccgagttgag	gcacaagctg	2280
aagtacgtgc	cccacagata	catcgagctg	atcgagatcg	cccgaacag	caccagggac	2340
cgtatcctgg	agatgaaggt	gatggagttc	ttcatgaagg	tgtacggcta	caggggcaag	2400
cacctgggcg	gctccaggaa	gcccgaacgc	gccatctaca	ccgtgggctc	ccccatcgac	2460
tacggcgtga	tcgtggacac	caaggccctac	tccggcggtc	acaacctgcc	catcggccag	2520
gccgacgaaa	tgagagagta	cgtggaggag	aaccagacca	ggaacaagca	catcaacccc	2580
aacgagtggt	ggaaggtgta	ccctccagc	gtgaccgagt	tcaagttcct	gttcgtgtcc	2640
ggccacttca	agggcaacta	caaggcccag	ctgaccaggc	tgaaccacat	caccaactgc	2700
aacggcgccg	tgctgtccgt	ggaggagctc	ctgatcgcg	gcgagatgat	caaggccggc	2760
accctgaccc	tgaggagggt	gaggagggaag	ttcaacaacg	gcgagatcaa	cttcgcggcc	2820
gactgataa						2829

<210> 97

<211> 2814

<212> DNA

<213> Artificial Sequence

<220>

<223> PDCD1_T03-L TALEN

<400> 97

atgggagatc	ctaaaaagaa	acgtaaggtc	atcgattacc	catacgaatg	tcagagattac	60
gctatcgata	tcgcccagat	acgcacgctc	ggctacagcc	agcagcaaca	ggagaagatc	120
aaaccgaagg	ttcggttcgac	agtggcgag	caccacgagg	cactggctcg	ccacgggttt	180
acacacgcgc	acatcgttgc	gttaagccaa	caccggcgag	cgtaggggac	cgtcgctgtc	240
aagtatcagg	acatgatcgc	agcgttgcca	gaggcgacac	acgaagcgat	cgttggcgctc	300
ggcaaacagt	ggtccggcg	acgcgctctg	gaggccttgc	tcacggtggc	gggagagttg	360
agaggtccac	cgttacagtt	ggacacaggc	caacttctca	agattgcaaa	acgtggcggc	420
gtgaccgcag	tgagggcagt	gcatgcatgg	cgcaatgcac	tgacgggtgc	cccgtcaac	480
ttgaccccgg	agcaggtggg	ggccatcgcc	agcaatattg	gtggcaagca	ggcgctggag	540
acggtgcagg	cgctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ggagcaggtg	600
gtggccatcg	ccagccacga	tgggcgcaag	caggcgctgg	agacggtcca	gcggctgttg	660
ccggtgctgt	gccaggccca	cggcttgacc	ccggagcagg	tggtggccat	cgccagccac	720
gatggcgcca	agcaggcgct	ggagacggtc	cagcgctgtg	tgccggtgct	gtgccaggcc	780
cacggcttga	ccccccagca	ggtgggtggc	atcgccagca	atggcggtgg	caagcaggcg	840
ctgggagcgg	tccagcggct	gttgccgggtg	ctgtgccagg	cccacggctt	gaccccgag	900
caggtgggtg	ccatcgccag	cgctggagac	ggcaagcagg	cgctggagac	ggtccagcgg	960
ctgttgccgg	tgctgtgcca	ggcccaacgc	ttgaccccc	agcaggtggt	ggccatcgcc	1020
agcaatggcg	gtggcaagca	ggcgctggag	acggtccagc	ggctgttgcc	ggtgctgtgc	1080
caggcccaacg	gcttgacccc	ccagcaggtg	gtggccatcg	ccagcaataa	tggtggcaag	1140
caggcgctgg	agacgggtcca	gcggtgtgtg	ccggtgctgt	gccaggccca	cggcttgacc	1200
ccccagcagg	tggtggccat	cgccagcaat	ggcggtggca	agcaggcgct	ggagacggtc	1260
cagcggtgtg	tgccgggtgct	gtgccaggcc	cacggcttga	ccccccagca	ggtgggtggc	1320
atcgccagca	ataatgggtg	caagcaggcg	ctggagacgg	tccagcggtc	gttgccgggtg	1380
ctgtgccagg	cccacggctt	gacccccag	caggtgggtg	ccatcgccag	caataatggt	1440
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggcccacggc	1500
ttgaccccc	agcaggtggg	ggccatcgcc	agcaataatg	gtggcaagca	ggcgctggag	1560
acggtggagg	ggtgtgtggc	ggtgtgtgtg	gagggggagg	ggttgaggag	gagggaggtg	1620

```

acgggtccagc  ggctgttgcg  ggtgtgtgtc  caggcccaag  gcttgacccc  ccagcaggtg  1620
gtggccatcg  ccagcaataa  tggtaggaag  caggcgctgg  agacgggtcc  ggggtgttg  1680
ccgggtgctgt  gccaggccca  cggcttgacc  ccggagcagg  tggtagccat  cgccagccac  1740
gatggcggca  agcaggcgct  ggagacggtc  caggcgctgt  tgccgggtgt  gtgccaggcc  1800
cacggcttga  ccccgagca  ggtggtggcc  atcgccagcc  acgatggcgg  caagcaggcg  1860
ctggagacgg  tccagcggt  gttgccgggt  ctgtgccagg  cccacggctt  gaccccgga  1920
caggtggtgg  ccacgcccag  caatattggt  ggcaagcagg  cgctggagac  ggtgcaggcg  1980
ctgttgccgg  tgctgtgcca  ggccacggc  ttgacccctc  agcaggtggt  ggccatcgcc  2040
agcaatggcg  ggggagggc  ggcgtggag  agcattgttg  cccagttatc  tcgccctgat  2100
ccggcggttg  ccgcttgac  caacgaccac  ctgctgcct  tggcctgcct  cggcgggcgt  2160
cctgcgctgg  atgcagtga  aaagggttg  ggggatccta  tcagccgttc  ccagctggtg  2220
aagtccgagc  tggaggagaa  gaaatccgag  ttgaggcaca  agctgaagta  cgtgccccac  2280
gagtacatcg  agctgatcga  gatcgcccg  aacagcacc  aggaccgtat  cctggagatg  2340
aaggtgatgg  agttcttcat  gaaggtgtac  ggctacagg  gcaagcacct  gggcggtcc  2400
aggaagcccg  acggcgccat  ctacacggc  ggtccccc  tcgactacgg  cgtgatcgtg  2460
gacaccaagg  cctactccg  cgctacaac  ctgcccacg  gccaggccga  cgaaatgcag  2520
aggtacgtgg  aggagaacca  gaccaggaac  aagcacatca  accccaacga  gtggtggaag  2580
gtgtaccct  ccagcgtgac  cgagttcaag  ttcctgttcg  tgtccggcca  cttcaagggc  2640
aactacaagg  cccagctgac  caggctgaac  cacatcacca  actgcaacgg  cgccgtgctg  2700
tccgtggagg  agctcctgat  cggcgcgag  atgatcaagg  cgggcaccct  gaccctggag  2760
gaggtgagga  ggaagttcaa  caacggcgag  atcaacttcg  cggcgactg  ataa  2814

```

<210> 98

<211> 2829

<212> DNA

<213> Artificial Sequence

<220>

<223> PDCD1_T03-R TALEN

<400> 98

```

atgggcatc  ctaaaaagaa  acgtaaggtc  atcgataagg  agaccggcgc  tgccaagtgc  60
gagagacagc  acatggacag  catcgatatc  gccgatctac  gcacgctcgg  ctacagccag  120
cagcaacagg  agaagatcaa  accgaagggt  cgttcgacag  tggcgagca  ccacgaggca  180
ctggtcggcc  acgggtttac  acacgcgcac  atcgttgctg  taagccaaca  cccggcagcg  240

```

```

ttagggaccg  tcgtgtcaa  gtatcaggac  atgatcgag  cgttgccaga  ggcgacacac  300
gaagcgatcg  ttggcgctcg  caaacagtg  tccggcgcac  gcgctctgga  ggccttgctc  360
acgggtggcg  gagagttgag  aggtccaccg  ttacagttgg  acacaggcca  acttctcaag  420
attgcaaaac  gtggcgcggt  gaccgcagtg  gaggcagtg  atgcatggcg  caatgcactg  480
acgggtgccc  cgctcaactt  gacccccgag  caagtcgtcg  caatcgccag  ccatgatgga  540
gggaagcaag  ccctcgaaac  cgtgcagcgg  ttgcttctg  tgctctgcca  ggcccacggc  600
cttaccctc  agcaggtggt  ggccatcgca  agtaacggag  gaggaaagca  agccttgagg  660
acagtgcagc  gcctgttgcc  cgtgctgtgc  caggcacacg  gcctcacacc  agagcaggtc  720
gtggccattg  cctcccatga  cggggggaaa  caggctctgg  agaccgtcca  gaggctgctg  780
cccgctcctc  gtcaggctca  cggcctgact  ccccaacaag  tggtcggcat  cgcctctaata  840
ggcgccggga  agcaggcact  ggaacagtg  cagagactgc  tccctgtgct  ttgccaagct  900
catgggttga  ccccccaaca  ggtcgtcgct  attgcctcaa  acgggggggg  caagcaggcc  960
cttgagactg  tgcagaggct  gttgccagtg  ctgtgtcagg  ctacggggt  cactccacaa  1020
caggtggtcg  caattgccag  caacggcggc  ggaaagcaag  ctcttgaaac  cgtgcaacgc  1080
ctcctgccc  tgctctgtca  ggctcatggc  ctgacaccac  aacaagtcgt  ggccatcgcc  1140
agtaataatg  ggggaaaca  ggctcttgag  accgtccaga  ggctgctccc  agtgctctgc  1200
caggcacacg  ggctgacccc  cgagcaggtg  gtggctatcg  ccagcaatat  tgggggcaag  1260
caggccctgg  aaacagttca  ggccctgctg  ccagtgcctt  gccaggctca  cgggctcact  1320
ccccagcagg  tcgtggcaat  cgcctccaac  ggcgagggga  agcaggctct  ggagaccgtg  1380
cagagactgc  tgcccgctct  gtgccaggcc  caggactca  cactgaaca  ggtcgtcgcc  1440
attgcctctc  acgatggggg  caaacaagcc  ctggagacag  tgcagcggt  gttgcctgtg  1500
ttgtgccaag  cccacggctt  gactcctcaa  caagtggctg  ccacgcctc  aaatggcggc  1560
ggaaaacaag  ctctggagac  agtgagagg  ttgtgccc  tcctctgcca  agccacggc  1620
ctgactcccc  aacaggctgt  cgccattgcc  agcaacaacg  gaggaaagca  ggctctcgaa  1680
actgtgcagc  ggctgcttcc  tgtgctgtgt  caggctcatg  ggctgacccc  cgagcaagtg  1740
gtggctattg  cctctaattg  aggcaagcaa  gcccttgaga  cagtccagag  gctgttgcca  1800
gtgctgtgcc  agggccacgg  gctcacaccc  caggcaggtg  tcgccatcgc  cagtaacaac  1860
gggggcaaac  aggcattgga  aaccgtccag  cgctgcttc  cagtgtctg  ccaggcacac  1920
ggactgacac  ccgaacagg  ggtggccatt  gcaccccatg  atgggggcaa  gcaggccctg  1980
gagaccgtgc  agagactcct  gccagtgttg  tgccaagctc  acggcctcac  cctcagcaa  2040
gtcgtggcca  tcgctcaaaa  cggggggggc  cggcctgcac  tggagagcat  tgttgcccag  2100
ttatctcgcc  ctgatccggc  gttggccgg  ttgaccaacg  accacctcgt  cgccttgccc  2160
tgccctggcg  ggcgtcctgc  gctggatgca  gtgaaaagg  gattggggga  tcctatcagc  2220
cgttcccagc  tgggtgaagt  cgagctggag  gagaagaaat  ccgagttgag  gcacaagctg  2280
aagtacgtgc  cccacagta  catcgagctg  atcgagatcg  cccggaacag  caccagggac  2340
cgtatcctgg  agatgaagg  gatggagttc  ttcatgaagg  tgtacggcta  caggggcaag  2400
cacctggcg  gctccaggaa  gcccgacggc  gccatctaca  ccgtgggctc  cccatcgac  2460
tacggcgtga  tcgtggacac  caaggcctac  tccggcggt  acaacctgcc  catcgccag  2520
gccgacgaaa  tgcagaggta  cgtggaggag  aaccagacca  ggaacaagca  catcaacccc  2580
aacgagtgg  ggaaggtgta  cccctccagc  gtgaccgagt  tcaagttcct  gttcgtgtcc  2640
ggccacttca  agggcaacta  caaggcccag  ctgaccaggc  tgaaccacat  caccaactgc  2700
aacggcgccg  tgctgtccgt  ggaggagctc  ctgatcgcg  gcgagatgat  caaggccggc  2760
accctgacct  tggaggagg  gaggaggaag  ttcaacaacg  gcgagatcaa  cttcgcgcc  2820
gactgataa  2829

```

<210> 99

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Forward primer CTLA4_T01

<220>

<221> misc_feature

<222> (31)..(40)

<223> n is a or c or t or g

<400> 99

c c a t c t c a t c c c t g c g t g t c t c c g a c t c a g n n n n n n n n n n c t c t a c t t c c t g a a g a c c t g 60

<210> 100

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Forward primer CTLA4_T03/T04

<220>

<221> misc_feature

<222> (31)..(40)

<223> n is a or c or t or g

<400> 100

c c a t c t c a t c c c t g c g t g t c t c c g a c t c a g n n n n n n n n n n a c a g t t g a g a g a t g g a g g g g g 60

<210> 101

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Forward primer PDCD1_T01

<220>

<221> misc_feature

<222> (31)..(40)

<223> n is a or c or t or g

<400> 101

c c a t c t c a t c c c t g c g t g t c t c c g a c t c a g n n n n n n n n n n c c a c a g a g g t a g g t g c c g c 59

<210> 102

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Forward primer PDCD1_T03

<220>

<221> misc_feature

<222> (31)..(40)

<223> n is a or c or t or g

<400> 102

cctatctcatc cctgcgtgtc tccgactcag nnnnnnnnnn gacagagatg ccggtcacca 60

<210> 103
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse primer CTLA4_T01

<400> 103
cctatcccct gtgtgccttg gcagtctcag tggaatacag agccagccaa 50

<210> 104
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse primer CTLA4_T03/04

<400> 104
cctatcccct gtgtgccttg gcagtctcag ggtgcccggtg cagatggaat 50

<210> 105
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse primer PDCD1_T01

<400> 105
cctatcccct gtgtgccttg gcagtctcag ggctctgcag tggaggccag 50

<210> 106
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse primer PDCD1_T03

<400> 106
cctatcccct gtgtgccttg gcagtctcag ggacaacgcc accttcacct 50

<210> 107
<211> 281
<212> PRT
<213> Artificial Sequence

<220>
<223> pTalpha-FL

<400> 107
Met Ala Gly Thr Trp Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
1 5 10 15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
20 25 30

Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu

35 40 45
 Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser
 50 55 60
 Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro
 65 70 75 80
 Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser
 85 90 95
 Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly
 100 105 110
 Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu
 115 120 125
 Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro
 130 135 140
 Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu
 145 150 155 160
 Leu Leu Phe Asp Leu Leu Leu Thr Cys Ser Cys Leu Cys Asp Pro Ala
 165 170 175
 Gly Pro Leu Pro Ser Pro Ala Thr Thr Thr Arg Leu Arg Ala Leu Gly
 180 185 190
 Ser His Arg Leu His Pro Ala Thr Glu Thr Gly Gly Arg Glu Ala Thr
 195 200 205
 Ser Ser Pro Arg Pro Gln Pro Arg Asp Arg Arg Trp Gly Asp Thr Pro
 210 215 220
 Pro Gly Arg Lys Pro Gly Ser Pro Val Trp Gly Glu Gly Ser Tyr Leu
 225 230 235 240
 Ser Ser Tyr Pro Thr Cys Pro Ala Gln Ala Trp Cys Ser Arg Ser Arg
 245 250 255
 Leu Arg Ala Pro Ser Ser Ser Leu Gly Ala Phe Phe Arg Gly Asp Leu
 260 265 270
 Pro Pro Pro Leu Gln Ala Gly Ala Ala
 275 280
 <210> 108
 <211> 263
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> pTalpha-Delta18
 <400> 108
 Met Ala Gly Thr Trp Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
 1 5 10 15
 Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
 20 25 30
 Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu
 35 40 45
 Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser
 50 55 60
 Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro

65		70		75		80
Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser	85		90		95	
Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly	100		105		110	
Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu	115		120		125	
Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro	130		135		140	
Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu	145		150		155	160
Leu Leu Phe Asp Leu Leu Leu Thr Cys Ser Cys Leu Cys Asp Pro Ala	165		170		175	
Gly Pro Leu Pro Ser Pro Ala Thr Thr Thr Arg Leu Arg Ala Leu Gly	180		185		190	
Ser His Arg Leu His Pro Ala Thr Glu Thr Gly Gly Arg Glu Ala Thr	195		200		205	
Ser Ser Pro Arg Pro Gln Pro Arg Asp Arg Arg Trp Gly Asp Thr Pro	210		215		220	
Pro Gly Arg Lys Pro Gly Ser Pro Val Trp Gly Glu Gly Ser Tyr Leu	225		230		235	240
Ser Ser Tyr Pro Thr Cys Pro Ala Gln Ala Trp Cys Ser Arg Ser Arg	245		250		255	
Leu Arg Ala Pro Ser Ser Ser	260					

<210> 109

<211> 233

<212> PRT

<213> Artificial Sequence

<220>

<223> pTalpha-Delta48

<400> 109

Met Ala Gly Thr Trp Leu Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala	1	5	10	15
Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro	20	25	30	
Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu	35	40	45	
Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser	50	55	60	
Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro	65	70	75	80
Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser	85	90	95	
Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly	100	105	110	

Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu
115 120 125

Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro
130 135 140

Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu
145 150 155 160

Leu Leu Phe Asp Leu Leu Leu Thr Cys Ser Cys Leu Cys Asp Pro Ala
165 170 175

Gly Pro Leu Pro Ser Pro Ala Thr Thr Thr Arg Leu Arg Ala Leu Gly
180 185 190

Ser His Arg Leu His Pro Ala Thr Glu Thr Gly Gly Arg Glu Ala Thr
195 200 205

Ser Ser Pro Arg Pro Gln Pro Arg Asp Arg Arg Trp Gly Asp Thr Pro
210 215 220

Pro Gly Arg Lys Pro Gly Ser Pro Val
225 230

<210> 110

<211> 219

<212> PRT

<213> Artificial Sequence

<220>

<223> pTalpha-Delta62

<400> 110

Met Ala Gly Thr Trp Leu Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
1 5 10 15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
20 25 30

Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu
35 40 45

Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser
50 55 60

Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro
65 70 75 80

Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser
85 90 95

Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly
100 105 110

Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu
115 120 125

Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro
130 135 140

Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu
145 150 155 160

Leu Leu Phe Asp Leu Leu Leu Thr Cys Ser Cys Leu Cys Asp Pro Ala
165 170 175

Gly Pro Leu Pro Ser Pro Ala Thr Thr Thr Arg Leu Arg Ala Leu Gly

180 185 190

Ser His Arg Leu His Pro Ala Thr Glu Thr Gly Gly Arg Glu Ala Thr
195 200 205

Ser Ser Pro Arg Pro Gln Pro Arg Asp Arg Arg
210 215

<210> 111
<211> 203
<212> PRT
<213> Artificial Sequence

<220>
<223> pTalpha-Delta78

<400> 111

Met Ala Gly Thr Trp Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
1 5 10 15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
20 25 30

Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu
35 40 45

Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser
50 55 60

Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro
65 70 75 80

Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser
85 90 95

Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly
100 105 110

Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu
115 120 125

Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro
130 135 140

Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu
145 150 155 160

Leu Leu Phe Asp Leu Leu Leu Thr Cys Ser Cys Leu Cys Asp Pro Ala
165 170 175

Gly Pro Leu Pro Ser Pro Ala Thr Thr Thr Arg Leu Arg Ala Leu Gly
180 185 190

Ser His Arg Leu His Pro Ala Thr Glu Thr Gly
195 200

<210> 112
<211> 189
<212> PRT
<213> Artificial Sequence

<220>
<223> pTalpha-Delta92

<400> 112

Met Ala Gly Thr Trp Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
1 5 10 15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
20 25 30

Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu
35 40 45

Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser
50 55 60

Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro
65 70 75 80

Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser
85 90 95

Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly
100 105 110

Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu
115 120 125

Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro
130 135 140

Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu
145 150 155 160

Leu Leu Phe Asp Leu Leu Leu Thr Cys Ser Cys Leu Cys Asp Pro Ala
165 170 175

Gly Pro Leu Pro Ser Pro Ala Thr Thr Thr Arg Leu Arg
180 185

<210> 113

<211> 171

<212> PRT

<213> Artificial Sequence

<220>

<223> pTalpha-Delta110

<400> 113

Met Ala Gly Thr Trp Leu Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
1 5 10 15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
20 25 30

Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu
35 40 45

Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser
50 55 60

Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro
65 70 75 80

Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser
85 90 95

Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly
100 105 110

Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu
115 120 125

Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro

130 135 140

Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu
145 150 155 160

Leu Leu Phe Asp Leu Leu Leu Thr Cys Ser Cys
 165 170

<210> 114

<211> 167

<212> PRT

<213> Artificial Sequence

<220>

<223> pTalpha-Delta114

<400> 114

Met Ala Gly Thr Trp Leu Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
1 5 10 15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
 20 25 30

Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu
 35 40 45

Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser
 50 55 60

Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro
65 70 75 80

Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser
 85 90 95

Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly
 100 105 110

Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu
 115 120 125

Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro
 130 135 140

Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu
145 150 155 160

Leu Leu Phe Asp Leu Leu Leu
 165

<210> 115

<211> 344

<212> PRT

<213> Artificial Sequence

<220>

<223> pTalpha-FL-CD28

<400> 115

Met Ala Gly Thr Trp Leu Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
1 5 10 15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
 20 25 30

Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu
 35 40 45

```

30          40          50
Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser
50          55          60

Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro
65          70          75          80

Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser
85          90          95

Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly
100         105         110

Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu
115         120         125

Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro
130         135         140

Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu
145         150         155         160

Leu Leu Phe Asp Leu Leu Leu Thr Cys Ser Cys Leu Cys Asp Pro Ala
165         170         175

Gly Pro Leu Pro Ser Pro Ala Thr Thr Thr Arg Leu Arg Ala Leu Gly
180         185         190

Ser His Arg Leu His Pro Ala Thr Glu Thr Gly Gly Arg Glu Ala Thr
195         200         205

Ser Ser Pro Arg Pro Gln Pro Arg Asp Arg Arg Trp Gly Asp Thr Pro
210         215         220

Pro Gly Arg Lys Pro Gly Ser Pro Val Trp Gly Glu Gly Ser Tyr Leu
225         230         235         240

Ser Ser Tyr Pro Thr Cys Pro Ala Gln Ala Trp Cys Ser Arg Ser Arg
245         250         255

Leu Arg Ala Pro Ser Ser Ser Leu Gly Ala Phe Phe Arg Gly Asp Leu
260         265         270

Pro Pro Pro Leu Gln Ala Gly Ala Ala Ala Ser Gly Gly Val Leu Ala
275         280         285

Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg
290         295         300

Ser Lys Arg Ser Arg Gly Gly His Ser Asp Tyr Met Asn Met Thr Pro
305         310         315         320

Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro
325         330         335

Arg Asp Phe Ala Ala Tyr Arg Ser
340

```

<210> 116

<211> 311

<212> PRT

<213> Artificial Sequence

<220>

<223> pTalpha-FL-CD8

<400> 116

Met Ala Gly Thr Trp Leu Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
1 5 10 15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
20 25 30

Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu
35 40 45

Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser
50 55 60

Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro
65 70 75 80

Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser
85 90 95

Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly
100 105 110

Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu
115 120 125

Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro
130 135 140

Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu
145 150 155 160

Leu Leu Phe Asp Leu Leu Leu Thr Cys Ser Cys Leu Cys Asp Pro Ala
165 170 175

Gly Pro Leu Pro Ser Pro Ala Thr Thr Thr Arg Leu Arg Ala Leu Gly
180 185 190

Ser His Arg Leu His Pro Ala Thr Glu Thr Gly Gly Arg Glu Ala Thr
195 200 205

Ser Ser Pro Arg Pro Gln Pro Arg Asp Arg Arg Trp Gly Asp Thr Pro
210 215 220

Pro Gly Arg Lys Pro Gly Ser Pro Val Trp Gly Glu Gly Ser Tyr Leu
225 230 235 240

Ser Ser Tyr Pro Thr Cys Pro Ala Gln Ala Trp Cys Ser Arg Ser Arg
245 250 255

Leu Arg Ala Pro Ser Ser Ser Leu Gly Ala Phe Phe Arg Gly Asp Leu
260 265 270

Pro Pro Pro Leu Gln Ala Gly Ala Ala Ala Ser His Arg Asn Arg Arg
275 280 285

Arg Val Cys Lys Cys Pro Arg Pro Val Val Lys Ser Gly Asp Lys Pro
290 295 300

Ser Leu Ser Ala Arg Tyr Val
305 310

<210> 117

<211> 325

<212> PRT

<213> Artificial Sequence

<220>

<223> pTalpha-FL-41BB

<400> 117

Met Ala Gly Thr Trp Leu Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala

```

1           5           10           15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
20           25           30

Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu
35           40           45

Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser
50           55           60

Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro
65           70           75           80

Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser
85           90           95

Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly
100          105          110

Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu
115          120          125

Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro
130          135          140

Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu
145          150          155          160

Leu Leu Phe Asp Leu Leu Leu Thr Cys Ser Cys Leu Cys Asp Pro Ala
165          170          175

Gly Pro Leu Pro Ser Pro Ala Thr Thr Thr Arg Leu Arg Ala Leu Gly
180          185          190

Ser His Arg Leu His Pro Ala Thr Glu Thr Gly Gly Arg Glu Ala Thr
195          200          205

Ser Ser Pro Arg Pro Gln Pro Arg Asp Arg Arg Trp Gly Asp Thr Pro
210          215          220

Pro Gly Arg Lys Pro Gly Ser Pro Val Trp Gly Glu Gly Ser Tyr Leu
225          230          235          240

Ser Ser Tyr Pro Thr Cys Pro Ala Gln Ala Trp Cys Ser Arg Ser Arg
245          250          255

Leu Arg Ala Pro Ser Ser Ser Leu Gly Ala Phe Phe Arg Gly Asp Leu
260          265          270

Pro Pro Pro Leu Gln Ala Gly Ala Ala Gly Ser Lys Arg Gly Arg Lys
275          280          285

Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr
290          295          300

Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu
305          310          315          320

Gly Gly Cys Glu Leu
325

```

<210> 118

<211> 296

<212> PRT

<213> Artificial Sequence

<220>

<223> pTalpha-Delta48-CD28

<400> 118

```

Met Ala Gly Thr Trp Leu Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
1      5      10      15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
20      25      30

Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu
35      40      45

Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser
50      55      60

Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro
65      70      75      80

Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser
85      90      95

Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly
100     105     110

Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu
115     120     125

Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro
130     135     140

Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu
145     150     155     160

Leu Leu Phe Asp Leu Leu Leu Thr Cys Ser Cys Leu Cys Asp Pro Ala
165     170     175

Gly Pro Leu Pro Ser Pro Ala Thr Thr Thr Arg Leu Arg Ala Leu Gly
180     185     190

Ser His Arg Leu His Pro Ala Thr Glu Thr Gly Gly Arg Glu Ala Thr
195     200     205

Ser Ser Pro Arg Pro Gln Pro Arg Asp Arg Arg Trp Gly Asp Thr Pro
210     215     220

Pro Gly Arg Lys Pro Gly Ser Pro Val Ala Ser Gly Gly Val Leu Ala
225     230     235     240

Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg
245     250     255

Ser Lys Arg Ser Arg Gly Gly His Ser Asp Tyr Met Asn Met Thr Pro
260     265     270

Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro
275     280     285

Arg Asp Phe Ala Ala Tyr Arg Ser
290     295

```

<210> 119

<211> 263

<212> PRT

<213> Artificial Sequence

<220>

<223> pTalpha-Delta48-CD8

<400> 119

Met Ala Gly Thr Trp Leu Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
 1 5 10 15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
 20 25 30

Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu
 35 40 45

Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser
 50 55 60

Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro
 65 70 75 80

Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser
 85 90 95

Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly
 100 105 110

Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu
 115 120 125

Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro
 130 135 140

Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu
 145 150 155 160

Leu Leu Phe Asp Leu Leu Leu Thr Cys Ser Cys Leu Cys Asp Pro Ala
 165 170 175

Gly Pro Leu Pro Ser Pro Ala Thr Thr Thr Arg Leu Arg Ala Leu Gly
 180 185 190

Ser His Arg Leu His Pro Ala Thr Glu Thr Gly Gly Arg Glu Ala Thr
 195 200 205

Ser Ser Pro Arg Pro Gln Pro Arg Asp Arg Arg Trp Gly Asp Thr Pro
 210 215 220

Pro Gly Arg Lys Pro Gly Ser Pro Val Ala Ser His Arg Asn Arg Arg
 225 230 235 240

Arg Val Cys Lys Cys Pro Arg Pro Val Val Lys Ser Gly Asp Lys Pro
 245 250 255

Ser Leu Ser Ala Arg Tyr Val
 260

<210> 120

<211> 277

<212> PRT

<213> Artificial Sequence

<220>

<223> pTalpha-Delta48-41BB

<400> 120

Met Ala Gly Thr Trp Leu Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
 1 5 10 15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
 20 25 30

[illegible]

<210> 121

<211> 172

<212> PRT

<213> Artificial Sequence

<220>

<223> pTalpha-Delta114-TCRalpha.IC

<400> 121

Met Ala Gly Thr Trp Leu Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
1 5 10 15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
20 25 30

Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu
35 40 45

1000 2000 3000 4000 5000 6000 7000 8000 9000 10000 11000 12000 13000 14000 15000 16000 17000 18000 19000 20000 21000 22000 23000 24000 25000 26000 27000 28000 29000 30000 31000 32000 33000 34000 35000 36000 37000 38000 39000 40000 41000 42000 43000 44000 45000 46000 47000 48000 49000 50000 51000 52000 53000 54000 55000 56000 57000 58000 59000 60000 61000 62000 63000 64000 65000 66000 67000 68000 69000 70000 71000 72000 73000 74000 75000 76000 77000 78000 79000 80000 81000 82000 83000 84000 85000 86000 87000 88000 89000 90000 91000 92000 93000 94000 95000 96000 97000 98000 99000 100000

Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser
50 55 60

Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro
65 70 75 80

Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser
85 90 95

Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly
100 105 110

Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu
115 120 125

Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro
130 135 140

Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu
145 150 155 160

Leu Leu Phe Asp Leu Leu Leu Arg Leu Trp Ser Ser
165 170

<210> 122

<211> 173

<212> PRT

<213> Artificial Sequence

<220>

<223> pTalpha.EC-TCRalpha. TM. IC

<400> 122

Met Ala Gly Thr Trp Leu Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
1 5 10 15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
20 25 30

Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu
35 40 45

Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser
50 55 60

Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro
65 70 75 80

Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser
85 90 95

Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly
100 105 110

Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu
115 120 125

Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro
130 135 140

Gly Gly Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala
145 150 155 160

Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
165 170

<210> 123

<211> 233

<212> PRT

<213> Artificial Sequence

<220>

<223> pTalpha.EC-Delta48-1xMUT

<400> 123

```

Met Ala Gly Thr Trp Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
1           5           10           15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
20           25           30

Ile Met Leu Leu Val Asp Gly Lys Gln Gln Met Val Val Val Cys Leu
35           40           45

Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Arg Phe Ser
50           55           60

Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro
65           70           75           80

Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser
85           90           95

Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly
100          105          110

Ala Glu Gly His Ser Arg Ser Thr Gln Pro Met His Leu Ser Gly Glu
115          120          125

Ala Ser Thr Ala Arg Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro
130          135          140

Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu
145          150          155          160

Leu Leu Phe Asp Leu Leu Leu Thr Cys Ser Cys Leu Cys Asp Pro Ala
165          170          175

Gly Pro Leu Pro Ser Pro Ala Thr Thr Thr Arg Leu Arg Ala Leu Gly
180          185          190

Ser His Arg Leu His Pro Ala Thr Glu Thr Gly Gly Arg Glu Ala Thr
195          200          205

Ser Ser Pro Arg Pro Gln Pro Arg Asp Arg Arg Trp Gly Asp Thr Pro
210          215          220

Pro Gly Arg Lys Pro Gly Ser Pro Val
225          230

```

<210> 124

<211> 233

<212> PRT

<213> Artificial Sequence

<220>

<223> pTalpha.EC-Delta48-4xMUT

<400> 124

```

Met Ala Gly Thr Trp Leu Leu Leu Leu Ala Leu Gly Cys Pro Ala
1           5           10           15

Leu Pro Thr Gly Val Gly Gly Thr Pro Phe Pro Ser Leu Ala Pro Pro
20           25           30

```

Ile Met Leu Leu Val Ala Gly Ala Gln Gln Met Val Val Val Cys Leu
35 40 45

Val Leu Asp Val Ala Pro Pro Gly Leu Asp Ser Pro Ile Trp Phe Ser
50 55 60

Ala Gly Asn Gly Ser Ala Leu Asp Ala Phe Thr Tyr Gly Pro Ser Pro
65 70 75 80

Ala Thr Asp Gly Thr Trp Thr Asn Leu Ala His Leu Ser Leu Pro Ser
85 90 95

Glu Glu Leu Ala Ser Trp Glu Pro Leu Val Cys His Thr Gly Pro Gly
100 105 110

Ala Glu Gly His Ser Ala Ser Thr Gln Pro Met His Leu Ser Gly Glu
115 120 125

Ala Ser Thr Ala Ala Thr Cys Pro Gln Glu Pro Leu Arg Gly Thr Pro
130 135 140

Gly Gly Ala Leu Trp Leu Gly Val Leu Arg Leu Leu Leu Phe Lys Leu
145 150 155 160

Leu Leu Phe Asp Leu Leu Leu Thr Cys Ser Cys Leu Cys Asp Pro Ala
165 170 175

Gly Pro Leu Pro Ser Pro Ala Thr Thr Thr Arg Leu Arg Ala Leu Gly
180 185 190

Ser His Arg Leu His Pro Ala Thr Glu Thr Gly Gly Arg Glu Ala Thr
195 200 205

Ser Ser Pro Arg Pro Gln Pro Arg Asp Arg Arg Trp Gly Asp Thr Pro
210 215 220

Pro Gly Arg Lys Pro Gly Ser Pro Val
225 230

<210> 125

<211> 848

<212> PRT

<213> Artificial Sequence

<220>

<223> Multi-chain CAR

<400> 125

Met Ala Pro Ala Met Glu Ser Pro Thr Leu Leu Cys Val Ala Leu Leu
1 5 10 15

Phe Phe Ala Pro Asp Gly Val Leu Ala Glu Val Gln Leu Gln Gln Ser
20 25 30

Gly Pro Glu Leu Ile Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys
35 40 45

Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Val Met His Trp Val Lys Gln
50 55 60

Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro Tyr Asn
65 70 75 80

Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr
85 90 95

Ser Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr

100	105	110
Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Thr Tyr Tyr Tyr 115 120 125		
Gly Ser Arg Val Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 130 135 140		
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 145 150 155 160		
Ser Asp Ile Val Met Thr Gln Ala Ala Pro Ser Ile Pro Val Thr Pro 165 170 175		
Gly Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Asn 180 185 190		
Ser Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln 195 200 205		
Ser Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val 210 215 220		
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg 225 230 235 240		
Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln 245 250 255		
His Leu Glu Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu 260 265 270		
Lys Arg Ala Asp Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala 275 280 285		
Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg 290 295 300		
Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys 305 310 315 320		
Asp Phe Phe Ile Pro Leu Leu Val Val Ile Leu Phe Ala Val Asp Thr 325 330 335		
Gly Leu Phe Ile Ser Thr Gln Gln Gln Val Thr Phe Leu Leu Lys Ile 340 345 350		
Lys Arg Thr Arg Lys Gly Phe Arg Leu Leu Asn Pro His Pro Lys Pro 355 360 365		
Asn Pro Lys Asn Asn Arg Ala Glu Gly Arg Gly Ser Leu Leu Thr Cys 370 375 380		
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Asp Thr Glu Ser Asn Arg 385 390 395 400		
Arg Ala Asn Leu Ala Leu Pro Gln Glu Pro Ser Ser Val Pro Ala Phe 405 410 415		
Glu Val Leu Glu Ile Ser Pro Gln Glu Val Ser Ser Gly Arg Leu Leu 420 425 430		
Lys Ser Ala Ser Ser Pro Pro Leu His Thr Trp Leu Thr Val Leu Lys 435 440 445		
Lys Glu Gln Glu Phe Leu Gly Val Thr Gln Ile Leu Thr Ala Met Ile 450 455 460		
Cys Leu Cys Phe Gly Thr Val Val Cys Ser Val Leu Asp Ile Ser His 465 470 475 480		

Ile Glu Gly Asp Ile Phe Ser Ser Phe Lys Ala Gly Tyr Pro Phe Trp
 485 490 495

Gly Ala Ile Phe Phe Ser Ile Ser Gly Met Leu Ser Ile Ile Ser Glu
 500 505 510

Arg Arg Asn Ala Thr Tyr Leu Val Arg Gly Ser Leu Gly Ala Asn Thr
 515 520 525

Ala Ser Ser Ile Ala Gly Gly Thr Gly Ile Thr Ile Leu Ile Ile Asn
 530 535 540

Leu Lys Lys Ser Leu Ala Tyr Ile His Ile His Ser Cys Gln Lys Phe
 545 550 555 560

Phe Glu Thr Lys Cys Phe Met Ala Ser Phe Ser Thr Glu Ile Val Val
 565 570 575

Met Met Leu Phe Leu Thr Ile Leu Gly Leu Gly Ser Ala Val Ser Leu
 580 585 590

Thr Ile Cys Gly Ala Gly Glu Glu Leu Lys Gly Asn Lys Val Pro Glu
 595 600 605

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met
 610 615 620

Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe
 625 630 635 640

Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Gly Ser Gly Val Lys Gln
 645 650 655

Thr Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn
 660 665 670

Pro Gly Pro Met Ile Pro Ala Val Val Leu Leu Leu Leu Leu Val
 675 680 685

Glu Gln Ala Ala Ala Leu Gly Glu Pro Gln Leu Cys Tyr Ile Leu Asp
 690 695 700

Ala Ile Leu Phe Leu Tyr Gly Ile Val Leu Thr Leu Leu Tyr Cys Arg
 705 710 715 720

Leu Lys Ile Gln Val Arg Lys Ala Ala Ile Thr Ser Tyr Glu Lys Ser
 725 730 735

Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
 740 745 750

Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
 755 760 765

Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
 770 775 780

Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
 785 790 795 800

Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
 805 810 815

Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
 820 825 830

Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
 835 840 845

<210> 126
 <211> 2547
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Multi-chain CAR

<400> 126
 atggctcctg ccatggaatc ccctactcta ctgtgtgtag ccttactgtt cttcgctcca 60
 gatggcgtgt tagcagaggt gcagttgcag cagtcagggc cagagttgat taagcccgga 120
 gcctccgtca agatgtcctg caaggccagc gggtagactt tcaccagcta cgtcatgcat 180
 tgggtgaagc agaagccagg ccaggggctt gagtggattg ggtacatcaa cccctacaac 240
 gacgggacca aatacaacga gaaattcaag ggcaaagcca cactcacctc cgataagtcc 300
 tcctctaccg cctacatgga gctcagctcc ctgacctccg aggatagcgc tgtgtattac 360
 tgcgcaaggg gcacatacta ctatggctct aggggtgttc actactgggg gcagggcact 420
 actctcacag tgagctcagg cggaggaggc agtggcggag ggggaagtgg gggcggcggc 480
 agcgatattg tcatgaccca ggagcccct agtatccctg tgactccagg cgagagcgtg 540
 agcatcagct gccgggtccag caagagcctg ctgaacagta acggaaacac atacctctac 600
 tggtttctgc agaggcccgg ccagagcccct cagctgctga tttaccgcat gtcaaactct 660
 gcctctgggg tgcccgatag atttagtggg agcggatccg gcacagcttt tacattgcgg 720
 atctccagag tcgaggccga agacgtgggg gtctattact gtatgcaaca cctggaatac 780
 ccctttacct tcggagccgg cacaagctg gagctgaagc gggctgacac cacaaccccc 840
 gctccaaggc cccctacccc cgcaccaact attgcctccc agccactctc actgcggcct 900
 gaggcctgtc ggcccgtgc tggaggcgca gtgcatacaa ggggcctcga tttcgctgc 960
 gattttttta tcccattgtt ggtggtgatt ctgtttgctg tggacacagg attatttatc 1020
 tcaactcagc agcaggtcac atttctcttg aagattaaga gaaccaggaa aggcttcaga 1080
 cttctgaacc cacatcctaa gccaaaacccc aaaaacaaca gagccgaggg cagaggcagc 1140
 ctgctgacct gcggcgacgt ggaggagaac ccaggcccca tggacacaga aagtaatagg 1200
 agagcaaatc ttgctctccc acaggagcct tccagtgtgc ctgcatttga agtcttgaa 1260
 atatctcccc aggaagtatc ttcaggcaga ctattgaagt cggcctcadc ccaccactg 1320
 catacatggc tgacagtttt gaaaaaagag caggagtctc tgggggtaac acaaattctg 1380
 actgctatga tatgcctttg ttttgaaca gttgtctgct ctgtacttga tatttcacac 1440
 attgagggag acattttttc atcatttaaa gcaggttatc cattctgggg agccatattt 1500
 ttttctattt ctggaatgtt gtcaattata tctgaaagga gaaatgcaac atatctggtg 1560
 agaggaagcc tgggagcaaa cactgccagc agcatagctg ggggaacggg aattaccatc 1620
 ctgatcatca acctgaagaa gagcttgccc tatatccaca tccacagttg ccagaaattt 1680
 tttgagacca agtgctttat ggcttccctt tccactgaaa ttgtagtgat gatgctgttt 1740
 ctaccattc tgggacttgg tagtgctgtg tcaactacaa tctgtggagc tggggaagaa 1800
 ctcaaaggaa acaaggttcc agagaaacgg gcccggaaga agctcctcta catttttaag 1860
 cagcctttca tgccggccagt gcagacaacc caagaggagg atgggtgttc ctgcagattc 1920
 cctgaggaag aggaaggcgg gtgcgagctg ggttctggcg tgaaacagac tttgaatttt 1980
 gaccttctca agttggcggg agacgtggag tccaacccag ggcccatgat tccagcagt 2040
 gtcttgctct tactcctttt ggttgaacaa gcagcggccc tgggagagcc tcagctctgc 2100
 tatatcctgg atgccatcct gtttctgtat ggaattgttc tcaccctcct ctactgtcga 2160
 ctgaagatcc aagtgcgaaa gccagctata accagctatg agaaatcaag agtgaagtcc 2220
 tccaggagcg cagatgcccc cgcctatcaa cagggccaga accagctcta caacgagctt 2280
 aacctcgga ggcgcgaaga atacgacgtg ttggataaga gaagggggcg ggaccccag 2340
 atgggaggaa agccccggag gaagaaccct caggagggcc tgtacaacga gctgcagaag 2400
 gataagatgg ccgaggccta ctcagagatc gggatgaagg gggagcggcg ccgcgggaag 2460
 gggcacgatg ggctctacca ggggctgagc acagccacaa aggacacata cgacgccttg 2520
 cacatgcagg cccttcacc ccggtga 2547

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US4683195A \[0027\]](#)
- [WO2012058458A \[0039\] \[0064\]](#)
- [WO2013009525A \[0039\]](#)
- [US6010613A \[0110\]](#)
- [WO2004083379A \[0110\]](#)

- [US6352694B \[0114\]](#)
- [US6534055B \[0114\]](#)
- [US6905680B \[0114\]](#)
- [US6692964B \[0114\]](#)
- [US5858353A \[0114\]](#)
- [US6887466B \[0114\]](#)
- [US6905681B \[0114\]](#)
- [US7144575B \[0114\]](#)
- [US7067318B \[0114\]](#)
- [US7172869B \[0114\]](#)
- [US7232566B \[0114\]](#)
- [US7175843B \[0114\]](#)
- [US5883223A \[0114\]](#)
- [US6905874B \[0114\]](#)
- [US6797514B \[0114\]](#)
- [US6867041B \[0114\]](#)
- [US20060121005 \[0114\]](#)
- [FR901228 \[0133\]](#)
- [WO2012138927A \[0140\]](#)
- [US4474893A \[0142\]](#)
- [WO2013017950A \[0149\]](#)
- [WO2004067736A \[0150\] \[0150\]](#)

Non-patent literature cited in the description

- **H. TORIKAI et al.**BLOOD, 2012, vol. 119, 5697-5705 [\[0004\]](#)
- **FREDERICK M. AUSUBEL**Current Protocols in Molecular BiologyWiley and son Inc20000000 [\[0027\]](#)
- **SAMBROOK et al.**Molecular Cloning: A Laboratory ManualCold Spring Harbor Laboratory Press20010000 [\[0027\]](#)
- **MULLIS**Oligonucleotide Synthesis, 1984, [\[0027\]](#)
- Nucleic Acid Hybridization, 1984, [\[0027\]](#)
- Transcription And Translation19840000 [\[0027\]](#)
- Culture Of Animal CellsAlan R. Liss, Inc.19870000 [\[0027\]](#)
- Immobilized Cells And EnzymesIRL Press19860000 [\[0027\]](#)
- **B. PERBALA** Practical Guide To Molecular Cloning, 1984, [\[0027\]](#)
- Methods In ENZYMOLOGYAcademic Press, Inc.vol. 154, 155, 185, [\[0027\]](#)
- Gene Expression Technology [\[0027\]](#)
- Gene Transfer Vectors For Mammalian CellsCold Spring Harbor Laboratory19870000 [\[0027\]](#)
- Immunochemical Methods In Cell And Molecular BiologyAcademic Press19870000 [\[0027\]](#)
- Handbook Of Experimental Immunology19860000vol. I-IV, [\[0027\]](#)
- Manipulating the Mouse EmbryoCold Spring Harbor Laboratory Press19860000 [\[0027\]](#)
- **DONNELLY et al.**J. of General Virology, 2001, vol. 82, 1013-1025 [\[0106\]](#)
- **DONNELLY et al.**J. of Gen. Virology, 1997, vol. 78, 13-21 [\[0106\]](#)
- **DORONINA et al.**Mol. And. Cell. Biology, 2008, vol. 28, 134227-4239 [\[0106\]](#)
- **ATKINS et al.**RNA, 2007, vol. 13, 803-810 [\[0106\]](#)
- **LIU et al.**Cell, vol. 66, 807-815 [\[0133\]](#)
- **HENDERSON et al.**Immun, 1991, vol. 73, 316-321 [\[0133\]](#)
- **BIERER et al.**Citr. Opin. mm n., 1993, vol. 5, 763-773 [\[0133\]](#)
- Retroviridae: The viruses and their replication**COFFIN, J. M. et al.**In Fundamental VirologyLippincott-Raven Publishers19960000 [\[0136\]](#)
- **KRANZ et al.**Proc. Natl. Acad. Sci. USA, 1981, vol. 78, 5807- [\[0142\]](#)

- **ARIMONDO, P. B.C. J. THOMAS et al.** Exploring the cellular activity of camptothecin-triple-helix-forming oligonucleotide conjugates *Mol Cell Biol*, 2006, vol. 26, 1324-33 [\[0205\]](#)
- **ARNOULD, S.P. CHAMES et al.** Engineering of large numbers of highly specific homing endonucleases that induce recombination on novel DNA targets *J Mol Biol*, 2006, vol. 355, 3443-58 [\[0205\]](#)
- **ASHWELL, J. D.R. D. KLUSNER** Genetic and mutational analysis of the T-cell antigen receptor *Annu Rev Immunol*, 1990, vol. 8, 139-67 [\[0205\]](#)
- **BETTS, M. R.J. M. BRENCHLEY et al.** Sensitive and viable identification of antigen-specific CD8⁺ T cells by a flow cytometric assay for degranulation *J Immunol Methods*, 2003, vol. 281, 1-265-78 [\[0205\]](#)
- **BOCH, J.H. SCHOLZE et al.** Breaking the code of DNA binding specificity of TAL-type III effectors *Science*, 2009, vol. 326, 59591509-12 [\[0205\]](#)
- **BONI, A.P. MURANSKI et al.** Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers *Blood*, 2008, vol. 112, 124746-54 [\[0205\]](#)
- **BRAHMER, J. R.C. G. DRAKE et al.** Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates *J Clin Oncol*, 2010, vol. 28, 193167-75 [\[0205\]](#)
- **CAMBIER, J. C.** Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM) *J Immunol*, 1995, vol. 155, 73281-5 [\[0205\]](#)
- **CARRASSO, Y. R.A. R. RAMIRO et al.** An endoplasmic reticulum retention function for the cytoplasmic tail of the human pre-T cell receptor (TCR) alpha chain: potential role in the regulation of cell surface pre-TCR expression levels *J Exp Med*, 2001, vol. 193, 91045-58 [\[0205\]](#)
- **CERMAK, T.E. L. DOYLE et al.** Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting *Nucleic Acids Res*, 2011, vol. 39, 12e82- [\[0205\]](#)
- **CHAMES, P.J. C. EPINAT et al.** In vivo selection of engineered homing endonucleases using double-strand break induced homologous recombination *Nucleic Acids Res*, 2005, vol. 33, 20e178- [\[0205\]](#)
- **CHOULIKA, A.A. PERRIN et al.** Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of *Saccharomyces cerevisiae* *Mol Cell Biol*, 1995, vol. 15, 41968-73 [\[0205\]](#)
- **CHRISTIAN, M.T. CERMAK et al.** Targeting DNA double-strand breaks with TAL effector nucleases *Genetics*, 2010, vol. 186, 2757-61 [\[0205\]](#)
- **COUTINHO, A. E.K. E. CHAPMAN** The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights *Mol Cell Endocrinol*, 2011, vol. 335, 12-13 [\[0205\]](#)
- **CRITCHLOW, S. E.S. P. JACKSON** DNA end-joining: from yeast to man *Trends Biochem Sci*, 1998, vol. 23, 10394-8 [\[0205\]](#)
- **DENG, D.C. YAN et al.** Structural basis for sequence-specific recognition of DNA by TAL effectors *Science*, 2012, vol. 335, 6069720-3 [\[0205\]](#)
- **EISENSCHMIDT, K.T. LANIO et al.** Developing a programmed restriction endonuclease for highly specific DNA cleavage *Nucleic Acids Res*, 2005, vol. 33, 227039-47 [\[0205\]](#)
- **EPINAT, J. C.S. ARNOULD et al.** A novel engineered meganuclease induces homologous recombination in yeast and mammalian cells *Nucleic Acids Res*, 2003, vol. 31, 112952-62 [\[0205\]](#)
- **GEISLER, R.H. SCHOLZE et al.** Transcriptional activators of human genes with programmable DNA-specificity *PLoS One*, 2011, vol. 6, 5e19509- [\[0205\]](#)
- **HOWARD, F. D.H. R. RODEWALD et al.** CD3 zeta subunit can substitute for the gamma subunit of Fc epsilon receptor type I in assembly and functional expression of the high-affinity IgE receptor: evidence for interreceptor complementation *Proc Natl Acad Sci U S A*, 1990, vol. 87, 187015-9 [\[0205\]](#)
- **HUANG, P.A. XIAO et al.** Heritable gene targeting in zebrafish using customized TALENs *Nat Biotechnol*, 2011, vol. 29, 8699-700 [\[0205\]](#)
- **JENA, B.G. DOTTI et al.** Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor *Blood*, 2010, vol. 116, 71035-44 [\[0205\]](#)
- **KALISH, J. M.P. M. GLAZER** Targeted genome modification via triple helix formation *Ann N Y Acad Sci*, 2005, vol. 1058, 151-61 [\[0205\]](#)
- **LI, L.M. J. PIATEK et al.** Rapid and highly efficient construction of TALE-based transcriptional regulators and nucleases for genome modification *Plant Mol Biol*, 2012, vol. 78, 4-5407-16 [\[0205\]](#)
- **LI, T.S. HUANG et al.** TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain *Nucleic Acids Res*, 2011, vol. 39, 1359-72 [\[0205\]](#)
- **LI, T.S. HUANG et al.** Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes *Nucleic Acids Res*, 2011, vol. 39, 146315-25 [\[0205\]](#)

- **MA, J. L.E. M. KIM et al.**Yeast Mre11 and Rad1 proteins define a Ku-independent mechanism to repair double-strand breaks lacking overlapping end sequences*Mol Cell Biol*, 2003, vol. 23, 238820-8 [\[0205\]](#)
- **MAHFOUZ, M. M.L. LI et al.**Targeted transcriptional repression using a chimeric TALE-SRDX repressor protein*Plant Mol Biol*, 2012, vol. 78, 3311-21 [\[0205\]](#)
- **MAHFOUZ, M. M.L. LI et al.**De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks*Proc Natl Acad Sci U S A*, 2011, vol. 108, 62623-8 [\[0205\]](#)
- **MAK, A. N.P. BRADLEY et al.**The crystal structure of TAL effector PthXo1 bound to its DNA target*Science*, 2012, vol. 335, 6069716-9 [\[0205\]](#)
- **METZGER, H.G. ALCARAZ et al.**The receptor with high affinity for immunoglobulin E*Annu Rev Immunol*, 1986, vol. 4, 419-70 [\[0205\]](#)
- **MILLER, J. C.S. TAN et al.**A TALE nuclease architecture for efficient genome editing*Nat Biotechnol*, 2011, vol. 29, 2143-8 [\[0205\]](#)
- **MORBITZER, R.P. ROMER et al.**Regulation of selected genome loci using de novo-engineered transcription activator-like effector (TALE)-type transcription factors*Proc Natl Acad Sci U S A*, 2011, vol. 107, 5021617-22 [\[0205\]](#)
- **MOSCOU, M. J.A. J. BOGDANOVA**A simple cipher governs DNA recognition by TAL effectors*Science*, 2009, vol. 326, 59591501- [\[0205\]](#)
- **MUSSOLINO, C.R. MORBITZER et al.**A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity*Nucleic Acids Res*, 2011, vol. 39, 219283-93 [\[0205\]](#)
- **PANG, S. S.R. BERRY et al.**The structural basis for autonomous dimerization of the pre-T-cell antigen receptor*Nature*, 2010, vol. 467, 7317844-8 [\[0205\]](#)
- **PAQUES, F.P. DUCHATEAU**Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy*Curr Gene Ther*, 2007, vol. 7, 149-66 [\[0205\]](#)
- **PARDOLL, D.C. DRAKE**Immunotherapy earns its spot in the ranks of cancer therapy*J Exp Med*, 2012, vol. 209, 2201-9 [\[0205\]](#)
- **PARDOLL, D. M.**The blockade of immune checkpoints in cancer immunotherapy*Nat Rev Cancer*, 2012, vol. 12, 4252-64 [\[0205\]](#)
- **PARK, T. S.S. A. ROSENBERG et al.**Treating cancer with genetically engineered T cells*Trends Biotechnol*, 2011, vol. 29, 11550-7 [\[0205\]](#)
- **PINGOUD, A.G. H. SILVA**Precision genome surgery*Nat Biotechnol*, 2007, vol. 25, 7743-4 [\[0205\]](#)
- **PORTEUS, M. H.D. CARROLL**Gene targeting using zinc finger nucleases*Nat Biotechnol*, 2005, vol. 23, 8967-73 [\[0205\]](#)
- **ROBERT, C.C. MATEUS**Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma*Med Sci (Paris)*, vol. 27, 10850-8 [\[0205\]](#)
- **ROUET, P.F. SMIH et al.**Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease*Mol Cell Biol*, 1994, vol. 14, 128096-106 [\[0205\]](#)
- **SAINT-RUF, C.O. LECHNER et al.**Genomic structure of the human pre-T cell receptor alpha chain and expression of two mRNA isoforms*Eur J Immunol*, 1998, vol. 28, 113824-31 [\[0205\]](#)
- **SANDER, J. D.L. CADE et al.**Targeted gene disruption in somatic zebrafish cells using engineered TALENs*Nat Biotechnol*, 2011, vol. 29, 8697-8 [\[0205\]](#)
- **SMITH, J.S. GRIZOT et al.**A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences*Nucleic Acids Res*, 2006, vol. 34, 22e149- [\[0205\]](#)
- **STODDARD, B. L.**Homing endonuclease structure and function*Q Rev Biophys*, 2005, vol. 38, 149-95 [\[0205\]](#)
- **TESSON, L.C. USAL et al.**Knockout rats generated by embryo microinjection of TALENs*Nat Biotechnol*, 2011, vol. 29, 8695-6 [\[0205\]](#)
- **VON BOEHMER, H.**Unique features of the pre-T-cell receptor alpha-chain: not just a surrogate*Nat Rev Immunol*, 2005, vol. 5, 7571-7 [\[0205\]](#)
- **WALDMANN, H.G. HALE**CAMPATH: from concept to clinic*Philos Trans R Soc Lond B Biol Sci*, 2005, vol. 360, 14611707-11 [\[0205\]](#)
- **WEBER, E.R. GRUETZNER et al.**Assembly of designer TAL effectors by Golden Gate cloning*PLoS One*, 2011, vol. 6, 5e19722- [\[0205\]](#)
- **YAMASAKI, S.E. ISHIKAWA et al.**Mechanistic basis of pre-T cell receptor-mediated autonomous signaling critical for thymocyte development*Nat Immunol*, 2006, vol. 7, 167-75 [\[0205\]](#)
- **ZHANG, F.L. CONG et al.**Efficient construction of sequence-specific TAL effectors for modulating mammalian

transcriptionNat Biotechnol, 2011, vol. 29, 2149-53 [0205]

PATENTKRAV

1. Fremgangsmåde til fremstilling af human(e) T-celle(r) til immunterapi omfattende:

5 (a) tilvejebringelse af human(e) T-celle(r) fra en cellekultur eller fra en blod-prøve;

(b) genmodificering af nævnte T-celle(r) ved inaktivering af mindst:

10 - et første gen, der koder for et immun-checkpoint-protein, og
- et andet gen, der koder for en komponent i T-celle-receptoren (TCR);

(c) indføring af en kimær antigenreceptor (CAR) i nævnte T-celle(r); og

(d) ekspansion af nævnte T-celle(r),

15 Hvor nævnte immun-checkpoint gen er udvalgt blandt gruppen bestående af: PD1, CTLA-4, LAG3, Tim3, BTLA, BY55, TIGIT, B7H5, LAIR1, SIG-LEC10 og 2B4.

2. Fremgangsmåde ifølge krav 1 omfattende modificering af T-celler ved:

20

(a) indføring, i nævnte T-celle, af mindst en sjælden spaltningsendonuklease, der er i stand til selektivt at inaktivere ved DNA-spaltning henholdsvis:

25 - nævnte gen, der koder for et immun-checkpoint-protein, og
- mindst et gen, der koder for en komponent i T-cellereceptoren (TCR); og

(b) ekspansion af nævnte T-celler.

30 3. Fremgangsmåde ifølge krav 1, hvor nævnte immun-checkpoint-gen er PD1 eller CTLA-4.

4. Fremgangsmåde ifølge krav 1, hvor de mindst første og anden inaktiverede gener er udvalgt blandt gruppen bestående af PD1 og TCR alfa, PD1 og TCR beta, CTLA-4 og TCR alfa, CTLA-4 og TCR beta, LAG3. og TCR alfa, LAG3 og TCR beta, Tim3 og TCR alfa, Tim3 og TCR beta, BTLA og TCR alfa, BTLA og TCR beta, BY55 og TCR alfa, BY55 og TCR beta, TIGIT og TCR alfa, TIGIT og TCR beta, B7H5 og TCR alfa, B7H5 og TCR beta, LAIR1 og TCR alfa, LAIR1 og TCR beta, SIGLEC10 og TCR alfa, SIGLEC10 og TCR beta, 2B4 og TCR alfa og 2B4 og TCR beta.
- 5
5. Fremgangsmåde ifølge krav 2, hvor mRNA, der koder for nævnte mindst ene sjælden spaltningsendonuklease, indføres i T-cellerne ved elektroporation.
- 10
6. Fremgangsmåde ifølge krav 2, hvor nævnte mindst ene mindst ene sjælden spaltningsendonuklease er en TALE-nuklease.
- 15
7. Fremgangsmåde ifølge krav 6, hvor mindst en TALE-nuklease er rettet mod en af gentarget-sekvenserne af TCRalpha udvalgt blandt SEQ ID NO: 37 eller SEQ ID NO: 57 til SEQ ID NO: 60.
- 20
8. Fremgangsmåde ifølge krav 6, hvor mindst en TALE-nuklease er rettet mod en af gentarget-sekvenserne af TCRbeta udvalgt blandt gruppen bestående af SEQ ID NO: 38 og SEQ ID NO: 39.
- 25
9. Fremgangsmåde ifølge krav 6, hvor mindst en TALE-nuklease er rettet mod en af gen-targetsekvenserne af PD1 udvalgt blandt gruppen bestående af SEQ ID NO: 77 og SEQ ID NO: 78.
- 30
10. Fremgangsmåde ifølge krav 6, hvor mindst en TALE-nuklease er rettet mod en af gentarget-sekvenserne af CTLA-4 udvalgt blandt gruppen bestående af SEQ ID NO: 74 og SEQ ID NO: 76.
11. Fremgangsmåde ifølge krav 1, hvor nævnte T-celle(r) i trin a) er afledt af inflammatoriske T-lymfocytter, cytotoksiske T-lymfocytter, regulatoriske T-lymfocytter eller hjælper T-lymfocytter og/eller fra CD4+ T-lymfocytter og/eller CD8+ T-lymfocytter.

12. En isoleret human T-celle, hvor mindst to gener er blevet inaktiveret, hvilke gener er udvalgt blandt gruppen bestående af: PD1 og TCR alfa, PD1 og TCR beta, CTLA-4 og TCR alfa, CTLA-4 og TCR beta, LAG3 og TCR alfa, LAG3 og TCR beta, Tim3 og TCR alfa, Tim3 og TCR beta, BTLA og TCR alfa, BTLA og TCR beta, BY55 og TCR alfa, BY55 og TCR beta, TIGIT og TCR alfa, TIGIT og TCR beta, B7H5 og TCR alfa, B7H5 og TCR beta, LAIR1 og TCR alfa, LAIR1 og TCR beta, SIGLEC10 og TCR alfa, SIGLEC10 og TCR beta, 2B4 og TCR alfa, og 2B4 og TCR beta, yderligere omfattende en eksogen polynukleotidsekvens, der koder for en kimær antigenreceptor.
13. Isoleret T-celle ifølge krav 12, hvor nævnte kimære antigenreceptor er en kimærisk flerkædet antigenreceptor.
14. Isoleret T-celle ifølge krav 13, hvor nævnte kimære antigenreceptor omfatter mindst et signaltransducerende domæne, hvor det signaltransducerende domæne er CD137 (4-1BB).
15. Isoleret T-celle ifølge krav 12 til anvendelse som et medikament.
16. Isoleret T-celle ifølge krav 12 til anvendelse i en fremgangsmåde til behandling af cancer eller en virusinfektion.
17. Isoleret T-celle ifølge krav 12 til anvendelse i en fremgangsmåde til behandling af lymphoma.
18. Farmaceutisk sammensætning omfattende mindst en isoleret T-celle ifølge krav 12.
19. En population af modificerede humane T-celler fremstillet ifølge fremgangsmåden ifølge krav 1 til anvendelse til behandling af en patient.
20. Population ifølge krav 19 til anvendelse ifølge krav 19, hvor patienten er diagnosticeret med cancer eller en virusinfektion.

DRAWINGS




Fig.1




Fig.2








Fig.3

***Fig. 4A******Fig. 4B***

***Fig.4C***



- 🔑 CD52 CD52 disruption provides chemotherapy resistance
- 🔑 TCR TCRα disruption removes alloreactivity (GvHD)
- CAR T-cell redirection / tumor recognition
- pTα pre-TCRα(pTα) drives cell proliferation

Fig.5




Fig. 6









Fig. 7

***Fig. 8A******Fig. 8B******Fig. 8C***

***Fig.8D******Fig.8E***

	LEFT HALF TARGET	Spacer size (bp)	RIGHT HALF TARGET		
TRAC	TTGTCCCACAGATATCC	15	CCGTGTACCCAGCTGAGA		
CD52	TTCCTCCTACTCACCAT	15	GGTACAGGTAAGAGCA A		
Potential offsite targets	Left matched sequence	Spacer size (bp)	Right matched sequence	Mis- matc hes	
1	ttgctctCaccAgtaTA	25	TTtTcaggtaagTgcaa	8	
2	tCActcttacctgGacc	19	CCtacaggttaagGgcCa	7	
3	tctcagAtgAtacacCC	24	AgtacaggCaTgagcCa	8	
4	tGAtcccacagaAatAc	18	gCatTtctgtgggaTCa	8	
5	ttCctctAacctgtaTT	25	gAtCcaggtaagGTcaa	8	
6	tAgtcccCagatatGA	19	aAggtgTgGaTgaggaa	8	
7	ttgtcAcacaTataCcG	21	TgGtatTtgtgTgacaa	8	
8	tAActcttacctgtaGT	16	AgatTtctCtgggGcaa	8	
9	ttActccAactAacTat	16	ccgtTtaccGgctTaga	7	
10	tGgctcAtacctgtaGT	14	aGgAtgagGTggaggaa	8	
11	ttgctcAtacAtgtGcA	21	atgCtgTgtaggTggTa	8	
12	ttgtcccacagaCatTc	18	ccACgtaGcagctgGga	6	
13	tcAcaCctggtacaTAG	27	GtgTtTagtaggGggaa	8	
14	ttgtcccacagCtaCcc	29	gAgtCtTtgtAggacaa	6	
15	tctcaActgAAacaAgg	23	TgtaAtgTCaagagcaa	8	

Fig. 9A

	Control transfection (no RNA)			CD52-TALEN+TRAC+TALEN transfection		
	Nb seq analyzed	Nb indels	Frequency indels (less than)	Nb seq analyzed	Nb indels	Frequency indels (less than)
	3965	0	2.52E-04	7560	3371	0.44
	1046	0	9.56E-04	2266	1056	0.47
Matched sequence						
CD52-R_TRAC-R	7132	0	1.4E-04	7644	1	1.3E-04
CD52-R_TRAC-R	6431	0	1.6E-04	7377	2	2.7E-04
CD52-R_TRAC-R	2771	0	3.6E-04	2704	80	3.7E-04
TRAC-L_CD52-L	5525	0	1.8E-04	4739	0	2.1E-04
CD52-R_TRAC-R	27958	0	3.6E-05	16646	0	6.0E-05
TRAC-L_CD52-L	22456	0	4.5E-05	32912	10	3.0E-04
TRAC-L_CD52-L	8275	0	1.2E-04	5629	0	1.8E-04
TRAC-L_CD52-R	23253	0	4.3E-05	22054	16	7.3E-04
CD52-L_TRAC-R	13371	0	7.5E-05	13688	1	7.3E-05
CD52	22856	0	4.4E-05	31292	0	3.2E-05
CD52	3238	1	3.1E-04	3064	0	3.3E-04
TRAC	4530	0	2.2E-04	4652	0	2.1E-04
CD52-L_TRAC-R	17361	0	5.8E-05	14454	0	6.9E-05
TRAC-L_CD52-L	32823	0	3.0E-05	33911	1	2.9E-05
CD52-R_TRAC-R	6479	0	1.5E-04	6088	0	1.6E-04

Fig. 9B





Fig. 10

*Fig. 11**Fig. 13*




Fig. 12





Fig.14A

**Fig. 14B**






Fig.14C

**Fig.15A****Fig.15B**






Fig.15C

**Fig. 16A****Fig. 16B**




Fig.17




Fig.17-1





Fig. 18

**Fig. 18-1**









Fig.19

***Fig.20A******Fig.20B***

***Fig.21A******Fig.21B******Fig.21C***




Figure 22




Figure 23




Figure 24A




Figure 24B




Figure 25A




Figure 25B




Figure 25C






Figure 26

Fig. 27








Fig. 28




Fig. 29




Fig. 30




Fig. 31